<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors - Arbyn, M - 2018 | Cochrane Library</title> <meta content="Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors - Arbyn, M - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009069.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors - Arbyn, M - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009069.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009069.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors" name="citation_title"/> <meta content="Marc Arbyn&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Sciensano" name="citation_author_institution"/> <meta content="marc.arbyn@sciensano.be" name="citation_author_email"/> <meta content="Lan Xu&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Sciensano" name="citation_author_institution"/> <meta content="Cindy Simoens" name="citation_author"/> <meta content="University of Antwerp" name="citation_author_institution"/> <meta content="Pierre PL Martin‐Hirsch" name="citation_author"/> <meta content="Royal Preston Hospital, Lancashire Teaching Hospital NHS Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD009069.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/05/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009069.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009069.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009069.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Human papillomavirus 16; Human papillomavirus 18; Papillomavirus Infections [complications, mortality, *prevention &amp; control]; Papillomavirus Vaccines [*administration &amp; dosage, adverse effects]; Precancerous Conditions [mortality, *prevention &amp; control, virology]; Pregnancy Outcome; Randomized Controlled Trials as Topic; Uterine Cervical Dysplasia [mortality, *prevention &amp; control, virology]; Uterine Cervical Neoplasms [mortality, *prevention &amp; control, virology]; Vaccination" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009069.pub3&amp;doi=10.1002/14651858.CD009069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009069\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009069\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","th","ms","ja","pl","fr","zh_HANS","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009069.pub3",title:"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors",firstPublishedDate:"May 9, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009069.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009069.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009069.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009069.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009069.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009069.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009069.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009069.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009069.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009069.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>54916 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009069.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-sec-0123"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-sec-0030"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-sec-0031"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-sec-0094"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/appendices#CD009069-sec-0128"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/table_n/CD009069StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/table_n/CD009069StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/information#CD009069-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Marc Arbyn</a><sup>a</sup></li> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/information#CD009069-cr-0003">Lan Xu</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/information#CD009069-cr-0004">Cindy Simoens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009069.pub3/information#CD009069-cr-0005">Pierre PL Martin‐Hirsch</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/information/en#CD009069-sec-0139">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 May 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009069.pub3">https://doi.org/10.1002/14651858.CD009069.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009069-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009069-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009069-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009069-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009069-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD009069-abs-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009069-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009069-abs-0001" lang="en"> <section id="CD009069-sec-0001"> <h3 class="title" id="CD009069-sec-0001">Background</h3> <p>Persistent infection with high‐risk human papillomaviruses (hrHPV) types is causally linked with the development of cervical precancer and cancer. HPV types 16 and 18 cause approximately 70% of cervical cancers worldwide. </p> </section> <section id="CD009069-sec-0002"> <h3 class="title" id="CD009069-sec-0002">Objectives</h3> <p>To evaluate the harms and protection of prophylactic human papillomaviruses (HPV) vaccines against cervical precancer and HPV16/18 infection in adolescent girls and women. </p> </section> <section id="CD009069-sec-0003"> <h3 class="title" id="CD009069-sec-0003">Search methods</h3> <p>We searched MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and Embase (June 2017) for reports on effects from trials. We searched trial registries and company results' registers to identify unpublished data for mortality and serious adverse events. </p> </section> <section id="CD009069-sec-0004"> <h3 class="title" id="CD009069-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing efficacy and safety in females offered HPV vaccines with placebo (vaccine adjuvants or another control vaccine). </p> </section> <section id="CD009069-sec-0005"> <h3 class="title" id="CD009069-sec-0005">Data collection and analysis</h3> <p>We used Cochrane methodology and GRADE to rate the certainty of evidence for protection against cervical precancer (cervical intraepithelial neoplasia grade 2 and above [CIN2+], CIN grade 3 and above [CIN3+], and adenocarcinoma‐in‐situ [AIS]), and for harms. We distinguished between the effects of vaccines by participants' baseline HPV DNA status. The outcomes were precancer associated with vaccine HPV types and precancer irrespective of HPV type. Results are presented as risks in control and vaccination groups and risk ratios (RR) with 95% confidence intervals in brackets. </p> </section> <section id="CD009069-sec-0006"> <h3 class="title" id="CD009069-sec-0006">Main results</h3> <p>We included 26 trials (73,428 participants). Ten trials, with follow‐up of 1.3 to 8 years, addressed protection against CIN/AIS. Vaccine safety was evaluated over a period of 6 months to 7 years in 23 studies. Studies were not large enough or of sufficient duration to evaluate cervical cancer outcomes. All but one of the trials was funded by the vaccine manufacturers. We judged most included trials to be at low risk of bias. Studies involved monovalent (N = 1), bivalent (N = 18), and quadrivalent vaccines (N = 7). Most women were under 26 years of age. Three trials recruited women aged 25 and over. We summarize the effects of vaccines in participants who had at least one immunisation. </p> <p><b>Efficacy endpoints by initial HPV DNA status</b> </p> <p><b>hrHPV negative</b> </p> <p>HPV vaccines reduce CIN2+, CIN3+, AIS associated with HPV16/18 compared with placebo in adolescent girls and women aged 15 to 26. There is high‐certainty evidence that vaccines lower CIN2+ from 164 to 2/10,000 (RR 0.01 (0 to 0.05)) and CIN3+ from 70 to 0/10,000 (RR 0.01 (0.00 to 0.10). There is moderate‐certainty evidence that vaccines reduce the risk of AIS from 9 to 0/10,000 (RR 0.10 (0.01 to 0.82). </p> <p>HPV vaccines reduce the risk of any CIN2+ from 287 to 106/10,000 (RR 0.37 (0.25 to 0.55), high certainty) and probably reduce any AIS lesions from 10 to 0/10,000 (RR 0.1 (0.01 to 0.76), moderate certainty). The size of reduction in CIN3+ with vaccines differed between bivalent and quadrivalent vaccines (bivalent: RR 0.08 (0.03 to 0.23), high certainty; quadrivalent: RR 0.54 (0.36 to 0.82), moderate certainty). Data in older women were not available for this comparison. </p> <p><b>HPV16/18 negative</b> </p> <p>In those aged 15 to 26 years, vaccines reduce CIN2+ associated with HPV16/18 from 113 to 6 /10,000 (RR 0.05 (0.03 to 0.10). In women 24 years or older the absolute and relative reduction in the risk of these lesions is smaller (from 45 to 14/10,000, (RR 0.30 (0.11 to 0.81), moderate certainty). HPV vaccines reduce the risk of CIN3+ and AIS associated with HPV16/18 in younger women (RR 0.05 (0.02 to 0.14), high certainty and RR 0.09 (0.01 to 0.72), moderate certainty, respectively). No trials in older women have measured these outcomes. </p> <p>Vaccines reduce any CIN2+ from 231 to 95/10,000, (RR 0.41 (0.32 to 0.52)) in younger women. No data are reported for more severe lesions. </p> <p><b>Regardless of HPV DNA status</b> </p> <p>In younger women HPV vaccines reduce the risk of CIN2+ associated with HPV16/18 from 341 to 157/10,000 (RR 0.46 (0.37 to 0.57), high certainty). Similar reductions in risk were observed for CIN3+ associated with HPV16/18 (high certainty). The number of women with AIS associated with HPV16/18 is reduced from 14 to 5/10,000 with HPV vaccines (high certainty). </p> <p>HPV vaccines reduce any CIN2+ from 559 to 391/10,000 (RR 0.70 (0.58 to 0.85, high certainty) and any AIS from 17 to 5/10,000 (RR 0.32 (0.15 to 0.67), high certainty). The reduction in any CIN3+ differed by vaccine type (bivalent vaccine: RR 0.55 (0.43 to 0.71) and quadrivalent vaccine: RR 0.81 (0.69 to 0.96)). </p> <p>In women vaccinated at 24 to 45 years of age, there is moderate‐certainty evidence that the risks of CIN2+ associated with HPV16/18 and any CIN2+ are similar between vaccinated and unvaccinated women (RR 0.74 (0.52 to 1.05) and RR 1.04 (0.83 to 1.30) respectively). No data are reported in this age group for CIN3+ or AIS. </p> <p><b>Adverse effects</b> </p> <p>The risk of serious adverse events is similar between control and HPV vaccines in women of all ages (669 versus 656/10,000, RR 0.98 (0.92 to 1.05), high certainty). Mortality was 11/10,000 in control groups compared with 14/10,000 (9 to 22) with HPV vaccine (RR 1.29 [0.85 to 1.98]; low certainty). The number of deaths was low overall but there is a higher number of deaths in older women. No pattern in the cause or timing of death has been established. </p> <p><b>Pregnancy outcomes</b> </p> <p>Among those who became pregnant during the studies, we did not find an increased risk of miscarriage (1618 versus 1424/10,000, RR 0.88 (0.68 to 1.14), high certainty) or termination (931 versus 838/10,000 RR 0.90 (0.80 to 1.02), high certainty). The effects on congenital abnormalities and stillbirths are uncertain (RR 1.22 (0.88 to 1.69), moderate certainty and (RR 1.12 (0.68 to 1.83), moderate certainty, respectively). </p> </section> <section id="CD009069-sec-0007"> <h3 class="title" id="CD009069-sec-0007">Authors' conclusions</h3> <p>There is high‐certainty evidence that HPV vaccines protect against cervical precancer in adolescent girls and young women aged 15 to 26. The effect is higher for lesions associated with HPV16/18 than for lesions irrespective of HPV type. The effect is greater in those who are negative for hrHPV or HPV16/18 DNA at enrolment than those unselected for HPV DNA status. There is moderate‐certainty evidence that HPV vaccines reduce CIN2+ in older women who are HPV16/18 negative, but not when they are unselected by HPV DNA status. </p> <p>We did not find an increased risk of serious adverse effects. Although the number of deaths is low overall, there were more deaths among women older than 25 years who received the vaccine. The deaths reported in the studies have been judged not to be related to the vaccine. Increased risk of adverse pregnancy outcomes after HPV vaccination cannot be excluded, although the risk of miscarriage and termination are similar between trial arms. Long‐term of follow‐up is needed to monitor the impact on cervical cancer, occurrence of rare harms and pregnancy outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009069-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009069-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009069-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009069-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009069-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009069-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009069-abs-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD009069-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009069-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD009069-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009069-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD009069-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009069-abs-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009069-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009069-abs-0004" lang="en"> <h3>HPV vaccination to prevent cancer and pre‐cancerous changes of the cervix</h3> <p><b>Background</b><br/> Human papillomaviruses (HPV) are sexually transmitted and are common in young people. Usually they are cleared by the immune system. However, when high‐risk (hr) types persist, they can cause the development of abnormal cervical cells, which are referred to as cervical precancer if at least two thirds of the surface layer of the cervix is affected. Precancer can develop into cervical cancer after several years. Not everyone who has cervical precancer goes on to develop cervical cancer, but predicting who will is difficult. There are a number of different hrHPV types which can cause cervical precancer and cancer. HPV16 and 18 are the most important high‐risk types, since they cause about 70% of cervical cancers worldwide. Preventive vaccination, by injection of HPV virus‐like particles in the muscle, triggers the production of antibodies which protect against future HPV infections. </p> <p><b>Review question</b><br/> Does HPV vaccination prevent the development of cervical precancer or cancer and what are the harms? </p> <p><b>Main results</b><br/> We included 26 studies involving 73,428 adolescent girls and women. All trials evaluated vaccine safety over a period 0.5 to 7 years and ten trials, with follow‐up 3.5 to 8 years, addressed protection against precancer. Cervical cancer outcomes are not available. Most participants enrolled were younger than 26 years of age. Three trials recruited women between 25 to 45 years. The studies compared HPV vaccine with a dummy vaccine. </p> <p>We assessed protection against precancer in individuals who were free of hrHPV, free of HPV16/18 or those with or without HPV infection at the time of vaccination. We separately assessed precancer associated with HPV16/18 and any precancer. </p> <p><i><b>Protection against cervical precancer</b> </i> </p> <p><i>1) Women free of hrHPV</i> </p> <p>Outcomes were only measured in the younger age group for this comparison (15 to 25 years). HPV vaccines reduce the risk of cervical precancer associated with HPV16/18 from 164 to 2/10,000 women (high certainty). They reduce also any precancer from 287 to 106/10,000 (high certainty). </p> <p><i>2) Women free of HPV16/18</i> </p> <p>The effect of HPV vaccines on risk of precancer differ by age group. In younger women, HPV vaccines reduce the risk of precancer associated with HPV16/18 from 113 to 6/10,000 women (high certainty). HPV vaccines lower the number of women with any precancer from 231 to 95/10,000 (high certainty). In women older than 25, the vaccines reduce the number with precancer associated with HPV16/18 from 45 to 14/10,000 (moderate certainty). </p> <p><i>3) All women with or without HPV infection</i> </p> <p>In those vaccinated between 15 to 26 years of age, HPV vaccination reduces the risk of precancer associated with HPV16/18 from 341 to 157/10,000 (high certainty) and any precancer from 559 to 391/10,000 (high certainty). </p> <p>In older women, vaccinated between 25 to 45 years of age, the effects of HPV vaccine on precancer are smaller, which may be due to previous exposure to HPV. The risk of precancer associated with HPV16/18 is probably reduced from 145/10,000 in unvaccinated women to 107/10,000 women following HPV vaccination (moderate certainty). The risk of any precancer is probably similar between unvaccinated and vaccinated women (343 versus 356/10,000, moderate certainty). </p> <p><i><b>Adverse effects</b> </i> </p> <p>The risk of serious adverse events is similar in HPV and control vaccines (placebo or vaccine against another infection than HPV (high certainty). The rate of death is similar overall (11/10,000 in control group, 14/10,000 in HPV vaccine group) (low certainty). The number of deaths overall is low although a higher number of deaths in older women was observed. No pattern in the cause or timing of death has been established. </p> <p><i><b>Pregnancy outcomes</b> </i> </p> <p>HPV vaccines did not increase the risk of miscarriage or termination of pregnancy. We do not have enough data to be certain about the risk of stillbirths and babies born with malformations (moderate certainty). </p> <p><b>Conclusion</b><br/> There is high‐certainty evidence that HPV vaccines protect against cervical precancer in adolescent girls and women who are vaccinated between 15 and 26 years of age. The protection is lower when a part of the population is already infected with HPV. Longer‐term follow‐up is needed to assess the impact on cervical cancer. The vaccines do not increase the risk of serious adverse events, miscarriage or pregnancy termination. There are limited data from trials on the effect of vaccines on deaths, stillbirth and babies born with malformations. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009069-sec-0123" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009069-sec-0123"></div> <h3 class="title" id="CD009069-sec-0124">Implications for practice</h3> <section id="CD009069-sec-0124"> <p>In studies designed to evaluate prevention of cervical precancer, an endpoint established by the World Health Organization (WHO) and regulatory agencies as a surrogate outcome for cervical cancer, high vaccine efficacy was demonstrated. The studies were not designed to evaluate cervical cancer and the duration of the studies was too short to determine the effects of human papillomaviruses (HPV) vaccination on cervical cancer outcomes. Although the trials were large and no safety concerns were established, vaccine safety requires evaluation in surveillance studies after introduction of vaccination programmes. </p> <p>In young women aged 15 to 26, who are high‐risk human papillomavirus (hrHPV) negative or HPV16/18 negative at baseline, HPV vaccination reduces the risk of persistent HPV16/18 infection, high‐grade cervical intraepithelial neoplasia or worse (CIN2+) and adenocarcinoma in situ (AIS) associated with the vaccine types. Average rates of CIN2+ reduced from 164 to 2 per 10,000 and CIN3+ from 70 per 10,000 to 0 per 10,000. The findings in these unexposed groups are relevant for adolescent girls prior to sexual debut. Our review suggests that fewer than three doses may offer protection against HPV16/18 endpoints in this age group. We found no evidence that one or two doses of bivalent or quadrivalent vaccine provide significant protection against any CIN2+, irrespective of HPV types, in young women (15 to 26 years) </p> <p>Since prophylactic HPV vaccines do not clear existing HPV infection, protection is less effective in populations already exposed to HPV. However, protection is still moderate in young women (15 to 26 years) considered as an overall cohort regardless of baseline HPV infection status, which may be relevant for decision making in relation to 'catch‐up' vaccination programmes. </p> <p>Whereas the efficacy of the bivalent and quadrivalent vaccines against cervical precancer associated with HPV16 or 18 is similar, protection of the bivalent vaccine against any cervical precancer irrespective of HPV types seems to be higher. </p> <p>Among mid‐adult women (24 to 45 years), while evidence shows that three doses given to HPV negative women provides significant protection against CIN2+ associated with HPV16/18, evidence to date suggests that fewer than three doses of HPV vaccine do not provide protection against CIN2+ associated with HPV16/18 or any CIN2+ irrespective of HPV type. </p> <p>The HPV vaccines are responsible for local effects at the injection site, which are generally well tolerated. No increased incidence of serious adverse effects was noted in vaccinated participants. We did not find conclusive evidence of increases in the risk of congenital anomalies and adverse pregnancy outcomes in vaccinated women who became pregnant throughout the trials. However, more evidence is needed to determine long‐term outcomes in pregnant women who received the vaccine. </p> <p>While deaths occurred during follow‐up of the trial participants, none were assessed to be due to vaccine and all occurred months to years after vaccination. More deaths occurred after vaccination of mid‐adult women. These deaths were deemed by study investigators as not related to vaccination due to the absence of clustering of the causes of death and the lack of a temporal relation (<a href="#CD009069-tbl-0009">Table 5</a> and <a href="#CD009069-tbl-0010">Table 6</a>). </p> <p>Evidence on rare potential harms, such as autoimmune disorders, are difficult to capture in randomised controlled trials (RCTs). The findings of this review should be seen in the context of surveillance studies which have been conducted globally since the licensing of the vaccines and have demonstrated a consistently good safety profile in population usage as reviewed by the Global Advisory Committee on Vaccine Safety (GACVS) of the WHO on multiple occasions. A single French study found a small increase in Guillain‐Barré syndrome among HPV vaccinated girls but this was not confirmed in seven other studies. </p> </section> <h3 class="title" id="CD009069-sec-0125">Implications for research</h3> <section id="CD009069-sec-0125"> <p>Long‐term surveillance and registry‐based research (linking of vaccination databases with screening, cyto‐histopathology, cancer registries and biobanks; and linking with morbidity, mortality and birth/maternity registries) are needed to establish vaccine efficacy and safety over time. This will help also to assess type replacement, cross‐protection, duration of protection associated with three or fewer doses and vaccine safety in pregnant women. </p> <p>Trials and registry‐based research combined with mathematical modelling are needed to define new integrated strategies of cervical cancer prevention through a combination of vaccination and screening. </p> <p>In mid‐adult women (24 to 45 years), limited data were reported with respect to outcomes other than targeted type infections and disease. Studies are more difficult to undertake in this age group due to the lower incidence of new infections and incident disease and because of prevalent infection and disease. For this reason, we recommend monitoring of vaccinated cohorts over time to assess the overall effectiveness of vaccination over time on the burden of cervical disease in mid‐adult women. Our review revealed the need to continuously update existing evidence and to complete gaps in the current accumulated knowledge with available, but unpublished data. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009069-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009069-sec-0022"></div> <div class="table" id="CD009069-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HPV vaccine effects on cervical lesions in adolescent girls and women negative for hrHPV DNA at baseline</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HPV vaccine effects on cervical lesions in adolescent girls and women who are hrHPV DNA negative at baseline</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination </p> <p><b>Setting:</b> Europe, Asia Pacific countries, South &amp; North America<br/> <b>Intervention:</b> HPV vaccines (at least one dose of bivalent or quadrivalent vaccines) </p> <p><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with HPV vaccination<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cervical cancer ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN2+ associated with HPV16/18.</p> <p>Follow‐up: 3 to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>164 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 per 10,000<br/> (0 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.01<br/> (0.00 to 0.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,676<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN3+ associated with HPV16/18</p> <p>Follow‐up: 3 to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>70 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 10,000<br/> (0 to 7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.01<br/> (0.00 to 0.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,214<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuity correction</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AIS associated with HPV16/18</p> <p>Follow‐up: 3 to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>9 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 10,000<br/> (0 to 7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.10<br/> (0.01 to 0.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,214<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuity correction</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any CIN2+ irrespective of HPV type, bivalent or quadrivalent vaccine</p> <p>Follow‐up: 2 to 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>287 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>106 per 10,000<br/> (72 to 158) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.37<br/> (0.25 to 0.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,180<br/> (5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial subgroup heterogeneity was observed (I<sup>2</sup>= 84.3%) for bi‐ and quadrivalent vaccines. So results are reported separately for the 2 vaccines (see next 2 rows). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Any CIN2+ irrespective of HPV type</p> <p>Follow‐up (bivalent): 3.5 to 6 years</p> <p>Follow‐up (quadrivalent): 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.33</p> <p>(0.25 to 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>15,884</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>285 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>94 per 10,000</p> <p>(71 to 122)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.57</p> <p>(0.44 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>9296</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>291 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>166 per 10,000</p> <p>(128 to 221)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any CIN3+ irrespective of HPV type, bivalent or quadrivalent vaccine</p> <p>Follow‐up: 3.5 to 4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>109 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 10,000<br/> (4 to 120) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.21<br/> (0.04 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,719<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial subgroup heterogeneity was observed (I<sup>2</sup> = 84.3%) for bi‐ and quadrivalent vaccines. So results are reported separately for the 2 vaccines (see next 2 rows). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Any CIN3+ irrespective of HPV type</p> <p>Follow‐up (bivalent): 4 years</p> <p>Follow‐up (quadrivalent): 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.08</p> <p>(0.03 to 0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>11,423</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>81 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 per 10,000</p> <p>(3 to 19)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.54</p> <p>(0.36 to 0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>9296</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>143 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>77 per 10,000</p> <p>(51 to 117 )</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any AIS irrespective of HPV type<br/> <br/> Follow‐up: 3 to 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 10,000<br/> (0 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.10<br/> (0.01 to 0.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,214<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuity correction</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><sup>1</sup><b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). When risk in vaccine group is zero, the 95% CI is computed using an exact binomial method.<br/> <br/> <b>AIS:</b> adenocarcinoma in situ; <b>CI:</b> Confidence interval; <b>CIN:</b> cervical intraepithelial neoplasia; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk calculated from the sum of control group event rates. </p> <p><sup>2</sup> Downgraded due to serious imprecision in effect estimate (width 95% CI around RR &gt; 0.6). </p> <p><sup>3</sup> Downgraded one level due to serious imprecision. Few events observed in the two studies (9 in placebo arms and 0 in vaccination arms for the outcome of AIS HPV16/18 and 7 in placebo arms and 0 in vaccination arms for outcome of AIS of any type). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009069-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">HPV vaccine effects on cervical lesions in adolescent girls and women negative for HPV16/18 DNA at baseline</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HPV vaccine effects on cervical lesions in adolescent girls and women negative for HPV16/18 DNA at baseline</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination<br/> <b>Setting:</b> Europe, Asia Pacific countries, South &amp; North America <br/> <b>Intervention:</b> HPV vaccines (at least one dose of bivalent or quadrivalent vaccines)<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with HPV vaccination<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cervical cancer ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>CIN2+ associated with HPV16/18</p> <p>Follow‐up (age 15 to 26 years): 1 to 8.5 years</p> <p>Follow‐up (age 24 to 45 years): 4 to 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>15 to 26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.05<br/> (0.03 to 0.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>34,478<br/> (6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>113 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 per 10,000<br/> (3 to 11) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>24 to 45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.30</p> <p>(0.11 to 0.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>7552</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝</p> <p>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>45 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 10,000</p> <p>(5 to 37)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN3+ associated with HPV16/18 (age 15 to 26 years)</p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>57 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 10,000</p> <p>(1 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.05</p> <p>(0.02 to 0.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33,199</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AIS associated with HPV16/18 or 6/11/16/18 (age 15 to 26 years)</p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>12 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 10,000<br/> (0 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.09<br/> (0.01 to 0.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,079<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuity</p> <p>correction</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any CIN2+ irrespective of HPV type (age 15 to 26 years)</p> <p>Follow‐up: 2 to 6.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>231 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>95 per 10,000<br/> (74 to 120) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.41<br/> (0.32 to 0.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,143<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any CIN3+ irrespective of HPV type ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any AIS irrespective of HPV type ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><sup>1</sup><b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Exception: when risk in vaccine group is zero, the 95% CI is computed using an exact binomial method..<br/> <br/> <b>AIS:</b> adenocarcinoma in situ; <b>CI:</b> Confidence interval; <b>CIN:</b> cervical intraepithelial neoplasia; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk calculated from the sum of control group event rates. </p> <p><sup>2</sup> Downgraded due to serious imprecision in effect estimate (width 95% CI around RR &gt; 0.6). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009069-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">HPV vaccine effects in adolescent girls and women regardless of HPV DNA status at baseline</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HPV vaccine effects on cervical lesions in adolescent girls and women unselected for HPV DNA status at baseline</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline<br/> <b>Setting:</b> Europe, Asia Pacific countries, South &amp; North America and Africa <br/> <b>Intervention:</b> HPV vaccines (at least one dose of bivalent or quadrivalent vaccines)<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with HPV vaccination<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cervical cancer ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>CIN2+ associated with HPV16/18</p> <p>Follow‐up (age 15 to 26 years): 3.5 to 8.5 years</p> <p>Follow‐up (age 24 to 45 years): 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>15 to 26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.46</p> <p>(0.37 to 0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>34,852<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>341 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>157 per 10,000<br/> (126 to 194) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>24 to 45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.74</p> <p>(0.52 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>9200</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>145 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>107 per 10,000</p> <p>(76 to 152)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN3+ associated with HPV16/18</p> <p>Follow‐up: 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>165 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>91 per 10,000</p> <p>(74 to 127)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.55</p> <p>(0.45 to 0.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,562</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adeno carcinoma in situ (AIS) associated with HPV16/18</p> <p>Follow‐up: 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 10,000<br/> (3 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.36<br/> (0.17 to 0.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,562<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Any CIN2+ irrespective of HPV type</p> <p>Follow‐up (age 15 to 26 years): 3.5 to 8.5 years</p> <p>Follow‐up (age 24 to 45 years): 3.5 to 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>15 to 26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.70<br/> (0.58 to 0.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>35,779<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>559 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>391 per 10,000<br/> (324 to 475) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>24 to 45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.04<br/> (0.83 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>9287<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>343 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>356 per 10,000<br/> (284 to 445) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any CIN3+ irrespective of HPV type (age 15 to 26 years)</p> <p>Follow‐up: 3.5 to 4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>266 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>178 per 10,000</p> <p>(231 to 247)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67</p> <p>(0.49 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35,489</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial subgroup heterogeneity was observed (I<sup>2</sup> = 84.3%) for bivalent and quadrivalent vaccines. So results are reported separately for two vaccines. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Any CIN3+ irrespective of HPV type (age 15 to 26 years),</p> <p>Follow‐up (bivalent): 3.5 to 4 years</p> <p>Follow‐up (quadrivalent): 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.55</p> <p>(0.43 to 0.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>18,329</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>188 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>104 per 10,000</p> <p>(81 to 134)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.81</p> <p>(0.69 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>17,160</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>349 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>283 per 10,000</p> <p>(241 to 335)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any AIS irrespective of HPV type (age 15 to 26 years)</p> <p>Follow‐up: 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>17 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 10,000<br/> (3 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.32<br/> (0.15 to 0.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,562<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>Follow‐up: 6 months to 7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>669 per 10,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>656 per 10,000<br/> (616 to 703) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98<br/> (0.92 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71,597<br/> (23 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deaths</p> <p>Follow‐up: 7 months to 10 years. Most of the information in the analysis comes from studies with follow‐up ranging from 5‐10 years. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 10,000<br/> (9 to 22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.29<br/> (0.85 to 1.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71,176<br/> (23 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Older women had higher fatality rate (RR 2.36, 95% CI 1.10 to 5.03). Assessment of the deaths in the studies has not been able to identify a pattern in the cause or timing of death. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AIS:</b> adenocarcinoma in situ; <b>CI:</b> Confidence interval; <b>CIN:</b> cervical intraepithelial neoplasia; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk calculated from the sum of control group event rates for all outcomes unless otherwise stated. </p> <p><sup>2</sup> Downgraded due to serious imprecision. Confidence interval is wide and includes large decrease and small increase in lesions with vaccination group in the older age group. </p> <p><sup>3</sup> Downgraded one level due to serious inconsistency. Reduction in lesions was greater in younger women than in older women (RR 0.46 in 15 to 26 years versus RR 0.74 in 24 to 45 years; P = 0.02 for interaction). </p> <p><sup>4</sup> Downgraded one level due to serious imprecision. Confidence interval includes potentially meaningful increase in risk of mortality. </p> <p><sup>5</sup> Downgraded one level due to serious inconsistency. Despite limited evidence of statistical variation, sub grouping studies by age showed higher fatality rate with vaccines in older age group. There is no clear pattern in causes or timing of deaths. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009069-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">HPV vaccine effects on pregnancy outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HPV vaccine adverse pregnancy outcomes (regardless of DNA status and age)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adolescent girls and women aged 15 to 45 years who became pregnant during the study<br/> <b>Setting:</b> Europe, Asia Pacific, North, Central and South America<br/> <b>Intervention:</b> HPV vaccines (bivalent or quadrivalent vaccines)<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with HPV vaccines</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Spontaneous abortion/miscarriage</p> <p>Follow‐up: 1 to 7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.68 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8618<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1618 per 10,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1,424 per 10,000<br/> (1,100 to 1844) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Elective termination/induced abortion</p> <p>Follow‐up: 1 to 7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.80 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,909<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>931 per 10,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>838 per 10,000<br/> (745 to 950) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Stillbirth</p> <p>Follow‐up: 1 to 3.5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/> (0.68 to 1.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8754<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 10,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 10,000<br/> (48 to 128) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Babies born with congenital malformations</p> <p>Follow‐up: 3 to 7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.22<br/> (0.88 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9252<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 10,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 10,000<br/> (180 to 346) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Confidence interval rules out an increased risk of termination so there is no downgrade for imprecision. </p> <p><sup>2</sup> Downgraded one level due to serious imprecision. Confidence intervals for both outcomes include meaningful increase and reduction in risk of stillbirth or abnormal infants following vaccination. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009069-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009069-sec-0023"></div> <section id="CD009069-sec-0024"> <h3 class="title" id="CD009069-sec-0024">Description of the condition</h3> <section id="CD009069-sec-0025"> <h4 class="title">Burden of cervical cancer</h4> <p>Cervical cancer is the fourth most common cancer in women worldwide. It is estimated that in 2012, approximately 528,000 women developed cervical cancer and that 266,000 died from the disease (<a href="./references#CD009069-bbs2-0169" title="FerlayJ , SoerjomataramI , DikshitR , EserS , MathersC , RebeloM , et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer2015;136(5):E359‐96. ">Ferlay 2015</a>). Eighty‐six per cent of cervical cancer cases occur in developing countries (<a href="./references#CD009069-bbs2-0124" title="ArbynM , CastellsaguéX , deSanjoséS , BruniL , SaraiyaM , BrayF , et al. Worldwide burden of cervical cancer in 2008. Annals of Oncology2011;22:2675‐86. ">Arbyn 2011</a>). Cervical cancer is the predominant cancer in women in Eastern Africa, South‐Central Asia and Melanesia, where a woman's risk of developing this disease by age 75 years ranges between 2.3% and 3.9%. In many developed countries, the incidence of, and mortality from, squamous cervical cancer has dropped substantially over the last decades, as a consequence of population‐based screening programmes (<a href="./references#CD009069-bbs2-0122" title="ArbynM , ReboljM , deKokIM , BeckerN , O'ReillyM , AndraeB . The challenges for organising cervical screening programmes in the 15 old member states of the European Union. European Journal of Cancer2009;45(15):2671‐8. ">Arbyn 2009</a>; <a href="./references#CD009069-bbs2-0138" title="BrayF , LoosAH , McCarronP , WeiderpassE , ArbynM , MollerH . Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiology, Biomarkers and Prevention2005;14(3):677‐86. ">Bray 2005a</a>; <a href="./references#CD009069-bbs2-0169" title="FerlayJ , SoerjomataramI , DikshitR , EserS , MathersC , RebeloM , et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer2015;136(5):E359‐96. ">Ferlay 2015</a>; <a href="./references#CD009069-bbs2-0198" title="IARC Expert team cervical cancer screening, (DayN , HakamaM , ArbynM) . Cervix Cancer Screening. IARC Handbooks of Cancer Prevention. Vol. 10, Lyon: IARC Press, 2005:1‐302. ">IARC 2005</a>). However, approximately 54,000 and 11,000 cases are reported each year in Europe and the USA, respectively (<a href="./references#CD009069-bbs2-0124" title="ArbynM , CastellsaguéX , deSanjoséS , BruniL , SaraiyaM , BrayF , et al. Worldwide burden of cervical cancer in 2008. Annals of Oncology2011;22:2675‐86. ">Arbyn 2011</a>; <a href="./references#CD009069-bbs2-0168" title="FerlayJ , Steliarova‐FoucherE , Lortet‐TieulentJ , RossoS , CoeberghJW , ComberH , et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer2013;49(6):1374‐403. ">Ferlay 2013</a>), and screening with cytology is less effective at preventing cervical adenocarcinoma (<a href="./references#CD009069-bbs2-0137" title="BrayF , CarstensenB , MollerH , ZappaM , ZakeljMP , LawrenceG . Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiology, Biomarkers and Prevention2005;14(9):2191‐9. ">Bray 2005</a>; <a href="./references#CD009069-bbs2-0276" title="SmithHO , TiffanyMF , QuallsCR , KeyCR . The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States‐a 24‐year population‐based study. Gynecologic Oncology2000; Vol. 78, issue 2:97‐105. ">Smith 2000</a>). In contrast to many other malignancies, cervical cancer primarily affects younger women, with the peak age of incidence in the UK now between 25 and 29 years; between 2012 and 2014, 52% of cancers occurred in those under 45 years of age (<a href="./references#CD009069-bbs2-0144" title="Cancer Researck UK. Cervical cancer incidence statistics. http://www.cancerresearchuk.org/health‐professional/cancer‐statistics/statistics‐by‐cancer‐type/cervical‐cancer/incidenceAccessed Jan 2018. ">Cancer Research UK 2018</a>). In the UK (2010 to 2011), despite a comprehensive screening programme, 37% of women with cervical cancer died from the disease within 10 years of diagnosis (<a href="./references#CD009069-bbs2-0144" title="Cancer Researck UK. Cervical cancer incidence statistics. http://www.cancerresearchuk.org/health‐professional/cancer‐statistics/statistics‐by‐cancer‐type/cervical‐cancer/incidenceAccessed Jan 2018. ">Cancer Research UK 2018</a>). </p> <p>High‐grade cervical intraepithelial neoplasia (CIN2+) is treated by local destruction (ablation) or excision of neoplastic tissue (<a href="./references#CD009069-bbs2-0204" title="JordanJ , Martin‐HirschP , ArbynM , SchenckU , BaldaufJ‐J , DaSilvaD , et al. European guidelines for management of abnormal cervical cytology, Part 2. Cytopathology2009;20(1):5‐16. ">Jordan 2009</a>). Therapeutic procedures are similarly effective (<a href="./references#CD009069-bbs2-0232" title="Martin‐HirschPP , ParaskevaidisE , BryantA , DickinsonHO . Surgery for cervical intraepithelial neoplasia. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD001318.pub3] ">Martin‐Hirsch 2013</a>), but are associated with an average risk of residual or recurrent CIN2+ of 7% (<a href="./references#CD009069-bbs2-0128" title="ArbynM , RedmanCW , VerdoodtF , KyrgiouM , TzafetasM , Ghaem‐MaghamiS , et al. Incomplete excision of cervical pre‐cancer as predictor of treatment failure: a systematic review and meta‐analysis. Lancet Oncology2017;18(12):1665‐79. ">Arbyn 2017</a>), and an increased risk of late miscarriage and premature labour (<a href="./references#CD009069-bbs2-0220" title="KyrgiouM , AthanasiouA , KallialaIEJ , ParaskevaidiM , MitraA , Martin‐HirschPPL , et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD012847] ">Kyrgiou 2017</a>). Primary prevention of CIN lesions by prophylactic (an agent used to prevent disease) vaccination can therefore reduce the burden, costs and adverse effects associated with its treatment. </p> </section> <section id="CD009069-sec-0026"> <h4 class="title">Association between human papillomavirus (HPV) infection and cervical cancer and other HPV‐related cancers and their precursors </h4> <p>Papillomaviruses are small, icosahedral DNA viruses, that consist of one single double‐stranded circular DNA molecule of approximately 8,000 base‐pairs, contained within a protein capsid. The capsid is composed of two structural proteins, both are encoded by the viral genome: L1 and L2 (<a href="./references#CD009069-bbs2-0199" title="IARC Monograph Working Group on Carcinogenesis (Coglinano V, BaanR , StraifK , SecretanB , ElGhissasiF , Zur HausenH , et al)  . In: CoglianoV , BaanR , StraifK , GrosseY , SecretanB , ElGhissassiF editor(s). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses. Vol. 90, Lyon: IARC Press, 2007:1‐670. ">IARC 2007</a>). The natural history of HPV infection towards cervical precancer and finally invasive cancer is well documented (<a href="./references#CD009069-bbs2-0133" title="BoschFX , LorinczA , MunozN , MeijerCJ , ShahKV . The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology2002;55:244‐65. ">Bosch 2002</a>; <a href="./references#CD009069-bbs2-0145" title="CastellsaguéX , DiazM , DeSanjoseS , MunozN , HerreroR , FranceschiS . Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. Journal of the National Cancer Institute2006;98(1460‐2105 (Electronic), 5):303‐15. ">Castellsagué 2006</a>; <a href="./references#CD009069-bbs2-0199" title="IARC Monograph Working Group on Carcinogenesis (Coglinano V, BaanR , StraifK , SecretanB , ElGhissasiF , Zur HausenH , et al)  . In: CoglianoV , BaanR , StraifK , GrosseY , SecretanB , ElGhissassiF editor(s). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses. Vol. 90, Lyon: IARC Press, 2007:1‐670. ">IARC 2007</a>). The development of cervical cancer passes through a number of phases: (a) infection of the cervical epithelium with high‐risk human papillomaviruses (hrHPV); (b) persistence of the HPV infection; (c) progression to precancerous lesions with malignant transformation of infected cells; and (d) invasion of surrounding tissue. The steps prior to development of cancer, can regress spontaneously, although regression rates decrease with increasing severity of the precancerous lesion. </p> <p>Twelve hrHPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) are causally linked with the development of cervical cancer (<a href="./references#CD009069-bbs2-0136" title="BouvardV , BaanR , StraifK , GrosseY , SecretanB , ElGhissassiF . A review of human carcinogens ‐ Part B: biological agents. Lancet Oncology2009;10(4):321‐2. ">Bouvard 2009</a>). HPV68 is considered as probably carcinogenic (<a href="./references#CD009069-bbs2-0266" title="SchiffmanM , CliffordG , BuonaguroFM . Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infectious Agents and Cancer2009; Vol. 4, issue 1:1‐8. ">Schiffman 2009</a>). Some other HPV types may in rare occasions also cause cervical cancer (<a href="./references#CD009069-bbs2-0126" title="ArbynM , TommasinoM , DepuydtC , DillnerJ . Are 20 human papillomavirus types causing cervical cancer?. Journal of Pathology2014;234(4):431‐5. ">Arbyn 2014</a>). HPV type 16, in particular, has a high potential for malignant transformation of infected cervical cells (<a href="./references#CD009069-bbs2-0265" title="SchiffmanMA , HerreroR , DesalleR , HildesheimA , WacholderS , RodriguezAC , et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology2005;337(1):76‐84. ">Schiffman 2005</a>). The HPV types 16 and 18 jointly cause seven out of 10 cervical cancers worldwide (<a href="./references#CD009069-bbs2-0239" title="MunozN , BoschFX , CastellsagueX , DiazM , DeSanjoseS , HammoudaD . Against which human papillomavirus types shall we vaccinate and screen? The international perspective. International Journal of Cancer2004;111:278‐85. ">Munoz 2004</a>). The five next most important high‐risk HPV types (HPV31, HPV33, HPV45, HPV52, and HPV58) together with HPV16/18 are causally linked with approximately 90% of cervical cancers (<a href="./references#CD009069-bbs2-0156" title="deSanjoseS , QuintWG , AlemanyL , GeraetsDT , KlaustermeierJE , LloverasB , et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross‐sectional worldwide study. Lancet Oncology2010;11(11):1048‐56. ">de Sanjose 2010</a>). HPV16 is also linked with rarer types of cancer, such as cancer of the vulva and vagina in women, penile cancer in men and anal and oropharyngeal cancer in women and men (<a href="./references#CD009069-bbs2-0150" title="CoglianoV , BaanR , StraifK , GrosseY , SecretanB , ElGhissassiF . Carcinogenicity of human papillomaviruses. Lancet Oncology2005;6(1470‐2045, 4):204. ">Cogliano 2005</a>; <a href="./references#CD009069-bbs2-0199" title="IARC Monograph Working Group on Carcinogenesis (Coglinano V, BaanR , StraifK , SecretanB , ElGhissasiF , Zur HausenH , et al)  . In: CoglianoV , BaanR , StraifK , GrosseY , SecretanB , ElGhissassiF editor(s). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses. Vol. 90, Lyon: IARC Press, 2007:1‐670. ">IARC 2007</a>). </p> <p>The low‐risk HPV types 6 and 11 cause approximately 90% of genital warts in women and men (<a href="./references#CD009069-bbs2-0221" title="LaceyCJ , LowndesCM , ShahKV . Chapter 4: Burden and management of non‐cancerous HPV‐related conditions: HPV‐6/11 disease. Vaccine2006;24(0264‐410X (Print), Suppl 3):35‐41. ">Lacey 2006</a>). They occur in low‐grade dysplastic cervical lesions, but are not associated with developing cervical cancer (<a href="./references#CD009069-bbs2-0199" title="IARC Monograph Working Group on Carcinogenesis (Coglinano V, BaanR , StraifK , SecretanB , ElGhissasiF , Zur HausenH , et al)  . In: CoglianoV , BaanR , StraifK , GrosseY , SecretanB , ElGhissassiF editor(s). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses. Vol. 90, Lyon: IARC Press, 2007:1‐670. ">IARC 2007</a>). HPV types 6 and 11 cause recurrent respiratory papillomatosis, a rare but very serious disease of the upper airways often requiring repetitive surgical interventions (<a href="./references#CD009069-bbs2-0221" title="LaceyCJ , LowndesCM , ShahKV . Chapter 4: Burden and management of non‐cancerous HPV‐related conditions: HPV‐6/11 disease. Vaccine2006;24(0264‐410X (Print), Suppl 3):35‐41. ">Lacey 2006</a>). </p> <p>The main route of HPV transmission is sexual contact. Infection usually occurs soon after the onset of sexual activity (<a href="./references#CD009069-bbs2-0304" title="WinerRL , LeeSK , HughesJP , AdamDE , KiviatNB , KoutskyLA . Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Journal of Epidemiology2003;157:218‐26. ">Winer 2003</a>; <a href="./references#CD009069-bbs2-0305" title="WinerRL , FengQ , HughesJP , O'ReillyS , KiviatNB , KoutskyLA . Risk of female human papillomavirus acquisition associated with first male sex partner. Journal of Infectious Diseases2008;197(0022‐1899 (Print), 2):279‐82. ">Winer 2008</a>). The prevalence of HPV infection in women generally peaks in late teenage or early twenties (<a href="./references#CD009069-bbs2-0155" title="deSanjoseS , DiazM , CastellsaguéX , CliffordG , BruniL , MunozN . Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta‐analysis. Lancet Infectious Diseases2007;7(7):453‐9. ">de Sanjose 2007</a>). HPV infection is usually cleared by the immune system (<a href="./references#CD009069-bbs2-0195" title="HoGYF , BiermanR , BeardsleyI , ChangCJ , BurkRD . Natural history of cervicovaginal papillomavirus infection in young women. New England Journal of Medicine1998;338:423‐8. ">Ho 1998</a>). HPV infection can result in cervical precancer (cervical intraepithelial neoplasia (CIN)), which can be detected by cervical cytological screening. By microscopic inspection of a cervical smear (also known as a Papanicolaou or 'Pap' test, cervical lesions can be detected (atypical squamous cells of undetermined significance (ASC‐US), low‐grade squamous intraepithelial lesion (LSIL), high‐grade squamous intraepithelial lesion (HSIL),: atypical glandular cells (AGC); for a complete list of abbreviations used in the review, see <a href="./appendices#CD009069-sec-0129">Appendix 1</a>), which can be confirmed histologically following a cervical biopsy at colposcopic examination (<a href="./references#CD009069-bbs2-0203" title="JordanJ , ArbynM , Martin‐HirschP , SchenckU , BaldaufJ‐J , DaSilvaD , et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology2008;19(6):342‐54. ">Jordan 2008</a>). In some countries, cytological cervical cancer screening is being replaced by HPV‐based screening, because the latter is more effective at preventing future CIN3 or invasive cancer (<a href="./references#CD009069-bbs2-0125" title="ArbynM , RoncoG , AnttilaA , MeijerCJ , PoljakM , OgilvieG , et al. Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine2012;30(Suppl 5):F88‐F99. ">Arbyn 2012</a>; <a href="./references#CD009069-bbs2-0259" title="RoncoG , DillnerJ , ElfstromKM , TunesiS , SnijdersPJ , ArbynM , et al. Efficacy of HPV‐based screening for prevention of invasive cervical cancer: follow‐up of four European randomised controlled trials. Lancet2014;383(9916):524‐32. ">Ronco 2014</a>). </p> <p>A World Health Organization (WHO) expert group accepted a reduction in the incidence of high‐grade CIN (CIN2+) and cervical adenocarcinoma in situ (AIS) or worse as an acceptable surrogate outcome of HPV vaccination trials (<a href="./references#CD009069-bbs2-0250" title="PagliusiSR , Teresa AguadoM . Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine2004;23(0264‐410X, 5):569‐78. ">Pagliusi 2004</a>). This is because the reduction of the incidence of invasive cervical cancer would require large and very long‐term studies, which are unlikely to be undertaken. The progression of HPV infection to invasive cancer is thought to take a minimum of 10 years (<a href="./references#CD009069-bbs2-0199" title="IARC Monograph Working Group on Carcinogenesis (Coglinano V, BaanR , StraifK , SecretanB , ElGhissasiF , Zur HausenH , et al)  . In: CoglianoV , BaanR , StraifK , GrosseY , SecretanB , ElGhissassiF editor(s). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses. Vol. 90, Lyon: IARC Press, 2007:1‐670. ">IARC 2007</a>). Although CIN can regress, from historical data, it has been estimated that CIN3 has a probability of progressing to invasive cancer of 12% to 30%, whereas for CIN2 this probability is substantially lower (<a href="./references#CD009069-bbs2-0233" title="McCredieMR , SharplesKJ , PaulC , BaranyaiJ , MedleyG , JonesRW . Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncology2008;9(5):425‐34. ">McCredie 2008</a>; <a href="./references#CD009069-bbs2-0247" title="OstorAG . Natural history of cervical intraepithelial neoplasia: a critical review. International Journal of Gynegological Pathology1993;12(2):186‐92. ">Ostor 1993</a>). </p> <p>The recognition of the strong causal association between HPV infection and cervical cancer led to the development of molecular HPV assays to detect cervical cancer precursors (<a href="./references#CD009069-bbs2-0201" title="IftnerT , VillaLL . Chapter 12: Human papillomavirus technologies. Journal of National Cancer Institute Monographs2003;31:80‐8. ">Iftner 2003</a>), and of vaccines that prevent HPV infection (prophylactic vaccines) or that aim to treat present HPV infection or HPV‐induced lesions (therapeutic vaccines) (<a href="./references#CD009069-bbs2-0171" title="FrazerIH . Prevention of cervical cancer through papillomavirus vaccination. Nature Reviews Immunology2004;4:46‐55. ">Frazer 2004</a>; <a href="./references#CD009069-bbs2-0173" title="GallowayDA . Papillomavirus vaccines in clinical trials. Lancet2003;3:469‐75. ">Galloway 2003</a>; <a href="./references#CD009069-bbs2-0270" title="SchneiderA , GissmannL . Cervical cancer. The potential role of human papillomavirus (HPV)‐specific vaccines in prevention and treatment. American Journal of Cancer2003;2:1‐253. ">Schneider 2003</a>). Therapeutic vaccines are still in early experimental phases and are not further considered in this review. </p> <p>Throughout this review, we will use the 2001 Bethesda System to define cytologically‐defined neoplastic lesions of the cervical epithelium (<a href="./references#CD009069-bbs2-0277" title="SolomonD , DaveyD , KurmanR , MoriartyA , O'ConnorD , PreyM . The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA2002;287:2114‐9. ">Solomon 2002</a>) and the CIN nomenclature to define histologically‐confirmed CIN (<a href="./references#CD009069-bbs2-0256" title="RichartRM . Cervical intraepithelial neoplasia. Pathology Annual1973;8:301‐23. ">Richart 1973</a>). </p> </section> </section> <section id="CD009069-sec-0027"> <h3 class="title" id="CD009069-sec-0027">Description of the intervention</h3> <p>The intervention evaluated in this review is prophylactic vaccination against the most carcinogenic HPV types. Prophylactic HPV vaccines are composed of virus‐like particles (VLPs) of the L1 protein, which is the major protein of the capsid (shell) of the HPV virus. VLPs, do not contain viral DNA, and so are incapable of causing an active infection. </p> <p>This review addresses evidence of three prophylactic HPV vaccines that have been clinically evaluated in randomised controlled trials (RCTs): a monovalent HPV16 vaccine (manufactured by Merck, Sharpe &amp; Dome (Merck), Whitehouse Station, NJ, USA); a quadrivalent vaccine, containing the L1 protein of HPV6, HPV11, HPV16 and HPV18 (Gardasil®, produced by the same manufacturer as the monovalent vaccine); and a bivalent vaccine containing L1 of HPV types 16 and 18 (Cervarix®, produced by GlaxoSmithKline (GSK), Rixensart, Belgium). The vaccines produced by Merck contain amorphous aluminium hydroxyphosphate sulphate as an adjuvant, whereas the GSK vaccine contains aluminium salt and AS04 or monophosphoryl lipid A, which is an immunostimulating molecule (<a href="./references#CD009069-bbs2-0301" title="Initiative for Vaccine Research of the Department of Immunization Vaccines and Biologicals (WHO). Human Papillomavirus (HPV) Vaccine Background Paper. World Health Organization (WHO)2009:1‐249. ">WHO 2009</a>). Recently, a nona‐valent vaccine targeting nine HPV types (HPV types 6, 11, 16, 18, 31, 33, 35, 45, 52 and 58) has been developed by Merck. We did not include the nona‐valent vaccine in the current review, since the randomised trials assessing the efficacy of the nona‐valent vaccine did not incorporate an arm with a non‐HPV vaccine control, Nevertheless, data regarding the nona‐valent vaccine are included in the <a href="#CD009069-sec-0094">Discussion</a>. More details about the prophylactic HPV vaccines used are described in <a href="./appendices#CD009069-sec-0130">Appendix 2</a>. </p> </section> <section id="CD009069-sec-0028"> <h3 class="title" id="CD009069-sec-0028">How the intervention might work</h3> <p>Animal experiments have shown that neutralising antibodies, elicited by vaccination with papillomavirus VLPs, prevent type‐specific infection and subsequent development of lesions after viral challenge (<a href="./references#CD009069-bbs2-0139" title="BreitburdF , KirnbauerR , HubbertNL , NonnenmacherB , Trin‐Dinh‐DesmarquetC , OrthG . Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. Journal of Virology1995;69(6):3959‐63. ">Breitburd 1995</a>; <a href="./references#CD009069-bbs2-0180" title="GhimS , NewsomeJ , BellJ , SundbergJP , SchlegelR , JensonAB . Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Experimental and Molecular Pathology2000;68(3):147‐51. ">Ghim 2000</a>; <a href="./references#CD009069-bbs2-0279" title="StanleyMA . Human papillomavirus vaccines. Reviews in Medical Virology2006;16(1052‐9276 (Print), 3):139‐49. ">Stanley 2006</a>). Vaccination by intramuscular injection of L1 VLPs in humans has been demonstrated to be highly immunogenic in phase I trials, which means that they induce high titres of anti‐HPV antibodies in serum which are considerably higher than after natural infection. (<a href="./references#CD009069-bbs2-0031" title="AultKA , GiulianoAR , EdwardsRP , TammsG , KimLL , SmithJF . A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine2004;22(23‐24):3004‐7. ">Ault 2004</a>; <a href="./references#CD009069-bbs2-0142" title="BrownDR , BryanJT , SchroederJM , RobinsonTS , FifeKH , WheelerCM . Neutralization of human papillomavirus type 11 (HPV‐11) by serum from women vaccinated with yeast‐derived HPV‐11 L1 virus‐like particles: correlation with competitive radioimmunoassay titer. Journal of Infectious Diseases2001;184(9):1183‐6. ">Brown 2001</a>; <a href="./references#CD009069-bbs2-0048" title="EvansTG , BonnezW , RoseRC , KoenigS , DemeterL , SuzichJA . A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. Journal of Infectious Diseases2001;183(0022‐1899, 10):1485‐93. ">Evans 2001</a>; <a href="./references#CD009069-bbs2-0055" title="HarroCD , PangYY , RodenRB , HildesheimA , WangZ , ReynoldsMJ . Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus‐like particle vaccine. Journal of the National Cancer Institute2001;93(4):284‐92. ">Harro 2001</a>). Serum anti‐L1 antibodies can transudate to the mucosa (cervical or other sites) where new HPV infection is impeded through virus‐neutralisation (<a href="./references#CD009069-bbs2-0280" title="StanleyM , PintoLA , TrimbleC . Human papillomavirus vaccines ‐ immune responses. Vaccine2012;30 (Suppl 5):F83‐7. ">Stanley 2012</a>). Prophylactic HPV vaccines may also induce specific memory B‐lymphocytes which play a role in long‐term humoral immunity (<a href="./references#CD009069-bbs2-0181" title="GianniniSL , HanonE , MorisP , VanMechelenM , MorelS , DessyF , et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine2006;24:5937‐49. ">Giannini 2006</a>). Anti‐HPV antibodies do not trigger the elimination of an existing HPV infection. Cell‐mediated immunity is required for viral clearance and regression of CIN lesions (<a href="./references#CD009069-bbs2-0280" title="StanleyM , PintoLA , TrimbleC . Human papillomavirus vaccines ‐ immune responses. Vaccine2012;30 (Suppl 5):F83‐7. ">Stanley 2012</a>). </p> </section> <section id="CD009069-sec-0029"> <h3 class="title" id="CD009069-sec-0029">Why it is important to do this review</h3> <p>Several phase II and III studies have been conducted to date and numerous reviews have tried to summarise the results (<a href="./references#CD009069-bbs2-0032" title="AultKA , Future II Study Group. Effect of prophylactic human papillomavirus L1 virus‐like‐particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet2007;369(9576):1861‐8. ">Ault 2007</a>; <a href="./references#CD009069-bbs2-0121" title="ArbynM , DillnerJ . Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. Journal of Clinical Virology2007;38(3):189‐97. ">Arbyn 2007</a>; <a href="./references#CD009069-bbs2-0189" title="HarperDM . Currently approved prophylactic HPV vaccines. Expert Review of Vaccines2009;8(12):1663‐79. ">Harper 2009</a>; <a href="./references#CD009069-bbs2-0202" title="Initiative for Vaccine Research of the Department of Immunization VaB. Human Papillomavirus (HPV) Vaccine Background Paper. World Health Organization (WHO). Geneva, 2009:1‐249. ">Initiative 2009</a>; <a href="./references#CD009069-bbs2-0206" title="KahnJA . HPV vaccination for the prevention of cervical intraepithelial neoplasia. New England Journal of Medicine2009;361(3):271‐8. ">Kahn 2009</a>; <a href="./references#CD009069-bbs2-0066" title="KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM , PerezG , et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high‐grade cervical and external genital lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2(1940‐6215 (Electronic), 10):868‐78. ">Kjaer 2009</a>; <a href="./references#CD009069-bbs2-0216" title="KoutskyLA , HarperDM . Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine2006;24(Suppl 3):114‐21. ">Koutsky 2006</a>; <a href="./references#CD009069-bbs2-0076" title="LuB , KumarA , CastellsagueX , GiulianoAR . Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review &amp; meta‐analysis. BMC Infectious Disease2011;11(1):13. ">Lu 2011</a>; <a href="./references#CD009069-bbs2-0234" title="MedeirosLR , RosaDD , DaRosaMI , BozzettiMC , ZaniniRR . Efficacy of human papillomavirus vaccines: a systematic quantitative review. International Journal of Gynecological Cancer2009;19(7):1166‐76. ">Medeiros 2009</a>; <a href="./references#CD009069-bbs2-0254" title="RamboutL , HopkinsL , HuttonB , FergussonD . Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. Canadian Medical Association Journal2007;177(5):469‐79. ">Rambout 2007</a>; <a href="./references#CD009069-bbs2-0283" title="SzarewskiA . HPV vaccine: Cervarix. Expert Opinion on Biological Therapy2010;10(3):477‐87. ">Szarewski 2010</a>). However, none of the reviews combined information on all the available endpoints. Our purpose was to pool efficacy outcomes only when outcomes were similarly defined, taking the timing of follow‐up into account. This review is also important since it provides a template for reporting future results of prophylactic vaccination trials according to the different outcomes (infections or cervical precancerous lesions, either associated with infection with vaccine types or irrespective of HPV infection) for different exposure groups (defined essentially by absence of hrHPV, absence of the HPV types included in the vaccine, or regardless of HPV infection at enrolment). Particular effort was undertaken to assess severe adverse effects in order to inform health professionals, stakeholders, adolescent girls and women, not only about the potential beneficial effects of HPV vaccines but also about possible harms. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009069-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009069-sec-0030"></div> <p>To evaluate the harms and protection of prophylactic human papillomaviruses (HPV) vaccines against cervical precancer and HPV16/18 infection in adolescent girls and women. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009069-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009069-sec-0031"></div> <section id="CD009069-sec-0032"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009069-sec-0033"> <h4 class="title">Types of studies</h4> <p>We considered only phase II and phase III randomised controlled trials (RCTs).</p> </section> <section id="CD009069-sec-0034"> <h4 class="title">Types of participants</h4> <p>We included studies enrolling female participants, without any age restriction, distinguishing:</p> <p> <ol id="CD009069-list-0001"> <li> <p>female participants with no evidence of baseline infection with high‐risk human papillomaviruses (hrHPV) types (this group reflects the first target of basic vaccination programmes, i.e. girls before onset of sexual activity); </p> </li> <li> <p>female participants with no evidence of baseline infection with HPV types included in the vaccines (per protocol population); </p> </li> <li> <p>all female participants regardless of baseline infection with HPV (this group reflects the target of catch‐up vaccination programs, adolescents or young adult women aged 15 to 26 years, where a considerable proportion may already have been exposed to HPV infection). </p> </li> </ol> </p> <p>The distinction of different participant categories by HPV status at enrolment is essential, since the trial outcomes are expected to differ in women who are already infected with HPV types included in the vaccine and those who are not infected, Further distinction was made by: </p> <p> <ol id="CD009069-list-0002"> <li> <p>broad age group (adolescents and young adult women, aged 15 to 26 years) and mid‐adult women (25 to 45 years); </p> </li> <li> <p>number of received doses: three doses in agreement with the trial protocol, at least one dose, and fewer than three doses (the latter analysis being a post‐hoc assessment); </p> </li> <li> <p>type of vaccine received (mono‐, bi‐ or quadrivalent vaccine).</p> </li> </ol> </p> <p>Studies with male participants or special target groups such as immunocompromised patients were not included. However, trials enrolling both female and male participants were potentially eligible under the condition that separate outcomes for female participants were reported or could be obtained from the authors. </p> </section> <section id="CD009069-sec-0035"> <h4 class="title">Types of interventions</h4> <section id="CD009069-sec-0036"> <h5 class="title">Intervention</h5> <p>Vaccination with prophylactic HPV vaccines containing virus‐like particles composed of the L1 capsid protein of HPV16 (monovalent vaccine), HPV16 and HPV18 (bivalent vaccine), or HPV6, HPV11, HPV16 and HPV18 (quadrivalent vaccine) (see <a href="./appendices#CD009069-sec-0130">Appendix 2</a>). All vaccines were administered by intramuscular injection over a period of six months. The monovalent and quadrivalent vaccines were injected at zero, two and six months, whereas the bivalent vaccine was administered at zero, one and six months. </p> </section> <section id="CD009069-sec-0037"> <h5 class="title">Comparison</h5> <p>Administration of placebo containing no active product or only the adjuvant of the HPV vaccine, without L1 VLP, or another non‐HPV vaccine. </p> <p>In head‐to‐head trials comparing directly the bivalent with the quadrivalent vaccine, participants who received the bivalent vaccine constituted the experimental group and participants who received the quadrivalent vaccine were considered as the comparison group. </p> </section> </section> <section id="CD009069-sec-0038"> <h4 class="title">Types of outcome measures</h4> <section id="CD009069-sec-0039"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009069-list-0003"> <li> <p>Histologically‐confirmed high‐grade cervical intraepithelial neoplasia (CIN2, CIN3 and adenocarcinoma in situ (AIS)) or worse, associated with the HPV types included in the vaccine or any lesions irrespective of HPV type. Association between HPV types and a diagnosed lesion means that the particular type or types have been detected in that lesion. These primary outcomes were judged by WHO to be adequate endpoints (<a href="./references#CD009069-bbs2-0250" title="PagliusiSR , Teresa AguadoM . Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine2004;23(0264‐410X, 5):569‐78. ">Pagliusi 2004</a>). </p> </li> <li> <p>Invasive cervical cancer.</p> </li> <li> <p>Safety/occurrence of adverse effects:</p> </li> </ol> <ul class="plain" id="CD009069-list-0004"> <li> <ul class="plain" id="CD009069-list-0005"> <li> <ol id="CD009069-list-0006"> <li> <p>local adverse effects (redness, swelling, pain, itching at the injection site);</p> </li> <li> <p>mild systemic effects;</p> </li> <li> <p>serious systemic effects;</p> </li> <li> <p>mortality;</p> </li> <li> <p>pregnancy outcomes observed during the trials, in particular occurrence of congenital anomalies. </p> </li> </ol> </li> </ul> </li> </ul> </p> </section> <section id="CD009069-sec-0040"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009069-list-0007"> <li> <p>Incident infection with vaccine HPV types (HPV16 and HPV18, jointly; and HPV6, HPV11, HPV16 and HPV18 jointly). </p> </li> <li> <p>Persistent infection (persisting during at least six months or at least 12 months) with vaccine HPV types. </p> </li> </ol> </p> </section> </section> </section> <section id="CD009069-sec-0041"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for papers in all languages and translations were undertaken, if necessary.</p> <section id="CD009069-sec-0042"> <h4 class="title">Electronic searches</h4> <p>We retrieved published studies from the Cochrane Central Register of Controlled Trials (CENTRAL the Cochrane Library), MEDLINE and Embase. </p> <p>Cochrane Central Register of Controlled Trials (CENTRAL 2002 to 2017, Issue 5).<br/> MEDLINE (2002 to June Week 1 2017).<br/> Embase (2002 to 2017 week 24). </p> <p>The search strategies for MEDLINE, CENTRAL and Embase are listed in <a href="./appendices#CD009069-sec-0131">Appendix 3</a>, <a href="./appendices#CD009069-sec-0132">Appendix 4</a> and <a href="./appendices#CD009069-sec-0133">Appendix 5</a>. </p> <p>The search string for MEDLINE was saved in <i>My NCBI,</i> an electronic search tool developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine, which saves searches and automatically retrieves newer references not picked‐up at previous searches. An auto‐alert was set up in Embase. </p> <p>The 'related articles' feature in PubMed was used, departing from the original included studies; similarly, Scopus was used to retrieve articles which cite the originally included studies. </p> <p>We searched databases were searched from 2002 (the year of publication of the results of the first phase II trial) until June 2017. </p> </section> <section id="CD009069-sec-0043"> <h4 class="title">Searching other resources</h4> <section id="CD009069-sec-0044"> <h5 class="title">Registries of randomised trials</h5> <p>We searched the following registries to identify unpublished or ongoing trials: <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>, <a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a><b>,</b> and <a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a>. </p> <p>Data on adverse effects published in the peer‐reviewed literature were complemented by searches in <a href="http://wwww.clinicaltrials.gov" target="_blank">wwww.clinicaltrials.gov</a> for the quadrivalent vaccine and on <a href="http://www.gsk-clinicalstudyregister.com/" target="_blank">http://www.gsk‐clinicalstudyregister.com/</a> for the bivalent vaccine. We collected data for the outcomes of serious adverse events, all‐cause mortality and pregnancy outcomes from these sources and compared them with data extracted from the primary trial publications. </p> </section> <section id="CD009069-sec-0045"> <h5 class="title">International public health organisations</h5> <p>We contacted international public health organisations that have investigated questions on HPV vaccine efficacy and safety or that have formulated recommendations on the use of HPV vaccines, to retrieve key documents. Concerned organisations included: the World Health Organization (WHO, Geneva), the US Centers for Disease Control and Prevention (CDC, Atlanta), the European Centre for Disease Prevention and Control (ECDC, Stockholm), and the International Agency for Research on Cancer (IARC, Lyon). </p> </section> <section id="CD009069-sec-0046"> <h5 class="title">Handsearching</h5> <p>We handsearched the citation lists of included studies.</p> <p>In addition, we searched the abstracts of the latest conferences of relevant scientific societies related to vaccination, virology (in particular the International Papillomavirus Society), paediatrics, and gynaecology for new or pending information not yet published in peer‐reviewed journals. </p> </section> <section id="CD009069-sec-0047"> <h5 class="title">Correspondence</h5> <p>We contacted study authors to request results on effects separated by gender, if the reports only contained data combined for both genders. </p> </section> </section> </section> <section id="CD009069-sec-0048"> <h3 class="title" id="CD009069-sec-0048">Data collection and analysis</h3> <section id="CD009069-sec-0049"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to a bibliographic database stored in Reference Manager. We added any references obtained by handsearching and removed any duplicates. </p> <p>We (MA, CS and LX) independently verified inclusion and exclusion of eligible studies and discussed any disagreements. In case of doubt, the full‐text report was read. If no consensus could be reached, review author PMH was consulted. We documented reasons for exclusion.   </p> </section> <section id="CD009069-sec-0050"> <h4 class="title">Data extraction and management</h4> <p>For included studies, we extracted the following study characteristics and outcome data. </p> <p> <ol id="CD009069-list-0008"> <li> <p>Study identification: first author, year of publication, journal, trial number.</p> </li> <li> <p>Geographical area where the study was conducted.</p> </li> <li> <p>Period when study was conducted.</p> </li> <li> <p>Inclusion and exclusion criteria.</p> </li> <li> <p>Characteristics of included participants (total number enrolled, age, number of previous sexual partners). </p> </li> <li> <p>Initial HPV status (presence or absence of hrHPV DNA; presence or absence of DNA of the vaccine HPV types; serological status (presence of antibodies against vaccine HPV types) at enrolment). Differences in efficacy outcomes by initial HPV status will reflect protection in women or girls previously exposed, or not exposed to prior HPV infection. </p> </li> <li> <p>Study design:</p> <ol id="CD009069-list-0009"> <li> <p>phase of the randomised trial (II or III);</p> </li> <li> <p>type of vaccine evaluated (monovalent, bivalent, or quadrivalent);</p> </li> <li> <p>control group: type of placebo or other vaccine administered;</p> </li> <li> <p>time points (mean duration of follow‐up after first dose) at which outcomes were collected and reported; </p> </li> <li> <p>study size at enrolment and at subsequent time points of follow‐up;</p> </li> <li> <p>number of doses received;</p> </li> <li> <p>scheduling of screening tests (HPV tests, cytology);</p> </li> <li> <p>diagnostic algorithms used to confirm outcomes;</p> </li> <li> <p>definition of study groups on which per‐protocol and intention‐to‐treat analyses were applied; </p> </li> <li> <p>risk of bias in study design (see below: <a href="#CD009069-sec-0051">Assessment of risk of bias in included studies</a>). </p> </li> </ol> </li> <li> <p>Outcomes, subdivided by (i) the association with vaccine HPV types and (ii) irrespective of HPV types: </p> <ol id="CD009069-list-0010"> <li> <p>outcome definition (including diagnostic criteria and assays);</p> </li> <li> <p>results: number of participants allocated to each intervention group; number of missing values and absolute values required to compute effect measures (see <a href="#CD009069-sec-0038">Types of outcome measures</a>); </p> </li> <li> <p>data for the efficacy outcomes and short‐term adverse events relating to the injection procedures were collected from primary trial publications. For outcomes relating to serious adverse events, all‐cause mortality and pregnancy outcomes, data were cross‐checked between trial registries, study results websites, correspondence with investigators and the primary trial reports. The primary analysis used the data derived from the reports with the longest follow‐up time. A sensitivity analysis on serious adverse effects and mortality was restricted to data derived from reports published in peer‐reviewed journals. </p> </li> </ol> </li> <li> <p>Involvement of manufacturers.</p> </li> </ol> </p> <p>We extracted data on outcomes as follows.</p> <p> <ol id="CD009069-list-0011"> <li> <p>For dichotomous outcomes, we extracted the number of participants in each treatment arm who experienced the outcome of interest and the number of participants assessed at endpoint in order to estimate a risk ratio (RR) or risk difference (RD). Where possible, we also extracted the number of person‐years at risk in order to compute incidence rates and incidence rate ratios or differences. </p> </li> </ol> </p> <p>We (MA, CS until 2011 and LX from 2012) independently extracted data onto a data abstraction form specially designed for the review. Differences between review authors were resolved by discussion or by appeal to a third review author (PMH) if necessary. </p> </section> <section id="CD009069-sec-0051"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in included RCTs using Cochrane's 'Risk of bias' tool and the criteria specified in chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009069-bbs2-0192" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). This included assessment of: </p> <p> <ol id="CD009069-list-0012"> <li> <p>the method used for randomisation to generate the sequence of participants allocated to the treatment arms; </p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding (of participants, healthcare providers;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>reporting of incomplete outcome data for each outcome;</p> </li> <li> <p>selective reporting of outcomes.</p> </li> </ol> </p> <p>We (MA, CS and LX) independently applied the Cochrane 'Risk of bias' tool and differences were resolved by discussion or by appeal to a third review author (PMH). Results were presented in both a 'Risk of bias' graph and a 'Risk of bias' summary. We interpreted the results of meta‐analyses in the light of the findings with respect to risk of bias. </p> </section> <section id="CD009069-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>We computed risk ratios (RR) from the ratio of proportions or rates of events among vaccine recipients versus placebo recipients. In the literature, protection against HPV infection or cervical precancer is usually presented as vaccine efficacy (VE), VE = (1‐RR)*100. However, pooling of VE is not supported by the Review Manager (RevMan) software (<a href="./references#CD009069-bbs2-0255" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). Where perfect efficacy corresponds with VE = 100%, the corresponding RR = 0; VE = 0% or RR = 1 means absence of protection. Negative VE or RR exceeding unity reflect adverse protection (vaccinated participants are more at risk than non‐vaccinated participants). When the 95% confidence interval contains unity, the protective effect is statistically insignificant. The number of participants needed to vaccinate (NNV) to avoid one outcome event was computed from the risk difference (NNV = 1/RD). </p> <p>To show vaccination effects at population level, Cates plots were drawn, showing effects in 1000 vaccinated and 1000 non‐vaccinated women (<a href="./references#CD009069-bbs2-0147" title="CatesM , KarnerC . Clinical importance cannot be ruled out using mean difference alone. BMJ2015;351:h5496. ">Cates 2015</a>). </p> </section> <section id="CD009069-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors or data owners to request data on the outcomes, separated by gender, if the reports only contained data combined for both genders in trials where both women and men were enrolled. We did not impute missing outcome data. </p> </section> <section id="CD009069-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between studies by visual inspection of forest plots, by estimation of the percentage heterogeneity between trials that could not be ascribed to sampling variation (<a href="./references#CD009069-bbs2-0191" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>), by a formal statistical test of the significance of the heterogeneity (<a href="./references#CD009069-bbs2-0157" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG (eds).  Systematic Reviews in Health Care: Meta‐Analysis in Context (2nd edition). London: BMJ Publication Group, 2001. ">Deeks 2001</a>) and, if possible, by subgroup analyses. If there was evidence of substantial heterogeneity, we investigated and reported the possible reasons. </p> <p>In order to avoid heterogeneity, we did not combine data series from participants with different baseline HPV status (presence of hrHPV DNA, presence of DNA of the HPV vaccine types). Age group and sexual history were investigated as potential sources that could explain possible heterogeneity. </p> </section> <section id="CD009069-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to construct funnel plots and to perform regression tests to identify asymmetry in the meta‐analysis (<a href="./references#CD009069-bbs2-0186" title="HarbordRM , HarrisRJ , SterneJAC . Updated tests for small‐study effects in meta‐analyses. Stata Journal2009;9(2):197‐210. ">Harbord 2009</a>). However, since each meta‐analysis contained seven or fewer studies, this was not feasible. Instead, we performed meta‐regression to identify possible small‐study effects grouping studies in two categories: large (&gt; = 3000 participants) and small (&lt; 3000 participants). </p> </section> <section id="CD009069-sec-0056"> <h4 class="title">Data synthesis</h4> <p>Random‐effects models with inverse variance weighting were applied using the RevMan 5 (<a href="./references#CD009069-bbs2-0159" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">DerSimonian 1986</a>). From the pooled RR, VE was computed (VE = 1‐RR). Pooled risk differences were computed also for the 'Summary of findings' tables. </p> </section> <section id="CD009069-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed separate analyses determined by the participant's HPV status as defined by the result of an HPV DNA tests at enrolment. Three groups were distinguished: a) initially hrHPV DNA negative, b) initially HPV16/18 DNA negative, and c) regardless of initial HPV DNA test results. Subgroup meta‐analyses were performed, if possible, using vaccine type and age group as a stratifying variable. We distinguished younger (15 to 26 years) from mid‐adult women (24 to 45 years), which were the two age groups assessed in the available randomised trials. If efficacy estimates were not significantly different by vaccine type, jointly pooled estimates were retained. Only when significant heterogeneity by vaccine types was noted, were separate efficacy estimates by vaccine type pooled. We used meta‐regression to investigate sources of heterogeneity such as serological status, study design items, study size and sexual history (<a href="./references#CD009069-bbs2-0272" title="SharpS . Meta‐analysis regression. Statistics Technical Bulletin1998;7(42):148‐55. [MEDLINE: 11989] ">Sharp 1998</a>; <a href="./references#CD009069-bbs2-0289" title="ThompsonSG , SharpSJ . Explaining heterogeneity in meta‐analysis: a comparison of methods. Statistics in Medicine1999;18(20):2693‐708. [MEDLINE: 11967] ">Thompson 1999</a>). The log relative risk (vaccinated versus placebo recipients) was used as the dependent variable. The antilog of coefficients of the meta‐regression yielded relative risk ratios (RRR). 95% confidence intervals around the RRR excluding unity indicated a statistically influential factor. </p> <p>We assessed the influence of covariates, which were not defined uniformly throughout the trials, by Poisson regression in each trial concerned, separately and using person‐years at risk as an offset. </p> <p>A posteriori analysis was performed to investigate vaccine efficacy in women who had received fewer than three doses of vaccine, by subtraction of the number of events and total number of participants who had received three doses from those who had received at least one dose. This was the only possible approach, since outcomes stratified by number of doses received, were not usually reported in the published papers. </p> </section> <section id="CD009069-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We assessed the robustness of data collected for serious adverse events, all‐cause mortality and pregnancy outcomes based on the source of data. The primary analysis for these outcomes included data that we considered to represent the most complete follow‐up. As a sensitivity analysis we used data for these same outcomes that had only been reported in the published trial reports. </p> <section id="CD009069-sec-0059"> <h5 class="title">'Summary of findings' tables</h5> <p>We created 'Summary of findings' tables for three populations of interest.</p> <p> <ol id="CD009069-list-0013"> <li> <p>Adolescent girls and women who were negative for hrHPV DNA at baseline</p> </li> <li> <p>Adolescent girls and women who were negative for HPV16/18 DNA at baseline</p> </li> <li> <p>Adolescent girls and women regardless of HPV DNA status at baseline</p> </li> </ol> </p> <p>We included findings for the following outcomes for each population.</p> <p> <ol id="CD009069-list-0014"> <li> <p>Cervical cancer</p> </li> <li> <p>CIN2+ or CIN3+ associated with HPV16/18; any CIN2+ or CIN3+, irrespective of HPV types</p> </li> <li> <p>AIS associated with HPV/16/18; any AIS irrespective of HPV types</p> </li> <li> <p>All‐cause mortality (in all enrolled women)</p> </li> <li> <p>Serious adverse events (in all enrolled women)</p> </li> </ol> </p> <p>We included a fourth table summarising pregnancy outcomes as follows.</p> <p> <ol id="CD009069-list-0015"> <li> <p>Spontaneous abortion/miscarriage</p> </li> <li> <p>Elective termination/induced abortion</p> </li> <li> <p>Spontaneous miscarriage</p> </li> <li> <p>Babies born with congenital malformations</p> </li> </ol> </p> <p>Since only randomised clinical trials were included in the review, the rating for each outcome started as high‐quality evidence and was downgraded for the following considerations according to <a href="https://gdt.gradepro.org/app/handbook/handbook.html" target="_blank">GRADE guidance</a> (<a href="./references#CD009069-bbs2-0193" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011b</a>). </p> <p> <ol id="CD009069-list-0016"> <li> <p>Risk of bias</p> </li> <li> <p>Inconsistency (both quantitative and qualitative)</p> </li> <li> <p>Imprecision (relating to the width of the 95% confidence interval and number of participants in the analysis) </p> </li> <li> <p>Indirectness</p> </li> <li> <p>Publication bias</p> </li> </ol> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009069-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009069-sec-0060"></div> <section id="CD009069-sec-0061"> <h3 class="title">Description of studies</h3> <section id="CD009069-sec-0062"> <h4 class="title">Results of the search</h4> <p>The search in MEDLINE, Embase and CENTRAL, conducted after the publication of the updated protocol (<a href="./references#CD009069-bbs2-0310" title="ArbynM , BryantA , Martin‐HirschPL , XuL , SimoensC , MarkowitzL . Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD009069.pub2] ">Arbyn 2013</a>), was updated up on 15 June 2017, which resulted in 1685 records and was completed with 112 citations of previously published reviews retrieved from Scopus and reports from the personal CERVIX bibliographic database, yielding 1797 records. After eliminating 34 duplicates, 1763 references were considered from which 1617 could be excluded based on title or objectives described in the abstract. Full reading of the abstracts and materials of 146 papers allowed exclusion of 90 reports. Finally, 56 relevant references describing characteristics and results of 26 randomised trials were selected for this review (<a href="./references#CD009069-sec-0146" title="">Characteristics of included studies</a>). The retrieval and selection of studies is summarised in the PRISMA flow chart in <a href="#CD009069-fig-0001">Figure 1</a>. In addition, we included two reports of pooled analyses of included randomised controlled trials (RCTs) with original data (<a href="./references#CD009069-bbs2-0010" title="BrownDR , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus‐like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV‐naive women aged 16 to 26 years. Journal of Infectious Diseases2009;199(7):926‐35. DillnerJ , KjaerSK , WheelerCM , SigurdssonK , IversenOE , Hernandez‐AvilaM . Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ2010;341:c3493. KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM , PerezG . A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high‐grade cervical and external genital lesions. Cancer Prevention Research2009;2(10):868‐78. MunozN , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM . Impact of human papillomavirus (HPV)‐6/11/16/18 vaccine on all HPV‐associated genital diseases in young women. Journal of the National Cancer Institute2010;102(5):325‐39. OlssonSE , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. The FUTURE II study group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. Journal of Infectious Diseases2007;196(10):1438‐46. WheelerCM , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , PerezG . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus‐like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16 to 26 years. Journal of Infectious Diseases2009;199(7):936‐44. ">FUT I/II trials (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0023" title="WacholderS , ChenBE , WilcoxA , MaconesG , GonzalezP , BefanoB . Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ2010;340:c712. ">PATRICIA &amp; CVT (ph3,2v)</a>). </p> <div class="figure" id="CD009069-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram summarising the retrieval, inclusion and exclusion of relevant reports of randomised trials assessing the safety and effects of prophylactic HPV vaccines." data-id="CD009069-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram summarising the retrieval, inclusion and exclusion of relevant reports of randomised trials assessing the safety and effects of prophylactic HPV vaccines. </p> </div> </div> </div> <p>Details about the completeness of publication of HPV vaccination trials, registered in <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>, can be found in <a href="./appendices#CD009069-sec-0134">Appendix 6</a>. No additional studies could be retrieved from <a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a> or <a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a>. </p> </section> <section id="CD009069-sec-0063"> <h4 class="title">Included studies</h4> <p>Twenty‐six randomised trials were identified that contained data on vaccine efficacy and/or safety, which all together enrolled 73,428 women. One trial (<a href="./references#CD009069-bbs2-0025" title="KoutskyLA , AultKA , WheelerCM , BrownDR , BarrE , AlvarezFB . A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine2002;347(21):1645‐51. MaoC , KoutskyLA , AultKA , WheelerCM , BrownDR , WileyDJ . Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and Gynecology2006;107(1):18‐27. Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Phase2 trial (ph2,1v)</a>) evaluated effects of a monovalent HPV16 vaccine, 18 trials evaluated the bivalent vaccine (<a href="./references#CD009069-bbs2-0001" title="SowPS , Watson‐JonesD , KiviatN , ChangaluchaJ , MbayeKD , BrownJ . Safety and immunogenicity of human papillomavirus‐16/18 AS04‐adjuvanted vaccine: a randomized trial in 10‐25‐year‐old HIV‐Seronegative African girls and young women. Journal of Infectious Diseases2013;207(11):1753‐63. ">African_2 country trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0003" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Chinese trial (ph3,2v)_ adolescent</a>; <a href="./references#CD009069-bbs2-0004" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Chinese trial (ph3,2v)_mid‐adult</a>; <a href="./references#CD009069-bbs2-0005" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX , et al. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(11):2612‐22. ZhuFC , HuSY , HongY , HuYM , ZhangX , ZhangYJ , et al. Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial. Cancer Medicine2017;6(2045‐7634 (Electronic), 2045‐7634 (Linking), 1):12‐25. ">Chinese trial (ph3,2v)_young</a>; <a href="./references#CD009069-bbs2-0006" title="Garcia‐SiciliaJ , SchwarzTF , CarmonaA , PetersK , MalkinJE , TranPM . Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine coadministered with combined diphtheria‐tetanus‐acellular pertussis‐inactivated poliovirus vaccine to girls and young women. Journal of Adolescent Health2010;46(2):142‐51. ">Co‐vaccination_dTpa_IPV trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0007" title="PedersenC , BreindahlM , AggarwalN , BerglundJ , OroszlanG , SilfverdalSA . Randomized trial: immunogenicity and safety of coadministered human papillomavirus‐16/18AS04‐adjuvanted vaccine and combined hepatitis A and B vaccine in girls. Journal of Adolescent Health2012;50(1):38‐46. ">Co‐vaccination_HAB trial (Ph3, 2v)</a>; <a href="./references#CD009069-bbs2-0008" title="SchmeinkCE , BekkersRL , JosefssonA , RichardusJH , Berndtsson BlomK , et al. Co‐administration of human papillomavirus‐16/18 AS04‐adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine2011;29(49):9276‐83. ">Co‐vaccination_HepB trial (ph3, 2v)</a>; <a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0014" title="NganHY , CheungAN , TamKF , ChanKK , TangHW , BiD , et al. Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Medical Journal2010;16(1024‐2708 (Print), 1024‐2708 (Linking), 3):171‐9. ">Hong Kong trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0015" title="MedinaDM , ValenciaA , deVelasquezA , HuangLM , PrymulaR , Garcia‐SiciliaJ . Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine: a randomized, controlled trial in adolescent girls. Journal of Adolescent Health2010;46(5):414‐21. ">Immunobridging(ph3,2v)</a>; <a href="./references#CD009069-bbs2-0016" title="BhatlaN , SuriV , BasuP , ShastriS , DattaSK , BiD , et al. Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine in healthy Indian women. Journal of Obstetrics and Gynaecology Research2010;36(1):123‐32. ">Indian trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>; <a href="./references#CD009069-bbs2-0020" title="KimYJ , KimKT , KimJH , ChaSD , KimJW , BaeDS , et al. Vaccination with a human papillomavirus (HPV)‐16/18 AS04‐adjuvanted cervical cancer vaccine in Korean girls aged 10‐14 years. Journal of Korean Medical Science2010;25(8):1197‐204. ">Korean trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0021" title="KimSC , SongYS , KimYT , KimYT , RyuKS , GunapalaiahB . Human papillomavirus 16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in 15 to 25 years old healthy Korean women. Journal of Gynecologic Oncology2011;22(2):67‐75. ">Korean trial (ph3b,2v)</a>; <a href="./references#CD009069-bbs2-0022" title="LimBK , NgKY , OmarJ , OmarSZ , GunapalaiahB , TeohYL , et al. Immunogenicity and safety of the AS04‐adjuvanted human papillomavirus‐16/18 cervical cancer vaccine in Malaysian women aged 18 to 35 years: a randomized controlled trial. Medical Journal of Malaysia2014;69(0300‐5283 (Print), 0300‐5283 (Linking), 1):2‐8. ">Malaysian trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0026" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. NaudPS , Roteli‐MartinsCM , DeCarvalhoNS , TeixeiraJC , deBorbaPC , SanchezN , et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination. Human Vaccines &amp; Immunotherapeutics2014;10(8):2147‐62. The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">Phase2 trial (ph2,2v)</a>; <a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a>) and seven others the quadrivalent vaccine (<a href="./references#CD009069-bbs2-0002" title="MugoN , AnsahNA , MarinoD , SaahA , GarnerE I . Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub‐Saharan Africa. Human Vaccines &amp; Immunotherapeutics2015;11(6):1323‐30. ">African_3 country trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0011" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age. British Journal of Cancer2011;105(1):28‐37. GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">FUTURE III trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0013" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">FUTURE I trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0018" title="YoshikawaH , EbiharaK , TanakaY , NodaK . Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18 to 26 years. Cancer Science2013;104(4):465‐72. ">Japanese trial (ph2,4v)</a>; <a href="./references#CD009069-bbs2-0019" title="KangS , KimKH , KimYT , KimYT , KimJH , SongYS . Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo‐controlled trial in 176 Korean subjects. International Journal of Gynecological Cancer2008;18(5):1013‐9. ">Korean trial (ph2,4v)</a>; <a href="./references#CD009069-bbs2-0027" title="OlssonSE , KjaerSK , SigurdssonK , IversenOE . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. VillaLL , AultKA , GiulianoAR , CostaRL , PettaCA , AndradeRP . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine2006;24(27):5571‐83. VillaLL , CostaRL , PettaCA , AndradeRP , AultKA , GiulianoAR . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial. Lancet Oncology2005;6(5):271‐8. VillaLL , CostaRL , PettaCA , AndradeRP , PaavonenJ , IversenOE . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up. British Journal of Cancer2006;95(11):1459‐66. ">Phase2 trial (ph2,4v)</a>). Six studies were phase II trials and 20 others were phase III trials. No phase I trials were included. </p> <p>All trials were funded by the respective manufacturers of the vaccines, except one trial, which was financed by the National Cancer Instituite (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>). The study size varied between 98 (<a href="./references#CD009069-bbs2-0002" title="MugoN , AnsahNA , MarinoD , SaahA , GarnerE I . Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub‐Saharan Africa. Human Vaccines &amp; Immunotherapeutics2015;11(6):1323‐30. ">African_3 country trial (ph3,4v)</a>) and 18,644 (<a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>). The smaller studies (&lt;1000) essentially assessed safety and immunogenicity (not assessed in this review) or only addressed protection against infection with the HPV vaccine types, whereas the larger phase III trials assessed also protection against cervical precancer (CIN2+, CIN3+ and AIS+). A listing of the 26 studies ranked by valency of the vaccine, phase (II or III) and alphabetic order is provided in <a href="#CD009069-tbl-0005">Table 1</a>. </p> <div class="table" id="CD009069-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Listing of included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appelation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Main References</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monovalent</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0025" title="KoutskyLA , AultKA , WheelerCM , BrownDR , BarrE , AlvarezFB . A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine2002;347(21):1645‐51. MaoC , KoutskyLA , AultKA , WheelerCM , BrownDR , WileyDJ . Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and Gynecology2006;107(1):18‐27. Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Phase2 trial (ph2,1v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2392</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0215" title="KoutskyLA , AultKA , WheelerCM , BrownDR , BarrE , AlvarezFB . A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine2002;347:1645‐51. ">Koutsky 2002</a> </p> <p><a href="./references#CD009069-bbs2-0230" title="MaoC , KoutskyLA , AultKA , WheelerCM , BrownDR , WileyDJ . Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and Gynecology2006;107(1):18‐27. ">Mao 2006</a> </p> <p><a href="./references#CD009069-bbs2-0260" title="Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Rowhani‐Rahbar 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="18" valign="top"> <p>Bivalent</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>II</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1040</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0212" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. ">Konno 2010</a> </p> <p><a href="./references#CD009069-bbs2-0213" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. ">Konno 2010a</a> </p> <p><a href="./references#CD009069-bbs2-0214" title="KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Konno 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0026" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. NaudPS , Roteli‐MartinsCM , DeCarvalhoNS , TeixeiraJC , deBorbaPC , SanchezN , et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination. Human Vaccines &amp; Immunotherapeutics2014;10(8):2147‐62. The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">Phase2 trial (ph2,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0187" title="HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. ">Harper 2004</a> </p> <p><a href="./references#CD009069-bbs2-0188" title="HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. ">Harper 2006</a> </p> <p><a href="./references#CD009069-bbs2-0288" title="The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">The GSK Study Group 2009</a> </p> <p><a href="./references#CD009069-bbs2-0154" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. ">De Carvalho 2010</a> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p>III</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0001" title="SowPS , Watson‐JonesD , KiviatN , ChangaluchaJ , MbayeKD , BrownJ . Safety and immunogenicity of human papillomavirus‐16/18 AS04‐adjuvanted vaccine: a randomized trial in 10‐25‐year‐old HIV‐Seronegative African girls and young women. Journal of Infectious Diseases2013;207(11):1753‐63. ">African_2 country trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>676</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0278" title="SowPS , Watson‐JonesD , KiviatN , ChangaluchaJ , MbayeKD , BrownJ . Safety and immunogenicity of human papillomavirus‐16/18 AS04‐adjuvanted vaccine: a randomized trial in 10‐25‐year‐old HIV‐seronegative African girls and young women. Journal of Infectious Diseases2013;207(11):1753‐63. ">Sow 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0005" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX , et al. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(11):2612‐22. ZhuFC , HuSY , HongY , HuYM , ZhangX , ZhangYJ , et al. Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial. Cancer Medicine2017;6(2045‐7634 (Electronic), 2045‐7634 (Linking), 1):12‐25. ">Chinese trial (ph3,2v)_young</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6051</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0307" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX . Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(1097‐0215 (Electronic), 0020‐7136 (Linking), 11):2612‐22. ">Zhu 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0003" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Chinese trial (ph3,2v)_ adolescent</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>750</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0308" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Zhu 2014a</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0004" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Chinese trial (ph3,2v)_mid‐adult</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1212</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0308" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Zhu 2014a</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0006" title="Garcia‐SiciliaJ , SchwarzTF , CarmonaA , PetersK , MalkinJE , TranPM . Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine coadministered with combined diphtheria‐tetanus‐acellular pertussis‐inactivated poliovirus vaccine to girls and young women. Journal of Adolescent Health2010;46(2):142‐51. ">Co‐vaccination_dTpa_IPV trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>494</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0174" title="Garcia‐SiciliaJ , SchwarzTF , CarmonaA , PetersK , MalkinJE , TranPM . Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine coadministered with combined diphtheria‐tetanus‐acellular pertussis‐inactivated poliovirus vaccine to girls and young women. Journal of Adolescent Health2010;46(2):142‐51. ">Garcia‐Sicilia 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0007" title="PedersenC , BreindahlM , AggarwalN , BerglundJ , OroszlanG , SilfverdalSA . Randomized trial: immunogenicity and safety of coadministered human papillomavirus‐16/18AS04‐adjuvanted vaccine and combined hepatitis A and B vaccine in girls. Journal of Adolescent Health2012;50(1):38‐46. ">Co‐vaccination_HAB trial (Ph3, 2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>494</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0252" title="PedersenC , BreindahlM , AggarwalN , BerglundJ , OroszlanG , SilfverdalSA . Randomized trial: immunogenicity and safety of coadministered human papillomavirus‐16/18AS04‐adjuvanted vaccine and combined hepatitis A and B vaccine in girls. Journal of Adolescent Health2012;50(1):38‐46. ">Pedersen 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0008" title="SchmeinkCE , BekkersRL , JosefssonA , RichardusJH , Berndtsson BlomK , et al. Co‐administration of human papillomavirus‐16/18 AS04‐adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine2011;29(49):9276‐83. ">Co‐vaccination_HepB trial (ph3, 2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>541</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0269" title="SchmeinkCE , BekkersRL , JosefssonA , RichardusJH , Berndtsson BlomK , DavidMP , et al. Co‐administration of human papillomavirus‐16/18 AS04‐adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine2011;29(1873‐2518):9276‐83. ">Schmeink 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7466</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0190" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR . Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. ">Herrero 2011</a> </p> <p><a href="./references#CD009069-bbs2-0217" title="KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. ">Kreimer 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0014" title="NganHY , CheungAN , TamKF , ChanKK , TangHW , BiD , et al. Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Medical Journal2010;16(1024‐2708 (Print), 1024‐2708 (Linking), 3):171‐9. ">Hong Kong trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0244" title="NganHY , CheungAN , TamKF , ChanKK , TangHW , BiD , et al. Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Medical Journal2010;16(1024‐2708 (Print), 1024‐2708 (Linking), 3):171‐9. ">Ngan 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0015" title="MedinaDM , ValenciaA , deVelasquezA , HuangLM , PrymulaR , Garcia‐SiciliaJ . Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine: a randomized, controlled trial in adolescent girls. Journal of Adolescent Health2010;46(5):414‐21. ">Immunobridging(ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0235" title="MedinaDM , ValenciaA , deVelasquezA , HuangLM , PrymulaR , Garcia‐SiciliaJ . Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine: a randomized, controlled trial in adolescent girls. Journal of Adolescent Health2010;46(1879‐1972 (Electronic), 1054‐139X (Linking), 5):414‐21. ">Medina 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0016" title="BhatlaN , SuriV , BasuP , ShastriS , DattaSK , BiD , et al. Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine in healthy Indian women. Journal of Obstetrics and Gynaecology Research2010;36(1):123‐32. ">Indian trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0132" title="BhatlaN , SuriV , BasuP , ShastriS , DattaSK , BiD , et al. Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine in healthy Indian women. Journal of Obstetrics and Gynaecology Research2010;36(1):123‐32. ">Bhatla 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0020" title="KimYJ , KimKT , KimJH , ChaSD , KimJW , BaeDS , et al. Vaccination with a human papillomavirus (HPV)‐16/18 AS04‐adjuvanted cervical cancer vaccine in Korean girls aged 10‐14 years. Journal of Korean Medical Science2010;25(8):1197‐204. ">Korean trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0210" title="KimYJ , KimKT , KimJH , ChaSD , KimJW , BaeDS , et al. Vaccination with a human papillomavirus (HPV)‐16/18 AS04‐adjuvanted cervical cancer vaccine in Korean girls aged 10‐14 years. Journal of Korean Medical Science2010;25(8):1197‐204. ">Kim 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0021" title="KimSC , SongYS , KimYT , KimYT , RyuKS , GunapalaiahB . Human papillomavirus 16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in 15 to 25 years old healthy Korean women. Journal of Gynecologic Oncology2011;22(2):67‐75. ">Korean trial (ph3b,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>321</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0211" title="KimSC , SongYS , KimYT , KimYT , RyuKS , GunapalaiahB . Human papillomavirus 16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in 15‐25 years old healthy Korean women. Journal of Gynecologic Oncology2011;22(2):67‐75. ">Kim 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0022" title="LimBK , NgKY , OmarJ , OmarSZ , GunapalaiahB , TeohYL , et al. Immunogenicity and safety of the AS04‐adjuvanted human papillomavirus‐16/18 cervical cancer vaccine in Malaysian women aged 18 to 35 years: a randomized controlled trial. Medical Journal of Malaysia2014;69(0300‐5283 (Print), 0300‐5283 (Linking), 1):2‐8. ">Malaysian trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0227" title="LimBK , NgKY , OmarJ , OmarSZ , GunapalaiahB , TeohYL , et al. Immunogenicity and safety of the AS04‐adjuvanted human papillomavirus‐16/18 cervical cancer vaccine in Malaysian women aged 18‐35 years: a randomized controlled trial. Medical Journal of Malaysia2014;69(0300‐5283 (Print), 0300‐5283 (Linking), 1):2‐8. ">Lim 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,644</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0248" title="PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. ">Paavonen 2007</a> </p> <p><a href="./references#CD009069-bbs2-0249" title="PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. ">Paavonen 2009</a> </p> <p><a href="./references#CD009069-bbs2-0284" title="SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15‐25 years with and without serological evidence of previous exposure to HPV‐16/18. Internaitonal Journal of Cancer2011;131(1):106‐16. ">Szarewski 2011</a> </p> <p><a href="./references#CD009069-bbs2-0115" title="WheelerCM , HarveyBM , PichicheroME , SimonMW , CombsSP , BlatterMM . Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatric Infectious Disease Journal2011;30(12):e225‐34. ">Wheeler 2011</a> </p> <p><a href="./references#CD009069-bbs2-0224" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. ">Lehtinen 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5752</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficay, safety,</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0273" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. ">Skinner 2014</a> </p> <p><a href="./references#CD009069-bbs2-0300" title="WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16 (10):1154‐68. ">Wheeler 2016</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Quadrivalent</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>II</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0018" title="YoshikawaH , EbiharaK , TanakaY , NodaK . Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18 to 26 years. Cancer Science2013;104(4):465‐72. ">Japanese trial (ph2,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0306" title="YoshikawaH , EbiharaK , TanakaY , NodaK . Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18‐26 years. Cancer Science2013;104(4):465‐72. ">Yoshikawa 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0019" title="KangS , KimKH , KimYT , KimYT , KimJH , SongYS . Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo‐controlled trial in 176 Korean subjects. International Journal of Gynecological Cancer2008;18(5):1013‐9. ">Korean trial (ph2,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0207" title="KangS , KimKH , KimYT , KimYT , KimJH , SongYS . Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo‐controlled trial in 176 Korean subjects. International Journal of Gynecological Cancer2008;18(5):1013‐9. ">Kang 2008</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0027" title="OlssonSE , KjaerSK , SigurdssonK , IversenOE . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. VillaLL , AultKA , GiulianoAR , CostaRL , PettaCA , AndradeRP . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine2006;24(27):5571‐83. VillaLL , CostaRL , PettaCA , AndradeRP , AultKA , GiulianoAR . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial. Lancet Oncology2005;6(5):271‐8. VillaLL , CostaRL , PettaCA , AndradeRP , PaavonenJ , IversenOE . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up. British Journal of Cancer2006;95(11):1459‐66. ">Phase2 trial (ph2,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0296" title="VillaLL , CostaRL , PettaCA , AndradeRP , AultKA , GiulianoAR . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial. Lancet Oncology2005;6(5):271‐8. ">Villa 2005</a> </p> <p><a href="./references#CD009069-bbs2-0297" title="VillaLL , AultKA , GiulianoAR , CostaRL , PettaCA , AndradeRP . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine2006;24(27):5571‐83. ">Villa 2006</a> </p> <p><a href="./references#CD009069-bbs2-0298" title="VillaLL , CostaRL , PettaCA , AndradeRP , PaavonenJ , IversenOE . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up. British Journal of Cancer2006;95(11):1459‐66. ">Villa 2006a</a> </p> <p><a href="./references#CD009069-bbs2-0086" title="OlssonSE , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM , et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(1554‐8619 (Electronic), 10):696‐704. ">Olsson 2009</a> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>III</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0002" title="MugoN , AnsahNA , MarinoD , SaahA , GarnerE I . Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub‐Saharan Africa. Human Vaccines &amp; Immunotherapeutics2015;11(6):1323‐30. ">African_3 country trial (ph3,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0238" title="MugoN , AnsahNA , MarinoD , SaahA , GarnerEIO . Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub‐Saharan Africa. Human Vaccines &amp; Immunotherapeutics2015;11(6):1323‐30. ">Mugo 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0013" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">FUTURE I trial (ph3,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0175" title="GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">Garland 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0172" title="The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE‐II 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0011" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age. British Journal of Cancer2011;105(1):28‐37. GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">FUTURE III trial (ph3,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0240" title="MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">Munoz 2009</a> </p> <p><a href="./references#CD009069-bbs2-0146" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24‐45 years of age. British Journal of Cancer2011;105(1):28‐37. ">Castellsagué 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73,428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <p>Other characteristics which are not described in <a href="./references#CD009069-sec-0146" title="">Characteristics of included studies</a>, are presented in <a href="./appendices#CD009069-sec-0135">Appendix 7</a> and <a href="./appendices#CD009069-sec-0136">Appendix 8</a>. </p> </section> <section id="CD009069-sec-0064"> <h4 class="title">Excluded studies</h4> <p>A list of 90 excluded studies and reasons for exclusion can be found below (<a href="./references#CD009069-sec-0147" title="">Characteristics of excluded studies</a>). We excluded a Chinese study (<a href="./references#CD009069-bbs2-0074" title="LiR , LiY , RadleyD , LiuY , HuangT , SingsHL . Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double‐blind, placebo‐controlled trial in Chinese males and females. Vaccine2012;30(28):4284‐91. ">Li 2012</a>) and an immuno‐bridging study (<a href="./references#CD009069-bbs2-0096" title="ReisingerKS , BlockSL , Lazcano‐PonceE , SamakosesR , EsserMT , ErickJ , et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus‐like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatric Infectious Disease Journal2007;26(3):201‐9. ">Reisinger 2007</a>), which contained safety and immunogenicity data reported jointly for men and women. We sent a request to the authors for separate data for women but we did not receive a reply from the former and an answer that gender‐separated data were not available from the latter. </p> </section> </section> <section id="CD009069-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p>The assessment of the risk of possible bias present in the selected studies according to the six criteria incorporated in Cochrane's tool for assessing risk of bias in randomised trials (<a href="./references#CD009069-bbs2-0193" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011b</a>) is shown in <a href="./references#CD009069-sec-0146" title="">Characteristics of included studies</a>. </p> <p>We judged the risk of bias related to the six Cochrane criteria as low in most of the included trials (<a href="#CD009069-fig-0002">Figure 2</a>, <a href="#CD009069-fig-0003">Figure 3</a> and <a href="#CD009069-fig-0004">Figure 4</a>). We judged the generation of a random sequence as adequate in 24/26 trials ( = 92%). In two studies, the system used for randomisation was insufficiently described (unclear risk of bias) (<a href="./references#CD009069-bbs2-0018" title="YoshikawaH , EbiharaK , TanakaY , NodaK . Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18 to 26 years. Cancer Science2013;104(4):465‐72. ">Japanese trial (ph2,4v)</a>; <a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>). </p> <div class="figure" id="CD009069-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.  V1 = Random sequence generation; V2 = Allocation concealment; V3 = Blinding participants &amp; personnel; V4 = Blinding of outcome assessment; V5 = Incomplete outcomes; V6 = Selective reporting." data-id="CD009069-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.<br/> V1 = Random sequence generation; V2 = Allocation concealment; V3 = Blinding participants &amp; personnel; V4 = Blinding of outcome assessment; V5 = Incomplete outcomes; V6 = Selective reporting. </p> </div> </div> </div> <div class="figure" id="CD009069-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD009069-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009069-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD009069-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <p>The allocation of participants to the vaccine or placebo arm was clearly concealed in 16/26 (62%) trials. In three studies, randomisation was by design not concealed (<a href="./references#CD009069-bbs2-0006" title="Garcia‐SiciliaJ , SchwarzTF , CarmonaA , PetersK , MalkinJE , TranPM . Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine coadministered with combined diphtheria‐tetanus‐acellular pertussis‐inactivated poliovirus vaccine to girls and young women. Journal of Adolescent Health2010;46(2):142‐51. ">Co‐vaccination_dTpa_IPV trial (ph3,2v)</a>); <a href="./references#CD009069-bbs2-0008" title="SchmeinkCE , BekkersRL , JosefssonA , RichardusJH , Berndtsson BlomK , et al. Co‐administration of human papillomavirus‐16/18 AS04‐adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine2011;29(49):9276‐83. ">Co‐vaccination_HepB trial (ph3, 2v)</a>; <a href="./references#CD009069-bbs2-0015" title="MedinaDM , ValenciaA , deVelasquezA , HuangLM , PrymulaR , Garcia‐SiciliaJ . Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine: a randomized, controlled trial in adolescent girls. Journal of Adolescent Health2010;46(5):414‐21. ">Immunobridging(ph3,2v)</a>). These studies did not assess efficacy but compared immunogenicity and safety of HPV vaccines with other vaccines or combination of HPV vaccine and other vaccines that were visually distinguishable. Concealment of allocation was unclear in seven studies (<a href="./references#CD009069-bbs2-0002" title="MugoN , AnsahNA , MarinoD , SaahA , GarnerE I . Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub‐Saharan Africa. Human Vaccines &amp; Immunotherapeutics2015;11(6):1323‐30. ">African_3 country trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0003" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Chinese trial (ph3,2v)_ adolescent</a>; <a href="./references#CD009069-bbs2-0004" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Chinese trial (ph3,2v)_mid‐adult</a>; <a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>; <a href="./references#CD009069-bbs2-0019" title="KangS , KimKH , KimYT , KimYT , KimJH , SongYS . Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo‐controlled trial in 176 Korean subjects. International Journal of Gynecological Cancer2008;18(5):1013‐9. ">Korean trial (ph2,4v)</a>; <a href="./references#CD009069-bbs2-0027" title="OlssonSE , KjaerSK , SigurdssonK , IversenOE . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. VillaLL , AultKA , GiulianoAR , CostaRL , PettaCA , AndradeRP . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine2006;24(27):5571‐83. VillaLL , CostaRL , PettaCA , AndradeRP , AultKA , GiulianoAR . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial. Lancet Oncology2005;6(5):271‐8. VillaLL , CostaRL , PettaCA , AndradeRP , PaavonenJ , IversenOE . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up. British Journal of Cancer2006;95(11):1459‐66. ">Phase2 trial (ph2,4v)</a>;<a href="./references#CD009069-bbs2-0007" title="PedersenC , BreindahlM , AggarwalN , BerglundJ , OroszlanG , SilfverdalSA . Randomized trial: immunogenicity and safety of coadministered human papillomavirus‐16/18AS04‐adjuvanted vaccine and combined hepatitis A and B vaccine in girls. Journal of Adolescent Health2012;50(1):38‐46. ">Co‐vaccination_HAB trial (Ph3, 2v)</a> ). </p> <p>Blinding of study participants and medical personnel and blind assessment of outcomes were assured in 16 trials but were not clearly documented in nine trials (9/ 26 = 35% unclear risk). One trial assessing immunogenicity and safety of HPV vaccine only versus vaccination of HPV vaccine with other vaccines was by design unblinded (<a href="./references#CD009069-bbs2-0008" title="SchmeinkCE , BekkersRL , JosefssonA , RichardusJH , Berndtsson BlomK , et al. Co‐administration of human papillomavirus‐16/18 AS04‐adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine2011;29(49):9276‐83. ">Co‐vaccination_HepB trial (ph3, 2v)</a>). Drop out of enrolled participants, who did not follow the foreseen vaccination schedule, occurred in all trials, but the reasons for exclusion were well described in 25/26 (96%) and outcomes were presented separately for restricted per‐protocol groups and larger intention‐to‐treat groups in nearly all trials with one exception. In the <a href="./references#CD009069-bbs2-0018" title="YoshikawaH , EbiharaK , TanakaY , NodaK . Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18 to 26 years. Cancer Science2013;104(4):465‐72. ">Japanese trial (ph2,4v)</a> only per‐protocol results were presented. All intended outcomes were reported according to pre‐published registered protocols in all included trials. </p> <p>We did not judge any of the included trials assessing efficacy outcomes as having a high risk of bias. In eight of the included efficacy trials were considered to be at low risk of bias. </p> <p>Only one study (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>) was funded and conducted by an independent research institution. </p> <p>Whether involvement of industry or other quality criteria influenced study outcomes will be explored below (<a href="./full#CD009069-sec-0060">Results</a>, section 9.3). </p> </section> <section id="CD009069-sec-0066"> <h3 class="title" id="CD009069-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD009069-tbl-0001"><b>Summary of findings for the main comparison</b> HPV vaccine effects on cervical lesions in adolescent girls and women negative for hrHPV DNA at baseline</a>; <a href="./full#CD009069-tbl-0002"><b>Summary of findings 2</b> HPV vaccine effects on cervical lesions in adolescent girls and women negative for HPV16/18 DNA at baseline</a>; <a href="./full#CD009069-tbl-0003"><b>Summary of findings 3</b> HPV vaccine effects in adolescent girls and women regardless of HPV DNA status at baseline</a>; <a href="./full#CD009069-tbl-0004"><b>Summary of findings 4</b> HPV vaccine effects on pregnancy outcomes</a> </p> <p>The duration of follow‐up post vaccination in the studies was too short to show effects on cervical cancer outcomes. The presentation of the results on vaccine efficacy focuses on protection against precancerous cervical lesions and of HPV16/18 infection. They are organised according to the following features (see <a href="./full#CD009069-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009069-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD009069-tbl-0003">summary of findings Table 3</a>; <a href="#CD009069-tbl-0006">Table 2</a>): </p> <div class="table" id="CD009069-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Results of all the efficacy outcomes</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes and exposure subgroups</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Absolute risk / per 10,000</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative risk<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Vaccine </b> </p> <p><b>efficacy </b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk difference/ per 10,000 </b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of evidence<br/> (GRADE)*</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccinated</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>1. High‐grade cervical lesions in women who were hrHPV DNA negative at baseline</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0013" title="">Analysis 1.1</a> CIN2+ associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01</b> </p> <p>(0.00 to 0.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>99%</b> </p> <p>(95% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>162</b> </p> <p>(157 to 164)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,676<br/> (3 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0014" title="">Analysis 1.2</a> CIN2+ associated with HPV6/11/16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>197</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.01</b> </p> <p>(0.00 to 0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>99%</b> </p> <p>(91% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>195</b> </p> <p>(179 to 197)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9296</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0015" title="">Analysis 1.3</a> CIN3+ associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.01</b> </p> <p>(0.00 to 0.10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>99%</b> </p> <p>(90% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>70</b> </p> <p>(63 to 70)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,214</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0016" title="">Analysis 1.4</a> CIN3+ associated with HPV6/11/16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.01</b> </p> <p>(0.00 to 0.18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>99%</b> </p> <p>(82% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94</b> </p> <p>(77 to 94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9296</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0017" title="">Analysis 1.5</a> AIS associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.10</b> </p> <p>(0.01 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90%</b> </p> <p>(18% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9</b> </p> <p>(2 to 9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,214<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0018" title="">Analysis 1.6</a> AIS associated with HPV6/11/16/18m at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.14</b> </p> <p>(0.01 to 2.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>86%</b> </p> <p>(‐180% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6</b> </p> <p>(‐12 to 6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9296</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0019" title="">Analysis 1.7</a>.1 Any CIN2+ irrespective of HPV types, at least 1 dose of the bivalent vaccine, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.33</b> </p> <p>(0.25 to 0.43)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>67%</b> </p> <p>(57% to 75%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>191</b> </p> <p>(163 to 214)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,884</p> <p>(4 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0019" title="">Analysis 1.7</a>.2 Any CIN2+ irrespective of HPV types, at least 1 dose of the quadrivalent vaccine, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>291</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.57</b> </p> <p>(0.44 to 0.76)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43%</p> <p>(24 to 56%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> <p>(70 to 163)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9296</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0020" title="">Analysis 1.8</a>.1 Any CIN3+ irrespective of HPV types, at least 1 dose of the bivalent vaccine, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.08</b> </p> <p>(0.03 to 0.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>92%</b> </p> <p>(77% to 97%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>74</b> </p> <p>(62 to 78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,423</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0020" title="">Analysis 1.8</a>.2 Any CIN3+ irrespective of HPV types, at least 1 dose of the quadrivalent vaccine, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.54</b> </p> <p>(0.36 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>46%</b> </p> <p>(17% to 64%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>66</b> </p> <p>(26 to 92)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9296</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0021" title="">Analysis 1.9</a> Any AIS irrespective of HPV types, at least 1 dose </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.10</b> </p> <p>(0.01 to 0.76)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>90%</b> </p> <p>(24% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10</b> </p> <p>(2 to 10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,214<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>2. High‐grade cervical lesions in women who were HPV16/18 negative at baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0022" title="">Analysis 2.1</a>.1 CIN2+ associated with HPV16/18, 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.07</b> </p> <p>(0.03 to 0.15)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>93%</b> </p> <p>(85% to 97%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69</b> </p> <p>(63 to 72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36,579</p> <p>(6 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0022" title="">Analysis 2.1</a>.2 CIN2+ associated with HPV16/18, 3 doses, 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.16</b> </p> <p>(0.04 to 0.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>84%</b> </p> <p>(26% to 96%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>30</b> </p> <p>(9 to 34)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6797</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0023" title="">Analysis 2.2</a>.1 CIN2+ associated with HPV16/18, at least 1 dose, 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.05</b> </p> <p>(0.03 to 0.10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95%</b> </p> <p>(90% to 97%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>107</b> </p> <p>(102 to 110)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,478</p> <p>(6 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0023" title="">Analysis 2.2</a>.2 CIN2+ associated with HPV16/18, at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.30</b> </p> <p>(0.11 to 0.81)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>70%</b> </p> <p>(19% to 89%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>32</b> </p> <p>(9 to 40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7552</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0024" title="">Analysis 2.3</a>.1 CIN2+ associated with HPV16/18, 1 or 2 doses, 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>436</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.10</b> </p> <p>(0.04 to 0.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90%</b> </p> <p>(74% to 96%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>392</b> </p> <p>(323 to 418)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2958</p> <p>(5 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1$</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0024" title="">Analysis 2.3</a>.2 CIN2+ associated with HPV16/18, 1 or 2 doses, age 24‐45 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.61</b> </p> <p>(0.14 to 2.67)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39%</b> </p> <p>(‐167% to 86%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>52</b> </p> <p>(‐2245 to 115)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>755</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊝⊝⊝</b> <br/> very <b>low<sup>1$,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0025" title="">Analysis 2.4</a> CIN2+ associated with HPV6/11/16/18, 3 doses, age 15‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06</b> </p> <p>(0.01 to 0.61)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94%</b> </p> <p>(39% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>93</b> </p> <p>(39 to 98)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7664</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0025" title="">Analysis 2.4</a>.1 CIN2+ associated with HPV6/11/16/18, 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> <p>(0.00 to 0.25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98%</p> <p>(75% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> <p>(93 to 190)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4499</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0025" title="">Analysis 2.4</a>.2 CIN2+ associated with HPV6/11/16/18, 3 doses, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> <p>(0.02 to 1.39)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83%</p> <p>(‐39% to 98%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> <p>(‐1 to 32)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3165</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0026" title="">Analysis 2.5</a>.1 CIN2+ associated with HPV6/11/16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>160</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.01</b> </p> <p>(0.00 to 0.19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>99%</b> </p> <p>(81% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>160</b> </p> <p>(130 to 159)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5351</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0026" title="">Analysis 2.5</a>.2 CIN2+ associated with HPV6/11/16/18, at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.37</b> </p> <p>(0.10 to 1.41)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63%</b> </p> <p>(‐41% to 90%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>28</b> </p> <p>(‐18 to 40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3629</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0027" title="">Analysis 2.6</a> CIN2+ associated with HPV6/11/16/18, 1 or 2 doses, age 15‐45 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.24</b> </p> <p>(0.01 to 5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>76%</b> </p> <p>(‐400% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>151</b> </p> <p>(‐795 to 197)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1316</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> very <b>low<sup>1$,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0027" title="">Analysis 2.6</a>.1 CIN2+ associated with HPV6/11/16/18, 1 or 2 doses, age 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>258</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> <p>(0.00 to 0.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96%</p> <p>(26% to 100%))</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>258</p> <p>(108 to 409)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>852</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> very <b>low<sup>1$,3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0027" title="">Analysis 2.6</a>.2 CIN2+ associated with HPV6/11/16/18, 1 or 2 doses, age 24‐45 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97</p> <p>(0.14 to 6.80)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3%</p> <p>(‐580% to 86%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> <p>(‐165 to 171)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>464</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> very <b>low<sup>1$,3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0028" title="">Analysis 2.7</a> CIN3+ associated with HPV16/18, 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.07</b> </p> <p>(0.02 to 0.29)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>93%</b> </p> <p>(71% to 98%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>37</b> </p> <p>(28 to 39)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29,720</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0029" title="">Analysis 2.8</a> CIN3+ associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.05</b> </p> <p>(0.02 to 0.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95%</b> </p> <p>(86% to 98%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54</b> </p> <p>(49 to 56)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33,199</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0030" title="">Analysis 2.9</a> CIN3+ associated with HPV16/18, 1 or 2 doses, age 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06</b> </p> <p>(0.01 to 0.24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94%</b> </p> <p>(26% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>188</b> </p> <p>(152 to 198)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3479</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1$</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0031" title="">Analysis 2.10</a> AIS+ associated with HPV16/18, 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.12</b> </p> <p>(0.02 to 0.70)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>88%</b> </p> <p>(36% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8</b> </p> <p>(2 to 8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29,707</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0032" title="">Analysis 2.11</a> AIS+ associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.09</b> </p> <p>(0.01 to 0.72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>81%</b> </p> <p>(28% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12</b> </p> <p>(3 to 12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,079</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0033" title="">Analysis 2.12</a> AIS+ associated with HPV16/18 or HPV6/11/16/18, 1 or 2 doses, age 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.15</b> </p> <p>(0.01 to 2.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>85%</b> </p> <p>(‐197% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29</b> </p> <p>(‐57 to 29)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2015</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1$,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0034" title="">Analysis 2.13</a> CIN2+ irrespective of HPV types, 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.40</b> </p> <p>(0.25 to 0.64)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>60%</b> </p> <p>(36% to 75%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>99</b> </p> <p>(60 to 124)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7320</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0035" title="">Analysis 2.14</a> CIN2+ irrespective of HPV types, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.41</b> </p> <p>(0.32 to 0.52)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>58%</b> </p> <p>(46% to 67%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>136</b> </p> <p>(111 to 157)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,143</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0036" title="">Analysis 2.15</a> CIN2+ irrespective of HPV types, 1 or 2 doses, age 20‐25 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>710</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.71</b> </p> <p>(0.15 to 3.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29%</b> </p> <p>(‐238% to 85%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>290</b> </p> <p>(‐2,380 to 850)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> very <b>low<sup>1$,3,4</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>3. High‐grade cervical lesions in all women regardless of HPV DNA status at baseline**</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0037" title="">Analysis 3.1</a>.1 CIN2+ associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.46</b> </p> <p>(0.37 to 0.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>54%</b> </p> <p>(43% to 63%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>184</b> </p> <p>(147 to 215)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34,852<br/> (3 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0037" title="">Analysis 3.1</a>.2 CIN2+ associated with HPV16/18, at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>157</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74</b> </p> <p>(0.52 to 1.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>26%</b> </p> <p>(‐5% to 48%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41</b> </p> <p>(‐8 to 75)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9200</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0038" title="">Analysis 3.2</a>.1 CIN2+ associated with HPV6/11/16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>436</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.50</b> </p> <p>(0.42 to 0.59)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50%</b> </p> <p>(41% to 58%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>219</b> </p> <p>(166 to 272)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,160</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0038" title="">Analysis 3.2</a>.2 CIN2+ associated with HPV6/11/16/18, at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.78</b> </p> <p>(0.44 to 1.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22%</b> </p> <p>(‐37% to 56%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>143</b> </p> <p>(72 to 204</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3723</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0039" title="">Analysis 3.3</a> CIN3+ associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55</b> </p> <p>(0.43 to 0.68)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>74%</b> </p> <p>(55% to 91%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>74</b> </p> <p>(55 to 91)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,562<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0040" title="">Analysis 3.4</a> CIN3+ associated with HPV16/18, 1 or 2 doses, age 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>230</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.54</b> </p> <p>(0.43 to 0.68)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>46%</b> </p> <p>(32% to 57%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>106</b> </p> <p>(74 to 131)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,160</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0041" title="">Analysis 3.5</a> AIS associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.36</b> </p> <p>(0.17 to 0.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>64%</b> </p> <p>(22% to 83%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9</b> </p> <p>(3 to 12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,562<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0042" title="">Analysis 3.6</a> AIS associated with HPV6/11/16/18, at least 1 dose, age 15‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.40</b> </p> <p>(0.16 to 0.98)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>60%</b> </p> <p>(2% to 84%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9</b> </p> <p>(0 to 13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,830</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0043" title="">Analysis 3.7</a>.1 Any CIN2+ irrespective of HPV types, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>559</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.70</b> </p> <p>(0.58 to 0.85)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>30%</b> </p> <p>(15% to 42%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>168</b> </p> <p>(84 to 235)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35,779<br/> (4 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0043" title="">Analysis 3.7</a> 2 Any CIN2+ irrespective of HPV types, at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>342</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.04</b> </p> <p>(0.83 to 1.30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐4%</b> </p> <p>(‐30% to 17%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐14</b> </p> <p>(‐103 to 58)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9287</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0044" title="">Analysis 3.8</a> Any CIN3+ irrespective of HPV types, at least 1 dose, age 18‐26 years, bivalent vaccine </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.55</b> </p> <p>(0.43 to 0.71)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>45%</b> </p> <p>(29% to 57%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>84</b> </p> <p>(54 to 1107)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,329</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0044" title="">Analysis 3.8</a> Any CIN3+ irrespective of HPV types, at least 1 dose, age 15‐26 years, quadrivalent vaccine </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>349</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.81</b> </p> <p>(0.69 to 0.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19%</b> </p> <p>(4% to 31%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>66</b> </p> <p>(14 to 108)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,160</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0045" title="">Analysis 3.9</a> Any AIS irrespective of HPV types, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.32</b> </p> <p>(0.15 to 0.67)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>68%</b> </p> <p>(33% to 0.85%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11</b> </p> <p>(6 to 14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,562<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>4. HPV16/18 infection in women who were hrHPV DNA negative at baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0046" title="">Analysis 4.1</a> Incident HPV16/18 infection, 3 doses, age 18‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,457</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06</b> </p> <p>(0.02 to 0.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94%</b> </p> <p>(80% to 98%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2,310</b> </p> <p>(1,966 to 2,408)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0047" title="">Analysis 4.2</a> Persistent HPV16/18 infection(6M), 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>971</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.02</b> </p> <p>(0.00 to 0.35)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>97%</b> </p> <p>(57% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>942</b> </p> <p>(554 to 971)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0048" title="">Analysis 4.3</a> Persistent HPV16/18 infection(6M), at least 1 dose, age 18‐25 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.07</b> </p> <p>(0.05 to 0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>93%</b> </p> <p>(81% to 95%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90</b> </p> <p>(88 to 91)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,826</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0049" title="">Analysis 4.4</a> Persistent HPV16/18 infection(12M), 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>571</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.04</b> </p> <p>(0.00 to 0.73)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>96%</b> </p> <p>(27% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>549</b> </p> <p>(154 to 571)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0050" title="">Analysis 4.5</a> Persistent HPV16/18 infection(12M), at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>462</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08</b> </p> <p>(0.05 to 0.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>92%</b> </p> <p>(88% to 95%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>425</b> </p> <p>(406 to 439)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14,153</p> <p>( 2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>5. HPV16/18 infection in women who were HPV16/18 negative at baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0051" title="">Analysis 5.1</a> Incident HPV16/18 infection, 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>474</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.17</b> </p> <p>(0.10 to 0.31)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>87%</b> </p> <p>(78% to 92%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>412</b> </p> <p>(369 to 436)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8,034</p> <p>(4 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0052" title="">Analysis 5.2</a> Incident HPV16/18 infection, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,326</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>305</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.23</b> </p> <p>(0.14 to 0.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>81%</b> </p> <p>(71% to 88%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1,074</b> </p> <p>(941 to 1,167)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,872</p> <p>(5 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0053" title="">Analysis 5.3</a> Incident HPV16/18 infection, 1 or 2 dose, age 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,568</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1207</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.47</b> </p> <p>(0.26 to 0.84)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>74%</b> </p> <p>(31% to 90%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1,901</b> </p> <p>(796 to 2,311)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>331</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0054" title="">Analysis 5.4</a>.1 Persistent HPV16/18 infection (6M), 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>581</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06</b> </p> <p>(0.05 to 0.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94%</b> </p> <p>(91% to 95%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>546</b> </p> <p>(534 to 552)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27,385</p> <p>(6 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0054" title="">Analysis 5.4</a>.2 Persistent HPV16/18 infection (6M), 3 doses, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>350</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.11</b> </p> <p>(0.06 to 0.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>89%</b> </p> <p>(80% to 94%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>311</b> </p> <p>(280 to 329)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6728</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0055" title="">Analysis 5.5</a>.1 Persistent HPV16/18 infection (6M), at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>657</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.10</b> </p> <p>(0.08 to 0.13<b>)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90%</b> </p> <p>(87% to 92%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>591</b> </p> <p>(572 to 605)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22,803</p> <p>(4 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0055" title="">Analysis 5.5</a>.2 Persistent HPV16/18 infection (6M), at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>441</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.17</b> </p> <p>(0.10 to 0.29)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>83%</b> </p> <p>(71% to 90%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>366</b> </p> <p>(313 to 397)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7520</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0056" title="">Analysis 5.6</a>.1 Persistent HPV16/18 infection (6M), 1 or 2 doses, age 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>996</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.12</b> </p> <p>(0.03 to 0.42)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>88%</b> </p> <p>(58% to 97%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>876</b> </p> <p>(577 to 966)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>437</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0056" title="">Analysis 5.6</a>.2 Persistent HPV16/18 infection (6M), 1 or 2 doses, age 24‐45 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,221</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>379</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.31</b> </p> <p>(0.18 to 0.54)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69%</b> </p> <p>(46% to 82%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>843</b> </p> <p>(562 to 1002)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>792</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0057" title="">Analysis 5.7</a> Persistent HPV6/11/16/18 infection (6M), 3 doses </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>518</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.12</b> </p> <p>(0.06 to 0.21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>88%</b> </p> <p>(79% to 94%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>456</b> </p> <p>(409 to 487)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4008</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0058" title="">Analysis 5.8</a> Persistent HPV6/11/16/18 infection (6M), at least 1 dose </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>907</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.13</b> </p> <p>(0.05 to 0.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>87%</b> </p> <p>(63% to 95%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>789</b> </p> <p>(571 to 862)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4129</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0059" title="">Analysis 5.9</a> Persistent HPV16/18 infection (12M), 3 doses </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>297</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.09</b> </p> <p>(0.06 to 0.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>91%</b> </p> <p>(87% to 94%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>270</b> </p> <p>(258 to 279)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22,267</p> <p>(4 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0060" title="">Analysis 5.10</a> Persistent HPV16/18 infection (12M), at least 1 dose </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>365</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.16</b> </p> <p>(0.01 to 0.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>84%</b> </p> <p>(87% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>306</b> </p> <p>(292 to 361)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29,464</p> <p>(5 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0061" title="">Analysis 5.11</a> Persistent HPV16/18 infection (12M), 1 or 2 doses*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>205</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.13</b> </p> <p>(0.06 to 0.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87%</p> <p>(67% to 94%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>178</b> </p> <p>(137 to 193)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3912</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>6. HPV16/18 infection regardless of HPV DNA status at baseline**</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0062" title="">Analysis 6.1</a> Incident HPV16/18 infection, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>807</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>194</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.24</b> </p> <p>(0.17 to 0.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>76%</b> </p> <p>(67% to 83%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>613</b> </p> <p>(541 to 670)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4210</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0063" title="">Analysis 6.2</a>.1 Persistent HPV16/18 infection (6M), at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,359</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>598</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.44</b> </p> <p>(0.38 to 0.51)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>56%</b> </p> <p>(49% to 62%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>761</b> </p> <p>(666 to 842)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,199</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0063" title="">Analysis 6.2</a>.2 Persistent HPV16/18 infection (6M), at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>642</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>366</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.57</b> </p> <p>(0.47 to 0.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43%</b> </p> <p>(31% to 53%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>276</b> </p> <p>(199 to 341)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8648</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0064" title="">Analysis 6.3</a> Persistent HPV6/11/16/18 infection (6M), at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,136</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>591</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.52</b> </p> <p>(0.42 to 0.65)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>48%</b> </p> <p>(35% to 58%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>545</b> </p> <p>(398 to 659)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3713</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0065" title="">Analysis 6.4</a> Persistent HPV16/18 infection (12M), at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>861</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>396</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.46</b> </p> <p>(0.40 to 0.54)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54%</b> </p> <p>(46% to 60%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>465</b> </p> <p>(396 to 516)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24,785</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. *The attribution of "high quality" depends on the following conditions: well‐conducted randomised trials, with consistent findings, direct outcome, precise estimates (narrow confidence intervals), absence of reporting bias (<a href="./references#CD009069-bbs2-0185" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>). </p> <p><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>In case of study flaws as assessed by the Cochrane Collaboration's tool for assessing risk of bias in randomised trials (<a href="./references#CD009069-bbs2-0193" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011b</a>), not observed but calculated outcome; </p> <p><sup>2</sup> Substantial heterogeneity defined as I<sup>2</sup> &gt;30%, when multiple studies were available for the considered outcome; </p> <p><sup>3</sup>When only one study was retrieved for the outcome; </p> <p><sup>4</sup>Imprecision, when the width of the 95% confidence interval around RR &gt;0.60. </p> <p>0* When zero events occurred in the vaccine group a continuity correction was applied to compute the RR and its confidence interval. Nevertheless, in this case the absolute risks in the vaccine arms in <a href="#CD009069-tbl-0006">Table 2</a> were computed considering an exact binomal distribution. </p> <p>** Relative and absolute effects in women regardless of HPV DNA status at baseline (headings 3 and 6) must be interpreted with care since influenced by the prevalence of HPV infection at enrolment in the respective trials. </p> <p>*** Post hoc analysis for women who received &lt;3 doses.</p> <p>$ For the precancer endpoints (CIN2/3 and AIS),a higher risk in the placebo arms was observed if &lt;3 doses were received compared to those who received 3 doses Therefore the quality of evidence was downgraded to low or very low. </p> </div> </div> <p> <ol id="CD009069-list-0017"> <li> <p>three types of exposure groups:</p> <ol id="CD009069-list-0018"> <li> <p>women with hrHPV DNA negative status at baseline</p> </li> <li> <p>women with HPV16/18 DNA negative status at baseline</p> </li> <li> <p>all women regardless of HPV DNA status at baseline</p> </li> </ol> </li> <li> <p>two main types of outcomes:</p> <ol id="CD009069-list-0019"> <li> <p>precancerous lesions (CIN2+, CIN3+ and AIS+)</p> <ol id="CD009069-list-0020"> <li> <p>associated with HPV vaccine types (HPV16/18 or HPV6/11/16/18)</p> </li> <li> <p>irrespective of HPV type</p> </li> </ol> </li> <li> <p>infection by the HPV types included in the vaccine:</p> <ol id="CD009069-list-0021"> <li> <p>incident infection</p> </li> <li> <p>persistent infection (observed over six months or over 12 months)</p> </li> </ol> </li> </ol> </li> <li> <p>number of doses received: one, two, three, at least one, one or two ( = difference between the number of women having received at least one dose and three‐dose recipients which was the majority of enrolled women. All trials were designed as three‐dose trials; women who received fewer than three were those who did not complete the planned schedule. We could not assess risk of bias due to differences in fewer than three‐dose recipients and control groups in our analysis) </p> </li> <li> <p>age group: 15 to 26 years; 24 to 45 years</p> </li> </ol> </p> <section id="CD009069-sec-0067"> <h4 class="title">1. Protection against high‐grade cervical lesions in women negative for hrHPV DNA at baseline </h4> <p>Data on the protection against CIN2+,CIN3+ and AIS+ associated with two HPV types included in the vaccines (HPV16 or 18) in adolescent girls and women aged 15 to 26 years could be extracted from three large phase III trials (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0010" title="BrownDR , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus‐like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV‐naive women aged 16 to 26 years. Journal of Infectious Diseases2009;199(7):926‐35. DillnerJ , KjaerSK , WheelerCM , SigurdssonK , IversenOE , Hernandez‐AvilaM . Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ2010;341:c3493. KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM , PerezG . A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high‐grade cervical and external genital lesions. Cancer Prevention Research2009;2(10):868‐78. MunozN , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM . Impact of human papillomavirus (HPV)‐6/11/16/18 vaccine on all HPV‐associated genital diseases in young women. Journal of the National Cancer Institute2010;102(5):325‐39. OlssonSE , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. The FUTURE II study group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. Journal of Infectious Diseases2007;196(10):1438‐46. WheelerCM , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , PerezG . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus‐like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16 to 26 years. Journal of Infectious Diseases2009;199(7):936‐44. ">FUT I/II trials (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>) for women having received at least one dose. The risk of CIN2+, CIN3+ and AIS+ was lower following both vaccines: for CIN2+ (risk ratio (RR) = 0.01, 95% confidence interval (CI) 0.00 to 0.05; participants = 23,676; studies = 3; I<sup>2</sup> = 0%; <a href="./references#CD009069-fig-0013" title="">Analysis 1.1</a>), for CIN3+ (RR = 0.01, 95% CI 0.00 to 0.10; participants = 20,214; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD009069-fig-0015" title="">Analysis 1.3</a>), and for AIS + (RR= 0.10, 95% CI 0.01 to 0.82; participants = 20,214; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD009069-fig-0017" title="">Analysis 1.5</a>). We graded the evidence as high quality for the outcomes CIN2+ and CIN3+ and as moderate quality for AIS+ (downgraded for imprecision due to the rarity of the AIS+ outcome). The efficacy of the quadrivalent vaccine was similar when lesions associated with four vaccine types (HPV6/11/16/18) were considered (<a href="./references#CD009069-fig-0014" title="">Analysis 1.2</a>; <a href="./references#CD009069-fig-0016" title="">Analysis 1.4</a> and <a href="./references#CD009069-fig-0018" title="">Analysis 1.6</a>). </p> <p>Protection against any high‐grade cervical lesions, irrespective of HPV type, was substantially lower than for lesions caused by the HPV types included in the vaccine. The test for subgroup differences suggested that efficacy differed significantly according to valency of the vaccine (P values = 0.004 and 0.001, for CIN2+ and CIN3+, respectively). The bivalent vaccine showed higher efficacy than the quadrivalent vaccine for protection against CIN2+ (RR = 0.33, 95% CI 0.25 to 0.43; participants = 15,884; studies = 4; I<sup>2</sup> = 0%) versus RR = 0.57 (95% CI 0.44 to 0.76; participants = 9296; studies = 1) see (<a href="./references#CD009069-fig-0019" title="">Analysis 1.7</a>), and against CIN3+ (RR = 0.08, 95% CI 0.03 to 0.23; participants = 11,423; studies = 2; I<sup>2</sup> = 0%) versus RR = 0.54, (95% CI 0.36 to 0.82; participants = 9296; studies = 1; <a href="./references#CD009069-fig-0020" title="">Analysis 1.8</a>). We graded the quality of evidence regarding vaccine efficacy against any high‐grade CIN, irrespective of HPV type, as high for bivalent and moderate for the quadrivalent vaccine. Both vaccines were similarly efficacious regarding protection against any AIS, irrespective of HPV type (RR 0.10, 95% CI 0.01 to 0.76), P value for inter‐vaccine heterogeneity = 0.71, <a href="./references#CD009069-fig-0021" title="">Analysis 1.9</a>). We graded this evidence as moderate quality (downgraded for imprecision due to the rarity of the AIS+ outcome). </p> </section> <section id="CD009069-sec-0068"> <h4 class="title">2. Protection against high‐grade cervical lesions in women negative for HPV16/18 DNA at baseline </h4> <p>Outcomes for women negative for HPV16/18 are more often reported as a per protocol analysis in vaccination trials. Some trials reported outcomes for women who received all three doses and for women who received at least one dose. This allows computation (by subtraction) of outcomes for women who receive one or two doses (see also Results section 9.4). </p> <section id="CD009069-sec-0069"> <h5 class="title">2.1. CIN2+ associated with HPV types included in the vaccine</h5> <p>In adolescent girls and women aged 15 to 26 years who received three vaccine doses, protection against CIN2+ associated with HPV16/18 was consistently high with a RR pooled from six trials, including the mono‐, bi‐ and quadrivalent vaccine of 0.07, (95% CI 0.03 to 0.15 ; participants = 36,579; studies = 6; I<sup>2</sup> = 0%, <a href="./references#CD009069-fig-0022" title="">Analysis 2.1</a>.1). We judged this to be high‐quality evidence. </p> <p>Among mid‐adult women, aged 24 to 45 years, vaccination with the bivalent or quadrivalent vaccine also showed protection (RR 0.16, 95% CI 0.04 to 0.74; participants = 6797; studies = 2; I<sup>2</sup> = 0%); moderate‐quality evidence; <a href="./references#CD009069-fig-0022" title="">Analysis 2.1</a>.2). We downgraded this evidence due to the imprecision of the estimate. Protection in the mid‐adult age groups was not significantly lower than that in the younger groups (P value for inter‐group heterogeneity of 0.31, I<sup>2</sup>= 3.8%). </p> <p>In women who received at least one dose, protection was also consistently high in adolescent girls and women aged 15 to 26 years: RR pooled from six trials of 0.05 (95% CI 0.03 to 0.10; participants = 34,478; studies = 6; I<sup>2</sup> = 0%; high‐quality evidence; <a href="./references#CD009069-fig-0023" title="">Analysis 2.2</a>). In women aged 24 to 45 years, protection was lower than in the younger group (RR 0.30, 95% CI 0.11 to 0.81; participants = 7552; studies = 2; I<sup>2</sup> = 0%; moderate‐quality evidence; <a href="./references#CD009069-fig-0023" title="">Analysis 2.2</a>.2). For efficacy from at least one dose, the difference in RR between age‐groups was significant (P value = for inter‐group heterogeneity of 0.005, I<sup>2</sup>= 87.1%). </p> <p>Considering women who received just one or two doses, the risk of CIN2+ was lower after vaccination in the younger age groups (RR 0.10, 95% CI 0.04 to 0.26; participants = 2958; studies = 5; I<sup>2</sup> = 0%, low‐quality evidence). The effect in mid‐adult women was uncertain (RR 0.61, 95% CI 0.14 to 2.67; participants = 755; studies = 2; I<sup>2</sup> = 0%; low‐quality evidence) (<a href="./references#CD009069-fig-0024" title="">Analysis 2.3</a>). The quadrivalent vaccine conferred similar degrees of protection against CIN2+ associated with the four types HPV16/18/6/11 as to those associated with HPV16/18 (<a href="./references#CD009069-fig-0025" title="">Analysis 2.4</a>; <a href="./references#CD009069-fig-0026" title="">Analysis 2.5</a>; <a href="./references#CD009069-fig-0027" title="">Analysis 2.6</a>). </p> </section> <section id="CD009069-sec-0070"> <h5 class="title">2.2. CIN3+ associated with HPV types included in the vaccine</h5> <p>Efficacy of vaccination against occurrence of CIN3+ associated with HPV16/18 or HPV16/18/6/11 was reported in three large phase III trials assessing the bivalent vaccine (<a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>) or quadrivalent vaccine (<a href="./references#CD009069-bbs2-0013" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">FUTURE I trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a>). Data were pooled in one outcome, given the similarity in direction and magnitude of effects. Protection with HPV vaccination was similarly high in women who received all three doses, (RR 0.07, 95% CI 0.02 to 0.29; participants = 29,720; studies = 3; I<sup>2</sup> = 28%; high‐quality evidence; <a href="./references#CD009069-fig-0028" title="">Analysis 2.7</a>); in those who received at least one dose (RR 0.05, 95% CI 0.02 to 0.14; participants = 33,199; studies = 3; I<sup>2</sup> = 0%; high‐quality evidence; <a href="./references#CD009069-fig-0029" title="">Analysis 2.8</a>); and in women who received only one or two doses (RR 0.06, 95% CI 0.01 to 0.24; participants = 3479; studies = 3; I<sup>2</sup> = 0%; low‐quality evidence; <a href="./references#CD009069-fig-0030" title="">Analysis 2.9</a>). </p> </section> <section id="CD009069-sec-0071"> <h5 class="title">2.3. AIS+ associated with HPV types included in the vaccine</h5> <p>Data were pooled for AIS+ associated with HPV16/18 or associated with HPV16/18/6/11 in one group, given the similarity in magnitude of protection and insignificance of heterogeneity. </p> <p>In women receiving three doses of bivalent or quadrivalent vaccine, at least one dose of quadrivalent, or one or two doses of bivalent or quadrivalent vaccine, the pooled protective effect was 100% (zero excluded from the 95% CI). Applying a continuity correction gave pooled RRs of 0.12 for three doses (95% CI 0.02 to 0.70; participants = 29,707; studies = 3; I<sup>2</sup> = 0%; moderate‐quality evidence; <a href="./references#CD009069-fig-0031" title="">Analysis 2.10</a>); 0.09 for at least one dose (95% CI 0.01 to 0.72; participants = 17,079; studies = 2; I<sup>2</sup> = 0%; moderate‐quality evidence; <a href="./references#CD009069-fig-0032" title="">Analysis 2.11</a>); and 0.15 for one or two doses (95% CI 0.01 to 2.97; participants = 2015; studies = 2; I<sup>2</sup> = 0%; very low‐quality evidence; <a href="./references#CD009069-fig-0033" title="">Analysis 2.12</a>). </p> </section> <section id="CD009069-sec-0072"> <h5 class="title">2.4. Any CIN2+ irrespective of HPV type</h5> <p>Protection against CIN2+ irrespective of HPV types was reported in five trials (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>; <a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0025" title="KoutskyLA , AultKA , WheelerCM , BrownDR , BarrE , AlvarezFB . A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine2002;347(21):1645‐51. MaoC , KoutskyLA , AultKA , WheelerCM , BrownDR , WileyDJ . Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and Gynecology2006;107(1):18‐27. Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Phase2 trial (ph2,1v)</a>; <a href="./references#CD009069-bbs2-0026" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. NaudPS , Roteli‐MartinsCM , DeCarvalhoNS , TeixeiraJC , deBorbaPC , SanchezN , et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination. Human Vaccines &amp; Immunotherapeutics2014;10(8):2147‐62. The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">Phase2 trial (ph2,2v)</a>). Vaccination with three doses reduced the risk of CIN2+ by 60% on average (RR 0.40, 95% CI 0.25 to 0.64; participants = 7,320; studies = 3; I<sup>2</sup> = 0%; high‐quality evidence <a href="./references#CD009069-fig-0034" title="">Analysis 2.13</a>). Vaccination with at least one dose of the bivalent vaccine produced similar effects (RR 0.41, 95% CI 0.32 to 0.52; participants = 19,143; studies = 3; I<sup>2</sup> = 0%; <a href="./references#CD009069-fig-0035" title="">Analysis 2.14</a>). We judged this to be high‐quality evidence. Protection generated from the vaccine of one or two doses was unclear since the quality of evidence was very low (RR 0.71, 95% CI 0.15 to 3.38; participants = 34; studies = 1), as this could only be assessed for one small trial (<a href="./references#CD009069-fig-0036" title="">Analysis 2.15</a>; <a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>). </p> <p>No results were found for the outcomes any CIN3+ or AIS+ irrespective of HPV type.</p> </section> </section> <section id="CD009069-sec-0073"> <h4 class="title">3. Protection against high‐grade lesions in women regardless of baseline HPV DNA status</h4> <p>Data on the protection induced by HPV vaccination against high‐grade lesions in all enrolled women regardless of HPV DNA status at enrolment are reported only for those who received at least one dose. </p> <section id="CD009069-sec-0074"> <h5 class="title">3.1. CIN2+ associated with the vaccine HPV types</h5> <p>In adolescent girls and women aged 15 to 26, the reduction of risk of CIN2+ associated with the HPV types included in the vaccine was lower than in the hrHPV‐naive or HPV16/18 negative groups (discussed in results sections 1 and 2), but was still significant with limited variation between mono‐, bi‐ and quadrivalent vaccines (RR 0.46, 95% CI 0.37 to 0.57; participants = 34,852; studies = 3; I<sup>2</sup> = 38%; high‐quality evidence) (<a href="./references#CD009069-fig-0037" title="">Analysis 3.1</a>.1 and <a href="./references#CD009069-fig-0038" title="">Analysis 3.2</a>.1). However, in mid‐adult women (24 to 45 years), the protection of the bi‐ and quadrivalent vaccine was not significant (RR 0.74, 95% CI 0.52 to 1.05; participants = 9200; studies = 2; I<sup>2</sup> = 0%; moderate‐quality evidence) (<a href="./references#CD009069-fig-0037" title="">Analysis 3.1</a>.2). Similar findings were observed for the protection induced by the quadrivalent vaccine against CIN2+ associated with HPV16/18/6/11 (<a href="./references#CD009069-fig-0038" title="">Analysis 3.2</a>.2). </p> </section> <section id="CD009069-sec-0075"> <h5 class="title">3.2. CIN3+ associated with HPV types included in the vaccine</h5> <p>Both the bivalent and quadrivalent vaccines protected against CIN3+ associated with HPV16/18 (RR 0.55, 95% CI 0.45 to 0.67; participants = 34,562; studies = 2; I<sup>2</sup> = 0%) <a href="./references#CD009069-fig-0039" title="">Analysis 3.3</a>) with similar protection against CIN3+ associated with HPV16/18/6/11 (<a href="./references#CD009069-fig-0040" title="">Analysis 3.4</a>). </p> </section> <section id="CD009069-sec-0076"> <h5 class="title">3.3. AIS+ associated with HPV types included in the vaccine</h5> <p>Both the bi‐ and quadrivalent vaccines offered protection against AIS+ associated with HPV16/18 (RR 0.36, 95% CI 0.17 to 0.78; participants = 34,562; studies = 2; I<sup>2</sup> = 0%; moderate‐quality evidence; <a href="./references#CD009069-fig-0041" title="">Analysis 3.5</a>) and associated with HPV16/18/6/11 ((RR 0.40, 95% CI 0.16 to 0.98; participants = 20,830; studies = 2; I<sup>2</sup> = 0%; moderate‐quality evidence; <a href="./references#CD009069-fig-0042" title="">Analysis 3.6</a>). </p> </section> </section> <section id="CD009069-sec-0077"> <h4 class="title">3.4. Any CIN2+ irrespective of HPV type</h4> <p>Limited protection against CIN2+ irrespective of HPV type was shown for the mono‐, bi‐, and quadrivalent vaccines in younger women aged 15 to 26 years (RR 0.70, 95% CI 0.58 to 0.85; participants = 35,779; studies = 4; high‐quality evidence; I<sup>2</sup> = 31%, see <a href="#CD009069-fig-0005">Figure 5</a>; <a href="./references#CD009069-fig-0043" title="">Analysis 3.7</a>.1), the efficacy did not vary by the valency of the vaccine (P value for subgroup difference = 0.24). </p> <div class="figure" id="CD009069-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Protection against CIN2+ irrespective of presence of HPV types in women, aged 15‐26 years, regardless of their HPV DNA status at baseline, who received at least one dose." data-id="CD009069-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Protection against CIN2+ irrespective of presence of HPV types in women, aged 15‐26 years, regardless of their HPV DNA status at baseline, who received at least one dose. </p> </div> </div> </div> <p>In the mid‐adult group (24 to 45 years), HPV vaccination with the bi‐ or quadrivalent vaccine was not protective (RR 1.04, 95% CI 0.83 to 1.30; participants = 9287; studies = 2; I<sup>2</sup> = 8%; <a href="./references#CD009069-fig-0043" title="">Analysis 3.7</a>.2). </p> </section> <section id="CD009069-sec-0078"> <h4 class="title">3.5. Any CIN3+ irrespective of HPV type</h4> <p>The vaccines showed different results in protection against any CIN3+ irrespective of HPV type. Among young women (16 to 26 year) bivalent vaccines reduced the risk of CIN3+ (RR 0.55 (95% CI 0.43 to 0.71; participants = 18,329; studies = 2; I<sup>2</sup> = 0%), and the quadrivalent vaccine gave a smaller degree of protection (RR 0.81 (95% CI 0.69 to 0.96, participants = 17,160, studies = 1) (<a href="./references#CD009069-fig-0044" title="">Analysis 3.8</a>). The interaction test for the subgroup differences gave a P value of 0.01. </p> <p>No data were reported for mid‐adult women.</p> </section> <section id="CD009069-sec-0079"> <h4 class="title">3.6. Any AIS+ irrespective of HPV type</h4> <p>The two vaccines reduced the risk of any AIS+ irrespective of hrHPV types in young women (age 16 to 26 years) (RR 0.32, 95% CI 0.15 to 0.67; participants = 34,562; studies = 2; I<sup>2</sup> = 0%; high‐quality evidence; <a href="./references#CD009069-fig-0045" title="">Analysis 3.9</a>). </p> <p>No data were reported for mid‐adult women.</p> </section> <section id="CD009069-sec-0080"> <h4 class="title">4. Protection against infection with HPV types included in the vaccine in women negative for hrHPV DNA at baseline </h4> <p>Protection against HPV16/18 infection among women negative for hrHPV DNA at baseline, aged 15 to 26 years, was documented only for the bivalent vaccine. One phase II trial (<a href="./references#CD009069-bbs2-0026" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. NaudPS , Roteli‐MartinsCM , DeCarvalhoNS , TeixeiraJC , deBorbaPC , SanchezN , et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination. Human Vaccines &amp; Immunotherapeutics2014;10(8):2147‐62. The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">Phase2 trial (ph2,2v)</a> provided data for the outcome of incident infection ((RR 0.06, 95% CI 0.02 to 0.20; participants = 368; studies = 1) <a href="./references#CD009069-fig-0046" title="">Analysis 4.1</a>) and six‐ and 12‐month‐persisting infections among women who received three doses ((RR 0.02, 95% CI 0.00 to 0.35; participants = 368; studies = 1), <a href="./references#CD009069-fig-0047" title="">Analysis 4.2</a>); (RR 0.04, 95% CI 0.00 to 0.73; participants = 368; studies = 1; moderate‐quality evidence) (<a href="./references#CD009069-fig-0049" title="">Analysis 4.4</a>), respectively). </p> <p>One large phase III trial (<a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>) assessed protection against 6‐ and 12‐month persisting infection among women who received at least one dose (RR 0.07, 95% CI 0.05 to 0.09; participants = 10,826; studies = 1; moderate‐quality evidence; <a href="./references#CD009069-fig-0048" title="">Analysis 4.3</a>); (RR 0.08, 95% CI 0.05 to 0.12; participants = 14,153; studies = 2; I<sup>2</sup> = 0%; moderate‐quality evidence;(<a href="./references#CD009069-fig-0050" title="">Analysis 4.5</a>), respectively). </p> </section> <section id="CD009069-sec-0081"> <h4 class="title">5. Protection against HPV16/18 infection in women negative for HPV16/18 DNA at baseline</h4> <p>In women who were initially HPV16/18 DNA negative at enrolment and who received three doses, protection against incident infection with HPV16/18 was consistently high in three trials assessing different vaccines and age groups: RR = 0.17, 95% CI 0.10 to 0.31; participants = 8034; studies = 4; I<sup>2</sup> = 52%, high‐quality evidence; <a href="./references#CD009069-fig-0051" title="">Analysis 5.1</a>). HPV vaccines also reduced the risk of incident infection in those who received at least one dose (RR 0.23, 95% CI 0.14 to 0.37; participants = 23,872; studies = 5; I<sup>2</sup> = 79%; high‐quality evidence; <a href="./references#CD009069-fig-0052" title="">Analysis 5.2</a>) or just one or two doses ((RR 0.47, 95% CI 0.26 to 0.84; participants = 331; studies = 3; I<sup>2</sup> = 14%; moderate‐quality evidence; <a href="./references#CD009069-fig-0053" title="">Analysis 5.3</a>). </p> <p>The reduction in risk of persistent HPV16/18 infection (lasting for at least six months) in women who received three doses was consistently high in younger women for all types of vaccine (RR 0.06, 95% CI 0.05 to 0.08; participants = 27,385; studies = 6; I<sup>2</sup> = 0%; high‐quality evidence) and was also high in mid‐adult women aged 24 to 45 years who received three doses ((RR 0.11, 95% CI 0.06 to 0.20; participants = 6728; studies = 2; I<sup>2</sup> = 0%); high‐quality evidence; <a href="./references#CD009069-fig-0054" title="">Analysis 5.4</a>). Similar protection was seen for the larger group of women who received at least one dose of bivalent or quadrivalent vaccine (RR 0.10, 95% CI 0.08 to 0.12; participants = 22,803; studies = 4; I<sup>2</sup> = 0%; for younger women aged 15 to 26 years, and RR 0.17, 95% CI 0.10 to 0.29; participants = 7520; studies = 2; I<sup>2</sup> = 43%) or mid‐adult women; high‐quality evidence; <a href="./references#CD009069-fig-0055" title="">Analysis 5.5</a>). In young and mid‐adult women, the reduction in risk following vaccination with one or two doses was 0.12 ( 95% CI 0.03 to 0.42; participants = 437; studies = 2; I<sup>2</sup> = 0%; moderate‐quality evidence) and 0.31 (95% CI 0.18 to 0.54; participants = 792; studies = 2; I<sup>2</sup> = 0%; high‐quality evidence), respectively. We did not have sufficient data to confirm the lower degree of protection associated with one or two doses in mid‐adult compared to young women. The number of events and participants is small and the difference was not statistically significant (P value for interaction test 0.18; <a href="./references#CD009069-fig-0056" title="">Analysis 5.6</a>). </p> <p>Protection induced by the quadrivalent vaccine against six‐month persistent HPV infection with one of the four HPV types included in the vaccine was comparable with the protection against the two oncogenic types (<a href="./references#CD009069-fig-0057" title="">Analysis 5.7</a> (after reception of three doses); <a href="./references#CD009069-fig-0058" title="">Analysis 5.8</a> (after reception of at least one dose)). </p> <p>Protection against 12‐month persistent HPV16/18 infection was only reported from trials assessing the bivalent vaccine. The efficacy was high if three doses were given (RR 0.09, 95% CI 0.06 to 0.13; participants = 22,267; studies = 4; I<sup>2</sup> = 0%); high‐quality evidence; <a href="./references#CD009069-fig-0059" title="">Analysis 5.9</a>), and slightly lower with at least one dose (RR 0.16, 95% CI 0.12 to 0.20; participants = 29,464; studies = 5; I<sup>2</sup> = 0%; high‐quality evidence; <a href="./references#CD009069-fig-0060" title="">Analysis 5.10</a>), or only one or two doses ((RR 0.13, 95% CI 0.06 to 0.33; participants = 3912; studies = 3; I<sup>2</sup> = 0%) high‐quality evidence; <a href="./references#CD009069-fig-0061" title="">Analysis 5.11</a>). </p> </section> <section id="CD009069-sec-0082"> <h4 class="title">6. Protection against infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline </h4> <p>Women aged 15 to 26 years, regardless of hrHPV DNA status, who received at least one dose of the bivalent vaccine were protected against incident HPV16/18 infection (RR 0.24, 95% CI 0.17 to 0.33; participants = 4210; studies = 1; moderate‐quality evidence; <a href="./references#CD009069-fig-0062" title="">Analysis 6.1</a>). In these women, bivalent and quadrivalent vaccines also protected against persistent HPV16/18 infection lasting for six months: RR = 0.44 (95% CI 0.38 to 0.51; participants = 25,199; studies = 2; I<sup>2</sup> = 62%; high‐quality evidence). In mid‐adult women (24 to 45 years), the vaccine also provided significant protection (RR 0.57, 95% CI 0.47 to 0.69; participants = 8648; studies = 2; I<sup>2</sup> = 0%; high‐quality evidence), but the protection was significantly lower compared to the younger women (P value for inter‐group heterogeneity = 0.03; <a href="./references#CD009069-fig-0063" title="">Analysis 6.2</a>). The protection against persistent HPV16/18/6/11 infection lasting for six months was similar: RR = 0.52 (95% CI 0.42 to 0.65; participants = 3713; studies = 1) (<a href="./references#CD009069-fig-0064" title="">Analysis 6.3</a>). </p> <p>The bivalent vaccine significantly reduced the occurrence of 12‐month persistent HPV16/18 infection after administration of at least one dose: RR 0.46 (95% CI 0.40 to 0.54; participants = 24,785; studies = 2; I<sup>2</sup> = 42%; high‐quality evidence; <a href="./references#CD009069-fig-0065" title="">Analysis 6.4</a>). </p> <p>In a post hoc analysis, the Costa‐Rica Vaccination Trial (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>) demonstrated that protection was not significantly different in women who had received one (RR = 0.05, 95% CI: 0 to 0.77), two (RR = 0.16, 95% CI: 0.05 to 0.54) or three doses (RR = 0.19, 95% CI: 0.13 to 0.29) of the bivalent vaccine (P value = 0.60, I<sup>2</sup>= 0%) (<a href="./references#CD009069-fig-0066" title="">Analysis 6.5</a>), however, it should be noted that these women were not randomised to one, two or three doses. </p> </section> <section id="CD009069-sec-0083"> <h4 class="title">7. Summary of vaccine efficacy estimates</h4> <p>Before assessing the adverse effects, we summarise the main efficacy outcomes described in previous sections. In <a href="#CD009069-fig-0006">Figure 6</a>, we present the pooled effects observed in women who received at least one dose of vaccine according to HPV DNA status at enrolment, i.e. hrHPV DNA negative (column A), HPV16/18 DNA negative (column B), and all enrolled regardless of baseline HPV DNA status (column C), separated by age group (15 to 26 years, 25 to 45 years). In each age group, we distinguish high grade lesions (CIN2+, CIN3+, AIS+) associated with HPV16/18 and all lesions irrespective of HPV type and six‐month persistent HPV16/18 infection. In each cell of the table, we provide the pooled RR and its 95% CI, a shading corresponding with the degree of protection, the level of evidence, the number of trials that contributed data and the reference to the respective analysis. <a href="#CD009069-fig-0007">Figure 7</a> provides a synthesis of the same outcomes in women who were HPV16/18 negative at enrolment according the number of vaccine doses received: three doses (column A), at least one dose (column B) and one or two doses (column C). A complete list of all outcomes can be found in <a href="#CD009069-tbl-0006">Table 2</a>. This table contains the absolute risks in the placebo and vaccination arms, the relative risks (risk vaccinated/risk placebo), the vaccine efficacy (VE = RR‐1) and the risk differences (RD = risk placebo ‐risk vaccinated, in %) and the level of evidence. </p> <div class="figure" id="CD009069-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Summary of vaccine efficacy estimates, by age group, outcome and HPV DNA status at enrolment (for women who received at least one dose). [REFS BETWEEN SQUARE BRACKETS MUST BE ADAPTED][" data-id="CD009069-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary of vaccine efficacy estimates, by age group, outcome and HPV DNA status at enrolment (for women who received at least one dose). [REFS BETWEEN SQUARE BRACKETS MUST BE ADAPTED][ </p> </div> </div> </div> <div class="figure" id="CD009069-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Summary of vaccine efficacy estimates by age group, outcome and number of received doses (for women who were HPV16/18 DNA negative at enrolment). [REFS BETWEEN SQUARE BRACKETS MUST BE ADAPTED][" data-id="CD009069-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary of vaccine efficacy estimates by age group, outcome and number of received doses (for women who were HPV16/18 DNA negative at enrolment). [REFS BETWEEN SQUARE BRACKETS MUST BE ADAPTED][ </p> </div> </div> </div> <p>From a public health point of view, the two most relevant groups are: 1) hrHPV negative participants who reflect the naive unexposed group and 2) all vaccinated participants regardless of initial HPV DNA status. </p> <p>In young women (15 to 26 years) who were hrHPV DNA negative and who received at least one dose of vaccine, the risk of CIN2+ associated with HPV16/18 was reduced on average from 164 to 2 per 10,000 women, a reduction or risk difference (RD) of 162 per 10,000 women vaccinated (Cates plot in <a href="#CD009069-fig-0008">Figure 8</a>). The reduction in any CIN2+ irrespective of HPV type was from 287 to 106 per 10,000 women (RD 181 per 10,000 women vaccinated, see (<a href="#CD009069-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD009069-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Modified Cates plot: Number of cases of CIN2+ associated with HPV16/18 occurring in women who were all hrHPV DNA negative at baseline. 16 out of 1000 non‐vaccinated women developed the lesion (left) whereas fewer than one (0.2) out 1000 vaccinated women developed the lesion (right). Relative risk= 0.01 (95% CI: 0.01 to 0.05)." data-id="CD009069-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Modified Cates plot: Number of cases of CIN2+ associated with HPV16/18 occurring in women who were all hrHPV DNA negative at baseline. 16 out of 1000 non‐vaccinated women developed the lesion (left) whereas fewer than one (0.2) out 1000 vaccinated women developed the lesion (right). Relative risk= 0.01 (95% CI: 0.01 to 0.05). </p> </div> </div> </div> <div class="figure" id="CD009069-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Modified Cates plot: Number of cases of CIN2+ irrespective of HPV types occurring in women who were all hrHPV DNA negative at baseline. 28 out of 1000 non‐vaccinated women developed the lesion (left) whereas 11 out 1000 vaccinated women developed the lesion (right). Relative risk= 0.37 (95% CI: 0.25 to 0.55)." data-id="CD009069-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Modified Cates plot: Number of cases of CIN2+ irrespective of HPV types occurring in women who were all hrHPV DNA negative at baseline. 28 out of 1000 non‐vaccinated women developed the lesion (left) whereas 11 out 1000 vaccinated women developed the lesion (right). Relative risk= 0.37 (95% CI: 0.25 to 0.55). </p> </div> </div> </div> <p>Among vaccinated women regardless of initial HPV DNA status, the risk reduction was from 341 to 157 per 10,000 women (RD 184 per 10,000 women vaccinated) and from 559 to 391 per 10,000 women (RD 168 per 10,000 women vaccinated), for CIN2+ associated with HPV16/18 or irrespective of HPV type, respectively (<a href="./full#CD009069-tbl-0003">summary of findings Table 3</a>). </p> <p>The number needed to vaccinate was computed from the risk differences (NNV = 1/RD) (see <a href="#CD009069-tbl-0007">Table 3</a>). The number of women to be vaccinated to prevent one case of CIN2+, CIN3+ or AIS, associated with HPV16/18, in young women of age 15 to 26 years who were hrHPV negative at enrolment and who had received at least one dose of vaccine, was estimated to be 62, 204 and 1111, respectively. Although vaccine efficacy was lower in all participants regardless of initial HPV status, the NNVs were similar or slightly lower. Also, for lesions irrespective of HPV type, the NNVs were lower or similar. It must be noted that in populations where considerable exposure to HPV infection occurred prior to vaccination, the absolute risk of lesions in the vaccinated group is likely to be considerable. </p> <div class="table" id="CD009069-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number needed to vaccinate (NNV) to prevent one outcome event (in young women aged 15‐26 years)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Initial HPV status at enrolment</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>hrHPV negative</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Regardless of HPV status</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lesions associated with HPV16/18</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNV (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNV (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN2+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (61 to 64)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54 (46 to 68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN3+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204 (149 to 333)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135 (110 to 263)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AIS+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1111 (714 to 5000)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1111 (625 to 3333)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lesions irrespective of HPV types</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNV (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNV (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN2+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (50 to 76)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68 (52 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN3+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 (106 to 208)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133 (94 to 227)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AIS+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 (556 to 10,000)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>833 (526 to 2000)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>AIS:</b> adenocarcinoma in situ, <b>CIN:</b> cervical intraepithelial neoplasia, <b>CIN2+:</b> CIN of degree II or worse, <b>CIN3+:</b> CIN of degree 3 or worse, <b>hrHPV:</b> high‐risk human papillomavirus types, <b>NNV:</b> number needed to vaccinate. </p> </div> </div> </section> <section id="CD009069-sec-0084"> <h4 class="title">8. Adverse effects</h4> <p>Safety issues are summarised in <a href="#CD009069-tbl-0008">Table 4</a>. All the vaccines were consistently associated with short‐term local adverse effects (RR 1.18, 95% CI 1.16 to 1.20; participants = 18,113; studies = 8; I<sup>2</sup> = 93%; moderate‐quality evidence; <a href="./references#CD009069-fig-0067" title="">Analysis 7.1</a>), such as pain at the injection site (RR 1.35, 95% CI 1.23 to 1.49; participants = 25,691; studies = 13; I<sup>2</sup> = 98%; moderate‐quality evidence; <a href="./references#CD009069-fig-0068" title="">Analysis 7.2</a>), local swelling (RR 1.73, 95% CI 1.32 to 2.27; participants = 22,106; studies = 9; I<sup>2</sup> = 95%; moderate‐quality evidence; <a href="./references#CD009069-fig-0069" title="">Analysis 7.3</a>) and redness (RR 1.72, 95% CI 1.50 to 1.97; participants = 19,996; studies = 6; I<sup>2</sup> = 82%; moderate‐quality evidence; <a href="./references#CD009069-fig-0070" title="">Analysis 7.4</a>). </p> <div class="table" id="CD009069-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Results of all the safety outcomes (adverse events, pregnancy outcomes)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Absolute risk/ per 10,000</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>vaccinated</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0067" title="">Analysis 7.1</a><b>Overall local/injection site adverse events</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6847</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8080</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.18</b> </p> <p>(1.16 to 1.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,113<br/> (8 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0068" title="">Analysis 7.2</a><b>Pain at injection site</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6505</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8782</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.35</b> </p> <p>(1.23 to 1.49)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,691<br/> (13 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0069" title="">Analysis 7.3</a><b>Swelling at injection site</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1582</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2737</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.73</b> </p> <p>(1.32 to 2.27)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22,106<br/> (9 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0070" title="">Analysis 7.4</a><b>Redness at injection site</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1938</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3333</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.72</b> </p> <p>(1.50 to 1.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,996<br/> (6 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0071" title="">Analysis 7.5</a><b>Overall systematic event and general symptoms</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6102</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6224</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.02</b> </p> <p>(0.98 to 1.07)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,191<br/> (8 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0072" title="">Analysis 7.6</a><b>Serious adverse events</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>605</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>611</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.01</b> </p> <p>(0.95 to 1.07)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6978<br/> (21studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0073" title="">Analysis 7.7</a><b>Deaths</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.25</b> </p> <p>(0.81 to 1.93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71,452</p> <p>(23 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊝⊝</b> <br/> <b>low</b><sup>2,4,†</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0074" title="">Analysis 8.1</a><b>Normal infant</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7171</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7171</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.00</b> </p> <p>(0.97 to 1.02)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8782<br/> (8 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0075" title="">Analysis 8.2</a><b>Spontaneous abortion/miscarriage</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1618</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1424</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.88</b> </p> <p>(0.68 to 1.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8618<br/> (9 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0076" title="">Analysis 8.3</a><b>Elective termination/induced abortion</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>931</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>838</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.90</b> </p> <p>(0.80 to 1.02)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.909<br/> (9 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0077" title="">Analysis 8.4</a><b>Stillbirth</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.12</b> </p> <p>(0.68 to 1.83)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8754<br/> (6 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>4</sup><br/> <b>moderate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0078" title="">Analysis 8.5</a><b>Abnormal infant</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>205</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.22</b> </p> <p>(0.88 to 1.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9252<br/> (5 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<sup>4</sup><br/> <b>moderate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. *The attribution of "high quality" depends on the following conditions: well‐conducted randomized trials, with consistent findings, direct outcome, precise estimates (narrow confidence intervals), absence of reporting bias (<a href="./references#CD009069-bbs2-0185" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>). </p> <p><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>In case of study flaws as assessed by Cochrane's tool for assessing risk of bias in randomised trials (<a href="./references#CD009069-bbs2-0193" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011b</a>), not observed but calculated outcome </p> <p><sup>2</sup> Substantial heterogeneity defined as I<sup>2</sup> &gt; 30%, when multiple studies were available for the considered outcome </p> <p><sup>3</sup>When only one study was retrieved for the outcome </p> <p><sup>4</sup>Imprecision, when the width of the 95% confidence interval around RR &gt; 0.60 </p> <p>† inter‐age group heterogeneity, absence of pattern in causes of deaths</p> </div> </div> <p>Systemic events with general mild symptoms were similarly frequent in vaccinated recipients and placebo or control vaccine recipients (RR 1.02, 95% CI 0.98 to 1.07; participants = 18,191; studies = 8; I<sup>2</sup> = 72%; moderate‐quality evidence; <a href="./references#CD009069-fig-0071" title="">Analysis 7.5</a>). The risk of serious adverse effects was similar in those vaccinated and those who received placebo or control vaccine (RR 0.98, 95% CI 0.92 to 1.05; participants = 71,597; studies = 23; I<sup>2</sup> = 6%)) high‐quality evidence). There was little or no difference between the different vaccines (P = 0.19; I<sup>2</sup> = 39.7%, <a href="./references#CD009069-fig-0072" title="">Analysis 7.6</a>). Restriction to data extracted only from publications in peer‐reviewed journals yielded very similar results: RR 1.01, 95% CI 0.95 to 1.06; 71,452 participants; studies = 22, I<sup>2</sup> = 0%, <a href="#CD009069-fig-0010">Figure 10</a>), with very minor differences between the vaccine types (P = 0.83, I<sup>2</sup> = 0%). </p> <div class="figure" id="CD009069-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Sensitivity analysis of Analysis 7.6 on severe adverse effects restricting to data extracted from publications in peer‐reviewed journals." data-id="CD009069-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sensitivity analysis of <a href="./references#CD009069-fig-0072" title="">Analysis 7.6</a> on severe adverse effects restricting to data extracted from publications in peer‐reviewed journals. </p> </div> </div> </div> <p>Mortality during the study follow‐up period in HPV vaccine recipients and control or placebo groups was reported in 23 trials (<a href="./references#CD009069-fig-0073" title="">Analysis 7.7</a>). We could not exclude an increased risk of mortality among vaccinated women (RR 1.29, 95% CI 0.85 to 1.98; participants = 71,176; studies = 23; I<sup>2</sup> = 0%). In absolute terms the rate of deaths in the control groups was 11 per 10,000 whereas in HPV vaccinated women the rate observed was between 9 and 22 women per 10,000. The difference between the bi‐ and quadrivalent vaccine was not significant (P = 0.62, I<sup>2</sup> = 0%). Again, results were very similar when data extraction was restricted to peer‐reviewed published reports (RR 1.31, 95% CI 0.84 to 2.05; participants = 71,452; studies = 23; I<sup>2</sup> = 0%, <a href="#CD009069-fig-0011">Figure 11</a>). We downgraded the quality of evidence for mortality to low. This was due to imprecision from the wide confidence interval and inconsistency due to a statistically different risk between the two age cohorts, with a higher risk of mortality in older women (<a href="./full#CD009069-tbl-0004">summary of findings Table 4</a>). </p> <div class="figure" id="CD009069-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Sensitivity analysis of Analysis 7.7 on deaths restricting to data extracted from publications in peer‐reviewed journals." data-id="CD009069-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sensitivity analysis of <a href="./references#CD009069-fig-0073" title="">Analysis 7.7</a> on deaths restricting to data extracted from publications in peer‐reviewed journals. </p> </div> </div> </div> <p>The higher number of deaths from both vaccination arms in the trials enrolling women older than 25 years may be expected due to the longer periods of follow‐up. In the <a href="./references#CD009069-bbs2-0011" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age. British Journal of Cancer2011;105(1):28‐37. GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">FUTURE III trial (ph3,4v)</a>, eight deaths were observed within a period of 10 years of follow‐up among women who received the quadrivalent vaccine versus four among women who received the placebo (RR 2.00, 95% CI 0.60 to 6.62, p<sub>exact</sub>= 0.25) (<a href="https://clinicaltrials.gov/ct2/show/results/NCT00090220?sect=X30156#evnt" target="_blank">https://clinicaltrials.gov/ct2/show/results/NCT00090220?sect=X30156#evnt</a>). In the <a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a>, 13 women died among women who received the bivalent vaccine compared with five among women in the placebo arm within six years of follow‐up (RR 2.59, 95% CI 0.93 to 7.27, p<sub>exact</sub> = 0.09) (<a href="./references#CD009069-bbs2-0300" title="WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16 (10):1154‐68. ">Wheeler 2016</a>). In the smaller Chinese trial, where 606 mid‐adult women were vaccinated with the bivalent vaccine, during 12 months of follow‐up, one women died in the vaccine group whereas no deaths occurred in the control arm (<a href="./references#CD009069-bbs2-0004" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Chinese trial (ph3,2v)_mid‐adult</a>; <a href="./references#CD009069-bbs2-0308" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Zhu 2014a</a>). When all the deaths among mid‐adult women enrolled in the three trials are pooled, a higher case fatality rate was observed among those who received HPV vaccine compared to those who received placebo: (RR 2.36, 95% CI 1.10 to 5.03; participants = 10,737; studies = 3; I<sup>2</sup> = 0%), with no differences between different HPV vaccines (P = 0.73). </p> <p>An overview of the causes of deaths observed after administration of HPV vaccine or control in the <a href="./references#CD009069-bbs2-0011" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age. British Journal of Cancer2011;105(1):28‐37. GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">FUTURE III trial (ph3,4v)</a> and <a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a> is shown in <a href="#CD009069-tbl-0009">Table 5</a> and <a href="#CD009069-tbl-0010">Table 6</a>, respectively. In the smaller Chinese trial, one woman who was vaccinated died from intracranial haemorrhage (<a href="./references#CD009069-bbs2-0308" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Zhu 2014a</a>; <a href="https://www.gsk-clinicalstudyregister.com/files2/ d6eb0c75-b164-41e6-8295-f2718bce6adc" target="_blank">https://www.gsk‐clinicalstudyregister.com/files2/ d6eb0c75‐b164‐41e6‐8295‐f2718bce6adc</a>). The higher number of deaths in the vaccine arms among mid‐adult women may be a chance occurrence, since there was no pattern either in the causes of death, or in the timing of the occurrence of death (period between vaccine administration and date of death). In the study reports, none of the deaths were deemed to be related to vaccination (<a href="./references#CD009069-bbs2-0146" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24‐45 years of age. British Journal of Cancer2011;105(1):28‐37. ">Castellsagué 2011</a>; <a href="./references#CD009069-bbs2-0273" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. ">Skinner 2014</a>; <a href="./references#CD009069-bbs2-0300" title="WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16 (10):1154‐68. ">Wheeler 2016</a>; <a href="https://www.gsk-clinicalstudyregister.com/files2/ d6eb0c75-b164-41e6-8295-f2718bce6adc" target="_blank">https://www.gsk‐clinicalstudyregister.com/files2/ d6eb0c75‐b164‐41e6‐8295‐f2718bce6adc</a>). </p> <div class="table" id="CD009069-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Deaths observed in the FUTURE III trial (quadrivalent vaccine, phase 3, women aged 24‐45 years)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death causes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary thromboembolism with background of acute lymphoblastic leukaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Breast cancer</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary tuberculosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thyrotoxicosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cerebral haemorrhage subsequent to hypertension</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pericarditis on a background of lupus erythematosus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nasopharyngeal cancer with metastases to brain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary embolism after intervention for uterine myoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>RR of deaths in vaccine vs placebo arm (7 over 1,890 vs 1 over 1888): RR = 6.99 (95% CI 0.86 to 56.78), 2‐sided p<sub>exact</sub>=0.070. </p> <p>The age at death varied between 29 and 45 years, seven of the deaths occurred in the Philippines and one in Columbia. </p> <p>All participants received three doses of HPV vaccine or placebo except one who received only two doses of vaccine. The time interval between last dose and date at death ranged between 6 and 37 months. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Group:V = vaccinated against HPV, C = control group.</p> <p>Source: end‐of‐study analysis after a median follow‐up of four years (<a href="./references#CD009069-bbs2-0146" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24‐45 years of age. British Journal of Cancer2011;105(1):28‐37. ">Castellsagué 2011</a>) and personal communication with Alfred Saah (MSD, 6/05/2016). </p> </div> </div> <div class="table" id="CD009069-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Deaths observed in the VIVIANE trial (bivalent vaccine, phase 3 trial, women aged &gt;25 years)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Patient</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cause of death</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Source</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Breast cancer metastatic</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suicide</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lower respiratory tract infection and sepsis*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cervix cancer metastatic**</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interstitial lung disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Breast cancer</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>***</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1***</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suicide</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac valve disease and liver disorder*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drug hypersensitivity and acute renal failure*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peru</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiorespiratory arrest</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phillipines</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute myocardial infarction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phillipines</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple myeloma and pulmonary embolism*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phillipines</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Homicide</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phillipines</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bronchopneumonia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Singapore</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lung neoplasm malignant</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thailand</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suicide</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glioblastoma multiforme</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaplastic astrocytoma</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>****</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nasopharyngeal cancer</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>****</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Remarks</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Multiple death causes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>**</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>This woman had normal cytology but was HPV‐18 DNA‐positive at study entry (May 2006). At the next scheduled cytology testing at Month 12 (April 2007), the cytology finding was atypical squamous cells cannot exclude high‐grade squamous intraepithelial lesion. She was diagnosed with metastatic cervical cancer in May 2007 (approximately 7 months after receiving the third dose of vaccine or control) and died in July 2008 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>***</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>One case of death due to breast cancer reported in the 48 month report (<a href="./references#CD009069-bbs2-0273" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. ">Skinner 2014</a>) had to be excluded from the analysis (<a href="./references#CD009069-bbs2-0300" title="WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16 (10):1154‐68. ">Wheeler 2016</a>). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>****</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Two additional cases of death occurring in the control arm were reported in the 84‐month report (<a href="./references#CD009069-bbs2-0300" title="WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16 (10):1154‐68. ">Wheeler 2016</a>). The country for these two cases was not reported. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Source: 1) interim analysis after 48 months of follow‐up (<a href="./references#CD009069-bbs2-0273" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. ">Skinner 2014</a>); 2) report at 84 months of follow‐up (<a href="./references#CD009069-bbs2-0300" title="WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16 (10):1154‐68. ">Wheeler 2016</a>) </p> <p>The 84‐month follow‐up report revealed 13 deaths in the HPV arm (N = 2877) versus 5 (N = 2870), with death causes allocated to the trial arms (vaccine versus placebo arm) the RR was 2.59 (95% CI 0.93 to 7.27), 2‐sided p<sub>exact</sub>=0.0957. No pattern was noticed which could indicate a causal role attributed to HPV vaccination. </p> </div> </div> </section> <section id="CD009069-sec-0085"> <h4 class="title">9. Pregnancy outcomes</h4> <p>Pregnancy outcomes were reported in a bivalent vaccine trial (<a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a>) and also through two pooled analyses of trials evaluating the bivalent (<a href="./references#CD009069-bbs2-0023" title="WacholderS , ChenBE , WilcoxA , MaconesG , GonzalezP , BefanoB . Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ2010;340:c712. ">PATRICIA &amp; CVT (ph3,2v)</a>) and quadrivalent vaccine (Pooled v4 trials), respectively (see <a href="#CD009069-tbl-0008">Table 4</a>). </p> <p>Similar rates of normal term deliveries of a healthy infant were noted (RR 1.00, 95% CI 0.97 to 1.02; participants = 8782; studies = 8; I<sup>2</sup> = 0%; <a href="./references#CD009069-fig-0074" title="">Analysis 8.1</a>). The risk of miscarriage also was similar between HPV vaccinees and control vaccinees (RR 0.88, 95% CI 0.68 to 1.14; participants = 8,618; studies = 9; I<sup>2</sup> = 78%; <a href="./references#CD009069-fig-0075" title="">Analysis 8.2</a>), as was elective termination of pregnancy (RR 0.90, 95% CI 0.80 to 1.02; participants = 10,909; studies = 9; I<sup>2</sup> = 0%; <a href="./references#CD009069-fig-0076" title="">Analysis 8.3</a>). Analyses of still births and abnormal infants lack sufficient power to rule out small increases or decreases in risk. The observed risk of stillbirth of 70 per 10,000 translates to a rate of 78 per 10,000 (48 to 128) based on the RR of 1.12 (95% CI 0.68 to 1.83; <a href="./references#CD009069-fig-0077" title="">Analysis 8.4</a>). The observed risk of an abnormal infant in the control groups was 205 per 10,000 and in the vaccination arms was 250 per 10,000 (180 to 346) based on the RR of 1.22 (0.88 to 1.69) (<a href="./references#CD009069-fig-0078" title="">Analysis 8.5</a>). We downgraded the quality of evidence for both of these outcomes to moderate due to imprecision. See further in <a href="./full#CD009069-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD009069-sec-0086"> <h4 class="title">10. Role of covariates</h4> <section id="CD009069-sec-0087"> <h5 class="title">10.1. Age</h5> <p>Most randomised trials assessing vaccine efficacy enrolled younger women, in the age range 15 to 26 years (<a href="#CD009069-tbl-0011">Table 7</a>). Only three randomised controlled trials (RCTs) evaluated the efficacy of the vaccines (<a href="./references#CD009069-bbs2-0011" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age. British Journal of Cancer2011;105(1):28‐37. GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">FUTURE III trial (ph3,4v)</a>, <a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0004" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Chinese trial (ph3,2v)_mid‐adult</a>) in mid‐adult women (aged 24 to 45 years). A small overlap was noted (24 to 26 years) between the young and the mid‐adult groups. </p> <div class="table" id="CD009069-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Trials for which vaccine efficacy is reported by smaller age subgroups</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target age group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age category</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reported age sub‐groups</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0025" title="KoutskyLA , AultKA , WheelerCM , BrownDR , BarrE , AlvarezFB . A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine2002;347(21):1645‐51. MaoC , KoutskyLA , AultKA , WheelerCM , BrownDR , WileyDJ . Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and Gynecology2006;107(1):18‐27. Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Phase2 trial (ph2,1v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16‐23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0026" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. NaudPS , Roteli‐MartinsCM , DeCarvalhoNS , TeixeiraJC , deBorbaPC , SanchezN , et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination. Human Vaccines &amp; Immunotherapeutics2014;10(8):2147‐62. The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">Phase2 trial (ph2,2v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0027" title="OlssonSE , KjaerSK , SigurdssonK , IversenOE . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. VillaLL , AultKA , GiulianoAR , CostaRL , PettaCA , AndradeRP . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine2006;24(27):5571‐83. VillaLL , CostaRL , PettaCA , AndradeRP , AultKA , GiulianoAR . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial. Lancet Oncology2005;6(5):271‐8. VillaLL , CostaRL , PettaCA , AndradeRP , PaavonenJ , IversenOE . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up. British Journal of Cancer2006;95(11):1459‐66. ">Phase2 trial (ph2,4v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16‐23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17, 18‐20, 21‐25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐19, 20‐21, 22‐23, 24‐25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>older</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26‐35, 36‐45, 46+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0013" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">FUTURE I trial (ph3,4v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16‐24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0011" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age. British Journal of Cancer2011;105(1):28‐37. GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">FUTURE III trial (ph3,4v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25‐45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>older</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> </tbody> </table> </div> <p>No difference in protection (difference in RR &lt;= 0.15 and P value for age effect non significant) was found between younger and mid‐adult women with respect to: </p> <p> <ol id="CD009069-list-0022"> <li> <p>CIN2+ associated with HPV16/18 in women who were HPV16/18 negative at baseline and who received three doses (<a href="./references#CD009069-fig-0022" title="">Analysis 2.1</a>); </p> </li> <li> <p>CIN2+ associated with HPV6/11/16/18 in women who were HPV16/18 negative at baseline and who received three doses (<a href="./references#CD009069-fig-0025" title="">Analysis 2.4</a>;. </p> </li> <li> <p>six‐month persistent HPV16/18 infection in women who were HPV16/18 negative at baseline and who receivedthree3 doses (<a href="./references#CD009069-fig-0054" title="">Analysis 5.4</a>) or at least one dose (<a href="./references#CD009069-fig-0055" title="">Analysis 5.5</a>). </p> </li> </ol> </p> <p>Lower protection was found in mid‐adult women compared to younger women with respect to: </p> <p> <ol id="CD009069-list-0023"> <li> <p>CIN2+ associated with HPV16/18 in women who were HPV16/18 negative at baseline and who received one or two doses (<a href="./references#CD009069-fig-0024" title="">Analysis 2.3</a>) or at least one dose (<a href="./references#CD009069-fig-0023" title="">Analysis 2.2</a>); </p> </li> <li> <p>CIN2+ associated with HPV6/11/16/18 in women who were HPV16/18 negative at baseline and who received at least one dose (<a href="./references#CD009069-fig-0026" title="">Analysis 2.5</a>); </p> </li> <li> <p>CIN2+ associated with HPV16/18 in all women, regardless of their baseline hrHPV DNA status, who received at least one dose (<a href="./references#CD009069-fig-0037" title="">Analysis 3.1</a>); </p> </li> <li> <p>six‐month persistent HPV16/18 infection in all women, regardless of their baseline hrHPV DNA status, who received at least one dose (<a href="./references#CD009069-fig-0063" title="">Analysis 6.2</a>). </p> </li> </ol> </p> <p>Lower protection (difference in RR &gt; 0.15) was found in mid‐adult women compared to younger women (RR, but the difference was not significant for the following outcomes: </p> <p> <ol id="CD009069-list-0024"> <li> <p>CIN2+ associated with HPV6/11/16/18 in women who were HPV16/18 negative at baseline who received one or two doses (<a href="./references#CD009069-fig-0027" title="">Analysis 2.6</a>); </p> </li> <li> <p>CIN2+ associated with HPV6/11/16/18 in all women, regardless of their baseline hrHPV DNA status, who received at least one dose (<a href="./references#CD009069-fig-0038" title="">Analysis 3.2</a>); </p> </li> <li> <p>Any CIN2+ irrespective of hrHPV types in all women, regardless of their baseline hrHPV DNA status, who received at least one dose (<a href="./references#CD009069-fig-0043" title="">Analysis 3.7</a>); </p> </li> <li> <p>six‐month persistent HPV16/18 infection in women who were HPV16/18 negative at baseline and who received one or two doses (<a href="./references#CD009069-fig-0056" title="">Analysis 5.6</a>). </p> </li> </ol> </p> <p>For the bivalent vaccine, three trials (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a>) reported the efficacy within smaller age subgroups (<a href="#CD009069-tbl-0011">Table 7</a>). Since the age groups were not uniformly defined, age effects were assessed by Poisson regression for each trial separately. The P value corresponding with the hypothesis of decreasing efficacy with increasing age is shown in the last column in <a href="#CD009069-tbl-0012">Table 8</a> (<a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>), <a href="#CD009069-tbl-0013">Table 9</a> (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a> and <a href="#CD009069-tbl-0014">Table 10</a> (<a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a>). This P value corresponds with checking the significance of the incorporation of the interaction term "vaccine*age" in the Poisson regression, treating age as a continuous variable. The protection against CIN2+ and CIN3+, associated with HPV16/18 or irrespective of hrHPV type, as well as the protection against six‐month persistent HPV16/18 infection, decreased significantly by age in the intention‐to‐treat groups where women were enrolled regardless of baseline HPV DNA status. Within the per‐protocol groups, enrolling women who were HPV16/18 DNA negative at baseline, no significant linear age effects were observed. Only for the outcome of persistent six‐month HPV16/18 infection a slight decrease in protection was observed in the PATRICIA trial (<a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>, P value = 0.042), but not in the Costa Rica trial (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>, P value = 0.145), and not in the VIVIANE trial (<a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a>, P value = 0.532). </p> <div class="table" id="CD009069-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Influence of age (PATRICIA trial)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Event/N</b> </p> <p><b>Vaccine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Event/N</b> </p> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative risk</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine efficacy</b> </p> <p><b>% (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value for linear effect of age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>In women with hrHPV DNA negative status at baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN2+ associated with HPV16/18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1997</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53/2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (0.00 to 0.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98% (86 to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.995</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/1096</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (0.00 to 0.32)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98% (68 to 100%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/2363</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/2281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (0.00 to 0.47)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97% (53 to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN2+ irrespective of HPV types</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/1997</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101/2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.23 to 0.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66% (50 to 77%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.355</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/1096</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 (0.14 to 0.55)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73% (45 to 86%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/2363</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/2281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 (0.28 to 0.89)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% (11 to 72%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN3+ associated with HPV16/18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/1997</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (0.00 to 0.61)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96% (39 to100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>1.000</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/1096</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07 (0.00 to 1.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93% (‐13 to 100%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/2363</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/2281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (0.00 to 1.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90%(‐74 to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN3+ irrespective of HPV types</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/1997</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08 (0.02 to 0.36)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92% (64 to 98%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.488</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1096</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09 (0.01 to 0.73)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91% (27 to 99%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/2363</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/2281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (0.00 to 0.92)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% (8 to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Persistent HPV16/18 infection (6M)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/1989</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303/2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (0.03 to 0.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% (92 to 97%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0..042</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/1090</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110/1125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08 (0.04 to 0.17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92%(83 to 96%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/2338</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108/2249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 (0.06 to 0.19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89% (81 to 94%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Regardless of women’s baseline HPV DNA status</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN2+ associated with HPV16/18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/2882</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100/2892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 (0.13 to 0.24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79% (66 to 87%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.000</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/1871</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66/1908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (0.22 to 0.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64% (43 to 78%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/3929</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62/3898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.50 to 1.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26% (‐8 to 50%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN2+ irrespective of HPV types</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112/2882</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200/2892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.45 to 0.70)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44% (30 to 55%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.006</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62/1871</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105/1908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.44 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40% (18 to 56%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113/3929</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123/3898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.09 to 1.17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9% (‐17 to 29%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN3+ associated with HPV16/18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/2882</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/2892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (0.09 to 0.44)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80% (56 to 91%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.000</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/1871</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/1908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.23 to 0.84)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56% (16 to 77%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31/3929</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/3898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.66 to 1.83)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐10% (‐83 to 34%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN3+ irrespective of HPV types</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/2882</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/2892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 (0.21 to 0.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65% (43 to 79%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.008</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/1871</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/1908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.31 to 0.85)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49% (15 to 69%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43/3929</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53/3898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.54 to 1.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20% (‐20 to 46%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Persistent HPV16/18 infection (6M)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167/2916</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>588/2920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.24 to 0.34)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72% (66 to 76%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.000</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143/1925</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283/1961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.43 to 0.62)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49% (38 to 57%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194/4009</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356/3979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 (0.46 to 0.64)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46% (36 to 54% )</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Source: <a href="./references#CD009069-bbs2-0224" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. ">Lehtinen 2012</a>. </p> <p><b>CIN:</b> cervical intraepithelial neoplasia, <b>CIN2+:</b> CIN of degree II or worse, <b>CIN3+:</b> CIN of degree 3 or worse, <b>HPV:</b> human papillomavirus types.. </p> </div> </div> <div class="table" id="CD009069-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Influence of age (CVT trial)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative risk</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine efficacy</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value for linear effect of age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>In women with</b> HPV16<b>/18 DNA negative status at baseline cohort</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Persistent HPV16/18 infection (6M)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/825</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51/870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (0.00 to 0.10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98% (90% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0.145</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20‐21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/659</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08 (0.02 to 0.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92% (76% to 98%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22‐23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/588</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06 (0.00 to 0.20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94% (80% to 100%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24‐25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/563</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14 (0.03 to 0.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86% (56% to 97%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Regardless if women’s baseline HPV DNA status</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Persistent HPV16/18 infection (6M)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47/1193</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165/1,244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (0.21 to 0.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70% (59% to 79%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0.000</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20‐21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64/946</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134/905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.34 to 0.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54% (39% to 66%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22‐23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59/818</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112/848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.40 to 0.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45% (25% to 60%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24‐25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/770</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75/742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.56 to 1.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 %(‐9.9 to 44%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Source: <a href="./references#CD009069-bbs2-0190" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR . Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. ">Herrero 2011</a>. </p> </div> </div> <div class="table" id="CD009069-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Influence of age (VIVIANE trial)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Event/NVaccine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Event/NPlacebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative risk</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vaccine efficacy</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value for linear effect of age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>In women with</b> HPV16<b>/18 DNA negative status at baseline cohort</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Persistent HPV16/18 infection (6M)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26‐35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13 (0.04 to 0.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (56% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.532</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36‐45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25 (0.07 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75%(12% to 93%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N.A.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N.A.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Regardless if women’s baseline HPV DNA status</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Persistent HPV16/18 infection (6M)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26‐35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48/1221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78/1242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (0.44 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37% (11% to 56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.177</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36‐45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/1244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43/1228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.26 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56% (26% to 74%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.12 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63% (‐15% to 88%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Source: <a href="./references#CD009069-bbs2-0273" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. ">Skinner 2014</a>. </p> </div> </div> </section> <section id="CD009069-sec-0088"> <h5 class="title">10.2. Serological status</h5> <p>As described above, vaccine efficacy depends upon whether an hrHPV infection is present prior to vaccination, but could also potentially be influenced by prior hrHPV infection that cleared (as defined by being no longer detectable using a hrHPV DNA test), but with a positive hrHPV serology status. In <a href="#CD009069-tbl-0015">Table 11</a>, we pooled the relative risk of, and the vaccine efficacy against, CIN2+ associated with HPV16/18 stratified by initial hrHPV serology and DNA status from two phase III trials (<a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a> and <a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>). In HPV16/18 DNA negative women, protection was strong, but varied by serology status: RR = 0.03 (95% CI 0.02 to 0.09) and 0.19 (95% CI 0.09 to 0.77) for HPV16/18 in seronegative and seropositive women, respectively. No significant protection was observed in the HPV16/18 DNA‐positive group, with RR being 0.79 (95% CI 0.60 to 1.05) and 1.10 (95% CI 0.88 to 1.36) for HPV16/18 seronegative and seropositive women, respectively. </p> <div class="table" id="CD009069-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Influence of the initial serological status on vaccine efficacy against cervical lesions associated with HPV16/18</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Initial HPV DNA/ status</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serology</b> </p> <p><b>status</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative Risk</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative Risk ratio</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0013" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">FUTURE I trial (ph3,4v)</a> (<a href="./references#CD009069-bbs2-0175" title="GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">Garland 2007</a>)* </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(‐)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/2,241</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/2258</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 (0.02 to 0.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>15.93</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/377</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/379</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (0.01 to 5.20)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(+)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/232</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31/213</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.49 to 1.29)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.50</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41/156</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/137</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (0.80 to 1.81)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a> (<a href="./references#CD009069-bbs2-0172" title="The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE‐II 2007</a>)** </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(‐)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/5,305</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/5260</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02(0.00 to 0.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>7.41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/498</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/524</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13 (0.01 to 2.43)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(+)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/423</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/402</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.57 to 1.41)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47/298</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/332</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (0.70 to 1.45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a> (<a href="./references#CD009069-bbs2-0249" title="PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. ">Paavonen 2009</a>)** </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(‐)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/8709</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92/8112</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (0.02 to 0.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>6.16</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/1710</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/1777</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.31 (0.09 to 1.13)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(+)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/309</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/293</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.38 to 1.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.70</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53/333</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/307</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (0.77 to 1.61)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pooled results for CIN2+ associated with HPV16/18</b> </p> <p><b>(</b><a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a> and <a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a><b>***</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(‐)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/14,014</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120/13,372</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03 (0.02 to 0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>5.85</p> <p>(0.53 to 65.10)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/2205</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/2301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19 (0.09 t0 o.77)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(+)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53/679</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64/695</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.60 to 1.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.37</p> <p>(0.97 to 1.93)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100/531</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96/639</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.88 to 1.36)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*RR against HPV 6/11/16/18 related cervical lesions</p> <p>** RR against HPV16/18 related CIN2+</p> <p>*** Pooled only for FUTURE II and PATRIACIA, since, in the FUTURE I trial, the endpoints were cervical lesions and not CIN2+ associated with HPV16/18 </p> </div> </div> <p>The effect of the serology status was computed by meta‐regression as a relative risk ratio (RRR). This relative risk corresponds with RR<sub>sero+</sub> / RR<sub>sero‐</sub>where RR is as usual the risk of lesions in vaccinated versus unvaccinated women. The RRRs were 5.85 (95% CI 0.53 to 65.10) for seropositive compared to seronegative women if HPV16/18 DNA‐negative and 1.37 (95% CI 0.97 to1.84) for seropositive compared to seronegative women if HPV16/18 DNA‐positive. Both RRRs were not statistically significantly different from unity. The RRRs were higher than unity, reflecting a tendency of higher risk of lesions or a lower vaccine efficacy in seropositive women. The effect of sero‐positivity was more pronounced in HPV DNA‐negative women, but even in this group, it was again not statistically significant. Whether the seropositivity effect is due to lower vaccine protection or presence of HPV virus prior to vaccination below the detection limit of the used HPV DNA test cannot be derived from the data. </p> </section> <section id="CD009069-sec-0089"> <h5 class="title">10.3. Study quality and involvement of vaccine manufacturers</h5> <p>The impact of six study quality items (V1‐V6) (see <a href="#CD009069-sec-0051">Assessment of risk of bias in included studies</a>; <a href="./references#CD009069-sec-0146" title="">Characteristics of included studies</a>) on the protection against six‐ and 12‐month persistent HPV16/18 infection was assessed by meta‐regression. No significant effects were observed: P values were all &gt; 0.05 (see <a href="#CD009069-tbl-0016">Table 12</a>). </p> <div class="table" id="CD009069-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Influence of the study quality and the involvement of vaccine manufacturers</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>P value </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V4</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V5</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V6</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V7</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent HPV16/18 infection (6M), in women being baseline HPV16/18 negative 3 doses</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent HPV16/18 infection (6M), in women being baseline HPV16/18 negative at least 1 dose </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent HPV16/18 infection (12M), in women being baseline HPV16/18 negative 3 doses</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent HPV16/18 infection (12M), in women being baseline HPV16/18 negative at least 1 dose </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Influence of study quality (items V1‐V6) and independence of the research team towards the vaccine manufacturer (V7) on protection against persistent HPV16/18 infection assessed by meta‐regression. </p> <p>The P values correspond with the statistical significance of the incorporation of each item in the meta‐regression. </p> <p><b>V1:</b> Random sequence generation; <b>V2:</b> Allocation concealment; <b>V3:</b> Blinding participants and personnel; <b>V4:</b> Blinding of outcome; <b>V5:</b> Incomplete outcomes; <b>V6:</b> Selective reporting; <b>V7:</b> Involvement of manufacturer, </p> <p><b>np:</b> meta‐regression not possible because of collinearity. </p> </div> </div> <p>The impact of the involvement of the vaccine manufacture in the trials was also assessed by meta‐regression. No significant effects were observed. </p> </section> <section id="CD009069-sec-0090"> <h5 class="title">10.4. Number of administered doses</h5> <p>In a post hoc pooled analysis of the Costa‐Rica Vaccination Trial (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>), it was demonstrated that efficacy against 12‐month incident persistent infection was no different (P value = 0.60, I<sup>2</sup> = 0%) in women who had received one, (RR = 0.05, 95% CI 0.00 to 0.77), two (RR = 0.16, 95% CI 0.05 to 0.52), or three doses (RR = 0.19, 95% CI 0.12 to 0.29) of the bivalent vaccine (<a href="./references#CD009069-fig-0066" title="">Analysis 6.5</a>). More outcomes were assessed in a pooled analysis of the Costa Rica and PATRICIA trials (<a href="./references#CD009069-bbs2-0067" title="KreimerAR , ShermanME , SahasrabuddheVV , SafaeianM . The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents. Journal of the National Cancer Institute2015;107(3 1460‐2105 (Electronic)):1‐4 0027‐8874 (Linking). ">Kreimer 2015</a>). Protection induced by the bivalent vaccine against incident and six‐ and 12‐month persistent HPV16/18 infection in 15 to 26 years old women, initially HPV16/18 or hrHPV negative, did not differ by number of received doses (<a href="#CD009069-tbl-0017">Table 13</a>). It is planned to continue the follow‐up in the Costa‐Rica Vaccination Trial (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>) for 10 years, to verify the durability of protection afforded by fewer than three doses of the bivalent vaccine (<a href="./references#CD009069-bbs2-0218" title="KreimerAR , ShermanME , SahasrabuddheVV , SafaeianM . The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents. Journal of the National Cancer Institute2015;107(3):dju436. ">Kreimer 2015b</a>). Results up to 6.9 years show that the cumulative incidence of HPV16/18 infections among women who received one dose, or two doses (received at months zero and six, or at months zero and one) are similarly low compared to those who received the three doses (see <a href="#CD009069-tbl-0018">Table 14</a>; <a href="./references#CD009069-bbs2-0261" title="SafaeianM , SampsonJN , PanY , PorrasC , KempTJ , HerreroR , et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: The CVT Trial. Journal of the National Cancer Institute2018;110(2):djx158. ">Safaeian 2018</a>). </p> <div class="table" id="CD009069-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Influence of the number of administered doses: one, two or three in two RCTs with four years of follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of doses</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine</b> </p> <p><b>arm</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p><b>arm</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative Risk </b> </p> <p><b>(95%CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value for linear</b> </p> <p><b>dose‐effect relation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12‐month</p> <p>persistent HPV16/18</p> <p>infection</p> <p>in women being</p> <p>HPV16/18 negative at baseline</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84/11,104</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>627/11,203</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.135 (0.108 to 0.169)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.303</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/611</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/574</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.108 (0.033 to 0.356)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/292</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/249</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.050 (0.007 to 0.374)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>6‐month</p> <p>persistent HPV16/18</p> <p>infection</p> <p>in women being</p> <p>HPV16/18 negative at baseline</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114/11,104</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000/11,209</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.115 (0.095 to 0.139)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.269</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/611</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35/574</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.107 (0.038 to 0.300)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/292</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/250</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.036 (0.005 to 0.261)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Incident HPV16/18 infection</p> <p>in women being HPV16/18</p> <p>negative at baseline</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>529/11,110</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2172/11,217</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.246 (0.224 to 0.269)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.337</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/611</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82/574</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.252 (0.160 to 0.398)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/292</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45/251</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.153 (0.073 to 0.318)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12‐month</p> <p>persistent HPV16/18</p> <p>infection</p> <p>in women being</p> <p>hrHPV negative at baseline</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/6634</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>351/6656</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.077 (0.052 to 0.114)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.996</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/273</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/276</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.168 (0.038 to 0.746)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/138</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/99</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.071 (0.004 to 1.289)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>6‐month</p> <p>persistent HPV16/18</p> <p>infection</p> <p>in women being</p> <p>hrHPV negative at baseline</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/6634</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>567/6660</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.067 (0.049 to 0.093)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.809</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/273</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/276</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.126 (0.029 to 0.544)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/138</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.045 (0.003 to 0.774)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Incident HPV16/18 infection</p> <p>in women being hrHPV</p> <p>negative at baseline</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/6634</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>567/6660</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.067 (0.049 to 0.093)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.809</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/273</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/276</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.126 (0.029 to 0.544)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/138</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.045 (0.003 to 0.774)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Source: <a href="./references#CD009069-bbs2-0023" title="WacholderS , ChenBE , WilcoxA , MaconesG , GonzalezP , BefanoB . Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ2010;340:c712. ">PATRICIA &amp; CVT (ph3,2v)</a> (<a href="./references#CD009069-bbs2-0067" title="KreimerAR , ShermanME , SahasrabuddheVV , SafaeianM . The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents. Journal of the National Cancer Institute2015;107(3 1460‐2105 (Electronic)):1‐4 0027‐8874 (Linking). ">Kreimer 2015</a>). </p> </div> </div> <div class="table" id="CD009069-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Influence of the number of administered doses in the CVT trial (seven years of follow‐up)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of doses</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n events</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N vaccinated</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% (95%CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P* for difference with 3 doses</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Cumulative</p> <p>incidence</p> <p>HPV16/18</p> <p>infections</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2023</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3 (3.5 to 5.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (at months 0 &amp; 6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (1.0 to 10.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (at months 0 &amp; 1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.6 (1.6 to 7.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.3 to 4.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Source: <a href="./references#CD009069-bbs2-0261" title="SafaeianM , SampsonJN , PanY , PorrasC , KempTJ , HerreroR , et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: The CVT Trial. Journal of the National Cancer Institute2018;110(2):djx158. ">Safaeian 2018</a>. </p> <p>* two‐sided exact test for difference between proportions.</p> </div> </div> <p>For several trials, results were provided for the same outcome among women being initially HPV16/18 DNA negative and having received all three doses and at least one dose. This allowed us to compute, in a post‐hoc analysis, by simple subtraction the number of events and women at risk having received only one or two doses (<a href="#CD009069-tbl-0019">Table 15</a>). </p> <div class="table" id="CD009069-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Influence of the number of administered doses: all three versus less than three doses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age</b> </p> <p><b>Group</b> </p> <p><b>(years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR if 3 doses</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR if 1‐2 doses</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>CIN2+</b> </p> <p><b>due to HPV16/18</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (<a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>; </p> <p><a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0025" title="KoutskyLA , AultKA , WheelerCM , BrownDR , BarrE , AlvarezFB . A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine2002;347(21):1645‐51. MaoC , KoutskyLA , AultKA , WheelerCM , BrownDR , WileyDJ . Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and Gynecology2006;107(1):18‐27. Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Phase2 trial (ph2,1v)</a>; <a href="./references#CD009069-bbs2-0005" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX , et al. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(11):2612‐22. ZhuFC , HuSY , HongY , HuYM , ZhangX , ZhangYJ , et al. Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial. Cancer Medicine2017;6(2045‐7634 (Electronic), 2045‐7634 (Linking), 1):12‐25. ">Chinese trial (ph3,2v)_young</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (0.03 to 0.14)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10 (0.04 to 0.26)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24‐45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (<a href="./references#CD009069-bbs2-0011" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age. British Journal of Cancer2011;105(1):28‐37. GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">FUTURE III trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14 (0.03 to 0.79)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.20 to 4.83)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CIN3+</b> </p> <p><b>due to HPV16/18</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15‐26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (<a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (0.04 to 0.91)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (0.01 to 0.74)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incident HPV16/18 infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (<a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>; <a href="./references#CD009069-bbs2-0025" title="KoutskyLA , AultKA , WheelerCM , BrownDR , BarrE , AlvarezFB . A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine2002;347(21):1645‐51. MaoC , KoutskyLA , AultKA , WheelerCM , BrownDR , WileyDJ . Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and Gynecology2006;107(1):18‐27. Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Phase2 trial (ph2,1v)</a>;<a href="./references#CD009069-bbs2-0005" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX , et al. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(11):2612‐22. ZhuFC , HuSY , HongY , HuYM , ZhangX , ZhangYJ , et al. Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial. Cancer Medicine2017;6(2045‐7634 (Electronic), 2045‐7634 (Linking), 1):12‐25. ">Chinese trial (ph3,2v)_young</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.10 to 0.41)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47 (0.26 to 0.84)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>6‐month persistent HPV16/18 infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (<a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>;<a href="./references#CD009069-bbs2-0005" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX , et al. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(11):2612‐22. ZhuFC , HuSY , HongY , HuYM , ZhangX , ZhangYJ , et al. Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial. Cancer Medicine2017;6(2045‐7634 (Electronic), 2045‐7634 (Linking), 1):12‐25. ">Chinese trial (ph3,2v)_young</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (0.01 to 0.27)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12 (0.03 to 0.42)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24‐45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (<a href="./references#CD009069-bbs2-0011" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age. British Journal of Cancer2011;105(1):28‐37. GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">FUTURE III trial (ph3,4v)</a>;<a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15 (0.09 to 0.27)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.19 to 0.61)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12‐month persistent HPV16/18 infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (<a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>;<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0005" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX , et al. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(11):2612‐22. ZhuFC , HuSY , HongY , HuYM , ZhangX , ZhangYJ , et al. Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial. Cancer Medicine2017;6(2045‐7634 (Electronic), 2045‐7634 (Linking), 1):12‐25. ">Chinese trial (ph3,2v)_young</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09 (0.05 to 0.19)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13 (0.06 to 0.33)*</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Vaccine efficacy in women being HPV16/18 DNA negative at enrolment and having received all three or less than three doses (computed from trials where per‐protocol [all doses administered] and intention‐to‐treat analyses [at least one dose administered] are reported). </p> </div> </div> <p>Significant protection was observed for women having received only one or two doses for the following outcomes: </p> <p> <ol id="CD009069-list-0025"> <li> <p>CIN2+ associated with HPV16/18 in women aged 16 to 25 years (observation for mono‐,bi‐ and quadrivalent vaccines, <a href="./references#CD009069-fig-0024" title="">Analysis 2.3</a>); </p> </li> <li> <p>CIN3+ associated with HPV16/18 in women aged 16 to 25 years (observation for the bivalent and the quadrivalent vaccine, <a href="./references#CD009069-fig-0030" title="">Analysis 2.9</a>); </p> </li> <li> <p>Incident HPV16/18 infection in women aged 15 to 26 years (observation only for the mono, and the bivalent vaccine, <a href="./references#CD009069-fig-0053" title="">Analysis 5.3</a>); </p> </li> <li> <p>six‐month persistent 16/18 infection in women aged 15 to 26 and 25 to 45 years (observation for the bivalent and quadrivalent vaccine, respectively, <a href="./references#CD009069-fig-0056" title="">Analysis 5.6</a>). </p> </li> </ol> </p> <p>No protection against CIN2+ associated with HPV16/18 was observed in women aged 24 to 45 who received only one or two doses. (<a href="./references#CD009069-fig-0024" title="">Analysis 2.3</a>). </p> <p>Protection against CIN2+ associated with HPV16/18 in women aged 15 to 26 years and were baseline HPV DNA 16/18 negative, no subgroup difference was observed for women having received three doses or only one or two doses (<a href="#CD009069-fig-0012">Figure 12</a>). </p> <div class="figure" id="CD009069-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Protection against CIN2+ associated with HPV16/18 in women, aged 15‐26 years, who were HPV DNA 16/18 negative at baseline, by number of doses." data-id="CD009069-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Protection against CIN2+ associated with HPV16/18 in women, aged 15‐26 years, who were HPV DNA 16/18 negative at baseline, by number of doses. </p> </div> </div> </div> </section> <section id="CD009069-sec-0091"> <h5 class="title">10.5. Duration of follow‐up</h5> <p>The assessment of possible changes in vaccine efficacy over time was impeded due to uneven spacing of periodic reports. Efficacy was reported at several time points in two trials (<a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>), varying between 15 and 44 months on average. Protection against CIN2+ associated with HPV16/18 infection did not drop by longer follow‐up time, either in women who were HPV16/18 DNA negative, or for those enrolled regardless of their HPV DNA status (<a href="#CD009069-tbl-0020">Table 16</a>). </p> <div class="table" id="CD009069-tbl-0020"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Influence of follow‐up time</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Report </b> </p> <p><b>(duration of follow‐up)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vaccine</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative Risk</b> </p> <p><b>(95%CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value for linear difference</b> </p> <p><b>of follow‐up time effect</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>CIN2+ associated with HPV16/18</p> <p>in women being HPV negative at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>PATRICIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paavonen 2007</p> <p>14.8 moths</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/7788</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/7838</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.096 (0.007 to 0.466)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>0.512</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paavonen 2009</p> <p>34.9 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/8040</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91/8080</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.054 (0.016 to 0.137)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Szarewski 2011</p> <p>39.4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/8079</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92/8112</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.054 (0.016 to 0.137)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lehtinen 2011</p> <p>43.7 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/7338</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97/7305</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.051 (0.016 to 0.123)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>FUTURE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The FUTURE II study group 2007</p> <p>36 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/5865</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87/5836</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.039 (0.011 to 0.109)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.994</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Munoz 2010*</p> <p>43 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/4616</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89/4680</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.006 (0.000 to 0.092)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>CIN2+ irrespective of HPV types</p> <p>regardless of women’s initial HPV DNA status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>PATRICIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paavonen 2009</p> <p>34.9 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>224/8667</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>322/8682</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.696 (0.579 to 0.8369)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.750</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lehtinen 2011</p> <p>43.7 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287/8694</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>428/8708</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.669 (0.574 to 0.778)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>FUTURE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The FUTURE II study group 2007</p> <p>36 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281/6087</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361/6080</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.780 (0.668 to 0.905)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.665</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Munoz 2010</p> <p>43 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>421/8562</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>520/8598</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.807 (0.690 to 0.943)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Assessment of the influence of duration of follow‐up on study outcomes using meta‐regression. p‐values correspond with the statistical significance of incorporating average follow‐up time as a continuous variable. </p> </div> </div> </section> <section id="CD009069-sec-0092"> <h5 class="title">10.6. Sexual history</h5> <p>The impact of sexual history on vaccine efficacy was assessed in only one trial (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>) for the outcome protection against 12‐month persistent HPV16/18 infection. The number of sexual partners had no effect in the analysis limited to participants who were HPV16/18 DNA negative at enrolment (P value = 0.7448). However, in the group of women enrolled regardless of their baseline HPV DNA status, a very significant decrease in protection by increasing number of sexual partners was observed (P value &lt; 0.00001) (see <a href="#CD009069-tbl-0021">Table 17</a>). </p> <div class="table" id="CD009069-tbl-0021"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Influence of the number of sexual partners</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of sex partners</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative Risk </b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value of number of sexual partners effect</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>In women being</b> HPV16<b>/18 DNA negative at baseline cohort</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Virgin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.064 (0.003 to 0.352)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>0.7448</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 partner</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.112 (0.007 to 0.335)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 partners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.056 (0.003 to 0.309)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3+ partners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.108 (0.026 to 0.321)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Regardless of women’s baseline HPV DNA status</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Virgin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.202 (0.059 to 0.551)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>&lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 partner</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/1237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83/1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.489 (0.333 to 0.711)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 partners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81/753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.455 (0.307 to 0.665)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3+ partners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71/940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116/911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.593 (0.440 to 0.796)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>The influence of the number of lifetime sexual partners on vaccine efficacy was assessed by Poisson regression. The P value corresponds with the likelihood ratio test comparing a Poisson model with and without inclusion of the sexual history with 3 possible categories. </p> <p>Source: <a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a> (<a href="./references#CD009069-bbs2-0190" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR . Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. ">Herrero 2011</a>). </p> </div> </div> </section> <section id="CD009069-sec-0093"> <h5 class="title">10.7. Study size</h5> <p>The vaccine efficacy did not vary between small or large trials (<a href="#CD009069-tbl-0022">Table 18</a>). </p> <div class="table" id="CD009069-tbl-0022"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Influence of the study size</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of </b> </p> <p><b>participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study size</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vaccine</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative </b> </p> <p><b>Risk</b> </p> <p><b>(95%CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>CIN2+ associated with</p> <p>HPV16/18</p> <p>in women being</p> <p>HPV16/18 negative at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phase2 trial (V1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2392</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/126</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/127</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.062*</p> <p>(0.004 to 1.071)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>0.598</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phase2 trial (V2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1113</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/219</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/212</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.161*</p> <p>(0.008 to 3.091)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japanese trial (ph2,2v)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1040</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/422</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/427</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.252*</p> <p>(0.012 to 5.241)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PATRICIA trial (ph3,2v)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,644</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/8040</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91/8080</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.055</p> <p>(0.022 to 0.136)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FUTURE II trial (ph3, 4v)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12,167</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/5865</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87/5863</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.034</p> <p>(0.011 to 0.109)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese trial (ph3,2V)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6051</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/2543</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/2554</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.125</p> <p>(0.001 to 8.681)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>CIN2+ irrespective of</p> <p>HPV types and</p> <p>regardless of women’s</p> <p>initial HPV DNA status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FUTURE I/II trial (ph3,4v)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,622</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>421/8562</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>520/8598</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.813</p> <p>(0.718 to 0.921)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.703</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PATRICIA trial (ph3,2v)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,644</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287/8694</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>428/8708</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.672</p> <p>(0.582 to 0.778)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phase2 trial (v1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2392</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/148</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/142</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.640</p> <p>(0.269 to 1.568)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Assesment of the influence of the study size on the protection against CIN2+ associated with HPV16/18 according to study size (S = small, &lt; 3000 participants, L = large &gt;= 3000 participants) in women aged 15‐26 years and received at least 1 dose. </p> <p>* P values correspond with the statistical significance of a meta‐regression with vs without study size category. </p> </div> </div> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009069-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009069-sec-0094"></div> <section id="CD009069-sec-0095"> <h3 class="title" id="CD009069-sec-0095">Summary of main results</h3> <section id="CD009069-sec-0096"> <h4 class="title">1. Comments on main results</h4> <p>We included 26 randomised controlled trials (RCTs) involving 73,428 participants, ranging from 98 to 18,644 participants per trial. Studies involved monovalent (one trial), bivalent (18 trials), and quadrivalent vaccines (seven trials). Most trials recruited adolescent girls and women 15 to 26 years of age; three trials recruited women aged 24 to 45 years. We judged most included trials to be at a low risk of bias. All the trials, except one (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>, were funded by the vaccine manufacturers. However, vaccine efficacy and adverse effects were not different in trials funded by manufacturers and the one trial conducted with public resources. </p> <section id="CD009069-sec-0097"> <h5 class="title">Protection against persistent human papillomavirus (HPV)16/18 infection and associated cervical precancer </h5> <p>HPV vaccine efficacy was very high among young women (15 to 26 years) against six‐month and 12‐month persisting HPV16/18 infection (risk ratio (RR) ≤ 0.10) (high‐quality evidence). It is also high against cervical intraepithelial neoplasia grade 2 and above (CIN2+) and CIN grade 3 and above (CIN3+) (RR ≤ 0.10) and against adenocarcinoma in situ (AIS+) (RR ≤ 0.12) associated with these types when women were high‐risk human papillomavirus (hrHPV) negative or HPV16/18 negative at enrolment (high‐quality evidence for CIN2+ and CIN3+; moderate‐quality evidence for AIS+). Absolute reductions in risk further illustrate the relative effects. HPV vaccines reduce the risk of CIN2+ from 164 per 10,000 people to 2 per 10,000, and AIS from 9 per 10,000 to 0 per 10,000 in hrHPV negative women (<a href="./full#CD009069-tbl-0001">summary of findings Table for the main comparison</a>). While all trials were designed as randomised trials of 3‐dose schedules, we included also analyses of fewer than three doses. Protection against precancerous lesions and persistent infection was also strong (RR ≤ 0.15) when fewer than three doses were received. We were not able to determine possible bias in these analyses due to women who did not complete the three‐dose schedule having different risk factors to those who completed the vaccination schedule as per protocol. Among all vaccinated women regardless of their initial HPV DNA test results, protection against persistent HPV16/18 infection and associated precancerous lesions was weaker. The RR varied between 0.36 and 0.55, corresponding to differences in risk of 1.8% for CIN2+ and 0.09% for AIS associated with HPV16/18 (<a href="./full#CD009069-tbl-0003">summary of findings Table 3</a>). Follow‐up ranged between two and eight years, with most studies contributing data collected between three and five years post‐vaccination, limiting the potential to measure cervical cancer outcomes, which would require very long follow‐up periods. </p> <p>Protection against persistent HPV16/18 infection and associated CIN2+ lesions (RR ≤ 0.15) was also observed in mid‐adult women (24 to 45 years) when they were HPV16/18 negative at baseline and received three doses of vaccine. Fewer than three doses offered some protection in HPV16/18 DNA negative mid‐adult women against persistent HPV16/18 infection (RR = 0.34), but not against CIN2+ associated with HPV16/18. When all vaccinated mid‐adult women were considered, regardless of their baseline HPV DNA status, vaccination offered some protection against six‐month persistent HPV16/18 infection (RR = 0.57), but not against CIN2+ associated with HPV16/18. </p> <p>The quality of evidence was moderate to high and there was little evidence of heterogeneity by valency of the vaccine for most outcomes. </p> <section id="CD009069-sec-0098"> <h6 class="title">Protection against any cervical precancer, irrespective of HPV type</h6> <p>The efficacy of HPV vaccines was generally lower when any high‐grade squamous lesions, irrespective of HPV infection type, was considered compared to efficacy for HPV16/18‐associated lesions. The protection in hrHPV negative women following bivalent vaccination against development of CIN3+ (RR = 0.08; <a href="./references#CD009069-fig-0020" title="">Analysis 1.8</a>.1), was greater than that observed for the quadrivalent vaccine (RR = 0.54; <a href="./references#CD009069-fig-0020" title="">Analysis 1.8</a>.2). The three‐dose efficacy against CIN2+ (RR = 0.40; <a href="./references#CD009069-fig-0034" title="">Analysis 2.13</a>) was no different between the bi‐ and quadrivalent vaccines in women who were initially HPV16/18 negative. No significant difference in protection was observed when fewer than three doses were given (<a href="./references#CD009069-fig-0035" title="">Analysis 2.14</a>). The efficacy against CIN3+ of the bivalent vaccine (RR = 0.55; <a href="./references#CD009069-fig-0044" title="">Analysis 3.8</a>.1) was again greater than the quadrivalent vaccine among all enrolled women regardless of their initial HPV DNA status (RR = 0.81; <a href="./references#CD009069-fig-0044" title="">Analysis 3.8</a>.2). However, differences in the population HPV prevalence in the trial sites, or differences in study protocols and assays used, may explain the contrast in efficacy. The quality of evidence regarding protection against any precancer, irrespective of HPV type, among mid‐adult women is low (<a href="#CD009069-tbl-0006">Table 2</a>). </p> </section> <section id="CD009069-sec-0099"> <h6 class="title">Vaccine safety</h6> <p>Short‐term local adverse events were more common in women who received the HPV vaccine compared to those in the control arms. The risk of mild or severe systemic adverse events were similar between intervention and control arms (high‐quality evidence for serious adverse events, see <a href="./full#CD009069-tbl-0003">summary of findings Table 3</a>). The deaths reported in the trials had an identified cause, and none were assessed to be due to vaccination. The risk in absolute terms was low in both trial arms. The rate of mortality was 11 per 10,000 in the control arms, and the confidence interval is wide enough to include a rate of between 9 and 22 per 10,000 following vaccination (moderate quality evidence). In trials enrolling mid‐adult women, a higher mortality rate in the HPV arms was observed. The deaths occurred months to years after vaccination. However, no pattern in the series of death causes was identified and study investigators did not establish a causal role of the HPV vaccines for any of the deaths. </p> <p>We have insufficient evidence available from RCTs to know how vaccination affects women who become pregnant during the vaccination period. Pregnancy outcomes indicated similar risks of miscarriage and elective termination between vaccination and control (high‐quality evidence). Analysis of stillbirth and congenital abnormality outcomes do not yet have enough information to confidently exclude slightly higher or slightly lower risk with vaccination: stillbirths: 70 per 10,000 versus 78 (48 to 128) per 10,000 following HPV vaccination (moderate‐quality evidence); abnormal infants: 205 per 10,000 versus 250 (180 to 346) per 10,000 following HPV vaccination (see <a href="./full#CD009069-tbl-0004">summary of findings Table 4</a>). </p> </section> </section> </section> <section id="CD009069-sec-0100"> <h4 class="title">2. Other important comments</h4> <section id="CD009069-sec-0101"> <h5 class="title">2.1. Duration of protection</h5> <p>The longest duration of follow‐up for which vaccine efficacy data are reported was 102 months for the monovalent HPV16 vaccine (<a href="./references#CD009069-bbs2-0260" title="Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Rowhani‐Rahbar 2009</a>), 113 months for the bivalent vaccine (<a href="./references#CD009069-bbs2-0243" title="NaudPS , Roteli‐MartinsCM , DeCarvalhoNS , TeixeiraJC , deBorbaPC , SanchezN , et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination. Human Vaccines &amp; Immunotherapeutics2014;10(8):2147‐62. ">Naud 2014</a>), and 60 months for the quadrivalent vaccine (<a href="./references#CD009069-bbs2-0297" title="VillaLL , AultKA , GiulianoAR , CostaRL , PettaCA , AndradeRP . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine2006;24(27):5571‐83. ">Villa 2006</a>). For all the vaccines, continued protection was observed at the end of the follow‐up period (<a href="#CD009069-tbl-0023">Table 19</a>). </p> <div class="table" id="CD009069-tbl-0023"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Vaccine efficacy endpoints derived from phase 2 trials with longest follow‐up time</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Initial HPV status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Doses</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative Risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><i><b>Monovalent vaccine (Rowhani‐Rahbar, 2009): 102 months of follow‐up</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;= 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incident HPV16 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incident HPV16 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;= 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incident HPV16 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>regardless of HPV infection</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;= 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ irrespective of HPV types</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>regardless of HPV infection</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;= 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><i><b>Bivalent vaccine (De Calvaho, 2012): 88 months of follow‐up</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6M persistent HPV16/18 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hrHPV‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12M persistent HPV16/18 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hrHPV‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV16/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16/18‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;= 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><i><b>Quadrivalent vaccine (Villa, 2006): 60 months of follow‐up</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent HPV6/11/16/18 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16/18‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;= 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD009069-sec-0102"> <h5 class="title">2.2. Differences in efficacy between the bivalent and quadrivalent vaccine</h5> <p>Based on subgroup analysis by vaccine brands, licensed bivalent and quadrivalent vaccines confer similar protection against HPV16/18 infection and cervical lesions associated with HPV16/18 . However, we did find some evidence that bivalent vaccine was more efficacious than the quadrivalent vaccine against any CIN2+ and CIN3+ (irrespective of HPV type) among women who were hrHPV DNA negative (<a href="./references#CD009069-fig-0019" title="">Analysis 1.7</a>; <a href="./references#CD009069-fig-0020" title="">Analysis 1.8</a>) and against any CIN3+ regardless of HPV DNA status at baseline (<a href="./references#CD009069-fig-0044" title="">Analysis 3.8</a>). This difference may be due to differences in the populations enrolled in the trials, differences in serological or DNA methods used, or better cross‐protection of the bivalent vaccine against other hrHPV types. Cross‐protective vaccine efficacy was assessed in a recent meta‐analysis including data from ; <a href="./references#CD009069-bbs2-0013" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">FUTURE I trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0078" title="MalagonT , DroletM , BoilyMC , FrancoEL , JitM , BrissonJ . Cross‐protective efficacy of two human papillomavirus vaccines: a systematic review and meta‐analysis. Lancet Infectious Diseases2012;12(10):781‐9. ">Malagon 2012</a>; <a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0026" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. NaudPS , Roteli‐MartinsCM , DeCarvalhoNS , TeixeiraJC , deBorbaPC , SanchezN , et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination. Human Vaccines &amp; Immunotherapeutics2014;10(8):2147‐62. The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">Phase2 trial (ph2,2v)</a>; <a href="./references#CD009069-bbs2-0027" title="OlssonSE , KjaerSK , SigurdssonK , IversenOE . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. VillaLL , AultKA , GiulianoAR , CostaRL , PettaCA , AndradeRP . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine2006;24(27):5571‐83. VillaLL , CostaRL , PettaCA , AndradeRP , AultKA , GiulianoAR . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial. Lancet Oncology2005;6(5):271‐8. VillaLL , CostaRL , PettaCA , AndradeRP , PaavonenJ , IversenOE . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up. British Journal of Cancer2006;95(11):1459‐66. ">Phase2 trial (ph2,4v)</a> . Better protection was found against six‐month persistent infection with HPV31 and HPV45 and against CIN2+ related to HPV33 and HPV45 using the bivalent versus the quadrivalent vaccine among women who were hrHPV negative at enrolment (<a href="./references#CD009069-bbs2-0078" title="MalagonT , DroletM , BoilyMC , FrancoEL , JitM , BrissonJ . Cross‐protective efficacy of two human papillomavirus vaccines: a systematic review and meta‐analysis. Lancet Infectious Diseases2012;12(10):781‐9. ">Malagon 2012</a>). Also, <a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a> and <a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a> provided significant cross‐protective efficacy of the bivalent vaccine with respect to CIN2+ associated with non‐vaccine hrHPV types (<a href="./references#CD009069-bbs2-0194" title="HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. ">Hildesheim 2014</a>) and persistent HPV31 and HPV45 infection (<a href="./references#CD009069-bbs2-0273" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. ">Skinner 2014</a>), respectively (<a href="#CD009069-tbl-0024">Table 20</a>). Although there may be some evidence of waning cross‐protection (<a href="./references#CD009069-bbs2-0078" title="MalagonT , DroletM , BoilyMC , FrancoEL , JitM , BrissonJ . Cross‐protective efficacy of two human papillomavirus vaccines: a systematic review and meta‐analysis. Lancet Infectious Diseases2012;12(10):781‐9. ">Malagon 2012</a>), efficacy of the bivalent vaccine lasting for more than nine years against incident HPV31, HPV33 and HPV45 (RR between 0.29 and 0.65) has been reported (<a href="./references#CD009069-bbs2-0282" title="Starkie CamejoH , LiX , VanKriekingeG , RyserM . Response letter regarding the letter to the editors by Butt et al. Does it matter Discounting and its role in the cost‐effectiveness of preventative interventions. The case of HPV vaccination. Public Health2016;132:110‐2. ">Starkie Camejo 2016</a>; <a href="./references#CD009069-bbs2-0287" title="TaylorS , RyserM , MihalyiA , vanEffelterreT . Response letter regarding the letter to the editors by Brown et al. Human Vaccinnes and Immunotherapeutics2016; Vol. 7:1943‐6. ">Taylor 2016</a>). </p> <div class="table" id="CD009069-tbl-0024"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Cross‐protective efficacy of the bivalent and quadrivalent vaccine</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ref</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Relative Risk (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value for</b> </p> <p><b>difference in VE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bivalent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quadrivalent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0010" title="BrownDR , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus‐like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV‐naive women aged 16 to 26 years. Journal of Infectious Diseases2009;199(7):926‐35. DillnerJ , KjaerSK , WheelerCM , SigurdssonK , IversenOE , Hernandez‐AvilaM . Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ2010;341:c3493. KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM , PerezG . A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high‐grade cervical and external genital lesions. Cancer Prevention Research2009;2(10):868‐78. MunozN , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM . Impact of human papillomavirus (HPV)‐6/11/16/18 vaccine on all HPV‐associated genital diseases in young women. Journal of the National Cancer Institute2010;102(5):325‐39. OlssonSE , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. The FUTURE II study group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. Journal of Infectious Diseases2007;196(10):1438‐46. WheelerCM , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , PerezG . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus‐like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16 to 26 years. Journal of Infectious Diseases2009;199(7):936‐44. ">FUT I/II trials (ph3,4v)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD009069-bbs2-0078" title="MalagonT , DroletM , BoilyMC , FrancoEL , JitM , BrissonJ . Cross‐protective efficacy of two human papillomavirus vaccines: a systematic review and meta‐analysis. Lancet Infectious Diseases2012;12(10):781‐9. ">Malagon 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐month persistent HPV31 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.229 (0.156 to 0.228)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.538 (0.336 to 0.847)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐month persistent HPV45 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.210 (0.106 to 0.387)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.922 (0.507 to 1.670)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0026" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. NaudPS , Roteli‐MartinsCM , DeCarvalhoNS , TeixeiraJC , deBorbaPC , SanchezN , et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination. Human Vaccines &amp; Immunotherapeutics2014;10(8):2147‐62. The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">Phase2 trial (ph2,2v)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.177 (0.053 to 0.466)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.760 (0.328 to 1.712)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0027" title="OlssonSE , KjaerSK , SigurdssonK , IversenOE . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. VillaLL , AultKA , GiulianoAR , CostaRL , PettaCA , AndradeRP . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine2006;24(27):5571‐83. VillaLL , CostaRL , PettaCA , AndradeRP , AultKA , GiulianoAR . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial. Lancet Oncology2005;6(5):271‐8. VillaLL , CostaRL , PettaCA , AndradeRP , PaavonenJ , IversenOE . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up. British Journal of Cancer2006;95(11):1459‐66. ">Phase2 trial (ph2,4v)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.000 (0.000 to 0.583)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.481 (0.174 to 1.177)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0194" title="HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. ">Hildesheim 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with other hrHPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.401 (0.192 to 0.793)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009069-bbs2-0273" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. ">Skinner 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐month persistent HPV31 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.209 (0.041 to 0.724)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐month persistent HPV45 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.221 (0.044 to 0.914)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> </div> <p><a href="./references#CD009069-bbs2-0219" title="KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">Kuhs 2014</a> explored whether different serological testing methods and HPV DNA criteria, used to define the sub‐cohort of HPV‐naïve women in the trials, could have influenced efficacy estimates. Applying the less restrictive criteria used in the FUTURE I/II trials (<a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0013" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">FUTURE I trial (ph3,4v)</a>) instead of those applied in the PATRICIA trial (<a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>) on the CVT decreased the estimated efficacy against any CIN2+ (irrespective of HPV type) from 81% to 69%, suggesting this is part of the explanation of the differences observed between vaccines. </p> <p>Note‐worthy is the limited inter‐vaccine difference in efficacy against any CIN2+ (irrespective of HPV type) (<a href="./references#CD009069-fig-0019" title="">Analysis 1.7</a>; <a href="./references#CD009069-fig-0043" title="">Analysis 3.7</a>), where the contribution of non‐HPV16/18 hrHPV types is greater than for CIN3+ (<a href="./references#CD009069-bbs2-0143" title="BzhalavaD , GuanP , FranceschiS , DillnerJ , CliffordG . A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology2013;445(1‐2):224‐31. ">Bzhalava 2013</a>). Comparable significant reductions in the prevalence of HPV31, HPV33 and HPV45 have been observed in vaccinated versus unvaccinated young women attending screening in Australia (vaccinated mainly with the quadrivalent vaccine: <a href="./references#CD009069-bbs2-0286" title="TabriziSN , BrothertonJM , KaldorJM , SkinnerSR , LiuB , BatesonD , et al. Assessment of herd immunity and cross‐protection after a human papillomavirus vaccination programme in Australia: a repeat cross‐sectional study. Lancet Infectious Diseases2014;14(10):958‐66. ">Tabrizi 2014</a>) and Scotland (vaccinated with the bivalent vaccine: <a href="./references#CD009069-bbs2-0208" title="KavanaghK , PollockKG , PottsA , LoveJ , CuschieriK , CubieH , et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. British Journal of Cancer2014;110(11):2804‐11. ">Kavanagh 2014</a>). </p> <p>Differences in safety between the vaccine brands are discussed in section 2.4.</p> </section> <section id="CD009069-sec-0103"> <h5 class="title">2.3. Adverse effects of HPV vaccines</h5> <p>Local adverse events at the injection site (pain, redness, swelling) were more common in vaccinated participants than in placebo recipients. However, systemic mild symptoms and serious adverse effects reported after an administered dose were equally distributed between the trial arms. </p> <p>A pooled analysis of safety data was conducted by the manufacturer of the AS04‐adjuvanted bivalent HPV vaccine involving 31,173 adolescent girls and women who received the vaccine and 24,241 controls (<a href="./references#CD009069-bbs2-0029" title="AngeloMG , DavidMP , ZimaJ , BarilL , DubinG , ArellanoF , et al. Pooled analysis of large and long‐term safety data from the human papillomavirus‐16/18‐AS04‐adjuvanted vaccine clinical trial programme. Pharmacoepidemiology and Drug Safety2014;23(1099‐557 (Electronic), 1053‐8569 (Linking), 5):466‐79. ">Angelo 2014</a>). Unsolicited adverse symptoms reported within 30 days after each dose were slightly more frequent in the vaccine group (30.8% versus 29.7%), whereas medically significant conditions (25.0% versus 28.3%), serious adverse effects (7.9% versus 9.3%) and potentially immune‐mediated diseases (0.52% versus 0.55%), reported over the whole study period, were not more frequent in vaccinated participants versus controls (<a href="./references#CD009069-bbs2-0029" title="AngeloMG , DavidMP , ZimaJ , BarilL , DubinG , ArellanoF , et al. Pooled analysis of large and long‐term safety data from the human papillomavirus‐16/18‐AS04‐adjuvanted vaccine clinical trial programme. Pharmacoepidemiology and Drug Safety2014;23(1099‐557 (Electronic), 1053‐8569 (Linking), 5):466‐79. ">Angelo 2014</a>). </p> <p>Occurrence of autoimmune events, possibly associated with the use of the adjuvants AS04 (3‐O‐desacyl‐4' monophosphoryl lipid A and aluminium) included in several vaccines, including the bivalent HPV vaccine, was assessed in a pooled analysis of trials conducted by the manufacturer (<a href="./references#CD009069-bbs2-0293" title="VerstraetenT , DescampsD , DavidMP , ZahafT , HardtK , IzurietaP , et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine2008;26(0264‐410X (Print), 0264‐410X (Linking), 51):6630‐8. ">Verstraeten 2008</a>). More than 68,000 records were included, among which 39,160 participants received the HPV16/18 L1 vaccine. The mean follow‐up time was 21 months. The overall rate of autoimmune‐related conditions was approximately 0.5% and the relative risk versus control groups was 0.98 (95% CI 0.80 to 1.21) for all AS04‐adjuvanted vaccines and 0.92 (95% CI 0.70 to 1.22) for HPV16/18 vaccine. For the individual autoimmune events, relative risks always included unity (<a href="./references#CD009069-bbs2-0293" title="VerstraetenT , DescampsD , DavidMP , ZahafT , HardtK , IzurietaP , et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine2008;26(0264‐410X (Print), 0264‐410X (Linking), 51):6630‐8. ">Verstraeten 2008</a>). </p> <p>All estimates of adverse effects in our review were restricted to those reported from randomised trials and therefore could not detect rare events, for which post‐marketing surveillance, pharmacovigilance activities and linkage studies, joining vaccine and morbidity registries, are needed. The post‐licensure safety surveillance in the USA confirmed the general safety profile of the quadrivalent vaccine, which was consistent with observations from the studies included in our review, but identified a disproportional reporting of syncope and venous thromboembolic events. However, no causal relation could be established (<a href="./references#CD009069-bbs2-0275" title="SladeBA , LeidelL , VellozziC , WooEJ , HuaW , SutherlandA , et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA2009;302(7):750‐7. ">Slade 2009</a>). Subsequent studies did not find an association with thromboembolic events (<a href="./references#CD009069-bbs2-0242" title="NalewayAL , CraneB , SmithN , DaleyMF , DonahueJ , GeeJ , et al. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008‐2011. Vaccine2016;34(1):167‐71. ">Naleway 2016</a>). Two healthcare organisations in California (USA) assessed new‐onset autoimmune conditions related to immunisation with the quadrivalent vaccine and did not identify significant associations, with the exception of Hashimoto thyroiditis (RR = 1.29, 95% CI 1.08 to 1.56). However, time‐relation and biological plausibility did not reveal evidence of causality (<a href="./references#CD009069-bbs2-0149" title="ChaoC , KleinNP , VelicerCM , SyLS , SlezakJM , TakharH , et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. Journal of Internal Medicine2012;271(2):193‐203. ">Chao 2012</a>). The Medicines and Healthcare products Regulatory Agency of the UK set up a comprehensive pharmacovigilance study assessing the temporal association between chronic fatigue syndromes and the administration of the bivalent HPV vaccine (<a href="./references#CD009069-bbs2-0161" title="DoneganK , Beau‐LejdstromR , KingB , SeabrokeS , ThomsonA , BryanP . Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine2013;31(43):4961‐7. ">Donegan 2013</a>). Despite the high coverage in girls and young women (age 12 to 20), no increased incidence of fatigue syndromes was observed after the introduction of HPV vaccination (incidence rate ratio: 0.94, 95% CI: 0.78 to 1.14). Detailed analysis of self‐controlled case series of 187 girls and young women did not reveal evidence that the HPV vaccine caused fatigue syndromes (ratio: 1.07, 95% CI: 0.57 to 2.00). A large linkage study, joining hospital records with HPV vaccine registries in Sweden and Denmark, did not reveal associations between administration of the quadrivalent vaccine and most autoimmune, neurological or venous thromboembolic adverse events. However, three autoimmune conditions were more common (Behcet’s disease, Raynaud’s disease and type 1 diabetes), and two neurological conditions were less common (epilepsy and paralysis) in vaccinated compared to non‐vaccinated cohorts. Authors considered that multiple comparisons may explain the significant findings (<a href="./references#CD009069-bbs2-0129" title="Arnheim‐DahlstromL , PasternakB , SvanstromH , SparenP , HviidA . Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ2013;347:f5906. ">Arnheim‐Dahlstrom 2013</a>). No increased incidence of thromboembolism or multiple sclerosis or other demyelating neurologic diseases after administration of the quadrivalent vaccine was detected from the Danish‐Swedish linkage studies (<a href="./references#CD009069-bbs2-0263" title="SchellerNM , PasternakB , SvanstromH , HviidA . Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. JAMA2014;312(2):187‐8. ">Scheller 2014</a>; <a href="./references#CD009069-bbs2-0264" title="SchellerNM , SvanstromH , PasternakB , Arnheim‐DahlstromL , SundstromK , FinkK , et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA2015;313:54‐61. ">Scheller 2015</a>). </p> <p>In March 2014, the World Health Organization (WHO) Global Advisory Committee on Vaccine Safety (GACVS) reviewed the evidence base on safety of HPV vaccines and responded to questions related to reports on possible adverse effects (such as syncope, anaphylaxis, venous thromboembolism, adverse pregnancy outcomes, Guillain‐Barré Syndrome (GBS), stroke, toxic effects of the aluminium adjuvant, multiple sclerosis, cerebral vasculitis, complex regional pain syndrome (CRPS) and/or other chronic pain conditions). The committee concluded that the risk‐benefit profile of prophylactic HPV vaccines remains favourable and expressed its concerns about unjustified claims of harm, which lack biological and epidemiological evidence, and which may affect the confidence of the public (<a href="./references#CD009069-bbs2-0222" title="LarsonHJ , CooperLZ , EskolaJ , KatzSL , RatzanS . Addressing the vaccine confidence gap. Lancet2011;378(9790):526‐35. ">Larson 2011</a>). At the same time, the Committee encouraged health authorities to continue surveillance and examination of potential adverse events (<a href="./references#CD009069-bbs2-0302" title="WHO . Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination. http://www.who.int/vaccine_safety/committee/topics/hpv/GACVS_Statement_HPV_12_Mar_2014.pdf2014. ">WHO 2014</a>). </p> <p>Seven large studies and one CDC review have investigated the association between HPV vaccination Guillain‐Barré syndrome (GBS) and found no evidence of increased risk (<a href="./references#CD009069-bbs2-0129" title="Arnheim‐DahlstromL , PasternakB , SvanstromH , SparenP , HviidA . Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ2013;347:f5906. ">Arnheim‐Dahlstrom 2013</a>; <a href="./references#CD009069-bbs2-0148" title="SukumaranL , Advisory Committee on Immunization Practices ‐ Immunization Safety Office ‐ Centers for Disease Control and Prevention (CDC, Atlanta) . Human Papillomavirus Vaccine Safety Update. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides‐2015‐10/hpv‐04‐sukumaran.pdf 21/10/2015. ">CDC 2015</a>; <a href="./references#CD009069-bbs2-0149" title="ChaoC , KleinNP , VelicerCM , SyLS , SlezakJM , TakharH , et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. Journal of Internal Medicine2012;271(2):193‐203. ">Chao 2012</a>; <a href="./references#CD009069-bbs2-0178" title="GeeJ , SukumaranL , WeintraubE . Risk of Guillain‐Barré syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink. Vaccine2017;35(43):5756‐8. ">Gee 2017</a>; <a href="./references#CD009069-bbs2-0183" title="Grimaldi‐BensoudaL , GuillemotD , GodeauB , BenichouJ , Lebrun‐FrenayC , PapeixC , et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. Journal of Internal Medicine2014;275(4):398‐408. ">Grimaldi‐Bensouda 2014</a>; <a href="./references#CD009069-bbs2-0246" title="OjhaRP , JacksonBE , TotaJE , Offutt‐PowellTN , SinghKP , BaeS . Guillain‐Barré syndrome following quadrivalent human papillomavirus vaccination among vaccine‐eligible individuals in the United States. Human Vaccines &amp; Immunotherapeutics2014;10(1):232‐7. ">Ojha 2014</a>; <a href="./references#CD009069-bbs2-0295" title="VichninM , BonanniP , KleinNP , GarlandSM , BlockSL , KjaerSK , et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatric Infectious Disease Journal2015;34(9):983‐1. ">Vichnin 2015</a>). In contrast, a French linkage study, linking HPV vaccination and morbidity registries, comprising more than 2 million girls found an increased risk of GBS: 0.4 versus 1.4 per 100,000 for non‐vaccinated and vaccinated girls and young women, respectively, adjusted hazard ratio (HR): 4.00, 95% CI 1.84 to 8.69) (<a href="./references#CD009069-bbs2-0120" title="ANSM/SANTE . Risk of auto‐immune diseases after vaccination against HPV: a pharmacoepidemiological study [Vaccins anti‐HPV et risque de maladies auto‐immunes : étude pharmacoépidémiologique]. http://ansm.sante.fr/S‐informer/Points‐d‐information‐Points‐d‐information/Vaccination‐contre‐les‐infections‐a‐HPV‐et‐risque‐de‐maladies‐auto‐immunes‐une‐etude‐Cnamts‐ANSM‐rassurante‐Point‐d‐informationSeptember 2015;Website accessed 10‐12‐15:1‐91. ">ANSM/SANTE 2015</a>). The association between GBS and HPV vaccination was strongest during the first three months after the last dose. </p> <p>Upon request of the Danish health authorities, the Pharmacovigilance Risk Assessment Committee of the European Medicine Agency investigated complaints of complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) among young women who received HPV vaccines (<a href="./references#CD009069-bbs2-0167" title="EMEA . Review concludes evidence does not support that HPV vaccines cause CRPS or POTS. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/11/news_detail_002429.jsp&amp;mid=WC0b01ac058004d5c1 05/11/2015. ">EMEA 2015</a>). No causal relation could be established. Preliminary conclusions were confirmed by the EMA Committee for Medicinal Products for Human Use (CHMP) completed with representations from patient groups (<a href="./references#CD009069-bbs2-0164" title="European Medicines Agency. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vaccines_20/European_Commission_final_decision/WC500196773.pdf 16/01/2016. ">EMA 2016</a>). A Danish case‐control study compared pre‐vaccination health‐seeking behaviour in HPV vaccinated girls who had reported adverse effects (cases) with matched cohorts of HPV vaccinated girls who had not reported adverse affects. Increased rates of health problems were reported in the case group (<a href="./references#CD009069-bbs2-0237" title="MolbakK , HansenND , Valentiner‐BranthP . Pre‐vaccination care‐seeking in females reporting severe adverse reactions to HPV vaccine. A registry based case‐control study. PLOS One2016;11(9):e0162520. ">Molbak 2016</a>). Increasing trends in the incidence of chronic fatigue syndrome, systemic exertion intolerance disease and POTS (assessed from hospital discharge records) were reported in girls aged 12 to 15 years in the decade preceding the introduction of HPV vaccination in Finland (<a href="./references#CD009069-bbs2-0274" title="SkufcaJ , OllgrenJ , RuokokoskiE , LyytikäinenO , NohynekH . Incidence rates of Guillain‐Barré‚ (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002‐2012. Papillomavirus Research2017;3:91‐6. ">Skufca 2017</a>). The authors warned for pre‐vaccination trends and variation in disease coding and healthcare‐seeking behaviour, which may influence the interpretation of associations with HPV vaccination (<a href="./references#CD009069-bbs2-0237" title="MolbakK , HansenND , Valentiner‐BranthP . Pre‐vaccination care‐seeking in females reporting severe adverse reactions to HPV vaccine. A registry based case‐control study. PLOS One2016;11(9):e0162520. ">Molbak 2016</a>, <a href="./references#CD009069-bbs2-0274" title="SkufcaJ , OllgrenJ , RuokokoskiE , LyytikäinenO , NohynekH . Incidence rates of Guillain‐Barré‚ (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002‐2012. Papillomavirus Research2017;3:91‐6. ">Skufca 2017</a>). </p> <p>In its last statement, the GACVS confirmed previous conclusions on HPV vaccine safety after revision of the recent signals on increased occurrence of GBS, POTS and CRPS (<a href="./references#CD009069-bbs2-0303" title="WHO . Safety of HPV vaccines (from meeting of 2‐3 December, 2015). Weekly Epidemiological Record2016;91(3):26‐8. ">WHO 2016</a>). </p> </section> <section id="CD009069-sec-0104"> <h5 class="title">2.4. Comparison of adverse effects of the bivalent versus quadrivalent vaccines</h5> <p>Our review revealed a significantly higher rate of localised effects (<a href="./references#CD009069-fig-0067" title="">Analysis 7.1</a>), such as pain (<a href="./references#CD009069-fig-0068" title="">Analysis 7.2</a>) and swelling (<a href="./references#CD009069-fig-0070" title="">Analysis 7.4</a>) at the injection site for women who received the bivalent vaccine. However, in a meta‐regression adjusting for age and type of adjuvants or other vaccine given to the control group, these differences became non‐significant (<a href="#CD009069-tbl-0025">Table 21</a>). The meta‐regression analysis suggested a higher rate of local adverse effects associated with bivalent compared with the quadrivalent vaccine (relative risk ratio (RRR) = 1.69, 95% CI 0.96 to 2.96, P value = 0.61). The non‐significance might be due to the low power of meta‐regression. Higher rates of local adverse effects at the injection site with the bivalent vaccine were also observed in a head‐to‐head trial comparing immunogenicity and safety of the two licensed vaccines (<a href="./references#CD009069-bbs2-0047" title="EinsteinMH , BaronM , LevinMJ , ChatterjeeA , FoxB , ScholarS . Comparative immunogenicity and safety of human papillomavirus (HPV) 16/18 vaccine and HPV‐6/11/16/18 vaccine: Follow‐up from months 12 to 24 in a Phase III randomized study of healthy women aged 18 to 45 years. Human Vaccines &amp; Immunotherapeutics2011;7(12):1343‐58. ">Einstein 2011</a>). A significantly higher rate of local injection site reactions was observed with the bivalent compared with the quadrivalent vaccine (RR for pain: 1.30 (95% CI 1.25 to 1.34); RR for swelling: 1.67 (95% CI 1.43 to 1.98); RR redness: 1.73 (95% CI 1.52 to 1.98). A marginally non‐significant higher frequency of medical significant conditions was noted among women who received the bivalent vaccine: RR = 1.15 (95% CI: 0.99 to 1.34). There were no statistically significant differences for the other adverse effects: new onset chronic diseases (RR = 0.95, 95% CI:0.52 to 1.74), new onset autoimmune disease (RR = 0.60, 95% CI:0.22 to 1.64), serious adverse effects (RR = 1.05, 95% CI:0.59 to 1.85) (<a href="./references#CD009069-bbs2-0047" title="EinsteinMH , BaronM , LevinMJ , ChatterjeeA , FoxB , ScholarS . Comparative immunogenicity and safety of human papillomavirus (HPV) 16/18 vaccine and HPV‐6/11/16/18 vaccine: Follow‐up from months 12 to 24 in a Phase III randomized study of healthy women aged 18 to 45 years. Human Vaccines &amp; Immunotherapeutics2011;7(12):1343‐58. ">Einstein 2011</a>). </p> <div class="table" id="CD009069-tbl-0025"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">Relative risk ratio of adverse effects associated with the bivalent versus the quadrivalent vaccine, adjusted for age group and products administered in the control group</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Adverse effect</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative risk</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative risk ratio</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>p value</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quadrivalent vs placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bivalent/Quadrivalent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall adverse effects at injection site</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.89 to 1.59)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69 (0.96 to 2.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.061</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain at injection site</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.78 to 1.85)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.67 to 2.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.501</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling at injection site</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.72 (0.77to 9.61)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.16 to 2.41)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.427</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Redness at injection site</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.46 (1.23 to 1.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.88 to 1.32)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.307</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall systemic events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.91 to 1.07)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.95 to 1.19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.210</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.70 to 1.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.80 to 1.45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.583</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deaths</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.25 to 5.62)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.14 to 4.91)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.775</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Relative risks of the quadrivalent vaccine versus placebo and the relative risk ratios were computed by meta‐regression including vaccine, age group and type of product injected in the control group (aluminium adjuvants alone or other vaccine such as Hepatitis A vaccine) as covariate. The relative risk ratio reflects how much more an adverse effect is observed after vaccination with the bivalent versus the quadrivalent vaccine. </p> </div> </div> </section> <section id="CD009069-sec-0105"> <h5 class="title">2.5. Pregnancy and infant outcomes</h5> <p>Pregnancy or sexual activity without contraception were exclusion criteria for enrolment in randomised HPV vaccination trials. However, if enrolled women became pregnant, pregnancy outcomes were surveyed carefully. In a pooled analysis of five phase III trials assessing the quadrivalent vaccine, miscarriage or congenital anomalies were not more common in the vaccine arm compared to the placebo arm (<a href="./references#CD009069-bbs2-0177" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 Vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. ">Garland 2009</a>). No relation was found between the time from administration of the vaccine to conception and adverse pregnancy outcomes or occurrence of congenital anomalies. The rate of miscarriage was not higher for women who conceived within 30 days of any vaccination (18.2% in the vaccine arm versus 21.0% in the placebo group (P values or 95% CIs not computable by lack of denominator). Also in a pooled analysis of the PATRICIA and Costa Rica Vaccination trial (<a href="./references#CD009069-bbs2-0299" title="WacholderS , ChenBE , WilcoxA , MaconesG , GonzalezP , BefanoB . Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ2010;340:c712. ">Wacholder 2010</a>), miscarriage was not more frequent in women who received the bivalent HPV vaccine (197/1709 = 11.5%) compared with those who received the hepatitis A vaccine in the control group (176/1727 = 10.2%): RR = 1.13, 95% CI 0.93 to 1.37. However, for women who became pregnant within 90 days of administration of the bivalent vaccine, a significant increase in the rate of miscarriage was observed in women who received the HPV vaccine (58/394 = 14.7%) versus the control group (34/374 = 9.1%): RR = 1.62, 95% CI: 1.08 to 2.41) (<a href="./references#CD009069-bbs2-0299" title="WacholderS , ChenBE , WilcoxA , MaconesG , GonzalezP , BefanoB . Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ2010;340:c712. ">Wacholder 2010</a>). However, this finding was not confirmed in a larger study (<a href="./references#CD009069-bbs2-0251" title="PanagiotouOA , BefanoBL , GonzalezP , RodriguezAC , HerreroR , SchillerJT , et al. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow‐up in the Costa Rica HPV Vaccine Trial. BMJ2015;351:h4358. ">Panagiotou 2015</a>). After completion of the CVT trial (<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>), women in the placebo arm were offered the bivalent vaccine. Pregnancy outcomes were monitored for vaccinated women (from the vaccine arm + cross‐over vaccination from the control arm) and for control women (from the placebo arm having received Hepatitis A vaccine only completed with an unvaccinated cohort). The miscarriage rate was 13.3% (451 / 3394) among women who conceived at any time since bivalent HPV vaccination) versus 12.8% (414/3227) in pregnant women from the control group RR = 1.04 (95% 0.91 to 1.17, P value = 0.29) (<a href="./references#CD009069-bbs2-0251" title="PanagiotouOA , BefanoBL , GonzalezP , RodriguezAC , HerreroR , SchillerJT , et al. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow‐up in the Costa Rica HPV Vaccine Trial. BMJ2015;351:h4358. ">Panagiotou 2015</a>). There was no increased risk of miscarriage among women conceiving within 90 days of vaccination (P value = 0.436) overall or in subgroups. However, among women who conceived at any time from vaccination, an increased rate was observed for miscarriage occurring at 13 to 20 weeks of gestation (RR = 1.35, 95% CI 1.02‐1.77) (<a href="./references#CD009069-bbs2-0251" title="PanagiotouOA , BefanoBL , GonzalezP , RodriguezAC , HerreroR , SchillerJT , et al. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow‐up in the Costa Rica HPV Vaccine Trial. BMJ2015;351:h4358. ">Panagiotou 2015</a>). </p> <p>In a post‐marketing surveillance study of 517 women who received the quadrivalent vaccine and became pregnant in the USA, Canada or France, the observed rates of miscarriage and birth defects were not higher than expected in the general population (<a href="./references#CD009069-bbs2-0153" title="DanaA , BuchananKM , GossMA , SeminackMM , ShieldsKE , KornS . Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstetrics and Gynaecology2009;114(1873‐233X (Electronic), 6):1170‐8. ">Dana 2009</a>). An updated analysis including 1752 pregnant women having received the quadrivalent vaccine confirmed previous conclusions (<a href="./references#CD009069-bbs2-0182" title="GossMA , LievanoF , BuchananKM , SeminackMM , CunninghamML , DanaA . Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine2015;33:3422‐8. ">Goss 2015</a>). No overall increased rate of adverse pregnancy outcomes was noted in British women who received the bivalent vaccine close to conception (‐30 to + 45 or ‐30 to +90 days) versus women who became pregnant six to 18 months after the last dose. However, in one subgroup, who received two doses of bivalent vaccine around conception, an increased hazard of miscarriage was found (HR 2.55, 95% CI 1.09 to 5.93) (<a href="./references#CD009069-bbs2-0131" title="BarilL , RosillonD , WillameC , AngeloMG , ZimaJ , van denBoschJH , et al. Risk of spontaneous abortion and other pregnancy outcomes in 15‐25 year old women exposed to human papillomavirus‐16/18 AS04‐adjuvanted vaccine in the United Kingdom. Vaccine2015;33:6884‐91. ">Baril 2015</a>). A retrospective cohort study assessed pregnancy outcomes in women with live births vaccinated with the quadrivalent HPV vaccine, according the co‐incident timing of vaccine administration and the pregnancy: a) 720 received the vaccine in the periconceptional period (two weeks before and after the last menstrual period); b) 638 during the pregnancy and c) 8196 four to 18 months before last menstrual period (<a href="./references#CD009069-bbs2-0228" title="LipkindHS , Vazquez‐BenitezG , NordinJD , RomittiPA , NalewayAL , KleinNP , et al. Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy. Obstetrics and Gynecology2017;130(3):599‐608. ">Lipkind 2017</a>). No increased risks neither in adverse obstetric events nor in birth outcomes were observed in the first two groups compared to the comparison group. </p> </section> <section id="CD009069-sec-0106"> <h5 class="title">2.6. Safety of HPV vaccines co‐administered with other vaccines</h5> <p>A systematic review comparing HPV vaccines administered alone versus co‐administered with other vaccines (meningococcal conjugate, hepatitis A, hepatitis B, combined hepatitis A and B, tetanus, diphtheria, acellular pertussis, and inactivated poliovirus vaccines) showed non‐inferior seroconversion rates and similar rates of adverse effects (<a href="./references#CD009069-bbs2-0245" title="NoronhaAS , MarkowitzLE , DunneEF . Systematic review of human papillomavirus vaccine coadministration. Vaccine2014;32(23):2670‐4. ">Noronha 2014</a>). </p> </section> <section id="CD009069-sec-0107"> <h5 class="title">2.7. Efficacy of the nona‐valent HPV vaccine</h5> <p>A recent paper reported the effects up to 48 months of the new nona‐valent vaccine which contains virus‐like particles (VLP) of the L1 protein of the HPV types 31, 33, 45, 52 and 58 as well as the four types included in the quadrivalent vaccine in women aged 16 to 26 years (<a href="./references#CD009069-bbs2-0205" title="JouraEA , GiulianoAR , IversenOE , BouchardC , MaoC , MehlsenJ , et al. A 9‐Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. New England Journal of Medicine2015;372(8):711‐23. ">Joura 2015</a>). The seven included high‐risk types comprise the most prevalent types in cervical cancer and nearly 90% of all cervical cancer cases worldwide can be attributed to these types (<a href="./references#CD009069-bbs2-0126" title="ArbynM , TommasinoM , DepuydtC , DillnerJ . Are 20 human papillomavirus types causing cervical cancer?. Journal of Pathology2014;234(4):431‐5. ">Arbyn 2014</a>; <a href="./references#CD009069-bbs2-0134" title="BoschFX , BurchellAN , SchiffmanM , GiulianoAR , deSanjoseS , BruniL , et al. Epidemiology and natural history of human papillomavirus infections and type‐specific implications in cervical neoplasia. Vaccine2008;26(Suppl 10):K1‐K16. ">Bosch 2008</a>). The randomised trial was not included in our review since it compared the nona‐valent with the quadrivalent vaccine. </p> <p>In women who were hrHPV DNA negative at baseline the relative risk (9‐ versus quadrivalent vaccinated) of persistent infection with HPV types 31, 33, 45, 52 and 58 as well as CIN2+ associated with these five types was 0.04 (95% CI 0.03 to 0.06). In this group, the risk of any CIN2+ irrespective of HPV types was 0.60 (95% CI 0.36 to 0.98). In the modified intention‐to‐treat group, including women without cytological lesions regardless of baseline HPV DNA status, no protection was observed against any CIN2+ irrespective of HPV (RR = 1.00, 95% CI 0.96 to 1.16) (<a href="./references#CD009069-bbs2-0205" title="JouraEA , GiulianoAR , IversenOE , BouchardC , MaoC , MehlsenJ , et al. A 9‐Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. New England Journal of Medicine2015;372(8):711‐23. ">Joura 2015</a>). Three per cent more local adverse reactions were observed in women who received the nona‐valent vaccine: RR = 1.03 (95% CI 1.02 to 1.04) but no significant differences in systemic of serious adverse events were noted. A more recent report confirmed efficacy findings over a follow‐up period of six years (<a href="./references#CD009069-bbs2-0197" title="HuhWK , JouraEA , GiulianoAR , IversenOE , deAndradeRP , AultKA , et al. Final efficacy, immunogenicity, and safety analyses of a nine‐valent human papillomavirus vaccine in women aged 16‐26 years: a randomised, double‐blind trial. Lancet2017;390(10108):2043‐59. ">Huh 2017</a>). </p> <p>A similar immune response of the nona‐valent vaccine compared to the quadrivalent vaccine against HPV6, HPV11, HPV16 and HPV18 was demonstrated for girls of age nine to 15 years (<a href="./references#CD009069-bbs2-0294" title="VesikariT , BrodszkiN , VanDammeP , Diez‐DomingoJ , IcardiG , KjeldPL , et al. A randomized, double‐blind, phase III study of the immunogenicity and safety of a 9‐valent human papillomavirus L1 virus‐like particle vaccine (V503) versus Gardasil(R) in 9‐15‐year‐old girls. Pediatric Infectious Disease Journal2015;34(9):992‐8. ">Vesikari 2015</a>). Non‐inferior immunogenicity of the nona‐valent vaccine was shown in girls and boys aged nine to 15 years compared to young women aged 16 to 25 years (<a href="./references#CD009069-bbs2-0292" title="VanDammeP , OlssonSE , BlockS , CastellsagueX , GrayGE , HerreraT , et al. Immunogenicity and Safety of a 9‐Valent HPV Vaccine. Pediatrics2015;136(1):e28‐e39. ">Van Damme 2015</a>). </p> <p>The efficacy and safety of the nona‐valent vaccine will be assessed in a future update of this Cochrane review, when results of more trials are available. This update will include also inter‐vaccine comparisons without a placebo arm. </p> </section> <section id="CD009069-sec-0108"> <h5 class="title">2.8. Post marketing surveillance of HPV vaccine effectiveness</h5> <p>This review summarises efficacy estimated from randomised trials, which are not necessarily transposable to field conditions. However, trend analyses and linkage studies joining cervical cancer screening records and vaccination registries report a significant reduction in prevalence of HPV vaccine types, cervical cytological abnormalities and CIN in countries where HPV vaccination has been introduced and where a considerable HPV vaccination coverage has been achieved (<a href="./references#CD009069-bbs2-0127" title="ArbynM , Vanden BroeckD , BenoyI , BogersJ , DepuydtC , PraetM , et al. Surveillance of effects of HPV vaccination in Belgium. Cancer Epidemiology2016;41:152‐8. ">Arbyn 2016</a>; <a href="./references#CD009069-bbs2-0130" title="Baldur‐FelskovB , DehlendorffC , MunkC , KjaerSK . Early impact of human papillomavirus vaccination on cervical neoplasia‐nationwide follow‐up of young Danish women. Journal of the National Cancer Institute2014;106(3):dtj460. ">Baldur‐Felskov 2014</a>; <a href="./references#CD009069-bbs2-0140" title="BrothertonJM , FridmanM , MayCL , ChappellG , SavilleAM , GertigDM . Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet2011;377(1474‐547X (Electronic), 0140‐6736 (Linking), 9783):2085‐92. ">Brotherton 2011</a>; <a href="./references#CD009069-bbs2-0208" title="KavanaghK , PollockKG , PottsA , LoveJ , CuschieriK , CubieH , et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. British Journal of Cancer2014;110(11):2804‐11. ">Kavanagh 2014</a>; <a href="./references#CD009069-bbs2-0209" title="KavanaghK , PollockKG , CuschieriK , PalmerT , CameronRL , WattC , et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7‐year cross‐sectional study. Lancet Infectious Diseases2017;17(12):1293‐302. ">Kavanagh 2017</a>; <a href="./references#CD009069-bbs2-0226" title="LevalA , HerweijerE , PlonerA , ElorantaS , Fridman SimardJ , DillnerJ , et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. Journal of the National Cancer Institute2013;105(7):469‐74. ">Leval 2013</a>; <a href="./references#CD009069-bbs2-0231" title="MarkowitzLE , HaririS , LinC , DunneEF , SteinauM , McQuillanG , et al. Reduction in in human papillomavirus (HPV) prevalence among young women following HPVvaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003‐2010. Journal of Infectious Diseases2013;208(3):385‐93. ">Markowitz 2013</a>; <a href="./references#CD009069-bbs2-0236" title="MerckxM , Vanden BroeckD , BenoyI , DepuydtC , WeyersS , ArbynM . Early effects of human papillomavirus vaccination in Belgium. European Journal of Cancer Prevention2015;24(4):340‐2. ">Merckx 2015</a>; <a href="./references#CD009069-bbs2-0285" title="TabriziSN , BrothertonJM , KaldorJM , SkinnerSR , CumminsE , LiuB , et al. Fall in human papillomavirus prevalence following a national vaccination program. Journal of Infectious Diseases2012;206(11):1645‐51. ">Tabrizi 2012</a>). A recent meta‐analysis assessed vaccination effects in the general population by comparing prevalence of HPV infection before and after introduction of HPV vaccination (<a href="./references#CD009069-bbs2-0163" title="DroletM , BenardE , BoilyMC , AliH , BaandrupL , BauerH , et al. Population‐level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta‐analysis. Lancet Infectious Diseases2015;15(5):565‐80. ">Drolet 2015</a>). Among girls and young women aged 13 to 19 years, a significant reduction was observed for infection with HPV16/18 infection (RR: 0.36, CI: 0.12 to 0.89) and of also of infection with HPV31, HPV33 and HPV45 (RR: 0.72, CI: 0.54 to 0.96), suggesting cross‐protection. No significant differences were observed in women of age 20 years and older (RR: 0.89, CI 0·79 to 1.02). The effects increased by vaccination coverage and years since vaccination. No differences by vaccine type (bi‐ or quadrivalent) were observed. These findings corroborate findings from the randomised trials. Women vaccinated at younger age reflect findings of young women who were free of HPV infection at enrolment in the RCTs. Herd immunity (protection of non‐vaccinated women living in populations with high HPV vaccination coverage) was shown from recent surveillance studies, linking HPV vaccination studies and HPV genotyping of cervical specimen of young women entering the screening programme, in Scotland (<a href="./references#CD009069-bbs2-0209" title="KavanaghK , PollockKG , CuschieriK , PalmerT , CameronRL , WattC , et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7‐year cross‐sectional study. Lancet Infectious Diseases2017;17(12):1293‐302. ">Kavanagh 2017</a>) and Australia (<a href="./references#CD009069-bbs2-0286" title="TabriziSN , BrothertonJM , KaldorJM , SkinnerSR , LiuB , BatesonD , et al. Assessment of herd immunity and cross‐protection after a human papillomavirus vaccination programme in Australia: a repeat cross‐sectional study. Lancet Infectious Diseases2014;14(10):958‐66. ">Tabrizi 2014</a>). </p> <p>The effect on the incidence of genital warts is the first clinical effect of HPV vaccination (with the quadrivalent vaccine) and may be an indicator of protection against cervical (pre‐) cancer. Decreased incidence of genital warts in young (12 to 26 years) heterosexual, but not homosexual, males and decreased incidence of HPV vaccine types in non‐vaccinated young women in Australia, indicate a certain level of herd immunity (<a href="./references#CD009069-bbs2-0162" title="DonovanB , FranklinN , GuyR , GrulichAE , ReganDG , AliH , et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infectious Diseases2011;11(1474‐4457 (Electronic), 1473‐3099 (Linking), 1):39‐44. ">Donovan 2011</a>; <a href="./references#CD009069-bbs2-0286" title="TabriziSN , BrothertonJM , KaldorJM , SkinnerSR , LiuB , BatesonD , et al. Assessment of herd immunity and cross‐protection after a human papillomavirus vaccination programme in Australia: a repeat cross‐sectional study. Lancet Infectious Diseases2014;14(10):958‐66. ">Tabrizi 2014</a>). However, in Sweden, higher (although not statistically significant) rates of genital warts were reported in vaccinated women older than 20 years (<a href="./references#CD009069-bbs2-0226" title="LevalA , HerweijerE , PlonerA , ElorantaS , Fridman SimardJ , DillnerJ , et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. Journal of the National Cancer Institute2013;105(7):469‐74. ">Leval 2013</a>). This phenomenon is most plausibly explained by an association between the tendency of opportunistic vaccination and high‐risk behaviour of adult sexually active women, who were vaccinated after exposure to HPV infection. The meta‐analysis of <a href="./references#CD009069-bbs2-0163" title="DroletM , BenardE , BoilyMC , AliH , BaandrupL , BauerH , et al. Population‐level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta‐analysis. Lancet Infectious Diseases2015;15(5):565‐80. ">Drolet 2015</a> suggests herd immunity by observing reduced prevalence of genital warts in males younger than 20 years (RR: 0.66, CI 0.47 to 0.91) and in women in the age range 20 to 39 (0.68, 0.510.89) in countries where vaccination coverage among young women exceeded 50%. </p> <p>To conclude, these real‐life effectiveness data are in line with conclusions of our review regarding efficacy derived from the randomised trials. </p> </section> </section> </section> <section id="CD009069-sec-0109"> <h3 class="title" id="CD009069-sec-0109">Overall completeness and applicability of evidence</h3> <section id="CD009069-sec-0110"> <h4 class="title">1. Completeness of evidence</h4> <p><a href="#CD009069-fig-0012">Figure 12</a> summarises the main efficacy estimates. We can distinguish seven endpoints (CIN2+, CIN3+, AIS+ associated with HPV types covered by the vaccines or any lesions irrespective of HPV types and persistent HPV16/18 infection), five exposure groups (defined by initial HPV DNA status and number of doses received), and two major age groups (15 to 26 and 25 to 45 years). Altogether, 70 data cells could potentially be completed from the trial databases. However, for 32 cells no data could be extracted and for the other 38 only a limited number of trials contributed data. Nonetheless, for the most relevant endpoint‐exposure group combinations, sufficient evidence could be derived allowing for evidence‐based decision making. </p> </section> <section id="CD009069-sec-0111"> <h4 class="title">2. Endpoint of cervical cancer</h4> <p>The purpose of prophylactic vaccination against HPV is to reduce the incidence of cervical cancer. However, this outcome could not be assessed in our review, since trials conducted were not powered and included insufficient follow‐up time to demonstrate this endpoint. In agreement with World Health Organization (WHO) recommendation, reduction of histologically‐classified cervical intraepithelial neoplasias (CIN) grade 2 or worse, associated with the HPV types targeted by the vaccine, was the proposed main endpoint of vaccination efficacy trials (<a href="./references#CD009069-bbs2-0250" title="PagliusiSR , Teresa AguadoM . Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine2004;23(0264‐410X, 5):569‐78. ">Pagliusi 2004</a>). Defining invasive cancer as an outcome of the trials was considered as an unethical and unfeasible endpoint and would require extremely expensive and lengthy observation periods and postpone the availability of vaccines for decades (<a href="./references#CD009069-bbs2-0250" title="PagliusiSR , Teresa AguadoM . Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine2004;23(0264‐410X, 5):569‐78. ">Pagliusi 2004</a>). The observation of a reduced incidence of cervical cancer (and other HPV‐related cancer) in vaccinated cohorts will have to be obtained from population‐based studies linking cancer and vaccination registries (<a href="./references#CD009069-bbs2-0223" title="LehtinenM , ApterD , DubinG , KosunenE , IsakssonR , KorpivaaraEL . Enrolment of 22,000 adolescent women to cancer registry follow‐up for long‐term human papillomavirus vaccine efficacy: guarding against guessing. International Journal of STD &amp; AIDS2006;17(0956‐4624 (Print), 8):517‐21. ">Lehtinen 2006</a>). </p> </section> <section id="CD009069-sec-0112"> <h4 class="title">3. Limited reported data for certain endpoints and exposure groups</h4> <p>This Cochrane review primarily used efficacy data extractable from peer‐reviewed published reports. Since, in principle all trials evaluated at baseline all enrolled women for presence of HPV genotypes and in addition cytology, and HPV serology, more efficacy data are available which would fit the defined analyses groups included in our Cochrane review. However, often only a restricted series of results were reported limiting the number of studies in each of the analyses (varying from one to eight), and gaps of non‐reported outcomes (<a href="#CD009069-fig-0006">Figure 6</a> and <a href="#CD009069-fig-0007">Figure 7</a>). Indeed, only the endpoints CIN2+ related to HPV16/18 (<a href="./references#CD009069-fig-0023" title="">Analysis 2.2</a>) and persistent infection of HPV16/18 at six months (<a href="./references#CD009069-fig-0054" title="">Analysis 5.4</a>) in women being negative for HPV16/18 DNA at enrolment have as many as eight trials in one forest plot. Originally, we planned requesting data from data owners, to fill in gaps with available unpublished data. However, due to constraints in time and other resources this was not possible. We do not believe that this has undermined the importance of our review. For each major outcome included in <a href="./full#CD009069-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD009069-tbl-0003">summary of findings Table 3</a>, we were able to obtain precise estimates of vaccine effects in the two main public health relevant groups: A) young women who were hrHPV negative at enrolment and received at least one dose of vaccine, who resemble the first target population of school‐based HPV vaccination programs (adolescent girls aged 12 to 14 years) and B) young women regardless of HPV status at enrolment, who received at least one vaccine dose, reflecting a catch‐up vaccination targeting older adolescents or young adult women. Among this latter category there is likely to be a considerable proportion who have already started sexual relations. In mid‐adult women (aged 24 to 45 years), almost no data were reported with respect to protection against any high‐grade CIN, irrespective of HPV type. </p> </section> <section id="CD009069-sec-0113"> <h4 class="title">4. Non‐published trials</h4> <p>We consulted the trial registry <a href="https://clinicaltrials.gov/" target="_blank">https://clinicaltrials.gov/</a> to identify randomised trials which potentially could contain efficacy or safety data from women vaccinated with prophylactic HPV vaccines, but which were not published, or from which data could not be extracted (<a href="./appendices#CD009069-sec-0134">Appendix 6</a>). A high level of reporting was noted for the safety outcome: results from 96% of women (97% and 95%, for the bi‐ and quadrivalent vaccine, respectively) enrolled in registered trials were comprised in studies included in our review. From four small trials with the bivalent vaccine, we could not retrieve data. Three trials (one bi‐bivalent (<a href="./references#CD009069-bbs2-0040" title="DennyL , HendricksB , GordonC , ThomasF , HezarehM , DobbelaereK . Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine in HIV‐positive women in South Africa: A partially‐blind randomised placebo‐controlled study. Vaccine2013;31(48):5745‐53. ">Denny 2013</a>); two quadrivalent (<a href="./references#CD009069-bbs2-0074" title="LiR , LiY , RadleyD , LiuY , HuangT , SingsHL . Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double‐blind, placebo‐controlled trial in Chinese males and females. Vaccine2012;30(28):4284‐91. ">Li 2012</a>; <a href="./references#CD009069-bbs2-0096" title="ReisingerKS , BlockSL , Lazcano‐PonceE , SamakosesR , EsserMT , ErickJ , et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus‐like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatric Infectious Disease Journal2007;26(3):201‐9. ">Reisinger 2007</a>)) were excluded. If the studies excluded from our Cochrane review were not taken into account, the inclusion coverage became 97.7% for the bivalent and 100% for the quadrivalent vaccine. </p> </section> <section id="CD009069-sec-0114"> <h4 class="title">5. Immunogenicity of HPV vaccines</h4> <p>Intramuscular injection of L1‐based HPV vaccines induce production of virus‐specific antibodies in serum which exudate to epithelia and, by binding to HPV particles, impede new infection (<a href="./references#CD009069-bbs2-0279" title="StanleyMA . Human papillomavirus vaccines. Reviews in Medical Virology2006;16(1052‐9276 (Print), 3):139‐49. ">Stanley 2006</a>). The demonstration of serological responses in girls younger than 15 years of age, which were non‐inferior to those in women aged 15 to 26 (where virological and clinical efficacy was demonstrated), was pivotal in accepting HPV vaccines for use before onset of sexual activity (<a href="./references#CD009069-bbs2-0267" title="SchillerJT , LowyDR . Immunogenicity testing in human papillomavirus virus‐like‐particle vaccine trials. Journal of Infectious Diseases2009;200(2):166‐71. ">Schiller 2009</a>). </p> <p>The trials of the bi‐ and quadrivalent HPV vaccine have used different assays to measure virus‐specific antibody titres, making quantitative comparison of the serological data difficult. The chemiluminescence Immunoassay (cLIA ), generally used to measure the serological response in quadrivalent vaccine trials, is known to be more specific for certain fractions of virus‐neutralising antibodies, whereas enzyme‐linked immunosorbent assayS (ELISA) may also detect non‐neutralising antibodies. Loss of detectable anti‐HPV18 antibody by cLIA was not associated with waning of protection. Moreover, in trial reports, each company has used assay‐ and type‐specific concentration measures. Recently, standardised international units have been proposed to quantify type‐specific anti‐HPV serological responses (<a href="./references#CD009069-bbs2-0290" title="UngerE , DillnerJ . Human Papillomavirus Laboratory Manual. 1st Edition. Geneva: WHO (Quality, Safety and Standards (QSS) team of the Department of Immunization, Vaccines and Biologicals), 2010. ">Unger 2010</a>). However, these international units have not yet been applied in vaccine trial reports. As yet, no immunological correlate for clinical efficacy has been identified. </p> <p>Therefore, immunogenicity of prophylactic HPV vaccines was not assessed in the current version of our Cochrane review, as was originally foreseen in the protocol (<a href="./references#CD009069-bbs2-0310" title="ArbynM , BryantA , Martin‐HirschPL , XuL , SimoensC , MarkowitzL . Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD009069.pub2] ">Arbyn 2013</a>). </p> <p>There was one head‐to‐head trial, where women were randomised to receive the bi‐ or quadrivalent vaccines (<a href="./references#CD009069-bbs2-0046" title="EinsteinMH , BaronM , LevinMJ , ChatterjeeA , EdwardsRP , ZeppF . Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18 to 45 years. Human Vaccines &amp; Immunotherapeutics2009;5(10):705‐19. ">Einstein 2009</a>). Immunogenicity of both vaccines could be directly compared by measuring the antibody responses in serum and cervico‐vaginal secretions with the same assays. Antibody titres and levels of memory B cells were significantly higher in all age groups for both HPV16 and HPV 18 with the bivalent, compared with the quadrivalent, vaccine. Differences were maintained 30 months after completion of vaccination. However, it was shown that adding VLP antigens from other HPV types to the AS04‐adjuvanted bivalent vaccine resulted in lower anti‐HPV16 and anti‐HPV18 responses (<a href="./references#CD009069-bbs2-0291" title="vanDammeP , Leroux‐RoelsG , SimonP , FoidartJM , DondersG , HoppenbrouwersK , et al. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Vaccine2014;32(29):3694‐705. ">Van Damme 2014</a>). </p> <p>As soon as an immunologically comparative framework for immunogenicity is agreed, this review will be updated and extended with serologically‐defined endpoints. </p> </section> </section> <section id="CD009069-sec-0115"> <h3 class="title" id="CD009069-sec-0115">Quality of the evidence</h3> <p>We rated the quality of evidence and present our findings in <a href="./full#CD009069-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009069-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD009069-tbl-0003">summary of findings Table 3</a> for efficacy outcomes across the three populations as defined by HPV status at baseline. We present analyses of pregnancy outcomes in <a href="./full#CD009069-tbl-0004">summary of findings Table 4</a>. </p> <p>The studies providing data to this review are large and we have judged them to be at low risk of bias for efficacy endpoints for women who received three doses or at least one dose. For a few outcomes, we judged that the number of events to be low, even with large sample sizes, meaning that we cannot rule out different effect sizes to those we have found for adenocarcinoma in situ (AIS) associated with HPV16/18 and any AIS, irrespective of HPV type, in women who were hrHPV negative at baseline (<a href="./full#CD009069-tbl-0001">summary of findings Table for the main comparison</a>). Although few trials could be identified for a given exposure group/endpoint combination, the results were generally consistent across the efficacy endpoints in women who are hrHPV negative and HPV16/18 negative at baseline (<a href="./full#CD009069-tbl-0002">summary of findings Table 2</a>). For protection against precancer associated with HPV16/18, conferred by fewer than three doses of HPV vaccine, we downgraded the level of evidence to low or very low, since the risk in the placebo arms varied by number of doses received (<a href="#CD009069-tbl-0006">Table 2</a>: <a href="./references#CD009069-fig-0024" title="">Analysis 2.3</a>, <a href="./references#CD009069-fig-0027" title="">Analysis 2.6</a>, <a href="./references#CD009069-fig-0030" title="">Analysis 2.9</a>, <a href="./references#CD009069-fig-0033" title="">Analysis 2.12</a>; <a href="./references#CD009069-fig-0036" title="">Analysis 2.15</a>). </p> <p>The quality of evidence was judged as high regarding absence of increased risk of severe systemic adverse effects associated with HPV vaccination. Regarding mortality associated with HPV vaccination, the quality of evidence is low. For the level of evidence regarding obstetrical safety, we judged the quality of evidence as moderate or high. </p> <p>More than 70,000 women were included overall in the randomised trials and in the most important exposure group/efficacy endpoint combinations more than 10,000 women were enrolled, resulting in precise estimates. For certain post‐hoc analyses with respect to effects in women having received only one or two doses, fewer than 1000 women were included, yielding pooled estimates, with wider confidence intervals. </p> <p>The natural history of CIN and cervical cancer is strongly linked to persistent infection with hrHPV infection (<a href="./references#CD009069-bbs2-0170" title="FormanD , deMartelC , LaceyCJ , SoerjomataramI , Lortet‐TieulentJ , BruniL , et al. Global burden of human papillomavirus and related diseases. Vaccine2012;30 Suppl 5:F12‐23. ">Forman 2012</a>; <a href="./references#CD009069-bbs2-0199" title="IARC Monograph Working Group on Carcinogenesis (Coglinano V, BaanR , StraifK , SecretanB , ElGhissasiF , Zur HausenH , et al)  . In: CoglianoV , BaanR , StraifK , GrosseY , SecretanB , ElGhissassiF editor(s). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses. Vol. 90, Lyon: IARC Press, 2007:1‐670. ">IARC 2007</a>), and the contribution of HPV types 16 and 18 in the overall burden of cervical cancer is around 71% (<a href="./references#CD009069-bbs2-0126" title="ArbynM , TommasinoM , DepuydtC , DillnerJ . Are 20 human papillomavirus types causing cervical cancer?. Journal of Pathology2014;234(4):431‐5. ">Arbyn 2014</a>). Given this strong link, we can accept a high level of directness between the observed prevention of persistent infection, CIN and the anticipated expected prevention of cervical cancer incurred by HPV vaccination. Nevertheless, it must be acknowledged that reduced incidence of invasive cervical cancer in HPV vaccinated women cannot be observed within the available trials (See <a href="#CD009069-sec-0094">Discussion</a> 2.2). </p> <p>Publication bias could not be assessed formally, given the small number of trials reporting clinical efficacy data. However, the level of completeness of reporting and absence of a correlation between study size and effects allow us to conclude that the risk of reporting bias may be small. </p> <section id="CD009069-sec-0116"> <h4 class="title">2. Strict separation by type of endpoint and HPV DNA status at enrolment</h4> <p>We have separated exposure groups in terms of age and enrolment status, mainly based on the presence or absence of hrHPV DNA or HPV16/18 DNA and the distinction of trial outcomes, such as cervical precancer associated with HPV vaccine types or irrespective of HPV type. This allowed us to pool comparable data which did not appear possible a priori because of the use of different definitions of exposure groups in the original trial reports, such as according‐to‐protocol, naive‐vaccinated population, intention‐to‐treat, total‐vaccinated‐cohort, modified intention‐to‐treat. Other meta‐analyses ignored this principle and pooled results from very heterogeneous groups. For instance, <a href="./references#CD009069-bbs2-0254" title="RamboutL , HopkinsL , HuttonB , FergussonD . Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. Canadian Medical Association Journal2007;177(5):469‐79. ">Rambout 2007</a> considered efficacy data from the FUTURE‐1 and ‐2 trials (<a href="./references#CD009069-bbs2-0013" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">FUTURE I trial (ph3,4v)</a>, <a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a>, including women positive for HPV16/18 at enrolment for vaccination with the quadrivalent vaccine, and combined them with efficacy data from the <a href="./references#CD009069-bbs2-0026" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. NaudPS , Roteli‐MartinsCM , DeCarvalhoNS , TeixeiraJC , deBorbaPC , SanchezN , et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination. Human Vaccines &amp; Immunotherapeutics2014;10(8):2147‐62. The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">Phase2 trial (ph2,2v)</a> and <a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>, excluding HPV16/18 positive women vaccinated with the bivalent vaccine. Protection was higher in the latter group, but this may be due to the enrolment of more hr HPV‐naïve women, rather than because of differences in the efficacy of the vaccine. By distinguishing exposure groups and outcomes in our review, homogenous data sets could be combined and significant protection could be demonstrated. We demonstrated protection against AIS associated with HPV16/18 in women vaccinated with the bi‐ or quadrivalent vaccines and who were initially hrHPV DNA negative or negative for the vaccine types (<a href="./references#CD009069-fig-0017" title="">Analysis 1.5</a>; <a href="./references#CD009069-fig-0021" title="">Analysis 1.9</a>; <a href="./references#CD009069-fig-0031" title="">Analysis 2.10</a>), or even regardless of initial HPV DNA status (<a href="./references#CD009069-fig-0041" title="">Analysis 3.5</a>). Without pooling trials with different vaccines, protection was not significant, since AIS is less common than high‐grade CIN. We considered meta‐analytical pooling as relevant only in the absence of heterogeneity. In contrast, we also found situations, where vaccine efficacy was significantly different between the two licensed vaccines. For instance, regarding protection against any CIN2+ or CIN3+, irrespective of HPV type, in women who were hrHPV DNA negative at baseline, greater protection was found for the bivalent compared to the quadrivalent vaccine (RR: 0.33 versus 0.57, P value = 0.0004 (<a href="./references#CD009069-fig-0019" title="">Analysis 1.7</a>) or RR: 0.08 versus 0.54, P value = 0.001 (<a href="./references#CD009069-fig-0020" title="">Analysis 1.8</a>), respectively). Also in total vaccinated cohorts, whatever the initial HPV DNA status, women who received at least one dose of the bivalent compared to the quadrivalent vaccine had better protection against any CIN3+ (RR: 0.55 versus 0.81, P value = 0.01 (<a href="./references#CD009069-fig-0044" title="">Analysis 3.8</a>]). See further discussion of potential methodologic reasons for this difference in Section 2.2 of the Discussion. </p> </section> <section id="CD009069-sec-0117"> <h4 class="title">3. Unreported estimated outcomes: vaccination effect when fewer than three doses were administered </h4> <p>An original approach of this review was the estimation of the efficacy of fewer than three doses by subtracting the number of events in the populations that received all three doses from those who received at least one dose. By doing this subtraction, we found significant protection, in women initially negative for HPV16/18, against CIN2+ and CIN3+ associated with HPV16/18 in younger, but not in mid‐adult, women (<a href="./references#CD009069-fig-0024" title="">Analysis 2.3</a>). It is important to remember that these were post hoc analyses and that the trials were not designed to assess the effects of fewer than three doses. Furthermore, we were not able to assess differences between three‐dose vaccine recipients and those who did not complete the series. </p> <p>Recent randomised trials have demonstrated non‐inferior anti‐HPV16 and anti‐HPV18 antibody levels induced after a two‐dose schedule at months zero and six in girls aged nine to 14 years compared to the usual three‐dose schedules of bivalent or quadrivalent vaccine in young women aged 15 to 26 years ( <a href="./references#CD009069-bbs2-0043" title="DobsonSR , McNeilS , DionneM , DawarM , OgilvieG , KrajdenM . Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA2013;309(17):1793‐802. ">Dobson 2013</a>; <a href="./references#CD009069-bbs2-0070" title="Lazcano‐PonceE , StanleyM , MunozN , TorresL , Cruz‐ValdezA , SalmeronJ , et al. Overcoming barriers to HPV vaccination: non‐inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two‐dose vs. a three‐dose schedule at 21 months. Vaccine2014;32(6):725‐32. ">Lazcano‐Ponce 2014</a>; <a href="./references#CD009069-bbs2-0258" title="RomanowskiB . Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines. Human Vaccines2011;7(2):161‐9. ">Romanowski 2011</a>). These observations have convinced some regulatory agencies to allow a two‐dose schedule for girls of nine to 14 years of age (<a href="./references#CD009069-bbs2-0165" title="European Medicines Agency. EMEA/H/C/000721‐Cervarix‐EPAR summary for the public 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000721/WC500024634.pdf.Februrary 2014;Accessed 10‐12‐15:1‐3. ">EMEA 2014a</a>; <a href="./references#CD009069-bbs2-0166" title="European Medicines Agency. EMEA/H/C/000703‐Gardasil‐EPAR summary for the public 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000703/WC500021146.pdfAugust 2014;Accessed 10‐12‐15:1‐4. ">EMEA 2014b</a>). Our findings suggest that two doses might provide protection in young women (aged 15 to 26 years), but not in mid‐adult women (24 to 45 years). Some experts have expressed concerns that the two‐dose schedule might affect the longevity of protection (<a href="./references#CD009069-bbs2-0281" title="StanleyMA , SudengaSL , GiulianoAR . Alternative dosage schedules with HPV virus‐like particle vaccines. Expert Review of Vaccines2014;13(8):1027‐38. ">Stanley 2014</a>). Public health authorities should set up careful surveillance of the duration of protection by age and by the number and timing of received doses. A recent pooled post hoc analysis (<a href="./references#CD009069-bbs2-0023" title="WacholderS , ChenBE , WilcoxA , MaconesG , GonzalezP , BefanoB . Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ2010;340:c712. ">PATRICIA &amp; CVT (ph3,2v)</a>) showed a similar efficacy of the bivalent vaccine against incident HPV16/18 infection among women who were HPV16/18 DNA negative at baseline and who received one dose (RR = 0.16, 95% CI 0.06 to 0.29), two doses (RR = 0.24, 95% CI 0.15 to 0.38), or three doses (RR = 0.23, 95% CI 0.21 to 0.25) (<a href="./references#CD009069-bbs2-0067" title="KreimerAR , ShermanME , SahasrabuddheVV , SafaeianM . The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents. Journal of the National Cancer Institute2015;107(3 1460‐2105 (Electronic)):1‐4 0027‐8874 (Linking). ">Kreimer 2015</a>), Protection appeared to be higher for those who received two doses when the interval between administration was six months compared to one month. No data on protection of fewer than three doses against cervical lesions were reported. Recent data show durability of protection against HPV16/18 afforded by fewer than three doses of the bivalent vaccine over at least seven years (<a href="./references#CD009069-bbs2-0261" title="SafaeianM , SampsonJN , PanY , PorrasC , KempTJ , HerreroR , et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: The CVT Trial. Journal of the National Cancer Institute2018;110(2):djx158. ">Safaeian 2018</a>). </p> <p>Post licensure studies of the effectiveness of the quadrivalent vaccine in the USA (<a href="./references#CD009069-bbs2-0196" title="HofstetterAM , OmpadDC , StockwellMS , RosenthalSL , SorenK . Human papillomavirus vaccination and cervical cytology outcomes among urban low‐income minority females. JAMA Pediatrics2016;170(5):445‐52. ">Hofstetter 2016</a>) and Australia (<a href="./references#CD009069-bbs2-0141" title="BrothertonJML , MalloyM , BuddAC , SavilleM , DrennanKT , GertigDM . Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia. Papillomavirus Research2015;1(1):59‐73. ">Brotherton 2015</a>; <a href="./references#CD009069-bbs2-0151" title="CroweE , PandeyaN , BrothertonJM , DobsonAJ , KiselyS , LambertSB , et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case‐control study nested within a population based screening programme in Australia. BMJ2014;348(g1458):1‐10. ">Crowe 2014</a>; <a href="./references#CD009069-bbs2-0179" title="GertigDM , BrothertonJM , BuddAC , DrennanK , ChappellG , SavilleAM . mpact of a population‐based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Medicine2013;11:227. ">Gertig 2013</a>) have shown decreased rates of high‐grade and/or low‐grade cervical lesions in partially vaccinated young women versus non‐vaccinated young women who started cervical cancer screening. However. vaccine effectiveness was of lower magnitude than when three doses were given. A recent report from a suspended cluster‐randomised trial, conducted in India, compared immunogenicity of the quadrivalent vaccine according to the actual number of doses administered to girls aged 10 to 18 years. The immune response (in terms of geometric mean antibody levels) in the group who received two doses at month zero and month six or later was not inferior to the group who received three doses at months zero, two and six or later. However, the immune response was inferior in the groups who received two doses at month zero and two or who received only one dose (<a href="./references#CD009069-bbs2-0262" title="SankaranarayananR , PrabhuPR , PawlitaM , GheitT , BhatlaN , MuwongeR , et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncology2016;17(1):67‐77. ">Sankaranarayanan 2016</a>). </p> <p>A recent Scottish surveillance study of the effectiveness of the bivalent vaccine demonstrated significant protection against prevalent HPV16/18 infection conferred by two doses (RR of 0.45, 95% CI 0.29 to 0.69) or one dose (RR of 0.52, 95% CI 0.31 to 0.83) among those reached by catch‐up vaccination targeting girls of age 14 to 18 years and who entered the screening programme (<a href="./references#CD009069-bbs2-0152" title="CuschieriK , KavanaghK , MooreC , BhatiaR , LoveJ , PollockKG . mpact of partial bivalent HPV vaccination on vaccine‐type infection: a population‐based analysis. British Journal of Cancer2016;114(11):1261‐4. ">Cuschieri 2016</a>). However, protection was lower than with three doses (RR of 0.27, 95% CI 0.20 to 0.36). No significant protection against cervical intra‐epithelial neoplastic lesions irrespective of HPV types associated with fewer than three doses was observed (<a href="./references#CD009069-bbs2-0253" title="PollockKG , KavanaghK , PottsA , LoveJ , CuschieriK , CubieH , et al. Reduction of low‐ and high‐grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. British Journal of Cancer2014;111(9):1261‐4. ">Pollock 2014</a>). </p> <p>It must be remarked that partially vaccinated women in published post‐licensure studies were older than fully vaccinated women (so more likely to have been exposed to HPV prior to vaccination) and most women with two doses had a one to two month interval between vaccine administrations. </p> </section> </section> <section id="CD009069-sec-0118"> <h3 class="title" id="CD009069-sec-0118">Potential biases in the review process</h3> <section id="CD009069-sec-0119"> <h4 class="title">Post hoc analysis of vaccine effects associated with one or two doses</h4> <p>In this review, we computed efficacy estimates for women who received only one or two doses, by subtracting events and total number of women who received three doses from those who received at least one dose. We computed this for data presented within the same report for a given follow‐up time. This is a post hoc analysis, which has limitations, since counting of events often started for the women who received at least one dose at day one, whereas for those who received all three doses counting started from the day of the last administration. Most of the women in the group that received at least one dose received three doses. We assumed that the possible protection, not accounted for in the group receiving three doses, induced by the vaccine in the period between 1<sup>st</sup> and 2<sup>nd</sup> dose, would be small. Reported observed data from the Costa Rica Trial, separated by groups receiving only one, two or three does, are in agreement with our estimates (<a href="./references#CD009069-bbs2-0217" title="KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. ">Kreimer 2011</a>). </p> <p>An important finding with public health relevance, was that one or two doses of bi‐ or quadrivalent vaccine did not protect against CIN2+ associated with HPV16/18, in women older than 24 years, even if they were negative for HPV16/18 at enrolment (RR = 0.98, 95% CI 0.20 to 4.83), whereas women younger than 26 years experienced protection against HPV16/18 related CIN2+, CIN3+ and AIS+ if HPV16/18 DNA negative at baseline. </p> </section> <section id="CD009069-sec-0120"> <h4 class="title">Other potential biases</h4> <p>As mentioned in <a href="#CD009069-sec-0109">Overall completeness and applicability of evidence</a>, for several outcomes no information was available for the group of mid‐adult women. We have focused efforts to obtain unpublished data from registered studies for adverse events. We tested the assumption that there is a difference between results obtained from published trial reports and trial registry and study results websites for serious adverse events and mortality by <a href="#CD009069-sec-0058">Sensitivity analysis</a>. Journal‐published trial reports provide data at fixed time points, whereas trial registry and study results websites can be updated over time as data are collected from more recent follow‐up. Sensitivity analysis by source of data gives us some confidence that published and registry or website‐sourced data are similar for the same study. However, data from regulatory sources and data from unregistered and unpublished studies were not consulted for efficacy endpoints and less than severe adverse events. </p> <p>The comparison of the risks of adverse events was compromised by the use of different products administered to participants in the control group, varying from adjuvant (often aluminium hydroxide or other aluminium compound) or an alternative vaccine (often Hepatitis A or Hepatitis B). Therefore, the pooled risks of adverse effects associated with HPV vaccines and the assumed risks for control groups must be interpreted cautiously (<a href="./full#CD009069-tbl-0004">summary of findings Table 4</a>). </p> </section> </section> <section id="CD009069-sec-0121"> <h3 class="title" id="CD009069-sec-0121">Agreements and disagreements with other studies or reviews</h3> <p>A multitude of reviews and combined analyses have been conducted over recent years by regulatory agencies and institutions developing practice guidelines (<a href="./references#CD009069-bbs2-0032" title="AultKA , Future II Study Group. Effect of prophylactic human papillomavirus L1 virus‐like‐particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet2007;369(9576):1861‐8. ">Ault 2007</a>; <a href="./references#CD009069-bbs2-0056" title="HauptRM , WheelerCM , BrownDR , GarlandSM , FerrisDG , PaavonenJA . Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. International Journal of Cancer2011;129(11):2632‐42. ">Haupt 2011</a>; <a href="./references#CD009069-bbs2-0189" title="HarperDM . Currently approved prophylactic HPV vaccines. Expert Review of Vaccines2009;8(12):1663‐79. ">Harper 2009</a>; <a href="./references#CD009069-bbs2-0066" title="KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM , PerezG , et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high‐grade cervical and external genital lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2(1940‐6215 (Electronic), 10):868‐78. ">Kjaer 2009</a>; <a href="./references#CD009069-bbs2-0225" title="LehtinenM , DillnerJ . Clinical trials of human papillomavirus vaccines and beyond. Nature Reviews Clinical Oncology2013;10(7):400‐10. ">Lehtinen 2013</a>; <a href="./references#CD009069-bbs2-0258" title="RomanowskiB . Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines. Human Vaccines2011;7(2):161‐9. ">Romanowski 2011</a>; <a href="./references#CD009069-bbs2-0268" title="SchillerJT , CastellsagueX , GarlandSM . A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine2012;30 Suppl 5:F123‐38. ">Schiller 2012</a>; <a href="./references#CD009069-bbs2-0281" title="StanleyMA , SudengaSL , GiulianoAR . Alternative dosage schedules with HPV virus‐like particle vaccines. Expert Review of Vaccines2014;13(8):1027‐38. ">Stanley 2014</a>; <a href="./references#CD009069-bbs2-0301" title="Initiative for Vaccine Research of the Department of Immunization Vaccines and Biologicals (WHO). Human Papillomavirus (HPV) Vaccine Background Paper. World Health Organization (WHO)2009:1‐249. ">WHO 2009</a>) and systematic reviewers (<a href="./references#CD009069-bbs2-0158" title="DelereY , WichmannO , KlugSJ , van derSandeM , TerhardtM , ZeppF . The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta‐analysis. Deutsches Arzteblatt International2014;111(35‐36):584‐91. ">Delere 2014</a>; <a href="./references#CD009069-bbs2-0225" title="LehtinenM , DillnerJ . Clinical trials of human papillomavirus vaccines and beyond. Nature Reviews Clinical Oncology2013;10(7):400‐10. ">Lehtinen 2013</a>; <a href="./references#CD009069-bbs2-0076" title="LuB , KumarA , CastellsagueX , GiulianoAR . Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review &amp; meta‐analysis. BMC Infectious Disease2011;11(1):13. ">Lu 2011</a>; <a href="./references#CD009069-bbs2-0078" title="MalagonT , DroletM , BoilyMC , FrancoEL , JitM , BrissonJ . Cross‐protective efficacy of two human papillomavirus vaccines: a systematic review and meta‐analysis. Lancet Infectious Diseases2012;12(10):781‐9. ">Malagon 2012</a>; <a href="./references#CD009069-bbs2-0080" title="McKeageK , RomanowskiB . Spotlight on AS04‐adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®). BioDrugs2011;25(4):265‐9. ">McKeage 2011</a>; <a href="./references#CD009069-bbs2-0234" title="MedeirosLR , RosaDD , DaRosaMI , BozzettiMC , ZaniniRR . Efficacy of human papillomavirus vaccines: a systematic quantitative review. International Journal of Gynecological Cancer2009;19(7):1166‐76. ">Medeiros 2009</a>; <a href="./references#CD009069-bbs2-0254" title="RamboutL , HopkinsL , HuttonB , FergussonD . Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. Canadian Medical Association Journal2007;177(5):469‐79. ">Rambout 2007</a>). Our review is distinguished from previous reviews by its currency because of the inclusion of later reports of data from included trials. This includes the most recent results of the VIVIANE trial (<a href="./references#CD009069-bbs2-0300" title="WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16 (10):1154‐68. ">Wheeler 2016</a>) and the latest safety reports of the bivalent Chinese trial (July 2016). In general, the review corroborates findings from other major reviews. However, two findings were not previously reported: 1) the statistically significant protection against AIS both associated with HPV16/18 and irrespective of HPV type, and 2) the significant protection induced by fewer than three vaccine doses against CIN2+ associated with HPV16/18 in women who were HPV16/18 negative at baseline, although this was a post hoc analysis. </p> <section id="CD009069-sec-0122"> <h4 class="title">Future work</h4> <p>The current review focused primarily on protection against cervical precancer related to the HPV types included in the vaccine or any cervical precancer irrespective of HPV type. In the future, six‐month persistent infection with HPV types included in the vaccine probably will become the main assessed outcome, which is a more objectively measurable endpoint and highly correlated with clinical outcomes (<a href="./references#CD009069-bbs2-0200" title="IARC HPV Working Group. Primary end‐points for prophylactic HPV vaccine trials. IARC Working Group Reports. Vol. 7, Lyon, France: WHO Press, 2013:1‐120. ">IARC 2013</a>). In future reviews, protection against persistent infection with the vaccine types may become the primary outcome. </p> <p>We propose conducting additional Cochrane reviews on HPV vaccine efficacy against other HPV‐related diseases such as genital warts, vaginal, vulvar, anal and penile intra‐epithelial neoplasia and cancer, as well as HPV infection at these anatomical sites and in the oral cavity. These reviews may include study designs, in addition to randomised trials, such as cohort studies, registry linkage studies and trend analyses, The incidence of respiratory papillomatosis, which is a rare but very serious condition related to HPV6 and HPV11, could also be considered. </p> <p>Reviews should assess effects in particular groups, such as men, immune‐depressed populations, men‐having‐sex‐with men (MSM) and women‐having‐sex‐with‐women (WSW), infants, and mid‐adult age groups. </p> <p>A particular important area for further research is the question of how to integrate primary protection against HPV‐related disease with current and future cytology‐based or HPV‐based screening for cervical cancer. This research, and subsequent pooled analyses, should address how to screen vaccinated cohorts and whether non‐vaccinated HPV‐negative cohorts would benefit from vaccination at the time of screening (<a href="./references#CD009069-bbs2-0135" title="BoschFX , RoblesC , DiazM , ArbynM , BaussanoI , ClavelC , et al. HPV‐FASTER: broadening the scope for prevention of HPV‐related cancer. Nature Reviews, Clinical Oncology2016;13:119‐32. ">Bosch 2016</a>). </p> <p>Regulatory agencies (<a href="./references#CD009069-bbs2-0165" title="European Medicines Agency. EMEA/H/C/000721‐Cervarix‐EPAR summary for the public 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000721/WC500024634.pdf.Februrary 2014;Accessed 10‐12‐15:1‐3. ">EMEA 2014a</a>; <a href="./references#CD009069-bbs2-0166" title="European Medicines Agency. EMEA/H/C/000703‐Gardasil‐EPAR summary for the public 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000703/WC500021146.pdfAugust 2014;Accessed 10‐12‐15:1‐4. ">EMEA 2014b</a>) approved two‐dose schedules for L1 HPV vaccines in young girls, based on non‐inferior seroconversion rates and anti‐HPV antibody levels (<a href="./references#CD009069-bbs2-0258" title="RomanowskiB . Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines. Human Vaccines2011;7(2):161‐9. ">Romanowski 2011</a>; <a href="./references#CD009069-bbs2-0281" title="StanleyMA , SudengaSL , GiulianoAR . Alternative dosage schedules with HPV virus‐like particle vaccines. Expert Review of Vaccines2014;13(8):1027‐38. ">Stanley 2014</a>). Our review provides some clinical efficacy evidence supporting this decision. Moreover, recent data suggest protection conferred by only one dose of HPV vaccine (<a href="./references#CD009069-bbs2-0067" title="KreimerAR , ShermanME , SahasrabuddheVV , SafaeianM . The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents. Journal of the National Cancer Institute2015;107(3 1460‐2105 (Electronic)):1‐4 0027‐8874 (Linking). ">Kreimer 2015</a>; <a href="./references#CD009069-bbs2-0261" title="SafaeianM , SampsonJN , PanY , PorrasC , KempTJ , HerreroR , et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: The CVT Trial. Journal of the National Cancer Institute2018;110(2):djx158. ">Safaeian 2018</a>). However, it cannot be excluded that schemes with fewer than three doses would induce a protection of shorter duration. Comprehensive vaccine registries linked to screening, cytopathology, HPV virology, cancer registry data and linkable to cervical cytology and histology bio‐banks will be extremely useful tools for epidemiological surveillance to answer questions on duration of protection, occurrence of cross‐protection and type replacement (<a href="./references#CD009069-bbs2-0123" title="ArbynM , VanVeenEB , AnderssonK , BogersJ , BouletG , BergeronC , et al. Cervical cytology biobanking in Europe. Internatonal Journal of Biological Markers2010;25(3):117‐25. ">Arbyn 2010</a>; <a href="./references#CD009069-bbs2-0160" title="DillnerJ , ArbynM , UngerE , DillnerL . Monitoring of human papillomavirus vaccination. Clinical &amp; Experimental Immunology2011;163(1):17‐25. ">Dillner 2011</a>). </p> <p>For reasons of statistical power and costs, trials often assess combined outcomes (persistent infection, cytological lesion, CIN1+, external ano‐genital lesions). Although this is acceptable for clinical decision making, authors should be invited to report separate outcomes to facilitate future meta‐analytical pooling. Editors of journals should also support publishing these detailed reports in appendices. </p> <p>In later updates, we foresee inclusion of efficacy and safety data from trials which evaluate the nona‐valent vaccine and possible other vaccines that do not involve comparisons with a placebo group but include comparisons with other HPV vaccines. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009069-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram summarising the retrieval, inclusion and exclusion of relevant reports of randomised trials assessing the safety and effects of prophylactic HPV vaccines." data-id="CD009069-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram summarising the retrieval, inclusion and exclusion of relevant reports of randomised trials assessing the safety and effects of prophylactic HPV vaccines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.  V1 = Random sequence generation; V2 = Allocation concealment; V3 = Blinding participants &amp; personnel; V4 = Blinding of outcome assessment; V5 = Incomplete outcomes; V6 = Selective reporting." data-id="CD009069-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.<br/> V1 = Random sequence generation; V2 = Allocation concealment; V3 = Blinding participants &amp; personnel; V4 = Blinding of outcome assessment; V5 = Incomplete outcomes; V6 = Selective reporting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD009069-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD009069-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Protection against CIN2+ irrespective of presence of HPV types in women, aged 15‐26 years, regardless of their HPV DNA status at baseline, who received at least one dose." data-id="CD009069-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Protection against CIN2+ irrespective of presence of HPV types in women, aged 15‐26 years, regardless of their HPV DNA status at baseline, who received at least one dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Summary of vaccine efficacy estimates, by age group, outcome and HPV DNA status at enrolment (for women who received at least one dose). [REFS BETWEEN SQUARE BRACKETS MUST BE ADAPTED][" data-id="CD009069-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Summary of vaccine efficacy estimates, by age group, outcome and HPV DNA status at enrolment (for women who received at least one dose). [REFS BETWEEN SQUARE BRACKETS MUST BE ADAPTED][ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Summary of vaccine efficacy estimates by age group, outcome and number of received doses (for women who were HPV16/18 DNA negative at enrolment). [REFS BETWEEN SQUARE BRACKETS MUST BE ADAPTED][" data-id="CD009069-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Summary of vaccine efficacy estimates by age group, outcome and number of received doses (for women who were HPV16/18 DNA negative at enrolment). [REFS BETWEEN SQUARE BRACKETS MUST BE ADAPTED][ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Modified Cates plot: Number of cases of CIN2+ associated with HPV16/18 occurring in women who were all hrHPV DNA negative at baseline. 16 out of 1000 non‐vaccinated women developed the lesion (left) whereas fewer than one (0.2) out 1000 vaccinated women developed the lesion (right). Relative risk= 0.01 (95% CI: 0.01 to 0.05)." data-id="CD009069-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Modified Cates plot: Number of cases of CIN2+ associated with HPV16/18 occurring in women who were all hrHPV DNA negative at baseline. 16 out of 1000 non‐vaccinated women developed the lesion (left) whereas fewer than one (0.2) out 1000 vaccinated women developed the lesion (right). Relative risk= 0.01 (95% CI: 0.01 to 0.05). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Modified Cates plot: Number of cases of CIN2+ irrespective of HPV types occurring in women who were all hrHPV DNA negative at baseline. 28 out of 1000 non‐vaccinated women developed the lesion (left) whereas 11 out 1000 vaccinated women developed the lesion (right). Relative risk= 0.37 (95% CI: 0.25 to 0.55)." data-id="CD009069-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Modified Cates plot: Number of cases of CIN2+ irrespective of HPV types occurring in women who were all hrHPV DNA negative at baseline. 28 out of 1000 non‐vaccinated women developed the lesion (left) whereas 11 out 1000 vaccinated women developed the lesion (right). Relative risk= 0.37 (95% CI: 0.25 to 0.55). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Sensitivity analysis of Analysis 7.6 on severe adverse effects restricting to data extracted from publications in peer‐reviewed journals." data-id="CD009069-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Sensitivity analysis of <a href="./references#CD009069-fig-0072" title="">Analysis 7.6</a> on severe adverse effects restricting to data extracted from publications in peer‐reviewed journals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Sensitivity analysis of Analysis 7.7 on deaths restricting to data extracted from publications in peer‐reviewed journals." data-id="CD009069-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Sensitivity analysis of <a href="./references#CD009069-fig-0073" title="">Analysis 7.7</a> on deaths restricting to data extracted from publications in peer‐reviewed journals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Protection against CIN2+ associated with HPV16/18 in women, aged 15‐26 years, who were HPV DNA 16/18 negative at baseline, by number of doses." data-id="CD009069-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Protection against CIN2+ associated with HPV16/18 in women, aged 15‐26 years, who were HPV DNA 16/18 negative at baseline, by number of doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 1 CIN2+ associated with HPV16/18, at least 1 dose." data-id="CD009069-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 1 CIN2+ associated with HPV16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 2 CIN2+ associated with HPV6/11/16/18, at least 1 dose." data-id="CD009069-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 2 CIN2+ associated with HPV6/11/16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 3 CIN3+ associated with HPV16/18, at least 1 dose." data-id="CD009069-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 3 CIN3+ associated with HPV16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 4 CIN3+ associated with HPV6/11/16/18, at least 1 dose." data-id="CD009069-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 4 CIN3+ associated with HPV6/11/16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 5 AIS associated with HPV16/18, at least 1 dose." data-id="CD009069-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 5 AIS associated with HPV16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 6 AIS associated with HPV6/11/16/18, at least 1 dose." data-id="CD009069-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 6 AIS associated with HPV6/11/16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 7 Any CIN2+ irrespective of HPV types, at least 1 dose." data-id="CD009069-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 7 Any CIN2+ irrespective of HPV types, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 8 Any CIN3+ irrespective of HPV types, at least 1 dose." data-id="CD009069-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 8 Any CIN3+ irrespective of HPV types, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 9 Any AIS irrespective of HPV types, at least 1 dose." data-id="CD009069-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 High‐grade cervical lesions in hrHPV DNA negative women at baseline, Outcome 9 Any AIS irrespective of HPV types, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 1 CIN2+ associated with HPV16/(18), 3 doses." data-id="CD009069-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 1 CIN2+ associated with HPV16/(18), 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 2 CIN2+ associated with HPV16/(18), at least 1 dose." data-id="CD009069-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 2 CIN2+ associated with HPV16/(18), at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 3 CIN2+ associated with HPV16/(18), 1 or 2 doses (post hoc analysis)." data-id="CD009069-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 3 CIN2+ associated with HPV16/(18), 1 or 2 doses (post hoc analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 4 CIN2+ associated with HPV6/11/16/18, 3 doses." data-id="CD009069-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 4 CIN2+ associated with HPV6/11/16/18, 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 5 CIN2+ associated with HPV6/11/16/18, at least 1 dose." data-id="CD009069-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 5 CIN2+ associated with HPV6/11/16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 6 CIN2+ associated with HPV6/11/16/18, 1 or 2 doses (post hoc analysis)." data-id="CD009069-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 6 CIN2+ associated with HPV6/11/16/18, 1 or 2 doses (post hoc analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 7 CIN3+ associated with HPV16/18 or HPV6/11/16/18, 3 doses." data-id="CD009069-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 7 CIN3+ associated with HPV16/18 or HPV6/11/16/18, 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 8 CIN3+ associated with HPV 16/18 or HPV6/11/16/18, at least 1 dose." data-id="CD009069-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 8 CIN3+ associated with HPV 16/18 or HPV6/11/16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 9 CIN3+ associated with HPV16/18 or HPV6/11/16/18, 1 or 2 doses (post hoc analysis)." data-id="CD009069-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 9 CIN3+ associated with HPV16/18 or HPV6/11/16/18, 1 or 2 doses (post hoc analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 10 AIS associated with HPV16/18 or HPV6/11/16/18, 3 doses." data-id="CD009069-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 10 AIS associated with HPV16/18 or HPV6/11/16/18, 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 11 AIS associated with HPV16/18 or 6/11/16/18, at least 1 dose." data-id="CD009069-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 11 AIS associated with HPV16/18 or 6/11/16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 12 AIS associated with HPV16/18 or HPV6/11/16/18, 1 or 2 doses (post hoc analysis)." data-id="CD009069-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 12 AIS associated with HPV16/18 or HPV6/11/16/18, 1 or 2 doses (post hoc analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 13 Any CIN2+ irrespective of HPV types, 3 doses." data-id="CD009069-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 13 Any CIN2+ irrespective of HPV types, 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 14 Any CIN2+ irrespective of HPV types, at least 1 dose." data-id="CD009069-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 14 Any CIN2+ irrespective of HPV types, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 15 Any CIN2+ irrespective of HPV types, 1 or 2 doses (post hoc analysis)." data-id="CD009069-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 High‐grade cervical lesions in HPV16/18 DNA negative women at baseline, Outcome 15 Any CIN2+ irrespective of HPV types, 1 or 2 doses (post hoc analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 1 CIN2+ associated with HPV16/18, at least 1 dose." data-id="CD009069-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 1 CIN2+ associated with HPV16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 2 CIN2+ associated with HPV6/11/16/18, at least 1 dose." data-id="CD009069-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 2 CIN2+ associated with HPV6/11/16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 3 CIN3+ associated with HPV16/18, at least 1 dose." data-id="CD009069-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 3 CIN3+ associated with HPV16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 4 CIN3+ associated with HPV6/11/16/18, at least 1 dose." data-id="CD009069-fig-0040" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 4 CIN3+ associated with HPV6/11/16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 5 AIS associated with HPV16/18, at least 1 dose." data-id="CD009069-fig-0041" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 5 AIS associated with HPV16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 6 AIS associated with HPV6/11/16/18, at least 1 dose." data-id="CD009069-fig-0042" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 6 AIS associated with HPV6/11/16/18, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 7 Any CIN2+ irrespective of HPV types, at least 1 dose." data-id="CD009069-fig-0043" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 7 Any CIN2+ irrespective of HPV types, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 8 Any CIN3+ HPV type, at least 1 dose." data-id="CD009069-fig-0044" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 8 Any CIN3+ HPV type, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 9 Any AIS irrespective of HPV types, at least 1 dose." data-id="CD009069-fig-0045" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 High‐grade cervical lesions in women regardless of baseline HPV DNA status, Outcome 9 Any AIS irrespective of HPV types, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Infection with HPV vaccine types in hrHPV DNA negative women at baseline, Outcome 1 Incident HPV16/18 infection, 3 doses." data-id="CD009069-fig-0046" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Infection with HPV vaccine types in hrHPV DNA negative women at baseline, Outcome 1 Incident HPV16/18 infection, 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Infection with HPV vaccine types in hrHPV DNA negative women at baseline, Outcome 2 Persistent HPV16/18 infection (6M), 3 doses." data-id="CD009069-fig-0047" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Infection with HPV vaccine types in hrHPV DNA negative women at baseline, Outcome 2 Persistent HPV16/18 infection (6M), 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Infection with HPV vaccine types in hrHPV DNA negative women at baseline, Outcome 3 Persistent HPV16/18 infection (6M), at least 1 dose." data-id="CD009069-fig-0048" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Infection with HPV vaccine types in hrHPV DNA negative women at baseline, Outcome 3 Persistent HPV16/18 infection (6M), at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Infection with HPV vaccine types in hrHPV DNA negative women at baseline, Outcome 4 Persistent HPV16/18 infection(12M), 3 doses." data-id="CD009069-fig-0049" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Infection with HPV vaccine types in hrHPV DNA negative women at baseline, Outcome 4 Persistent HPV16/18 infection(12M), 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Infection with HPV vaccine types in hrHPV DNA negative women at baseline, Outcome 5 Persistent HPV16/18 infection (12M), at least 1 dose." data-id="CD009069-fig-0050" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Infection with HPV vaccine types in hrHPV DNA negative women at baseline, Outcome 5 Persistent HPV16/18 infection (12M), at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 1 Incident HPV16/18 infection, 3 doses." data-id="CD009069-fig-0051" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 1 Incident HPV16/18 infection, 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 2 Incident HPV16/18 infection, at least 1 dose." data-id="CD009069-fig-0052" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 2 Incident HPV16/18 infection, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 3 Incident HPV16/18 infection, 1 or 2 doses (post hoc analysis)." data-id="CD009069-fig-0053" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 3 Incident HPV16/18 infection, 1 or 2 doses (post hoc analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 4 Persistent HPV16/18 infection (6M), 3 doses." data-id="CD009069-fig-0054" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 4 Persistent HPV16/18 infection (6M), 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 5 Persistent HPV16/18 infection (6M), at least 1 dose." data-id="CD009069-fig-0055" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 5 Persistent HPV16/18 infection (6M), at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 6 Persistent HPV16/18 infection (6M), 1 or 2 doses (post hoc analysis)." data-id="CD009069-fig-0056" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 6 Persistent HPV16/18 infection (6M), 1 or 2 doses (post hoc analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 7 Persistent HPV6/11/16/18 infection (6M), 3 doses." data-id="CD009069-fig-0057" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 7 Persistent HPV6/11/16/18 infection (6M), 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 8 Persistent HPV6/11/16/18 infection (6M), at least 1 dose." data-id="CD009069-fig-0058" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 8 Persistent HPV6/11/16/18 infection (6M), at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 9 Persistent HPV16/18 infection (12M), 3 doses." data-id="CD009069-fig-0059" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 9 Persistent HPV16/18 infection (12M), 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 10 Persistent HPV16/18 infection (12M), at least 1 dose." data-id="CD009069-fig-0060" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 10 Persistent HPV16/18 infection (12M), at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 11 Persistent HPV16/18 infection (12M), 1 or 2 doses (post hoc analysis)." data-id="CD009069-fig-0061" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 HPV16/18 infection in HPV16/18 DNA negative women at baseline, Outcome 11 Persistent HPV16/18 infection (12M), 1 or 2 doses (post hoc analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline, Outcome 1 Incident HPV16/18 infection, at least 1 dose." data-id="CD009069-fig-0062" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline, Outcome 1 Incident HPV16/18 infection, at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline, Outcome 2 Persistent HPV16/18 infection (6M), at least 1 dose." data-id="CD009069-fig-0063" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline, Outcome 2 Persistent HPV16/18 infection (6M), at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline, Outcome 3 Persistent HPV6/11/16/18 infection (6M), at least 1 dose." data-id="CD009069-fig-0064" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline, Outcome 3 Persistent HPV6/11/16/18 infection (6M), at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline, Outcome 4 Persistent HPV16/18 infection (12M), at least 1 dose." data-id="CD009069-fig-0065" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline, Outcome 4 Persistent HPV16/18 infection (12M), at least 1 dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline, Outcome 5 Persistent HPV16/18 infection (12M) by dose (post hoc analysis)." data-id="CD009069-fig-0066" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline, Outcome 5 Persistent HPV16/18 infection (12M) by dose (post hoc analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse events, Outcome 1 Overall local/injection site adverse events." data-id="CD009069-fig-0067" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Adverse events, Outcome 1 Overall local/injection site adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse events, Outcome 2 Pain at injection site." data-id="CD009069-fig-0068" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Adverse events, Outcome 2 Pain at injection site.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse events, Outcome 3 Swelling at injection site." data-id="CD009069-fig-0069" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Adverse events, Outcome 3 Swelling at injection site.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse events, Outcome 4 Redness at injection site." data-id="CD009069-fig-0070" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Adverse events, Outcome 4 Redness at injection site.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse events, Outcome 5 Overall systemic event and general symptoms." data-id="CD009069-fig-0071" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Adverse events, Outcome 5 Overall systemic event and general symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse events, Outcome 6 Serious adverse events." data-id="CD009069-fig-0072" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Adverse events, Outcome 6 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse events, Outcome 7 Deaths." data-id="CD009069-fig-0073" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Adverse events, Outcome 7 Deaths.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Pregnancy outcomes, Outcome 1 Normal infant." data-id="CD009069-fig-0074" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Pregnancy outcomes, Outcome 1 Normal infant.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Pregnancy outcomes, Outcome 2 Spontaneous abortion/miscarriage." data-id="CD009069-fig-0075" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Pregnancy outcomes, Outcome 2 Spontaneous abortion/miscarriage.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Pregnancy outcomes, Outcome 3 Elective termination/induced abortion." data-id="CD009069-fig-0076" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Pregnancy outcomes, Outcome 3 Elective termination/induced abortion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Pregnancy outcomes, Outcome 4 Stillbirth." data-id="CD009069-fig-0077" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Pregnancy outcomes, Outcome 4 Stillbirth.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009069-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/urn:x-wiley:14651858:media:CD009069:CD009069-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_t/tCD009069-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Pregnancy outcomes, Outcome 5 Abnormal infant." data-id="CD009069-fig-0078" src="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Pregnancy outcomes, Outcome 5 Abnormal infant.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/media/CDSR/CD009069/image_n/nCD009069-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009069-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HPV vaccine effects on cervical lesions in adolescent girls and women negative for hrHPV DNA at baseline</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HPV vaccine effects on cervical lesions in adolescent girls and women who are hrHPV DNA negative at baseline</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination </p> <p><b>Setting:</b> Europe, Asia Pacific countries, South &amp; North America<br/> <b>Intervention:</b> HPV vaccines (at least one dose of bivalent or quadrivalent vaccines) </p> <p><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with HPV vaccination<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cervical cancer ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN2+ associated with HPV16/18.</p> <p>Follow‐up: 3 to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>164 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 per 10,000<br/> (0 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.01<br/> (0.00 to 0.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,676<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN3+ associated with HPV16/18</p> <p>Follow‐up: 3 to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>70 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 10,000<br/> (0 to 7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.01<br/> (0.00 to 0.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,214<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuity correction</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AIS associated with HPV16/18</p> <p>Follow‐up: 3 to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>9 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 10,000<br/> (0 to 7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.10<br/> (0.01 to 0.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,214<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuity correction</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any CIN2+ irrespective of HPV type, bivalent or quadrivalent vaccine</p> <p>Follow‐up: 2 to 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>287 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>106 per 10,000<br/> (72 to 158) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.37<br/> (0.25 to 0.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,180<br/> (5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial subgroup heterogeneity was observed (I<sup>2</sup>= 84.3%) for bi‐ and quadrivalent vaccines. So results are reported separately for the 2 vaccines (see next 2 rows). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Any CIN2+ irrespective of HPV type</p> <p>Follow‐up (bivalent): 3.5 to 6 years</p> <p>Follow‐up (quadrivalent): 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.33</p> <p>(0.25 to 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>15,884</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>285 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>94 per 10,000</p> <p>(71 to 122)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.57</p> <p>(0.44 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>9296</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>291 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>166 per 10,000</p> <p>(128 to 221)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any CIN3+ irrespective of HPV type, bivalent or quadrivalent vaccine</p> <p>Follow‐up: 3.5 to 4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>109 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 10,000<br/> (4 to 120) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.21<br/> (0.04 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,719<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial subgroup heterogeneity was observed (I<sup>2</sup> = 84.3%) for bi‐ and quadrivalent vaccines. So results are reported separately for the 2 vaccines (see next 2 rows). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Any CIN3+ irrespective of HPV type</p> <p>Follow‐up (bivalent): 4 years</p> <p>Follow‐up (quadrivalent): 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.08</p> <p>(0.03 to 0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>11,423</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>81 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 per 10,000</p> <p>(3 to 19)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.54</p> <p>(0.36 to 0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>9296</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>143 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>77 per 10,000</p> <p>(51 to 117 )</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any AIS irrespective of HPV type<br/> <br/> Follow‐up: 3 to 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 10,000<br/> (0 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.10<br/> (0.01 to 0.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,214<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuity correction</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><sup>1</sup><b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). When risk in vaccine group is zero, the 95% CI is computed using an exact binomial method.<br/> <br/> <b>AIS:</b> adenocarcinoma in situ; <b>CI:</b> Confidence interval; <b>CIN:</b> cervical intraepithelial neoplasia; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk calculated from the sum of control group event rates. </p> <p><sup>2</sup> Downgraded due to serious imprecision in effect estimate (width 95% CI around RR &gt; 0.6). </p> <p><sup>3</sup> Downgraded one level due to serious imprecision. Few events observed in the two studies (9 in placebo arms and 0 in vaccination arms for the outcome of AIS HPV16/18 and 7 in placebo arms and 0 in vaccination arms for outcome of AIS of any type). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HPV vaccine effects on cervical lesions in adolescent girls and women negative for hrHPV DNA at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009069-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">HPV vaccine effects on cervical lesions in adolescent girls and women negative for HPV16/18 DNA at baseline</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HPV vaccine effects on cervical lesions in adolescent girls and women negative for HPV16/18 DNA at baseline</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination<br/> <b>Setting:</b> Europe, Asia Pacific countries, South &amp; North America <br/> <b>Intervention:</b> HPV vaccines (at least one dose of bivalent or quadrivalent vaccines)<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with HPV vaccination<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cervical cancer ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>CIN2+ associated with HPV16/18</p> <p>Follow‐up (age 15 to 26 years): 1 to 8.5 years</p> <p>Follow‐up (age 24 to 45 years): 4 to 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>15 to 26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.05<br/> (0.03 to 0.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>34,478<br/> (6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>113 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 per 10,000<br/> (3 to 11) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>24 to 45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.30</p> <p>(0.11 to 0.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>7552</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝</p> <p>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>45 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 10,000</p> <p>(5 to 37)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN3+ associated with HPV16/18 (age 15 to 26 years)</p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>57 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 10,000</p> <p>(1 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.05</p> <p>(0.02 to 0.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33,199</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AIS associated with HPV16/18 or 6/11/16/18 (age 15 to 26 years)</p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>12 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 10,000<br/> (0 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.09<br/> (0.01 to 0.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,079<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuity</p> <p>correction</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any CIN2+ irrespective of HPV type (age 15 to 26 years)</p> <p>Follow‐up: 2 to 6.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>231 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>95 per 10,000<br/> (74 to 120) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.41<br/> (0.32 to 0.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,143<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any CIN3+ irrespective of HPV type ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any AIS irrespective of HPV type ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><sup>1</sup><b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Exception: when risk in vaccine group is zero, the 95% CI is computed using an exact binomial method..<br/> <br/> <b>AIS:</b> adenocarcinoma in situ; <b>CI:</b> Confidence interval; <b>CIN:</b> cervical intraepithelial neoplasia; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk calculated from the sum of control group event rates. </p> <p><sup>2</sup> Downgraded due to serious imprecision in effect estimate (width 95% CI around RR &gt; 0.6). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">HPV vaccine effects on cervical lesions in adolescent girls and women negative for HPV16/18 DNA at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009069-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">HPV vaccine effects in adolescent girls and women regardless of HPV DNA status at baseline</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HPV vaccine effects on cervical lesions in adolescent girls and women unselected for HPV DNA status at baseline</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline<br/> <b>Setting:</b> Europe, Asia Pacific countries, South &amp; North America and Africa <br/> <b>Intervention:</b> HPV vaccines (at least one dose of bivalent or quadrivalent vaccines)<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with HPV vaccination<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cervical cancer ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>CIN2+ associated with HPV16/18</p> <p>Follow‐up (age 15 to 26 years): 3.5 to 8.5 years</p> <p>Follow‐up (age 24 to 45 years): 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>15 to 26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.46</p> <p>(0.37 to 0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>34,852<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>341 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>157 per 10,000<br/> (126 to 194) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>24 to 45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.74</p> <p>(0.52 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>9200</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>145 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>107 per 10,000</p> <p>(76 to 152)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN3+ associated with HPV16/18</p> <p>Follow‐up: 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>165 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>91 per 10,000</p> <p>(74 to 127)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.55</p> <p>(0.45 to 0.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,562</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adeno carcinoma in situ (AIS) associated with HPV16/18</p> <p>Follow‐up: 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 10,000<br/> (3 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.36<br/> (0.17 to 0.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,562<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Any CIN2+ irrespective of HPV type</p> <p>Follow‐up (age 15 to 26 years): 3.5 to 8.5 years</p> <p>Follow‐up (age 24 to 45 years): 3.5 to 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>15 to 26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.70<br/> (0.58 to 0.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>35,779<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>559 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>391 per 10,000<br/> (324 to 475) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>24 to 45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.04<br/> (0.83 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>9287<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>343 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>356 per 10,000<br/> (284 to 445) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any CIN3+ irrespective of HPV type (age 15 to 26 years)</p> <p>Follow‐up: 3.5 to 4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>266 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>178 per 10,000</p> <p>(231 to 247)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67</p> <p>(0.49 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35,489</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial subgroup heterogeneity was observed (I<sup>2</sup> = 84.3%) for bivalent and quadrivalent vaccines. So results are reported separately for two vaccines. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Any CIN3+ irrespective of HPV type (age 15 to 26 years),</p> <p>Follow‐up (bivalent): 3.5 to 4 years</p> <p>Follow‐up (quadrivalent): 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.55</p> <p>(0.43 to 0.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>18,329</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>188 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>104 per 10,000</p> <p>(81 to 134)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.81</p> <p>(0.69 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>17,160</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>349 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>283 per 10,000</p> <p>(241 to 335)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any AIS irrespective of HPV type (age 15 to 26 years)</p> <p>Follow‐up: 3.5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>17 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 10,000<br/> (3 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.32<br/> (0.15 to 0.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,562<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>Follow‐up: 6 months to 7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>669 per 10,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>656 per 10,000<br/> (616 to 703) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98<br/> (0.92 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71,597<br/> (23 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deaths</p> <p>Follow‐up: 7 months to 10 years. Most of the information in the analysis comes from studies with follow‐up ranging from 5‐10 years. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 10,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 10,000<br/> (9 to 22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.29<br/> (0.85 to 1.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71,176<br/> (23 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Older women had higher fatality rate (RR 2.36, 95% CI 1.10 to 5.03). Assessment of the deaths in the studies has not been able to identify a pattern in the cause or timing of death. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AIS:</b> adenocarcinoma in situ; <b>CI:</b> Confidence interval; <b>CIN:</b> cervical intraepithelial neoplasia; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk calculated from the sum of control group event rates for all outcomes unless otherwise stated. </p> <p><sup>2</sup> Downgraded due to serious imprecision. Confidence interval is wide and includes large decrease and small increase in lesions with vaccination group in the older age group. </p> <p><sup>3</sup> Downgraded one level due to serious inconsistency. Reduction in lesions was greater in younger women than in older women (RR 0.46 in 15 to 26 years versus RR 0.74 in 24 to 45 years; P = 0.02 for interaction). </p> <p><sup>4</sup> Downgraded one level due to serious imprecision. Confidence interval includes potentially meaningful increase in risk of mortality. </p> <p><sup>5</sup> Downgraded one level due to serious inconsistency. Despite limited evidence of statistical variation, sub grouping studies by age showed higher fatality rate with vaccines in older age group. There is no clear pattern in causes or timing of deaths. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">HPV vaccine effects in adolescent girls and women regardless of HPV DNA status at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009069-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">HPV vaccine effects on pregnancy outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HPV vaccine adverse pregnancy outcomes (regardless of DNA status and age)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adolescent girls and women aged 15 to 45 years who became pregnant during the study<br/> <b>Setting:</b> Europe, Asia Pacific, North, Central and South America<br/> <b>Intervention:</b> HPV vaccines (bivalent or quadrivalent vaccines)<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with HPV vaccines</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Spontaneous abortion/miscarriage</p> <p>Follow‐up: 1 to 7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.68 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8618<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1618 per 10,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1,424 per 10,000<br/> (1,100 to 1844) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Elective termination/induced abortion</p> <p>Follow‐up: 1 to 7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.80 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,909<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>931 per 10,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>838 per 10,000<br/> (745 to 950) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Stillbirth</p> <p>Follow‐up: 1 to 3.5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/> (0.68 to 1.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8754<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 10,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 10,000<br/> (48 to 128) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Babies born with congenital malformations</p> <p>Follow‐up: 3 to 7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.22<br/> (0.88 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9252<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 10,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 10,000<br/> (180 to 346) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Confidence interval rules out an increased risk of termination so there is no downgrade for imprecision. </p> <p><sup>2</sup> Downgraded one level due to serious imprecision. Confidence intervals for both outcomes include meaningful increase and reduction in risk of stillbirth or abnormal infants following vaccination. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">HPV vaccine effects on pregnancy outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Listing of included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appelation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Main References</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monovalent</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0025" title="KoutskyLA , AultKA , WheelerCM , BrownDR , BarrE , AlvarezFB . A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine2002;347(21):1645‐51. MaoC , KoutskyLA , AultKA , WheelerCM , BrownDR , WileyDJ . Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and Gynecology2006;107(1):18‐27. Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Phase2 trial (ph2,1v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2392</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0215" title="KoutskyLA , AultKA , WheelerCM , BrownDR , BarrE , AlvarezFB . A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine2002;347:1645‐51. ">Koutsky 2002</a> </p> <p><a href="./references#CD009069-bbs2-0230" title="MaoC , KoutskyLA , AultKA , WheelerCM , BrownDR , WileyDJ . Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and Gynecology2006;107(1):18‐27. ">Mao 2006</a> </p> <p><a href="./references#CD009069-bbs2-0260" title="Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Rowhani‐Rahbar 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="18" valign="top"> <p>Bivalent</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>II</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1040</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0212" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. ">Konno 2010</a> </p> <p><a href="./references#CD009069-bbs2-0213" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. ">Konno 2010a</a> </p> <p><a href="./references#CD009069-bbs2-0214" title="KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Konno 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0026" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. NaudPS , Roteli‐MartinsCM , DeCarvalhoNS , TeixeiraJC , deBorbaPC , SanchezN , et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination. Human Vaccines &amp; Immunotherapeutics2014;10(8):2147‐62. The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">Phase2 trial (ph2,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0187" title="HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. ">Harper 2004</a> </p> <p><a href="./references#CD009069-bbs2-0188" title="HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. ">Harper 2006</a> </p> <p><a href="./references#CD009069-bbs2-0288" title="The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">The GSK Study Group 2009</a> </p> <p><a href="./references#CD009069-bbs2-0154" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. ">De Carvalho 2010</a> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p>III</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0001" title="SowPS , Watson‐JonesD , KiviatN , ChangaluchaJ , MbayeKD , BrownJ . Safety and immunogenicity of human papillomavirus‐16/18 AS04‐adjuvanted vaccine: a randomized trial in 10‐25‐year‐old HIV‐Seronegative African girls and young women. Journal of Infectious Diseases2013;207(11):1753‐63. ">African_2 country trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>676</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0278" title="SowPS , Watson‐JonesD , KiviatN , ChangaluchaJ , MbayeKD , BrownJ . Safety and immunogenicity of human papillomavirus‐16/18 AS04‐adjuvanted vaccine: a randomized trial in 10‐25‐year‐old HIV‐seronegative African girls and young women. Journal of Infectious Diseases2013;207(11):1753‐63. ">Sow 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0005" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX , et al. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(11):2612‐22. ZhuFC , HuSY , HongY , HuYM , ZhangX , ZhangYJ , et al. Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial. Cancer Medicine2017;6(2045‐7634 (Electronic), 2045‐7634 (Linking), 1):12‐25. ">Chinese trial (ph3,2v)_young</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6051</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0307" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX . Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(1097‐0215 (Electronic), 0020‐7136 (Linking), 11):2612‐22. ">Zhu 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0003" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Chinese trial (ph3,2v)_ adolescent</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>750</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0308" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Zhu 2014a</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0004" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Chinese trial (ph3,2v)_mid‐adult</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1212</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0308" title="ZhuF , LiJ , HuY , ZhangX , YangX , ZhaoH , et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines &amp; Immunotherapeutics2014;10(7):1795‐806. ">Zhu 2014a</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0006" title="Garcia‐SiciliaJ , SchwarzTF , CarmonaA , PetersK , MalkinJE , TranPM . Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine coadministered with combined diphtheria‐tetanus‐acellular pertussis‐inactivated poliovirus vaccine to girls and young women. Journal of Adolescent Health2010;46(2):142‐51. ">Co‐vaccination_dTpa_IPV trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>494</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0174" title="Garcia‐SiciliaJ , SchwarzTF , CarmonaA , PetersK , MalkinJE , TranPM . Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine coadministered with combined diphtheria‐tetanus‐acellular pertussis‐inactivated poliovirus vaccine to girls and young women. Journal of Adolescent Health2010;46(2):142‐51. ">Garcia‐Sicilia 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0007" title="PedersenC , BreindahlM , AggarwalN , BerglundJ , OroszlanG , SilfverdalSA . Randomized trial: immunogenicity and safety of coadministered human papillomavirus‐16/18AS04‐adjuvanted vaccine and combined hepatitis A and B vaccine in girls. Journal of Adolescent Health2012;50(1):38‐46. ">Co‐vaccination_HAB trial (Ph3, 2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>494</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0252" title="PedersenC , BreindahlM , AggarwalN , BerglundJ , OroszlanG , SilfverdalSA . Randomized trial: immunogenicity and safety of coadministered human papillomavirus‐16/18AS04‐adjuvanted vaccine and combined hepatitis A and B vaccine in girls. Journal of Adolescent Health2012;50(1):38‐46. ">Pedersen 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0008" title="SchmeinkCE , BekkersRL , JosefssonA , RichardusJH , Berndtsson BlomK , et al. Co‐administration of human papillomavirus‐16/18 AS04‐adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine2011;29(49):9276‐83. ">Co‐vaccination_HepB trial (ph3, 2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>541</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0269" title="SchmeinkCE , BekkersRL , JosefssonA , RichardusJH , Berndtsson BlomK , DavidMP , et al. Co‐administration of human papillomavirus‐16/18 AS04‐adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine2011;29(1873‐2518):9276‐83. ">Schmeink 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7466</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0190" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR . Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. ">Herrero 2011</a> </p> <p><a href="./references#CD009069-bbs2-0217" title="KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. ">Kreimer 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0014" title="NganHY , CheungAN , TamKF , ChanKK , TangHW , BiD , et al. Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Medical Journal2010;16(1024‐2708 (Print), 1024‐2708 (Linking), 3):171‐9. ">Hong Kong trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0244" title="NganHY , CheungAN , TamKF , ChanKK , TangHW , BiD , et al. Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Medical Journal2010;16(1024‐2708 (Print), 1024‐2708 (Linking), 3):171‐9. ">Ngan 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0015" title="MedinaDM , ValenciaA , deVelasquezA , HuangLM , PrymulaR , Garcia‐SiciliaJ . Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine: a randomized, controlled trial in adolescent girls. Journal of Adolescent Health2010;46(5):414‐21. ">Immunobridging(ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0235" title="MedinaDM , ValenciaA , deVelasquezA , HuangLM , PrymulaR , Garcia‐SiciliaJ . Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine: a randomized, controlled trial in adolescent girls. Journal of Adolescent Health2010;46(1879‐1972 (Electronic), 1054‐139X (Linking), 5):414‐21. ">Medina 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0016" title="BhatlaN , SuriV , BasuP , ShastriS , DattaSK , BiD , et al. Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine in healthy Indian women. Journal of Obstetrics and Gynaecology Research2010;36(1):123‐32. ">Indian trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0132" title="BhatlaN , SuriV , BasuP , ShastriS , DattaSK , BiD , et al. Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine in healthy Indian women. Journal of Obstetrics and Gynaecology Research2010;36(1):123‐32. ">Bhatla 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0020" title="KimYJ , KimKT , KimJH , ChaSD , KimJW , BaeDS , et al. Vaccination with a human papillomavirus (HPV)‐16/18 AS04‐adjuvanted cervical cancer vaccine in Korean girls aged 10‐14 years. Journal of Korean Medical Science2010;25(8):1197‐204. ">Korean trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0210" title="KimYJ , KimKT , KimJH , ChaSD , KimJW , BaeDS , et al. Vaccination with a human papillomavirus (HPV)‐16/18 AS04‐adjuvanted cervical cancer vaccine in Korean girls aged 10‐14 years. Journal of Korean Medical Science2010;25(8):1197‐204. ">Kim 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0021" title="KimSC , SongYS , KimYT , KimYT , RyuKS , GunapalaiahB . Human papillomavirus 16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in 15 to 25 years old healthy Korean women. Journal of Gynecologic Oncology2011;22(2):67‐75. ">Korean trial (ph3b,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>321</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0211" title="KimSC , SongYS , KimYT , KimYT , RyuKS , GunapalaiahB . Human papillomavirus 16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in 15‐25 years old healthy Korean women. Journal of Gynecologic Oncology2011;22(2):67‐75. ">Kim 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0022" title="LimBK , NgKY , OmarJ , OmarSZ , GunapalaiahB , TeohYL , et al. Immunogenicity and safety of the AS04‐adjuvanted human papillomavirus‐16/18 cervical cancer vaccine in Malaysian women aged 18 to 35 years: a randomized controlled trial. Medical Journal of Malaysia2014;69(0300‐5283 (Print), 0300‐5283 (Linking), 1):2‐8. ">Malaysian trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0227" title="LimBK , NgKY , OmarJ , OmarSZ , GunapalaiahB , TeohYL , et al. Immunogenicity and safety of the AS04‐adjuvanted human papillomavirus‐16/18 cervical cancer vaccine in Malaysian women aged 18‐35 years: a randomized controlled trial. Medical Journal of Malaysia2014;69(0300‐5283 (Print), 0300‐5283 (Linking), 1):2‐8. ">Lim 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,644</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0248" title="PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. ">Paavonen 2007</a> </p> <p><a href="./references#CD009069-bbs2-0249" title="PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. ">Paavonen 2009</a> </p> <p><a href="./references#CD009069-bbs2-0284" title="SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15‐25 years with and without serological evidence of previous exposure to HPV‐16/18. Internaitonal Journal of Cancer2011;131(1):106‐16. ">Szarewski 2011</a> </p> <p><a href="./references#CD009069-bbs2-0115" title="WheelerCM , HarveyBM , PichicheroME , SimonMW , CombsSP , BlatterMM . Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatric Infectious Disease Journal2011;30(12):e225‐34. ">Wheeler 2011</a> </p> <p><a href="./references#CD009069-bbs2-0224" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. ">Lehtinen 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5752</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficay, safety,</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0273" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. ">Skinner 2014</a> </p> <p><a href="./references#CD009069-bbs2-0300" title="WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16 (10):1154‐68. ">Wheeler 2016</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Quadrivalent</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>II</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0018" title="YoshikawaH , EbiharaK , TanakaY , NodaK . Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18 to 26 years. Cancer Science2013;104(4):465‐72. ">Japanese trial (ph2,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0306" title="YoshikawaH , EbiharaK , TanakaY , NodaK . Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18‐26 years. Cancer Science2013;104(4):465‐72. ">Yoshikawa 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0019" title="KangS , KimKH , KimYT , KimYT , KimJH , SongYS . Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo‐controlled trial in 176 Korean subjects. International Journal of Gynecological Cancer2008;18(5):1013‐9. ">Korean trial (ph2,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0207" title="KangS , KimKH , KimYT , KimYT , KimJH , SongYS . Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo‐controlled trial in 176 Korean subjects. International Journal of Gynecological Cancer2008;18(5):1013‐9. ">Kang 2008</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0027" title="OlssonSE , KjaerSK , SigurdssonK , IversenOE . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. VillaLL , AultKA , GiulianoAR , CostaRL , PettaCA , AndradeRP . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine2006;24(27):5571‐83. VillaLL , CostaRL , PettaCA , AndradeRP , AultKA , GiulianoAR . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial. Lancet Oncology2005;6(5):271‐8. VillaLL , CostaRL , PettaCA , AndradeRP , PaavonenJ , IversenOE . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up. British Journal of Cancer2006;95(11):1459‐66. ">Phase2 trial (ph2,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0296" title="VillaLL , CostaRL , PettaCA , AndradeRP , AultKA , GiulianoAR . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial. Lancet Oncology2005;6(5):271‐8. ">Villa 2005</a> </p> <p><a href="./references#CD009069-bbs2-0297" title="VillaLL , AultKA , GiulianoAR , CostaRL , PettaCA , AndradeRP . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine2006;24(27):5571‐83. ">Villa 2006</a> </p> <p><a href="./references#CD009069-bbs2-0298" title="VillaLL , CostaRL , PettaCA , AndradeRP , PaavonenJ , IversenOE . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up. British Journal of Cancer2006;95(11):1459‐66. ">Villa 2006a</a> </p> <p><a href="./references#CD009069-bbs2-0086" title="OlssonSE , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM , et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(1554‐8619 (Electronic), 10):696‐704. ">Olsson 2009</a> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>III</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0002" title="MugoN , AnsahNA , MarinoD , SaahA , GarnerE I . Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub‐Saharan Africa. Human Vaccines &amp; Immunotherapeutics2015;11(6):1323‐30. ">African_3 country trial (ph3,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0238" title="MugoN , AnsahNA , MarinoD , SaahA , GarnerEIO . Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub‐Saharan Africa. Human Vaccines &amp; Immunotherapeutics2015;11(6):1323‐30. ">Mugo 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0013" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">FUTURE I trial (ph3,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0175" title="GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">Garland 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0172" title="The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE‐II 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0011" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age. British Journal of Cancer2011;105(1):28‐37. GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">FUTURE III trial (ph3,4v)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy, safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0240" title="MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">Munoz 2009</a> </p> <p><a href="./references#CD009069-bbs2-0146" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24‐45 years of age. British Journal of Cancer2011;105(1):28‐37. ">Castellsagué 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73,428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Listing of included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Results of all the efficacy outcomes</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes and exposure subgroups</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Absolute risk / per 10,000</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative risk<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Vaccine </b> </p> <p><b>efficacy </b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk difference/ per 10,000 </b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of evidence<br/> (GRADE)*</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccinated</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>1. High‐grade cervical lesions in women who were hrHPV DNA negative at baseline</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0013" title="">Analysis 1.1</a> CIN2+ associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01</b> </p> <p>(0.00 to 0.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>99%</b> </p> <p>(95% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>162</b> </p> <p>(157 to 164)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,676<br/> (3 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0014" title="">Analysis 1.2</a> CIN2+ associated with HPV6/11/16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>197</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.01</b> </p> <p>(0.00 to 0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>99%</b> </p> <p>(91% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>195</b> </p> <p>(179 to 197)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9296</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0015" title="">Analysis 1.3</a> CIN3+ associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.01</b> </p> <p>(0.00 to 0.10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>99%</b> </p> <p>(90% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>70</b> </p> <p>(63 to 70)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,214</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0016" title="">Analysis 1.4</a> CIN3+ associated with HPV6/11/16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.01</b> </p> <p>(0.00 to 0.18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>99%</b> </p> <p>(82% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94</b> </p> <p>(77 to 94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9296</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0017" title="">Analysis 1.5</a> AIS associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.10</b> </p> <p>(0.01 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90%</b> </p> <p>(18% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9</b> </p> <p>(2 to 9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,214<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0018" title="">Analysis 1.6</a> AIS associated with HPV6/11/16/18m at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.14</b> </p> <p>(0.01 to 2.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>86%</b> </p> <p>(‐180% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6</b> </p> <p>(‐12 to 6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9296</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0019" title="">Analysis 1.7</a>.1 Any CIN2+ irrespective of HPV types, at least 1 dose of the bivalent vaccine, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.33</b> </p> <p>(0.25 to 0.43)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>67%</b> </p> <p>(57% to 75%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>191</b> </p> <p>(163 to 214)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,884</p> <p>(4 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0019" title="">Analysis 1.7</a>.2 Any CIN2+ irrespective of HPV types, at least 1 dose of the quadrivalent vaccine, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>291</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.57</b> </p> <p>(0.44 to 0.76)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43%</p> <p>(24 to 56%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> <p>(70 to 163)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9296</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0020" title="">Analysis 1.8</a>.1 Any CIN3+ irrespective of HPV types, at least 1 dose of the bivalent vaccine, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.08</b> </p> <p>(0.03 to 0.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>92%</b> </p> <p>(77% to 97%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>74</b> </p> <p>(62 to 78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,423</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0020" title="">Analysis 1.8</a>.2 Any CIN3+ irrespective of HPV types, at least 1 dose of the quadrivalent vaccine, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.54</b> </p> <p>(0.36 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>46%</b> </p> <p>(17% to 64%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>66</b> </p> <p>(26 to 92)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9296</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0021" title="">Analysis 1.9</a> Any AIS irrespective of HPV types, at least 1 dose </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.10</b> </p> <p>(0.01 to 0.76)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>90%</b> </p> <p>(24% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10</b> </p> <p>(2 to 10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,214<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>2. High‐grade cervical lesions in women who were HPV16/18 negative at baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0022" title="">Analysis 2.1</a>.1 CIN2+ associated with HPV16/18, 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.07</b> </p> <p>(0.03 to 0.15)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>93%</b> </p> <p>(85% to 97%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69</b> </p> <p>(63 to 72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36,579</p> <p>(6 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0022" title="">Analysis 2.1</a>.2 CIN2+ associated with HPV16/18, 3 doses, 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.16</b> </p> <p>(0.04 to 0.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>84%</b> </p> <p>(26% to 96%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>30</b> </p> <p>(9 to 34)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6797</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0023" title="">Analysis 2.2</a>.1 CIN2+ associated with HPV16/18, at least 1 dose, 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.05</b> </p> <p>(0.03 to 0.10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95%</b> </p> <p>(90% to 97%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>107</b> </p> <p>(102 to 110)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,478</p> <p>(6 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0023" title="">Analysis 2.2</a>.2 CIN2+ associated with HPV16/18, at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.30</b> </p> <p>(0.11 to 0.81)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>70%</b> </p> <p>(19% to 89%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>32</b> </p> <p>(9 to 40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7552</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0024" title="">Analysis 2.3</a>.1 CIN2+ associated with HPV16/18, 1 or 2 doses, 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>436</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.10</b> </p> <p>(0.04 to 0.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90%</b> </p> <p>(74% to 96%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>392</b> </p> <p>(323 to 418)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2958</p> <p>(5 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1$</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0024" title="">Analysis 2.3</a>.2 CIN2+ associated with HPV16/18, 1 or 2 doses, age 24‐45 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.61</b> </p> <p>(0.14 to 2.67)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39%</b> </p> <p>(‐167% to 86%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>52</b> </p> <p>(‐2245 to 115)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>755</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊝⊝⊝</b> <br/> very <b>low<sup>1$,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0025" title="">Analysis 2.4</a> CIN2+ associated with HPV6/11/16/18, 3 doses, age 15‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06</b> </p> <p>(0.01 to 0.61)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94%</b> </p> <p>(39% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>93</b> </p> <p>(39 to 98)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7664</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0025" title="">Analysis 2.4</a>.1 CIN2+ associated with HPV6/11/16/18, 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> <p>(0.00 to 0.25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98%</p> <p>(75% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> <p>(93 to 190)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4499</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0025" title="">Analysis 2.4</a>.2 CIN2+ associated with HPV6/11/16/18, 3 doses, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> <p>(0.02 to 1.39)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83%</p> <p>(‐39% to 98%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> <p>(‐1 to 32)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3165</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0026" title="">Analysis 2.5</a>.1 CIN2+ associated with HPV6/11/16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>160</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.01</b> </p> <p>(0.00 to 0.19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>99%</b> </p> <p>(81% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>160</b> </p> <p>(130 to 159)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5351</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0026" title="">Analysis 2.5</a>.2 CIN2+ associated with HPV6/11/16/18, at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.37</b> </p> <p>(0.10 to 1.41)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63%</b> </p> <p>(‐41% to 90%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>28</b> </p> <p>(‐18 to 40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3629</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0027" title="">Analysis 2.6</a> CIN2+ associated with HPV6/11/16/18, 1 or 2 doses, age 15‐45 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.24</b> </p> <p>(0.01 to 5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>76%</b> </p> <p>(‐400% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>151</b> </p> <p>(‐795 to 197)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1316</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> very <b>low<sup>1$,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0027" title="">Analysis 2.6</a>.1 CIN2+ associated with HPV6/11/16/18, 1 or 2 doses, age 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>258</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> <p>(0.00 to 0.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96%</p> <p>(26% to 100%))</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>258</p> <p>(108 to 409)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>852</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> very <b>low<sup>1$,3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0027" title="">Analysis 2.6</a>.2 CIN2+ associated with HPV6/11/16/18, 1 or 2 doses, age 24‐45 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97</p> <p>(0.14 to 6.80)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3%</p> <p>(‐580% to 86%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> <p>(‐165 to 171)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>464</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> very <b>low<sup>1$,3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0028" title="">Analysis 2.7</a> CIN3+ associated with HPV16/18, 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.07</b> </p> <p>(0.02 to 0.29)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>93%</b> </p> <p>(71% to 98%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>37</b> </p> <p>(28 to 39)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29,720</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0029" title="">Analysis 2.8</a> CIN3+ associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.05</b> </p> <p>(0.02 to 0.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95%</b> </p> <p>(86% to 98%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54</b> </p> <p>(49 to 56)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33,199</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0030" title="">Analysis 2.9</a> CIN3+ associated with HPV16/18, 1 or 2 doses, age 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06</b> </p> <p>(0.01 to 0.24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94%</b> </p> <p>(26% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>188</b> </p> <p>(152 to 198)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3479</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1$</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0031" title="">Analysis 2.10</a> AIS+ associated with HPV16/18, 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.12</b> </p> <p>(0.02 to 0.70)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>88%</b> </p> <p>(36% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8</b> </p> <p>(2 to 8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29,707</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0032" title="">Analysis 2.11</a> AIS+ associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.09</b> </p> <p>(0.01 to 0.72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>81%</b> </p> <p>(28% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12</b> </p> <p>(3 to 12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,079</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0033" title="">Analysis 2.12</a> AIS+ associated with HPV16/18 or HPV6/11/16/18, 1 or 2 doses, age 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.15</b> </p> <p>(0.01 to 2.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>85%</b> </p> <p>(‐197% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29</b> </p> <p>(‐57 to 29)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2015</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1$,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0034" title="">Analysis 2.13</a> CIN2+ irrespective of HPV types, 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.40</b> </p> <p>(0.25 to 0.64)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>60%</b> </p> <p>(36% to 75%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>99</b> </p> <p>(60 to 124)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7320</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0035" title="">Analysis 2.14</a> CIN2+ irrespective of HPV types, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.41</b> </p> <p>(0.32 to 0.52)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>58%</b> </p> <p>(46% to 67%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>136</b> </p> <p>(111 to 157)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,143</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0036" title="">Analysis 2.15</a> CIN2+ irrespective of HPV types, 1 or 2 doses, age 20‐25 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>710</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.71</b> </p> <p>(0.15 to 3.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29%</b> </p> <p>(‐238% to 85%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>290</b> </p> <p>(‐2,380 to 850)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> very <b>low<sup>1$,3,4</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>3. High‐grade cervical lesions in all women regardless of HPV DNA status at baseline**</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0037" title="">Analysis 3.1</a>.1 CIN2+ associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.46</b> </p> <p>(0.37 to 0.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>54%</b> </p> <p>(43% to 63%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>184</b> </p> <p>(147 to 215)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34,852<br/> (3 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0037" title="">Analysis 3.1</a>.2 CIN2+ associated with HPV16/18, at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>157</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74</b> </p> <p>(0.52 to 1.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>26%</b> </p> <p>(‐5% to 48%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41</b> </p> <p>(‐8 to 75)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9200</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0038" title="">Analysis 3.2</a>.1 CIN2+ associated with HPV6/11/16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>436</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.50</b> </p> <p>(0.42 to 0.59)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50%</b> </p> <p>(41% to 58%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>219</b> </p> <p>(166 to 272)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,160</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0038" title="">Analysis 3.2</a>.2 CIN2+ associated with HPV6/11/16/18, at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.78</b> </p> <p>(0.44 to 1.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22%</b> </p> <p>(‐37% to 56%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>143</b> </p> <p>(72 to 204</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3723</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0039" title="">Analysis 3.3</a> CIN3+ associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55</b> </p> <p>(0.43 to 0.68)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>74%</b> </p> <p>(55% to 91%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>74</b> </p> <p>(55 to 91)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,562<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0040" title="">Analysis 3.4</a> CIN3+ associated with HPV16/18, 1 or 2 doses, age 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>230</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.54</b> </p> <p>(0.43 to 0.68)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>46%</b> </p> <p>(32% to 57%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>106</b> </p> <p>(74 to 131)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,160</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0041" title="">Analysis 3.5</a> AIS associated with HPV16/18, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.36</b> </p> <p>(0.17 to 0.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>64%</b> </p> <p>(22% to 83%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9</b> </p> <p>(3 to 12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,562<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0042" title="">Analysis 3.6</a> AIS associated with HPV6/11/16/18, at least 1 dose, age 15‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.40</b> </p> <p>(0.16 to 0.98)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>60%</b> </p> <p>(2% to 84%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9</b> </p> <p>(0 to 13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,830</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0043" title="">Analysis 3.7</a>.1 Any CIN2+ irrespective of HPV types, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>559</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.70</b> </p> <p>(0.58 to 0.85)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>30%</b> </p> <p>(15% to 42%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>168</b> </p> <p>(84 to 235)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35,779<br/> (4 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0043" title="">Analysis 3.7</a> 2 Any CIN2+ irrespective of HPV types, at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>342</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.04</b> </p> <p>(0.83 to 1.30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐4%</b> </p> <p>(‐30% to 17%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐14</b> </p> <p>(‐103 to 58)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9287</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0044" title="">Analysis 3.8</a> Any CIN3+ irrespective of HPV types, at least 1 dose, age 18‐26 years, bivalent vaccine </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.55</b> </p> <p>(0.43 to 0.71)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>45%</b> </p> <p>(29% to 57%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>84</b> </p> <p>(54 to 1107)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,329</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0044" title="">Analysis 3.8</a> Any CIN3+ irrespective of HPV types, at least 1 dose, age 15‐26 years, quadrivalent vaccine </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>349</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.81</b> </p> <p>(0.69 to 0.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19%</b> </p> <p>(4% to 31%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>66</b> </p> <p>(14 to 108)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,160</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0045" title="">Analysis 3.9</a> Any AIS irrespective of HPV types, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.32</b> </p> <p>(0.15 to 0.67)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>68%</b> </p> <p>(33% to 0.85%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11</b> </p> <p>(6 to 14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,562<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>4. HPV16/18 infection in women who were hrHPV DNA negative at baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0046" title="">Analysis 4.1</a> Incident HPV16/18 infection, 3 doses, age 18‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,457</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06</b> </p> <p>(0.02 to 0.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94%</b> </p> <p>(80% to 98%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2,310</b> </p> <p>(1,966 to 2,408)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0047" title="">Analysis 4.2</a> Persistent HPV16/18 infection(6M), 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>971</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.02</b> </p> <p>(0.00 to 0.35)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>97%</b> </p> <p>(57% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>942</b> </p> <p>(554 to 971)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0048" title="">Analysis 4.3</a> Persistent HPV16/18 infection(6M), at least 1 dose, age 18‐25 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.07</b> </p> <p>(0.05 to 0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>93%</b> </p> <p>(81% to 95%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90</b> </p> <p>(88 to 91)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,826</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0049" title="">Analysis 4.4</a> Persistent HPV16/18 infection(12M), 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>571</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.04</b> </p> <p>(0.00 to 0.73)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>96%</b> </p> <p>(27% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>549</b> </p> <p>(154 to 571)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0050" title="">Analysis 4.5</a> Persistent HPV16/18 infection(12M), at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>462</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08</b> </p> <p>(0.05 to 0.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>92%</b> </p> <p>(88% to 95%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>425</b> </p> <p>(406 to 439)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14,153</p> <p>( 2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>5. HPV16/18 infection in women who were HPV16/18 negative at baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0051" title="">Analysis 5.1</a> Incident HPV16/18 infection, 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>474</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.17</b> </p> <p>(0.10 to 0.31)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>87%</b> </p> <p>(78% to 92%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>412</b> </p> <p>(369 to 436)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8,034</p> <p>(4 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0052" title="">Analysis 5.2</a> Incident HPV16/18 infection, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,326</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>305</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.23</b> </p> <p>(0.14 to 0.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>81%</b> </p> <p>(71% to 88%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1,074</b> </p> <p>(941 to 1,167)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,872</p> <p>(5 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0053" title="">Analysis 5.3</a> Incident HPV16/18 infection, 1 or 2 dose, age 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,568</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1207</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.47</b> </p> <p>(0.26 to 0.84)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>74%</b> </p> <p>(31% to 90%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1,901</b> </p> <p>(796 to 2,311)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>331</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0054" title="">Analysis 5.4</a>.1 Persistent HPV16/18 infection (6M), 3 doses, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>581</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06</b> </p> <p>(0.05 to 0.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94%</b> </p> <p>(91% to 95%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>546</b> </p> <p>(534 to 552)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27,385</p> <p>(6 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0054" title="">Analysis 5.4</a>.2 Persistent HPV16/18 infection (6M), 3 doses, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>350</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.11</b> </p> <p>(0.06 to 0.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>89%</b> </p> <p>(80% to 94%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>311</b> </p> <p>(280 to 329)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6728</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0055" title="">Analysis 5.5</a>.1 Persistent HPV16/18 infection (6M), at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>657</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.10</b> </p> <p>(0.08 to 0.13<b>)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90%</b> </p> <p>(87% to 92%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>591</b> </p> <p>(572 to 605)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22,803</p> <p>(4 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0055" title="">Analysis 5.5</a>.2 Persistent HPV16/18 infection (6M), at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>441</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.17</b> </p> <p>(0.10 to 0.29)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>83%</b> </p> <p>(71% to 90%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>366</b> </p> <p>(313 to 397)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7520</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0056" title="">Analysis 5.6</a>.1 Persistent HPV16/18 infection (6M), 1 or 2 doses, age 15‐26 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>996</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.12</b> </p> <p>(0.03 to 0.42)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>88%</b> </p> <p>(58% to 97%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>876</b> </p> <p>(577 to 966)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>437</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0056" title="">Analysis 5.6</a>.2 Persistent HPV16/18 infection (6M), 1 or 2 doses, age 24‐45 years*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,221</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>379</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.31</b> </p> <p>(0.18 to 0.54)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69%</b> </p> <p>(46% to 82%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>843</b> </p> <p>(562 to 1002)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>792</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0057" title="">Analysis 5.7</a> Persistent HPV6/11/16/18 infection (6M), 3 doses </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>518</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.12</b> </p> <p>(0.06 to 0.21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>88%</b> </p> <p>(79% to 94%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>456</b> </p> <p>(409 to 487)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4008</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0058" title="">Analysis 5.8</a> Persistent HPV6/11/16/18 infection (6M), at least 1 dose </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>907</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.13</b> </p> <p>(0.05 to 0.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>87%</b> </p> <p>(63% to 95%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>789</b> </p> <p>(571 to 862)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4129</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0059" title="">Analysis 5.9</a> Persistent HPV16/18 infection (12M), 3 doses </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>297</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.09</b> </p> <p>(0.06 to 0.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>91%</b> </p> <p>(87% to 94%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>270</b> </p> <p>(258 to 279)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22,267</p> <p>(4 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0060" title="">Analysis 5.10</a> Persistent HPV16/18 infection (12M), at least 1 dose </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>365</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.16</b> </p> <p>(0.01 to 0.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>84%</b> </p> <p>(87% to 99%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>306</b> </p> <p>(292 to 361)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29,464</p> <p>(5 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0061" title="">Analysis 5.11</a> Persistent HPV16/18 infection (12M), 1 or 2 doses*** </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>205</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.13</b> </p> <p>(0.06 to 0.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87%</p> <p>(67% to 94%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>178</b> </p> <p>(137 to 193)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3912</p> <p>(3 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>6. HPV16/18 infection regardless of HPV DNA status at baseline**</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0062" title="">Analysis 6.1</a> Incident HPV16/18 infection, at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>807</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>194</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.24</b> </p> <p>(0.17 to 0.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>76%</b> </p> <p>(67% to 83%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>613</b> </p> <p>(541 to 670)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4210</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0063" title="">Analysis 6.2</a>.1 Persistent HPV16/18 infection (6M), at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,359</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>598</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.44</b> </p> <p>(0.38 to 0.51)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>56%</b> </p> <p>(49% to 62%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>761</b> </p> <p>(666 to 842)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,199</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0063" title="">Analysis 6.2</a>.2 Persistent HPV16/18 infection (6M), at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>642</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>366</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.57</b> </p> <p>(0.47 to 0.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43%</b> </p> <p>(31% to 53%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>276</b> </p> <p>(199 to 341)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8648</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0064" title="">Analysis 6.3</a> Persistent HPV6/11/16/18 infection (6M), at least 1 dose, age 24‐45 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,136</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>591</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.52</b> </p> <p>(0.42 to 0.65)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>48%</b> </p> <p>(35% to 58%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>545</b> </p> <p>(398 to 659)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3713</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0065" title="">Analysis 6.4</a> Persistent HPV16/18 infection (12M), at least 1 dose, age 15‐26 years </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>861</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>396</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.46</b> </p> <p>(0.40 to 0.54)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54%</b> </p> <p>(46% to 60%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>465</b> </p> <p>(396 to 516)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24,785</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. *The attribution of "high quality" depends on the following conditions: well‐conducted randomised trials, with consistent findings, direct outcome, precise estimates (narrow confidence intervals), absence of reporting bias (<a href="./references#CD009069-bbs2-0185" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>). </p> <p><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>In case of study flaws as assessed by the Cochrane Collaboration's tool for assessing risk of bias in randomised trials (<a href="./references#CD009069-bbs2-0193" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011b</a>), not observed but calculated outcome; </p> <p><sup>2</sup> Substantial heterogeneity defined as I<sup>2</sup> &gt;30%, when multiple studies were available for the considered outcome; </p> <p><sup>3</sup>When only one study was retrieved for the outcome; </p> <p><sup>4</sup>Imprecision, when the width of the 95% confidence interval around RR &gt;0.60. </p> <p>0* When zero events occurred in the vaccine group a continuity correction was applied to compute the RR and its confidence interval. Nevertheless, in this case the absolute risks in the vaccine arms in <a href="#CD009069-tbl-0006">Table 2</a> were computed considering an exact binomal distribution. </p> <p>** Relative and absolute effects in women regardless of HPV DNA status at baseline (headings 3 and 6) must be interpreted with care since influenced by the prevalence of HPV infection at enrolment in the respective trials. </p> <p>*** Post hoc analysis for women who received &lt;3 doses.</p> <p>$ For the precancer endpoints (CIN2/3 and AIS),a higher risk in the placebo arms was observed if &lt;3 doses were received compared to those who received 3 doses Therefore the quality of evidence was downgraded to low or very low. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Results of all the efficacy outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number needed to vaccinate (NNV) to prevent one outcome event (in young women aged 15‐26 years)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Initial HPV status at enrolment</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>hrHPV negative</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Regardless of HPV status</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lesions associated with HPV16/18</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNV (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNV (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN2+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (61 to 64)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54 (46 to 68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN3+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204 (149 to 333)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135 (110 to 263)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AIS+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1111 (714 to 5000)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1111 (625 to 3333)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lesions irrespective of HPV types</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNV (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNV (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN2+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (50 to 76)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68 (52 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIN3+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 (106 to 208)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133 (94 to 227)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AIS+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 (556 to 10,000)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>833 (526 to 2000)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><b>AIS:</b> adenocarcinoma in situ, <b>CIN:</b> cervical intraepithelial neoplasia, <b>CIN2+:</b> CIN of degree II or worse, <b>CIN3+:</b> CIN of degree 3 or worse, <b>hrHPV:</b> high‐risk human papillomavirus types, <b>NNV:</b> number needed to vaccinate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number needed to vaccinate (NNV) to prevent one outcome event (in young women aged 15‐26 years)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Results of all the safety outcomes (adverse events, pregnancy outcomes)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Absolute risk/ per 10,000</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>vaccinated</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0067" title="">Analysis 7.1</a><b>Overall local/injection site adverse events</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6847</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8080</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.18</b> </p> <p>(1.16 to 1.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,113<br/> (8 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0068" title="">Analysis 7.2</a><b>Pain at injection site</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6505</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8782</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.35</b> </p> <p>(1.23 to 1.49)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,691<br/> (13 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0069" title="">Analysis 7.3</a><b>Swelling at injection site</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1582</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2737</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.73</b> </p> <p>(1.32 to 2.27)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22,106<br/> (9 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0070" title="">Analysis 7.4</a><b>Redness at injection site</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1938</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3333</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.72</b> </p> <p>(1.50 to 1.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,996<br/> (6 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0071" title="">Analysis 7.5</a><b>Overall systematic event and general symptoms</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6102</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6224</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.02</b> </p> <p>(0.98 to 1.07)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,191<br/> (8 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0072" title="">Analysis 7.6</a><b>Serious adverse events</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>605</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>611</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.01</b> </p> <p>(0.95 to 1.07)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6978<br/> (21studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0073" title="">Analysis 7.7</a><b>Deaths</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.25</b> </p> <p>(0.81 to 1.93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71,452</p> <p>(23 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊝⊝</b> <br/> <b>low</b><sup>2,4,†</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0074" title="">Analysis 8.1</a><b>Normal infant</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7171</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7171</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.00</b> </p> <p>(0.97 to 1.02)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8782<br/> (8 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0075" title="">Analysis 8.2</a><b>Spontaneous abortion/miscarriage</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1618</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1424</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.88</b> </p> <p>(0.68 to 1.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8618<br/> (9 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0076" title="">Analysis 8.3</a><b>Elective termination/induced abortion</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>931</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>838</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.90</b> </p> <p>(0.80 to 1.02)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.909<br/> (9 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-fig-0077" title="">Analysis 8.4</a><b>Stillbirth</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.12</b> </p> <p>(0.68 to 1.83)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8754<br/> (6 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>4</sup><br/> <b>moderate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-fig-0078" title="">Analysis 8.5</a><b>Abnormal infant</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>205</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.22</b> </p> <p>(0.88 to 1.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9252<br/> (5 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<sup>4</sup><br/> <b>moderate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. *The attribution of "high quality" depends on the following conditions: well‐conducted randomized trials, with consistent findings, direct outcome, precise estimates (narrow confidence intervals), absence of reporting bias (<a href="./references#CD009069-bbs2-0185" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>). </p> <p><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>In case of study flaws as assessed by Cochrane's tool for assessing risk of bias in randomised trials (<a href="./references#CD009069-bbs2-0193" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011b</a>), not observed but calculated outcome </p> <p><sup>2</sup> Substantial heterogeneity defined as I<sup>2</sup> &gt; 30%, when multiple studies were available for the considered outcome </p> <p><sup>3</sup>When only one study was retrieved for the outcome </p> <p><sup>4</sup>Imprecision, when the width of the 95% confidence interval around RR &gt; 0.60 </p> <p>† inter‐age group heterogeneity, absence of pattern in causes of deaths</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Results of all the safety outcomes (adverse events, pregnancy outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Deaths observed in the FUTURE III trial (quadrivalent vaccine, phase 3, women aged 24‐45 years)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death causes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary thromboembolism with background of acute lymphoblastic leukaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Breast cancer</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary tuberculosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thyrotoxicosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cerebral haemorrhage subsequent to hypertension</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pericarditis on a background of lupus erythematosus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nasopharyngeal cancer with metastases to brain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary embolism after intervention for uterine myoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>RR of deaths in vaccine vs placebo arm (7 over 1,890 vs 1 over 1888): RR = 6.99 (95% CI 0.86 to 56.78), 2‐sided p<sub>exact</sub>=0.070. </p> <p>The age at death varied between 29 and 45 years, seven of the deaths occurred in the Philippines and one in Columbia. </p> <p>All participants received three doses of HPV vaccine or placebo except one who received only two doses of vaccine. The time interval between last dose and date at death ranged between 6 and 37 months. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Group:V = vaccinated against HPV, C = control group.</p> <p>Source: end‐of‐study analysis after a median follow‐up of four years (<a href="./references#CD009069-bbs2-0146" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24‐45 years of age. British Journal of Cancer2011;105(1):28‐37. ">Castellsagué 2011</a>) and personal communication with Alfred Saah (MSD, 6/05/2016). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Deaths observed in the FUTURE III trial (quadrivalent vaccine, phase 3, women aged 24‐45 years)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Deaths observed in the VIVIANE trial (bivalent vaccine, phase 3 trial, women aged &gt;25 years)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Patient</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cause of death</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Source</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Breast cancer metastatic</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suicide</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lower respiratory tract infection and sepsis*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cervix cancer metastatic**</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interstitial lung disease</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Breast cancer</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>***</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1***</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suicide</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac valve disease and liver disorder*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mexico</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drug hypersensitivity and acute renal failure*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peru</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiorespiratory arrest</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phillipines</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute myocardial infarction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phillipines</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple myeloma and pulmonary embolism*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phillipines</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Homicide</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phillipines</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bronchopneumonia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Singapore</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lung neoplasm malignant</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thailand</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suicide</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glioblastoma multiforme</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaplastic astrocytoma</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>****</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nasopharyngeal cancer</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>****</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Remarks</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Multiple death causes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>**</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>This woman had normal cytology but was HPV‐18 DNA‐positive at study entry (May 2006). At the next scheduled cytology testing at Month 12 (April 2007), the cytology finding was atypical squamous cells cannot exclude high‐grade squamous intraepithelial lesion. She was diagnosed with metastatic cervical cancer in May 2007 (approximately 7 months after receiving the third dose of vaccine or control) and died in July 2008 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>***</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>One case of death due to breast cancer reported in the 48 month report (<a href="./references#CD009069-bbs2-0273" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. ">Skinner 2014</a>) had to be excluded from the analysis (<a href="./references#CD009069-bbs2-0300" title="WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16 (10):1154‐68. ">Wheeler 2016</a>). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>****</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Two additional cases of death occurring in the control arm were reported in the 84‐month report (<a href="./references#CD009069-bbs2-0300" title="WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16 (10):1154‐68. ">Wheeler 2016</a>). The country for these two cases was not reported. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Source: 1) interim analysis after 48 months of follow‐up (<a href="./references#CD009069-bbs2-0273" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. ">Skinner 2014</a>); 2) report at 84 months of follow‐up (<a href="./references#CD009069-bbs2-0300" title="WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16 (10):1154‐68. ">Wheeler 2016</a>) </p> <p>The 84‐month follow‐up report revealed 13 deaths in the HPV arm (N = 2877) versus 5 (N = 2870), with death causes allocated to the trial arms (vaccine versus placebo arm) the RR was 2.59 (95% CI 0.93 to 7.27), 2‐sided p<sub>exact</sub>=0.0957. No pattern was noticed which could indicate a causal role attributed to HPV vaccination. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Deaths observed in the VIVIANE trial (bivalent vaccine, phase 3 trial, women aged &gt;25 years)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0011"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Trials for which vaccine efficacy is reported by smaller age subgroups</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target age group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age category</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reported age sub‐groups</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0025" title="KoutskyLA , AultKA , WheelerCM , BrownDR , BarrE , AlvarezFB . A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine2002;347(21):1645‐51. MaoC , KoutskyLA , AultKA , WheelerCM , BrownDR , WileyDJ . Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and Gynecology2006;107(1):18‐27. Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Phase2 trial (ph2,1v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16‐23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0026" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. NaudPS , Roteli‐MartinsCM , DeCarvalhoNS , TeixeiraJC , deBorbaPC , SanchezN , et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination. Human Vaccines &amp; Immunotherapeutics2014;10(8):2147‐62. The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">Phase2 trial (ph2,2v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0027" title="OlssonSE , KjaerSK , SigurdssonK , IversenOE . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. VillaLL , AultKA , GiulianoAR , CostaRL , PettaCA , AndradeRP . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine2006;24(27):5571‐83. VillaLL , CostaRL , PettaCA , AndradeRP , AultKA , GiulianoAR . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial. Lancet Oncology2005;6(5):271‐8. VillaLL , CostaRL , PettaCA , AndradeRP , PaavonenJ , IversenOE . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up. British Journal of Cancer2006;95(11):1459‐66. ">Phase2 trial (ph2,4v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16‐23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17, 18‐20, 21‐25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐19, 20‐21, 22‐23, 24‐25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>older</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26‐35, 36‐45, 46+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0013" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">FUTURE I trial (ph3,4v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16‐24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>younger</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0011" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age. British Journal of Cancer2011;105(1):28‐37. GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">FUTURE III trial (ph3,4v)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25‐45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>older</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Trials for which vaccine efficacy is reported by smaller age subgroups</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0012"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Influence of age (PATRICIA trial)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Event/N</b> </p> <p><b>Vaccine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Event/N</b> </p> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative risk</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine efficacy</b> </p> <p><b>% (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value for linear effect of age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>In women with hrHPV DNA negative status at baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN2+ associated with HPV16/18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1997</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53/2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (0.00 to 0.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98% (86 to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.995</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/1096</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (0.00 to 0.32)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98% (68 to 100%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/2363</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/2281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (0.00 to 0.47)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97% (53 to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN2+ irrespective of HPV types</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/1997</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101/2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.23 to 0.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66% (50 to 77%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.355</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/1096</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 (0.14 to 0.55)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73% (45 to 86%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/2363</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/2281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 (0.28 to 0.89)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% (11 to 72%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN3+ associated with HPV16/18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/1997</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (0.00 to 0.61)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96% (39 to100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>1.000</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/1096</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07 (0.00 to 1.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93% (‐13 to 100%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/2363</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/2281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (0.00 to 1.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90%(‐74 to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN3+ irrespective of HPV types</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/1997</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08 (0.02 to 0.36)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92% (64 to 98%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.488</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1096</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09 (0.01 to 0.73)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91% (27 to 99%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/2363</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/2281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (0.00 to 0.92)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% (8 to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Persistent HPV16/18 infection (6M)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/1989</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303/2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (0.03 to 0.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% (92 to 97%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0..042</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/1090</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110/1125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08 (0.04 to 0.17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92%(83 to 96%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/2338</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108/2249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 (0.06 to 0.19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89% (81 to 94%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Regardless of women’s baseline HPV DNA status</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN2+ associated with HPV16/18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/2882</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100/2892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 (0.13 to 0.24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79% (66 to 87%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.000</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/1871</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66/1908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (0.22 to 0.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64% (43 to 78%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/3929</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62/3898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.50 to 1.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26% (‐8 to 50%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN2+ irrespective of HPV types</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112/2882</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200/2892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.45 to 0.70)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44% (30 to 55%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.006</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62/1871</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105/1908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.44 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40% (18 to 56%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113/3929</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123/3898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.09 to 1.17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9% (‐17 to 29%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN3+ associated with HPV16/18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/2882</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/2892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (0.09 to 0.44)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80% (56 to 91%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.000</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/1871</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/1908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.23 to 0.84)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56% (16 to 77%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31/3929</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/3898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.66 to 1.83)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐10% (‐83 to 34%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>CIN3+ irrespective of HPV types</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/2882</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/2892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 (0.21 to 0.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65% (43 to 79%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.008</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/1871</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/1908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.31 to 0.85)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49% (15 to 69%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43/3929</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53/3898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.54 to 1.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20% (‐20 to 46%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Persistent HPV16/18 infection (6M)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167/2916</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>588/2920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.24 to 0.34)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72% (66 to 76%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.000</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143/1925</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283/1961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.43 to 0.62)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49% (38 to 57%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194/4009</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356/3979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 (0.46 to 0.64)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46% (36 to 54% )</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Source: <a href="./references#CD009069-bbs2-0224" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. ">Lehtinen 2012</a>. </p> <p><b>CIN:</b> cervical intraepithelial neoplasia, <b>CIN2+:</b> CIN of degree II or worse, <b>CIN3+:</b> CIN of degree 3 or worse, <b>HPV:</b> human papillomavirus types.. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Influence of age (PATRICIA trial)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0013"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Influence of age (CVT trial)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative risk</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine efficacy</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value for linear effect of age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>In women with</b> HPV16<b>/18 DNA negative status at baseline cohort</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Persistent HPV16/18 infection (6M)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/825</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51/870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (0.00 to 0.10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98% (90% to 100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0.145</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20‐21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/659</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08 (0.02 to 0.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92% (76% to 98%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22‐23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/588</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06 (0.00 to 0.20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94% (80% to 100%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24‐25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/563</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14 (0.03 to 0.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86% (56% to 97%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Regardless if women’s baseline HPV DNA status</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Persistent HPV16/18 infection (6M)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47/1193</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165/1,244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (0.21 to 0.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70% (59% to 79%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0.000</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20‐21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64/946</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134/905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.34 to 0.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54% (39% to 66%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22‐23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59/818</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112/848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.40 to 0.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45% (25% to 60%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24‐25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/770</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75/742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.56 to 1.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 %(‐9.9 to 44%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Source: <a href="./references#CD009069-bbs2-0190" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR . Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. ">Herrero 2011</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Influence of age (CVT trial)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0014"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Influence of age (VIVIANE trial)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Event/NVaccine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Event/NPlacebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative risk</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vaccine efficacy</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value for linear effect of age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>In women with</b> HPV16<b>/18 DNA negative status at baseline cohort</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Persistent HPV16/18 infection (6M)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26‐35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13 (0.04 to 0.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (56% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.532</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36‐45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25 (0.07 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75%(12% to 93%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N.A.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N.A.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Regardless if women’s baseline HPV DNA status</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Persistent HPV16/18 infection (6M)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26‐35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48/1221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78/1242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (0.44 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37% (11% to 56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.177</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36‐45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/1244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43/1228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.26 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56% (26% to 74%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.12 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63% (‐15% to 88%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Source: <a href="./references#CD009069-bbs2-0273" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. ">Skinner 2014</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Influence of age (VIVIANE trial)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0015"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Influence of the initial serological status on vaccine efficacy against cervical lesions associated with HPV16/18</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Initial HPV DNA/ status</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serology</b> </p> <p><b>status</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative Risk</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative Risk ratio</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><a href="./references#CD009069-bbs2-0013" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">FUTURE I trial (ph3,4v)</a> (<a href="./references#CD009069-bbs2-0175" title="GarlandSM , Hernandez‐AvilaM , WheelerCM , PerezG , HarperDM , LeodolterS . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine2007;356(19):1928‐43. ">Garland 2007</a>)* </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(‐)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/2,241</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/2258</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 (0.02 to 0.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>15.93</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/377</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/379</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (0.01 to 5.20)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(+)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/232</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31/213</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.49 to 1.29)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.50</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41/156</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/137</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (0.80 to 1.81)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a> (<a href="./references#CD009069-bbs2-0172" title="The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE‐II 2007</a>)** </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(‐)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/5,305</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/5260</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02(0.00 to 0.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>7.41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/498</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/524</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13 (0.01 to 2.43)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(+)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/423</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/402</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.57 to 1.41)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47/298</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/332</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (0.70 to 1.45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a> (<a href="./references#CD009069-bbs2-0249" title="PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. ">Paavonen 2009</a>)** </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(‐)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/8709</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92/8112</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (0.02 to 0.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>6.16</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/1710</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/1777</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.31 (0.09 to 1.13)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(+)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/309</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/293</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.38 to 1.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.70</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53/333</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/307</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (0.77 to 1.61)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pooled results for CIN2+ associated with HPV16/18</b> </p> <p><b>(</b><a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a> and <a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a><b>***</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(‐)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/14,014</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120/13,372</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03 (0.02 to 0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>5.85</p> <p>(0.53 to 65.10)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/2205</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/2301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19 (0.09 t0 o.77)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>DNA(+)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sero‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53/679</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64/695</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.60 to 1.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.37</p> <p>(0.97 to 1.93)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sero+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100/531</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96/639</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.88 to 1.36)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>*RR against HPV 6/11/16/18 related cervical lesions</p> <p>** RR against HPV16/18 related CIN2+</p> <p>*** Pooled only for FUTURE II and PATRIACIA, since, in the FUTURE I trial, the endpoints were cervical lesions and not CIN2+ associated with HPV16/18 </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Influence of the initial serological status on vaccine efficacy against cervical lesions associated with HPV16/18</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0016"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Influence of the study quality and the involvement of vaccine manufacturers</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>P value </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V4</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V5</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V6</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>V7</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent HPV16/18 infection (6M), in women being baseline HPV16/18 negative 3 doses</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent HPV16/18 infection (6M), in women being baseline HPV16/18 negative at least 1 dose </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent HPV16/18 infection (12M), in women being baseline HPV16/18 negative 3 doses</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent HPV16/18 infection (12M), in women being baseline HPV16/18 negative at least 1 dose </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>np</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Influence of study quality (items V1‐V6) and independence of the research team towards the vaccine manufacturer (V7) on protection against persistent HPV16/18 infection assessed by meta‐regression. </p> <p>The P values correspond with the statistical significance of the incorporation of each item in the meta‐regression. </p> <p><b>V1:</b> Random sequence generation; <b>V2:</b> Allocation concealment; <b>V3:</b> Blinding participants and personnel; <b>V4:</b> Blinding of outcome; <b>V5:</b> Incomplete outcomes; <b>V6:</b> Selective reporting; <b>V7:</b> Involvement of manufacturer, </p> <p><b>np:</b> meta‐regression not possible because of collinearity. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Influence of the study quality and the involvement of vaccine manufacturers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0017"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Influence of the number of administered doses: one, two or three in two RCTs with four years of follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of doses</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine</b> </p> <p><b>arm</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p><b>arm</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative Risk </b> </p> <p><b>(95%CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value for linear</b> </p> <p><b>dose‐effect relation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12‐month</p> <p>persistent HPV16/18</p> <p>infection</p> <p>in women being</p> <p>HPV16/18 negative at baseline</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84/11,104</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>627/11,203</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.135 (0.108 to 0.169)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.303</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/611</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/574</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.108 (0.033 to 0.356)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/292</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/249</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.050 (0.007 to 0.374)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>6‐month</p> <p>persistent HPV16/18</p> <p>infection</p> <p>in women being</p> <p>HPV16/18 negative at baseline</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114/11,104</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000/11,209</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.115 (0.095 to 0.139)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.269</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/611</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35/574</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.107 (0.038 to 0.300)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/292</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/250</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.036 (0.005 to 0.261)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Incident HPV16/18 infection</p> <p>in women being HPV16/18</p> <p>negative at baseline</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>529/11,110</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2172/11,217</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.246 (0.224 to 0.269)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.337</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/611</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82/574</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.252 (0.160 to 0.398)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/292</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45/251</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.153 (0.073 to 0.318)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12‐month</p> <p>persistent HPV16/18</p> <p>infection</p> <p>in women being</p> <p>hrHPV negative at baseline</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/6634</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>351/6656</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.077 (0.052 to 0.114)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.996</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/273</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/276</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.168 (0.038 to 0.746)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/138</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/99</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.071 (0.004 to 1.289)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>6‐month</p> <p>persistent HPV16/18</p> <p>infection</p> <p>in women being</p> <p>hrHPV negative at baseline</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/6634</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>567/6660</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.067 (0.049 to 0.093)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.809</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/273</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/276</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.126 (0.029 to 0.544)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/138</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.045 (0.003 to 0.774)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Incident HPV16/18 infection</p> <p>in women being hrHPV</p> <p>negative at baseline</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/6634</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>567/6660</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.067 (0.049 to 0.093)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.809</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/273</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/276</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.126 (0.029 to 0.544)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/138</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.045 (0.003 to 0.774)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Source: <a href="./references#CD009069-bbs2-0023" title="WacholderS , ChenBE , WilcoxA , MaconesG , GonzalezP , BefanoB . Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ2010;340:c712. ">PATRICIA &amp; CVT (ph3,2v)</a> (<a href="./references#CD009069-bbs2-0067" title="KreimerAR , ShermanME , SahasrabuddheVV , SafaeianM . The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents. Journal of the National Cancer Institute2015;107(3 1460‐2105 (Electronic)):1‐4 0027‐8874 (Linking). ">Kreimer 2015</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Influence of the number of administered doses: one, two or three in two RCTs with four years of follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0018"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Influence of the number of administered doses in the CVT trial (seven years of follow‐up)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of doses</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n events</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N vaccinated</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% (95%CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P* for difference with 3 doses</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Cumulative</p> <p>incidence</p> <p>HPV16/18</p> <p>infections</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2023</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3 (3.5 to 5.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (at months 0 &amp; 6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (1.0 to 10.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (at months 0 &amp; 1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.6 (1.6 to 7.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.3 to 4.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Source: <a href="./references#CD009069-bbs2-0261" title="SafaeianM , SampsonJN , PanY , PorrasC , KempTJ , HerreroR , et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: The CVT Trial. Journal of the National Cancer Institute2018;110(2):djx158. ">Safaeian 2018</a>. </p> <p>* two‐sided exact test for difference between proportions.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Influence of the number of administered doses in the CVT trial (seven years of follow‐up)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0019"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Influence of the number of administered doses: all three versus less than three doses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age</b> </p> <p><b>Group</b> </p> <p><b>(years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR if 3 doses</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR if 1‐2 doses</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>CIN2+</b> </p> <p><b>due to HPV16/18</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (<a href="./references#CD009069-bbs2-0012" title="GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. New England Journal of Medicine2007;356(19):1915‐27. ">FUTURE II trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>; </p> <p><a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0025" title="KoutskyLA , AultKA , WheelerCM , BrownDR , BarrE , AlvarezFB . A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine2002;347(21):1645‐51. MaoC , KoutskyLA , AultKA , WheelerCM , BrownDR , WileyDJ . Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and Gynecology2006;107(1):18‐27. Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Phase2 trial (ph2,1v)</a>; <a href="./references#CD009069-bbs2-0005" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX , et al. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(11):2612‐22. ZhuFC , HuSY , HongY , HuYM , ZhangX , ZhangYJ , et al. Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial. Cancer Medicine2017;6(2045‐7634 (Electronic), 2045‐7634 (Linking), 1):12‐25. ">Chinese trial (ph3,2v)_young</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (0.03 to 0.14)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10 (0.04 to 0.26)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24‐45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (<a href="./references#CD009069-bbs2-0011" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age. British Journal of Cancer2011;105(1):28‐37. GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">FUTURE III trial (ph3,4v)</a>; <a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14 (0.03 to 0.79)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.20 to 4.83)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CIN3+</b> </p> <p><b>due to HPV16/18</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15‐26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (<a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (0.04 to 0.91)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (0.01 to 0.74)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incident HPV16/18 infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (<a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>; <a href="./references#CD009069-bbs2-0025" title="KoutskyLA , AultKA , WheelerCM , BrownDR , BarrE , AlvarezFB . A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine2002;347(21):1645‐51. MaoC , KoutskyLA , AultKA , WheelerCM , BrownDR , WileyDJ . Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and Gynecology2006;107(1):18‐27. Rowhani‐RahbarA , MaoC , HughesJP , AlvarezFB , BryanJT , HawesSE . Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine2009;27(41):5612‐9. ">Phase2 trial (ph2,1v)</a>;<a href="./references#CD009069-bbs2-0005" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX , et al. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(11):2612‐22. ZhuFC , HuSY , HongY , HuYM , ZhangX , ZhangYJ , et al. Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial. Cancer Medicine2017;6(2045‐7634 (Electronic), 2045‐7634 (Linking), 1):12‐25. ">Chinese trial (ph3,2v)_young</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.10 to 0.41)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47 (0.26 to 0.84)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>6‐month persistent HPV16/18 infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (<a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>;<a href="./references#CD009069-bbs2-0005" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX , et al. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(11):2612‐22. ZhuFC , HuSY , HongY , HuYM , ZhangX , ZhangYJ , et al. Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial. Cancer Medicine2017;6(2045‐7634 (Electronic), 2045‐7634 (Linking), 1):12‐25. ">Chinese trial (ph3,2v)_young</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (0.01 to 0.27)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12 (0.03 to 0.42)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24‐45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (<a href="./references#CD009069-bbs2-0011" title="CastellsaguéX , MunozN , PitisuttithumP , FerrisD , MonsonegoJ , AultK . End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age. British Journal of Cancer2011;105(1):28‐37. GarlandSM , AultKA , GallSA , PaavonenJ , SingsHL , CipreroKL , et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology2009;114(6):1179‐88. MunozN , ManalastasRJr , PitisuttithumP , TresukosolD , MonsonegoJ , AultK . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial. Lancet2009;373(9679):1949‐57. ">FUTURE III trial (ph3,4v)</a>;<a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15 (0.09 to 0.27)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.19 to 0.61)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12‐month persistent HPV16/18 infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (<a href="./references#CD009069-bbs2-0017" title="KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial. International Journal of Gynecological Cancer2010;20(3):404‐10. KonnoR , TamuraS , DobbelaereK , YoshikawaH . Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial. International Journal of Gynecological Cancer2010;20(5):847‐55. KonnoR , YoshikawaH , OkutaniM , QuintW , SuryakiranV , LinL , et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines &amp; Immunotherapeutics2014;10(7):1781‐94. ">Japanese trial (ph2,2v)</a>;<a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a>; <a href="./references#CD009069-bbs2-0005" title="ZhuFC , ChenW , HuYM , HongY , LiJ , ZhangX , et al. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial. International Journal of Cancer2014;135(11):2612‐22. ZhuFC , HuSY , HongY , HuYM , ZhangX , ZhangYJ , et al. Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial. Cancer Medicine2017;6(2045‐7634 (Electronic), 2045‐7634 (Linking), 1):12‐25. ">Chinese trial (ph3,2v)_young</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09 (0.05 to 0.19)*</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13 (0.06 to 0.33)*</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*Vaccine efficacy in women being HPV16/18 DNA negative at enrolment and having received all three or less than three doses (computed from trials where per‐protocol [all doses administered] and intention‐to‐treat analyses [at least one dose administered] are reported). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Influence of the number of administered doses: all three versus less than three doses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0020"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Influence of follow‐up time</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Report </b> </p> <p><b>(duration of follow‐up)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vaccine</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative Risk</b> </p> <p><b>(95%CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value for linear difference</b> </p> <p><b>of follow‐up time effect</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>CIN2+ associated with HPV16/18</p> <p>in women being HPV negative at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>PATRICIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paavonen 2007</p> <p>14.8 moths</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/7788</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/7838</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.096 (0.007 to 0.466)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>0.512</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paavonen 2009</p> <p>34.9 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/8040</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91/8080</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.054 (0.016 to 0.137)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Szarewski 2011</p> <p>39.4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/8079</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92/8112</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.054 (0.016 to 0.137)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lehtinen 2011</p> <p>43.7 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/7338</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97/7305</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.051 (0.016 to 0.123)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>FUTURE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The FUTURE II study group 2007</p> <p>36 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/5865</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87/5836</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.039 (0.011 to 0.109)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.994</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Munoz 2010*</p> <p>43 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/4616</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89/4680</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.006 (0.000 to 0.092)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>CIN2+ irrespective of HPV types</p> <p>regardless of women’s initial HPV DNA status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>PATRICIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paavonen 2009</p> <p>34.9 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>224/8667</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>322/8682</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.696 (0.579 to 0.8369)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.750</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lehtinen 2011</p> <p>43.7 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287/8694</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>428/8708</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.669 (0.574 to 0.778)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>FUTURE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The FUTURE II study group 2007</p> <p>36 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281/6087</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361/6080</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.780 (0.668 to 0.905)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.665</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Munoz 2010</p> <p>43 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>421/8562</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>520/8598</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.807 (0.690 to 0.943)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Assessment of the influence of duration of follow‐up on study outcomes using meta‐regression. p‐values correspond with the statistical significance of incorporating average follow‐up time as a continuous variable. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Influence of follow‐up time</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0021"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Influence of the number of sexual partners</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of sex partners</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative Risk </b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value of number of sexual partners effect</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>In women being</b> HPV16<b>/18 DNA negative at baseline cohort</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Virgin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.064 (0.003 to 0.352)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>0.7448</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 partner</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.112 (0.007 to 0.335)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 partners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.056 (0.003 to 0.309)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3+ partners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.108 (0.026 to 0.321)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Regardless of women’s baseline HPV DNA status</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Virgin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.202 (0.059 to 0.551)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>&lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 partner</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/1237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83/1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.489 (0.333 to 0.711)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 partners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81/753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.455 (0.307 to 0.665)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3+ partners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71/940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116/911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.593 (0.440 to 0.796)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>The influence of the number of lifetime sexual partners on vaccine efficacy was assessed by Poisson regression. The P value corresponds with the likelihood ratio test comparing a Poisson model with and without inclusion of the sexual history with 3 possible categories. </p> <p>Source: <a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a> (<a href="./references#CD009069-bbs2-0190" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR . Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. ">Herrero 2011</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Influence of the number of sexual partners</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0022"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Influence of the study size</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of </b> </p> <p><b>participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study size</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vaccine</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative </b> </p> <p><b>Risk</b> </p> <p><b>(95%CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>CIN2+ associated with</p> <p>HPV16/18</p> <p>in women being</p> <p>HPV16/18 negative at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phase2 trial (V1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2392</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/126</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/127</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.062*</p> <p>(0.004 to 1.071)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>0.598</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phase2 trial (V2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1113</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/219</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/212</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.161*</p> <p>(0.008 to 3.091)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japanese trial (ph2,2v)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1040</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/422</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/427</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.252*</p> <p>(0.012 to 5.241)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PATRICIA trial (ph3,2v)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,644</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/8040</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91/8080</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.055</p> <p>(0.022 to 0.136)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FUTURE II trial (ph3, 4v)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12,167</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/5865</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87/5863</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.034</p> <p>(0.011 to 0.109)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese trial (ph3,2V)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6051</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/2543</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/2554</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.125</p> <p>(0.001 to 8.681)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>CIN2+ irrespective of</p> <p>HPV types and</p> <p>regardless of women’s</p> <p>initial HPV DNA status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FUTURE I/II trial (ph3,4v)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,622</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>421/8562</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>520/8598</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.813</p> <p>(0.718 to 0.921)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.703</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PATRICIA trial (ph3,2v)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,644</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287/8694</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>428/8708</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.672</p> <p>(0.582 to 0.778)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phase2 trial (v1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2392</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/148</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/142</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.640</p> <p>(0.269 to 1.568)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Assesment of the influence of the study size on the protection against CIN2+ associated with HPV16/18 according to study size (S = small, &lt; 3000 participants, L = large &gt;= 3000 participants) in women aged 15‐26 years and received at least 1 dose. </p> <p>* P values correspond with the statistical significance of a meta‐regression with vs without study size category. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Influence of the study size</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0023"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Vaccine efficacy endpoints derived from phase 2 trials with longest follow‐up time</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Initial HPV status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Doses</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative Risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><i><b>Monovalent vaccine (Rowhani‐Rahbar, 2009): 102 months of follow‐up</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;= 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incident HPV16 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incident HPV16 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;= 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incident HPV16 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>regardless of HPV infection</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;= 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ irrespective of HPV types</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>regardless of HPV infection</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;= 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><i><b>Bivalent vaccine (De Calvaho, 2012): 88 months of follow‐up</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6M persistent HPV16/18 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hrHPV‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12M persistent HPV16/18 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hrHPV‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV16/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16/18‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;= 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><i><b>Quadrivalent vaccine (Villa, 2006): 60 months of follow‐up</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent HPV6/11/16/18 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HPV16/18‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;= 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Vaccine efficacy endpoints derived from phase 2 trials with longest follow‐up time</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0024"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Cross‐protective efficacy of the bivalent and quadrivalent vaccine</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ref</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Relative Risk (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value for</b> </p> <p><b>difference in VE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bivalent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quadrivalent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0010" title="BrownDR , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus‐like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV‐naive women aged 16 to 26 years. Journal of Infectious Diseases2009;199(7):926‐35. DillnerJ , KjaerSK , WheelerCM , SigurdssonK , IversenOE , Hernandez‐AvilaM . Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ2010;341:c3493. KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM , PerezG . A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high‐grade cervical and external genital lesions. Cancer Prevention Research2009;2(10):868‐78. MunozN , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM . Impact of human papillomavirus (HPV)‐6/11/16/18 vaccine on all HPV‐associated genital diseases in young women. Journal of the National Cancer Institute2010;102(5):325‐39. OlssonSE , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , WheelerCM . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. The FUTURE II study group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. Journal of Infectious Diseases2007;196(10):1438‐46. WheelerCM , KjaerSK , SigurdssonK , IversenOE , Hernandez‐AvilaM , PerezG . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus‐like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16 to 26 years. Journal of Infectious Diseases2009;199(7):936‐44. ">FUT I/II trials (ph3,4v)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD009069-bbs2-0078" title="MalagonT , DroletM , BoilyMC , FrancoEL , JitM , BrissonJ . Cross‐protective efficacy of two human papillomavirus vaccines: a systematic review and meta‐analysis. Lancet Infectious Diseases2012;12(10):781‐9. ">Malagon 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐month persistent HPV31 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.229 (0.156 to 0.228)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.538 (0.336 to 0.847)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0024" title="LehtinenM , PaavonenJ , WheelerCM , JaisamrarnU , GarlandS , CastellsaguéX . Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2012;13(1):89‐99. PaavonenJ , JenkinsD , BoschFX , NaudP , SalmeronJ , WheelerCM . Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet2007;369(9580):2161‐70. PaavonenJ , NaudP , SalmeronJ , WheelerCM , ChowS‐N , ApterD . Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet2009;374:301‐14. SzarewskiA , PoppeWA , SkinnerSR , WheelerCM , PaavonenJ , NaudP . Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer2011;131(1):106‐16. WheelerCM , CastellsaguéX , GarlandSM , SzarewskiA , PaavonenJ , NaudP . Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial. Lancet Oncology2011;13(1):100‐10. ">PATRICIA trial (ph3,2v)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐month persistent HPV45 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.210 (0.106 to 0.387)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.922 (0.507 to 1.670)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0026" title="DeCarvalhoN , TeixeiraJ , Roteli‐MartinsCM , NaudP , DeBorbaP , ZahafT . Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women. Vaccine2010;28(38):6247‐55. HarperDM , FrancoEL , WheelerC , FerrisDG , JenkinsD , SchuindA . Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;364(9447):1757‐65. HarperDM , FrancoEL , WheelerCM , MoscickiAB , RomanowskiB , Roteli‐MartinsCM . Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet2006;367(9518):1247‐55. NaudPS , Roteli‐MartinsCM , DeCarvalhoNS , TeixeiraJC , deBorbaPC , SanchezN , et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination. Human Vaccines &amp; Immunotherapeutics2014;10(8):2147‐62. The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years. Lancet2009;374:1975‐85. ">Phase2 trial (ph2,2v)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.177 (0.053 to 0.466)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.760 (0.328 to 1.712)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0027" title="OlssonSE , KjaerSK , SigurdssonK , IversenOE . Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines2009;5(10):696‐704. VillaLL , AultKA , GiulianoAR , CostaRL , PettaCA , AndradeRP . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine2006;24(27):5571‐83. VillaLL , CostaRL , PettaCA , AndradeRP , AultKA , GiulianoAR . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial. Lancet Oncology2005;6(5):271‐8. VillaLL , CostaRL , PettaCA , AndradeRP , PaavonenJ , IversenOE . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up. British Journal of Cancer2006;95(11):1459‐66. ">Phase2 trial (ph2,4v)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with HPV45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.000 (0.000 to 0.583)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.481 (0.174 to 1.177)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0009" title="HerreroR , WacholderS , RodriguezAC , SolomonD , GonzalezP , KreimerAR , et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery2011;1(5):408‐19. HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. KreimerAR , GonzalezP , KatkiHA , PorrasC , SchiffmanM , RodriguezAC . Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology2011;12(9):862‐70. KreimerAR , RodriguezAC , HildesheimA , HerreroR , PorrasC , SchiffmanM , et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute2011;103(19):1444‐51. Lang KuhsKA , PorrasC , SchillerJT , RodriguezAC , SchiffmanM , GonzalezP . Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. American Journal of Epidemiology2014;180(6):599‐607. ">CVT (ph3,2v)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009069-bbs2-0194" title="HildesheimA , WacholderS , CatteauG , StruyfF , DubinG , HerreroR . Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial. Vaccine2014;32(39):5087‐97. ">Hildesheim 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIN2+ associated with other hrHPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.401 (0.192 to 0.793)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009069-bbs2-0028" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. WheelerCM , SkinnerSR , DelRosario‐RaymundoMR , GarlandSM , ChatterjeeA , Lazcano‐PonceE , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet Infectious Diseases2016;16(10):1154–68. ">VIVIANE trial (ph3,2v)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009069-bbs2-0273" title="SkinnerSR , SzarewskiA , RomanowskiB , GarlandSM , Lazcano‐PonceE , SalmeronJ . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet2014;384(9961):2213‐27. ">Skinner 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐month persistent HPV31 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.209 (0.041 to 0.724)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐month persistent HPV45 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.221 (0.044 to 0.914)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Cross‐protective efficacy of the bivalent and quadrivalent vaccine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009069-tbl-0025"> <div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">Relative risk ratio of adverse effects associated with the bivalent versus the quadrivalent vaccine, adjusted for age group and products administered in the control group</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Adverse effect</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative risk</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative risk ratio</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>p value</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quadrivalent vs placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bivalent/Quadrivalent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall adverse effects at injection site</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.89 to 1.59)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69 (0.96 to 2.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.061</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain at injection site</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.78 to 1.85)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.67 to 2.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.501</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling at injection site</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.72 (0.77to 9.61)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.16 to 2.41)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.427</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Redness at injection site</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.46 (1.23 to 1.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.88 to 1.32)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.307</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall systemic events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.91 to 1.07)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.95 to 1.19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.210</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.70 to 1.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.80 to 1.45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.583</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deaths</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.25 to 5.62)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.14 to 4.91)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.775</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Relative risks of the quadrivalent vaccine versus placebo and the relative risk ratios were computed by meta‐regression including vaccine, age group and type of product injected in the control group (aluminium adjuvants alone or other vaccine such as Hepatitis A vaccine) as covariate. The relative risk ratio reflects how much more an adverse effect is observed after vaccination with the bivalent versus the quadrivalent vaccine. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">Relative risk ratio of adverse effects associated with the bivalent versus the quadrivalent vaccine, adjusted for age group and products administered in the control group</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/full#CD009069-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009069-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">High‐grade cervical lesions in hrHPV DNA negative women at baseline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 CIN2+ associated with HPV16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 CIN2+ associated with HPV6/11/16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 CIN3+ associated with HPV16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 CIN3+ associated with HPV6/11/16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 AIS associated with HPV16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 AIS associated with HPV6/11/16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Any CIN2+ irrespective of HPV types, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.25, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.25, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.44, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Any CIN3+ irrespective of HPV types, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.04, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.03, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.36, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Any AIS irrespective of HPV types, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">High‐grade cervical lesions in hrHPV DNA negative women at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009069-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">High‐grade cervical lesions in HPV16/18 DNA negative women at baseline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 CIN2+ associated with HPV16/(18), 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.04, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Age group 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.03, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Age group 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.04, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 CIN2+ associated with HPV16/(18), at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.05, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Age group 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.03, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Age group 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.11, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 CIN2+ associated with HPV16/(18), 1 or 2 doses (post hoc analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.07, 0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 women age 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.04, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 women age 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.14, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 CIN2+ associated with HPV6/11/16/18, 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.01, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Age group 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Age group 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.02, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 CIN2+ associated with HPV6/11/16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Age group 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Age group 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.10, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 CIN2+ associated with HPV6/11/16/18, 1 or 2 doses (post hoc analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.01, 5.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Age group 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.00, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Age group 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.14, 6.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 CIN3+ associated with HPV16/18 or HPV6/11/16/18, 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.02, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 CIN3+ associated with HPV 16/18 or HPV6/11/16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.02, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 CIN3+ associated with HPV16/18 or HPV6/11/16/18, 1 or 2 doses (post hoc analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.01, 0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 AIS associated with HPV16/18 or HPV6/11/16/18, 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 AIS associated with HPV16/18 or 6/11/16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 AIS associated with HPV16/18 or HPV6/11/16/18, 1 or 2 doses (post hoc analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Any CIN2+ irrespective of HPV types, 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.25, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Any CIN2+ irrespective of HPV types, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.32, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Any CIN2+ irrespective of HPV types, 1 or 2 doses (post hoc analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.15, 3.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">High‐grade cervical lesions in HPV16/18 DNA negative women at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009069-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">High‐grade cervical lesions in women regardless of baseline HPV DNA status</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 CIN2+ associated with HPV16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.41, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Age group 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.37, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Age group 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.52, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 CIN2+ associated with HPV6/11/16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20883</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.38, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Age group 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.42, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Age group 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.44, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 CIN3+ associated with HPV16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.45, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 CIN3+ associated with HPV6/11/16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.43, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 AIS associated with HPV16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.17, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 AIS associated with HPV6/11/16/18, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.16, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Any CIN2+ irrespective of HPV types, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.65, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Age group 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.58, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Age group 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.83, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Any CIN3+ HPV type, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.49, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.43, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.69, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Any AIS irrespective of HPV types, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.15, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">High‐grade cervical lesions in women regardless of baseline HPV DNA status</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009069-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Infection with HPV vaccine types in hrHPV DNA negative women at baseline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incident HPV16/18 infection, 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.02, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Persistent HPV16/18 infection (6M), 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Persistent HPV16/18 infection (6M), at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.05, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Persistent HPV16/18 infection(12M), 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.00, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Persistent HPV16/18 infection (12M), at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.05, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Infection with HPV vaccine types in hrHPV DNA negative women at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009069-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">HPV16/18 infection in HPV16/18 DNA negative women at baseline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incident HPV16/18 infection, 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.10, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incident HPV16/18 infection, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.14, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Incident HPV16/18 infection, 1 or 2 doses (post hoc analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.26, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Persistent HPV16/18 infection (6M), 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.06, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Age group 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.05, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Age group 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.06, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Persistent HPV16/18 infection (6M), at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.08, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Age group 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.08, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Age group 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.10, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Persistent HPV16/18 infection (6M), 1 or 2 doses (post hoc analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.16, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Age group 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.03, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Age group 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.18, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Persistent HPV6/11/16/18 infection (6M), 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.06, 0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Persistent HPV6/11/16/18 infection (6M), at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.05, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Persistent HPV16/18 infection (12M), 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.06, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Persistent HPV16/18 infection (12M), at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.12, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Persistent HPV16/18 infection (12M), 1 or 2 doses (post hoc analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.06, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">HPV16/18 infection in HPV16/18 DNA negative women at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009069-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incident HPV16/18 infection, at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.17, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Persistent HPV16/18 infection (6M), at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.41, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Age group 15‐26 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.38, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Age group 24‐45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.47, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Persistent HPV6/11/16/18 infection (6M), at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.42, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Persistent HPV16/18 infection (12M), at least 1 dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.40, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Persistent HPV16/18 infection (12M) by dose (post hoc analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.12, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009069-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall local/injection site adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.16, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.26, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.12, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pain at injection site <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25691</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.23, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Monovalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [1.01, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.26, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.07, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Swelling at injection site <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.32, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.15, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [0.85, 9.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Redness at injection site <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.50, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.32, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.53, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Overall systemic event and general symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.98, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.97, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.98, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Monovalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.51, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.65, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.85, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Monovalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Bivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.66, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Quadrivalent vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.73, 3.23]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009069-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Pregnancy outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Normal infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.97, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Spontaneous abortion/miscarriage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.68, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Elective termination/induced abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.80, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Stillbirth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.68, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Abnormal infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.88, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Pregnancy outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009069.pub3/references#CD009069-tbl-0033">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009069.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009069-note-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009069-note-0039">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009069-note-0038">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009069-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009069-note-0037">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD009069-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD009069-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD009069-note-0009">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD009069-note-0005">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD009069-note-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009069-note-0004">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009069-note-0034">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009069\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009069\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009069\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009069\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009069\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009069.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009069.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009069.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009069.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009069.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714403894"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009069.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714403897"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009069.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6dd22d659377',t:'MTc0MDcxNDQwNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 